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A B S T R A C T
Background
A promising approach to the treatment of chronic ischaemic heart disease and congestive heart failure is the use of stem cells. The last
decade has seen a plethora of randomised controlled trials developed worldwide, which have generated conflicting results.
Objectives
The critical evaluation of clinical evidence on the safety and eJicacy of autologous adult bone marrow-derived stem/progenitor cells as a
treatment for chronic ischaemic heart disease and congestive heart failure.
Search methods
We searched CENTRAL in the Cochrane Library, MEDLINE, Embase, CINAHL, LILACS, and four ongoing trial databases for relevant trials up
to 14 December 2015.
Selection criteria
Eligible studies were randomised controlled trials comparing autologous adult stem/progenitor cells with no cells in people with chronic
ischaemic heart disease and congestive heart failure. We included co-interventions, such as primary angioplasty, surgery, or administration
of stem cell mobilising agents, when administered to treatment and control arms equally.
Data collection and analysis
Two review authors independently screened all references for eligibility, assessed trial quality, and extracted data. We undertook a
quantitative evaluation of data using random-eJects meta-analyses. We evaluated heterogeneity using the I2 statistic and explored
substantial heterogeneity (I2 greater than 50%) through subgroup analyses. We assessed the quality of the evidence using the GRADE
approach. We created a 'Summary of findings' table using GRADEprofiler (GRADEpro), excluding studies with a high or unclear risk of
selection bias. We focused our summary of findings on long-term follow-up of mortality, morbidity outcomes, and leM ventricular ejection
fraction measured by magnetic resonance imaging.
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Main results
We included 38 randomised controlled trials involving 1907 participants (1114 cell therapy, 793 controls) in this review update. Twenty-
three trials were at high or unclear risk of selection bias. Other sources of potential bias included lack of blinding of participants (12 trials)
and full or partial commercial sponsorship (13 trials).
Cell therapy reduced the incidence of long-term mortality (≥ 12 months) (risk ratio (RR) 0.42, 95% confidence interval (CI) 0.21 to 0.87;
participants = 491; studies = 9; I2 = 0%; low-quality evidence). Periprocedural adverse events associated with the mapping or cell/placebo
injection procedure were infrequent. Cell therapy was also associated with a long-term reduction in the incidence of non-fatal myocardial
infarction (RR 0.38, 95% CI 0.15 to 0.97; participants = 345; studies = 5; I2 = 0%; low-quality evidence) and incidence of arrhythmias (RR 0.42,
95% CI 0.18 to 0.99; participants = 82; studies = 1; low-quality evidence). However, we found no evidence that cell therapy aJects the risk of
rehospitalisation for heart failure (RR 0.63, 95% CI 0.36 to 1.09; participants = 375; studies = 6; I2 = 0%; low-quality evidence) or composite
incidence of mortality, non-fatal myocardial infarction, and/or rehospitalisation for heart failure (RR 0.64, 95% CI 0.38 to 1.08; participants
= 141; studies = 3; I2 = 0%; low-quality evidence), or long-term leM ventricular ejection fraction when measured by magnetic resonance
imaging (mean diJerence -1.60, 95% CI -8.70 to 5.50; participants = 25; studies = 1; low-quality evidence).
Authors' conclusions
This systematic review and meta-analysis found low-quality evidence that treatment with bone marrow-derived stem/progenitor cells
reduces mortality and improves leM ventricular ejection fraction over short- and long-term follow-up and may reduce the incidence of non-
fatal myocardial infarction and improve New York Heart Association (NYHA) Functional Classification in people with chronic ischaemic
heart disease and congestive heart failure. These findings should be interpreted with caution, as event rates were generally low, leading
to a lack of precision.
P L A I N   L A N G U A G E   S U M M A R Y
Stem cell treatment for chronic ischaemic heart disease and congestive heart failure
Review question
Are adult stem/progenitor cells derived from bone marrow safe and eJective as a treatment for chronic ischaemic heart disease and heart
failure?
Background
The current treatment for people suJering from heart disease and heart failure is drugs and, when possible, restoration of the blood supply
in the heart (revascularisation) either by opening the arteries with a tiny balloon in a procedure called primary angioplasty (or percutaneous
coronary intervention) or by heart surgery (or coronary artery bypass graM). Revascularisation has reduced the death rate associated with
these conditions. In some people, heart disease and heart failure symptoms persist even aMer revascularisation. Recently, bone marrow
stem/progenitor cells have been investigated as a new treatment for people with heart disease and heart failure, whether or not they also
undergo revascularisation.
Search date
We searched electronic databases for relevant randomised controlled trials to December 2015.
Study characteristics
We included 38 randomised controlled trials involving more than 1900 participants in this review, with 14 trials of chronic ischaemic heart
disease, 17 trials of ischaemic heart failure secondary to heart disease, and seven trials of refractory or intractable angina. The mean age
of participants ranged from 55 to 70 years, and the proportion of male participants ranged from 51% to 100%.
Key results
Results indicated that treatment with bone marrow-derived cells can lead to a reduction in deaths in participants followed for at least
12 months. Adverse events occurring around the time of treatment were generally rare. Participants who received cell treatment also
experienced fewer heart attacks and arrhythmias when compared to those who received no cells. However, cell therapy does not appear
to reduce the risk of rehospitalisation for heart failure or the combined risk of death, non-fatal heart attack, or rehospitalisation, and did
not result in any improvement over standard treatment in tests of heart function. These results suggest that cell therapy may be of benefit
in people with chronic ischaemic heart disease or heart failure, or both.
Quality of the evidence
The quality of the evidence was low, as the number of included studies and participants is not currently high enough to draw robust
conclusions. Thirteen studies received commercial funding, of which four were fully commercially sponsored, and 12 studies did not report
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that participants were blinded to the treatment they received. Further research involving a larger number of participants is required to
confirm our results.
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Summary of findings for the main comparison.   Bone marrow-derived cell therapy for people with chronic ischaemic heart disease and congestive
heart failure
Bone marrow-derived cell therapy for people with chronic ischaemic heart disease and congestive heart failure
Patient or population: people with chronic ischaemic heart disease and congestive heart failure
Settings: hospitalisation
Intervention: bone marrow-derived cell therapy
Comparison: no cell therapy
Illustrative comparative risks* (95%
CI)
Assumed risk Corresponding risk
Outcomes
No cell thera-
py
Bone marrow-de-
rived cell therapy
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)¶
Quality of the
evidence
(GRADE)
Comments
Mortality (all cause)
Long-term follow-up (≥ 12
months)
102 per 1000 43 per 1000
(21 to 89)
RR 0.42 
(0.21 to 0.87)
491
(9 studies)
⊕⊕⊝⊝
low1,2
The required information size of 1899 partic-
ipants to detect a RRR of 35% has not been
reached.
Periprocedural adverse
events
See comment See comment Not estimable 1695
(34 studies)
See comment Adverse events occurring during the mapping
or cell/placebo injection procedure included
ventricular tachycardia (7), ventricular fibril-
lation (1), atrial fibrillation (1), transient com-
plete heart block (1), transient pulmonary
oedema (3), thrombus on mapping catheter tip
(1), visual disturbances (2), myocardial perfora-
tion (2), limited retrograde catheter-related dis-
section of the abdominal aorta (1).
Non-fatal myocardial in-
farction
Long-term follow-up (≥ 12
months)
83 per 1000 31 per 1000
(12 to 80)
RR 0.38 
(0.15 to 0.97)
345
(5 studies)
⊕⊕⊝⊝
low2,3
The required information size of 2383 partic-
ipants to detect a RRR of 35% has not been
reached.
Rehospitalisation due to
heart failure
155 per 1000 98 per 1000
(56 to 169)
RR 0.63 
(0.36 to 1.09)
375
(6 studies)
⊕⊕⊝⊝
low2,4
The required information size of 1193 partic-
ipants to detect a RRR of 35% has not been
reached.
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Long-term follow-up (≥ 12
months)
Arrhythmias
Long-term follow-up (≥ 12
months)
333 per 1000 140 per 1000
(60 to 330)
RR 0.42 
(0.18 to 0.99)
82
(1 study)
⊕⊕⊝⊝
low5,6
The required information size of 461 partic-
ipants to detect a RRR of 35% has not been
reached.
Composite MACE
Long-term follow-up (≥ 12
months)
350 per 1000 224 per 1000
(133 to 378)
RR 0.64 
(0.38 to 1.08)
141
(3 studies)
⊕⊕⊝⊝
low7,8
The required information size of 431 partic-
ipants to detect a RRR of 35% has not been
reached.
LVEF (%) measured by
MRI
Long-term follow-up (≥ 12
months)
- The mean LVEF (%)
measured by MRI
in the intervention
groups was 1.6 low-
er (8.7 lower to 5.5
higher).
- 25
(1 study)
⊕⊕⊝⊝
low6,7
The required information size of 322 partici-
pants to detect a mean difference of 4% has not
been reached.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
¶Only studies with a low risk of selection bias are included.
CI: confidence interval; LVEF: leM ventricular ejection fraction; MACE: major adverse clinical events; MD: mean difference; MRI: magnetic resonance imaging; NYHA: New
York Heart Assocation; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; RRR: relative risk reduction
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Six trials received full or partial commercial funding, which could have resulted in a biased assessment of the intervention eJect and were therefore deemed to have a high risk
of bias. One trial was not blinded (high risk of performance bias) and had a high risk of attrition bias.
2The number of observed events was low, leading to imprecision.
3Four studies received full or partial commercial funding with a high risk of bias.
4Five trials received full or partial commercial funding with a high risk of bias.
5The included trial received partial commercial funding with a high risk of bias.
6Only one trial with a low number of observed events was included in the analysis, leading to imprecision.
7All three included trials received partial commercial funding with a high risk of bias.
8The number of included studies was low with a low number of observed events, leading to imprecision.
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B A C K G R O U N D
Description of the condition
Ischaemic heart disease (IHD) is a major health burden worldwide
(BHF 2014). Survival following myocardial infarction (MI) has
increased in recent years due to state-of-the-art revascularisation
techniques such as percutaneous coronary intervention (PCI) and
coronary artery bypass graM (CABG) (Skinner 2011). In contrast,
the number of people with congestive heart failure (CHF) is
rapidly becoming an epidemic (Ambrosy 2014; Lloyd-Jones 2002).
Preventing the progression of IHD and the development of CHF thus
remains a challenge.
In IHD, there may be non-contractile scar tissue that has replaced
damaged myocardium, which could cause further damage. The
heart also may prevent the death of more cardiomyocytes by
reducing the energy demands of contraction, resulting in non-
contracting or hibernating myocardium. This typical physiological
response to chronic hypoxic stress, which is identifiable by
abnormalities in contractile function, can potentially be reversed
by revascularisation of the hibernating myocardium in order
to restore cardiac function (Taggart 2012). In some cases,
revascularisation is not possible or may not be complete, and
in cases with non-ischaemic cardiomyopathy revascularisation
is not relevant and symptoms of chronic myocardial ischaemia,
sometimes with refractory angina pectoris, are still present
(Taggart 2012).
Alternative and complementary approaches in the treatment of
CHF are being developed in the form of cell-based therapies for
CHF. The rationale behind developing cell therapies as treatment
for IHD is based on the notion that the heart has limited ability to
repair itself following a major injury. Preclinical and clinical studies
have suggested that cell therapies could potentially reverse leM
ventricular dysfunction in chronic IHD and CHF (Heldman 2014;
Perin 2012a).
Description of the intervention
The procedure is currently as follows: either the bone marrow is
harvested from the recipient, or bone marrow cells are mobilised
into circulation by a growth factor stimulant (most commonly
granulocyte colony-stimulating factor (G-CSF)) (Assmus 2006;
Erbs 2005). In the former procedure, cells are usually collected
(sometimes under general anaesthesia) from the pelvic bone using
large suction needles. The stem/progenitor cells are thereaMer
separated from other bone marrow cells in sterile conditions
(Assmus 2006). The bone marrow harvest and cell separation
procedures may take several hours. In the G-CSF mobilisation
procedure, mononuclear cells or progenitor cells are collected
as a blood sample and then separated from other blood cells
in sterile conditions (Erbs 2005). In both procedures, the cells
are infused directly into the recipient's coronary arteries or
heart (Ang 2008; Hamshere 2015). The first procedure delivers
the cells to the coronary arteries via a special balloon-catheter
during angioplasty (e.g. percutaneous coronary intervention) using
a stop-flow technique (Ang 2008; Hamshere 2015). The latter
procedure administers the cells into the heart muscle during
an angioplasty-like procedure using electromechanical mapping
and direct intramyocardial injection (e.g. NOGA system) or during
cardiac surgery (e.g. coronary artery bypass graMing) (Ang 2008;
Hamshere 2015), although this option may be limited by high
costs associated with NOGA percutaneous procedure. The interval
between the cell collection and their reinfusion varies; some are
administered fresh, and others undergo some form of culture and
expansion ex vivo that could take two to three weeks (Assmus 2006;
Bartunek 2012; Mathiasen 2015).
A haematologist usually undertakes the collection of cells. A
specialised technician or scientist undertakes the cell separation
from the other bone marrow cells, and the cardiologist or cardiac
surgeon peforms the infusion or intramyocardial injection of the
cells.
Adverse eJects associated with the administration of bone marrow
or blood cells as a treatment for people with chronic IHD or CHF
are infrequent and generally not serious (Behfar 2014). In those
trials where G-CSF has been administered prior to the cell harvest,
transient complications arising from the G-CSF treatment may
occur. However, no long-term adverse eJects have been reported.
This treatment is currently only available in research-associated
facilities, but it is conceivable that, if long-term eJectiveness
is confirmed, it might become available to some or all people
with chronic heart disease, since bone marrow and peripheral
blood harvest is a standard procedure used in bone marrow
transplantation. The costs may be high, depending on the
procedures used, and currently relate to the costs of cell collection
and cell processing (approximately a 10th of the overall cost of the
trial). The potential for a large multicentre randomised controlled
trial (RCT) is limited by funds and by discordant results from
previous RCTs.
How the intervention might work
Clinical trials that have administered bone marrow-derived cells to
people suJering from IHD or CHF have yielded divergent results,
and therefore the mechanism of action of such therapies remains
unclear. The selection of optimal cell type and the optimal patient
cohort to be treated is thus a challenge. Although incorporation
into blood vessels and direct generation of cardiomyocytes have
been proposed as mechanisms of action (Beltrami 2003; Carr 2008;
Martin-Rendon 2008a; Mathur 2004; Stuckey 2006; Yoon 2005), it
is now accepted that a paracrine mechanism may be the major
contribution to promoting cardiac repair and limit fibrosis in the
damaged myocardium (Ibrahim 2016; Li 2012).
Why it is important to do this review
Cell therapies have the potential to become an exciting new
form of treatment for many diseases. Heart disease is one of the
clinical settings in which to address this new form of therapy,
although the exact clinical role for cell therapy remains to be
defined. Cell therapy as treatment for ischaemic heart disease
is an experimental therapy that is not widely available and is
not part of standard clinical practice. Currently, there are no
clinical guidelines on the use of cell therapies for ischaemic
heart disease and heart failure. Evidence from early trials and
systematic reviews has suggested that cell therapy may result
in some improvements over conventional therapy as measured
by surrogate tests of heart function (Abdel-Latif 2007; Assmus
2006; Chen 2006; Jeevanantham 2012). More recent systematic
reviews and meta-analyses have shown conflicting results (Afzal
2015; Fisher 2015b). A recent Cochrane review concluded that
there is insuJicient evidence for a beneficial eJect of cell therapy
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for people with acute myocardial infarction, with most evidence
coming from small trials that showed no diJerence in clinically
relevant outcomes (Fisher 2015a). However, there seems to be
robust evidence to suggest that cell therapies have a beneficial
eJect on people with heart failure (Fisher 2016).
A Cochrane review of cell therapy for people with chronic IHD
and CHF included 23 RCTs and found some evidence that bone
marrow-derived cells improve leM ventricular ejection fraction
(LVEF), reduce the number of deaths and are associated with
improved measures of performance in the long term (Fisher 2014).
Since publication of the original review, several key new trials have
been published (Heldman 2014_BMMNC; Heldman 2014_BM-MSC;
Jimenez-Quevedo 2011; Mathiasen 2015; Nasseri 2012; Patel 2015;
Patila 2014; Santoso 2014; Trifunovic 2015; Wang 2014; Wang 2015).
It is important to update the review with these new trials to re-
evaluate and improve the quality of the available evidence.
O B J E C T I V E S
The critical evaluation of clinical evidence on the safety and eJicacy
of autologous adult bone marrow-derived stem/progenitor cells as
a treatment for chronic IHD and CHF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Anyone with a clinical diagnosis of IHD or CHF, excluding people
with acute myocardial infarction. We included studies evaluating
both ischaemic and non-ischaemic disease only if data for the
participants with ischaemic disease could be extracted separately.
Types of interventions
Studies involving the administration of autologous adult bone
marrow-derived stem/progenitor cells on their own or in
combination with co-interventions, such as cardiac surgery, as
treatment for IHD or CHF.
Participants in the comparator treatment arm of the trial received
either no intervention or a placebo (e.g. the medium in which the
cells were suspended or plasma). Trials where co-interventions
(e.g. CABG, PCI, G-CSF, extracorporal shockwave therapy) were
additionally administered were eligible as long as the co-
interventions were equal in both arms and administered to an
equivalent proportion of participants.
In summary:
1. any autologous human adult bone marrow-derived stem/
progenitor cells
2. any single dose
3. any method of stem/progenitor cell isolation
4. any route of administration
5. any co-intervention
6. repeated intervention or multiple doses
Types of outcome measures
Primary outcomes
1. Mortality
2. Periprocedural adverse events (defined as occurring at the time
of bone marrow aspiration or administration of cell therapy
(or placebo), or documented adverse events within 30 days of
treatment)
Secondary outcomes
1. Morbidity: non-fatal MI, rehospitalisation for heart failure (HF),
arrhythmias, composite measure of major adverse clinical
events (MACE, mortality, non-fatal MI, and/or rehospitalisation
for HF)
2. Health-related quality of life (QoL)
3. Performance status (e.g. New York Heart Association (NYHA)
classification, Canadian Cardiovascular Society (CCS) class,
exercise capacity)
4. LeM ventricular ejection fraction (LVEF).
We divided beneficial outcomes into clinically based and surrogate
outcomes. At the protocol stage of this review, we had intended to
consider clinical and surrogate outcome data at 30 days, 6 months,
and 12 months aMer baseline; however, this was not possible due
to the variation in follow-up periods reported in individual studies.
We therefore stratified outcome data into short term (up to 12
months) and long term (12 months or longer) follow-up. The scope
of this version of the review was to assess the clinical benefit or
harm of cell therapies in people with ischaemic heart disease and
heart failure, and we have therefore focused on clinical outcomes.
However, the surrogate outcome of LVEF is a standard, widely
reported surrogate for cardiac function and has been retained as
a reference point in other trials and systematic reviews of IHD. We
have excluded surrogate outcomes other than LVEF reported in
previous versions of this review, namely engraMment and survival
of the infused cells, end-systolic volume, end-diastolic volume,
wall motion score, and stroke volume index, in agreement with
the Cochrane Heart Group. However, we consider that relevant
surrogate outcomes such as leM ventricular volumes may be more
meaningful than LVEF, and as such, we will consider these surrogate
outcomes in the next update of this review.
Search methods for identification of studies
Electronic searches
We updated and expanded the electronic database searches,
originally run in March 2013 (see Appendix 1 for details), in June
2014, March 2015, and December 2015 (Appendix 2). We identified
relevant studies from searching the following:
• Cochrane Central Register of Controlled Trials (CENTRAL) (the
Cochrane Library, 2015 Issue 11);
• MEDLINE (OvidSP, 1948 to 14 December 2015);
• Embase (OvidSP, 1974 to 14 December 2015);
• CINAHL (EBSCOHost, 1982 to 14 December 2015);
• PubMed (in process and epublications ahead of print only, on 14
December 2015);
• LILACS (1982 to 14 December 2015);
• IndMED (1986 to 14 December 2015);
• KoreaMed (1997 to 14 December 2015);
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• PakMediNet (1995 to 14 December 2015);
• Web of Science: Conference Proceedings Citation Index - Science
(CPCI-S) (1990 to 14 December 2015);
• four databases of ongoing trials on 14 December 2015:
* ClinicalTrials.gov (clinicaltrials.gov/);
* ISRCTN Register (www.isrctn.com/);
* World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/);
* HKU Clinical Trials Registry (www.hkuctr.com).
Searching other resources
We checked the reference lists of all identified eligible papers
and relevant systematic reviews. We applied no language or date
restrictions.
Data collection and analysis
Selection of studies
The Information Specialist (CD) conducted the electronic search
for potentially relevant papers and removed references that were
duplicates, clearly irrelevant, and/or included in previous search
results. Two review authors (SF, EMR) independently screened
all titles and abstracts identified by the review search strategy
for relevance to the review question. We excluded studies that
clearly did not meet the eligibility criteria at this stage. Two review
authors (SF, EMR) independently assessed all other studies based
on their full text for inclusion/exclusion using the criteria indicated
above (type of studies, participants, interventions, and outcome
measures). Disagreements were resolved through discussion.
Data extraction and management
Two review authors (SF, EMR) extracted data onto customised data
extraction forms that were created and piloted specifically for this
review and independently undertook data extraction for all eligible
studies. Aside from details relating to the quality of the included
studies, we extracted the following two groups of data.
1. Trial characteristics: place of publication, date of publication,
population characteristics, setting, detailed nature of
intervention, detailed nature of comparator, detailed nature of
outcomes. A key purpose of these data was to explain clinical
heterogeneity between included studies independently from
analysis of the results.
2. Results of included studies for each of the main outcomes
indicated in the review question. For dichotomous outcomes,
we recorded the numbers of outcomes in treatment and
control groups. For continuous outcomes, we recorded the
mean and standard deviation. Where standard deviations of
mean change from baseline values were not explicitly reported,
where possible we calculated the standard deviation based
on reported confidence intervals or P values as described in
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and we used these values in the analysis.
Disagreements between the review authors over data extraction
were resolved by consensus. When disagreements regarding any
of the above could not be resolved through discussion, we
attempted to contact authors of the original trials to provide further
details. One review author (SF) then transcribed the data into the
systematic review computer soMware Review Manager 5 (Review
Manager 2014).
Assessment of risk of bias in included studies
The two review authors (SF, EMR) independently undertaking the
data extraction assessed the risk of bias for each trial using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). For trials included in the previous
version of this review, we re-evaluated the risk of bias in the
context of the revised outcomes and long-term follow-up studies,
and updated accordingly. Disagreements were resolved through
discussion.
A study of trials published in Chinese medical journals that were
described as randomised found that a high proportion of these
trials did not adhere to accepted methodology for randomisation,
and hence could not be deemed authentic RCTs (Wu 2009). It is
now widely accepted that trials carried out in China may lack
appropriate randomisation; we therefore deemed any Chinese
studies for which methods of randomisation were not described
and could not be clarified with trial authors to have a high risk
of selection bias, and evaluated sensitivity to these trials through
sensitivity analyses (see Sensitivity analysis section below).
Measures of treatment e>ect
We carried out separate analyses according to the duration of
follow-up aMer treatment: short term (less than 12 months) and
long term (equal to or greater than 12 months). We expressed
dichotomous data for each arm in a particular study as a
proportion or risk and the treatment eJect as a risk ratio (RR)
with 95% confidence intervals (CIs), calculated using Mantel-
Haenszel methods. We expressed continuous data for each arm
in a particular study as a mean and standard deviation, and the
treatment eJect as the mean diJerence (MD) if outcomes were
measured in the same way across trials. For outcomes measured
using diJerent methods, we combined the treatment eJect data
and analysed them using the standardised mean diJerence (SMD).
Although we intended to analyse continuous outcomes as mean
change from baseline, several studies only reported baseline
and endpoint data. Where possible, we calculated the standard
deviation of the mean change from baseline based on reported
confidence intervals or P values, and used these values in the
analysis. However, for several studies, insuJicient information
was reported to calculate the standard deviation. Since the
mean diJerence based on the change from baseline can be
assumed to address the same underlying intervention eJects as
an analysis based on final measures (i.e. the diJerences in mean
final values will on average be the same as the diJerences in
mean change scores), we combined studies reporting mean change
from baseline values with those reporting endpoint values, but
have presented mean change and endpoint values separately as
well as in combined analyses for clarity, as suggested in the
Cochrane Handbook (Higgins 2011). We did not conduct this pooling
of studies by method of reporting of continuous measures for
analyses of exercise capacity, since the assumption of consistent
underlying eJects does not hold for standardised mean diJerences.
Unit of analysis issues
Three published reports of trials randomised participants to one
of two treatment arms, each with a comparator control group
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(Hamshere 2015_IC; Hamshere 2015_IM; Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Mozid 2014_IC; Mozid 2014_IM); we have
considered each of these studies as reporting two separate
trials within one publication and treat them as such throughout
this review. In the first trial (Heldman 2014_BMMNC; Heldman
2014_BM-MSC), exercise capacity, quality of life, and LVEF measures
were reported pooled for both control groups; for these outcomes
the pooled control data are used as the comparator for both
intervention arms. In other studies in which there were multiple
interventions in the same trial compared with a single control
group, we combined the intervention trial arms for a single
comparison with the comparator (control) arm to avoid double
counting of participants and potential correlation of results. We
thus pooled data across diJerent methods of administration
(intramyocardial/intracoronary) (Ang 2008), cell types (Assmus
2006), and cell doses (Losordo 2007; Losordo 2011). However, for
subgroup and sensitivity analyses, where the two intervention
arms were classified into diJerent categories (e.g. type of cell, cell
dose, route of administration of cells), we included results for each
treatment arm in the corresponding group, with the control group
included in both groups. In order to avoid unit of analysis issues, we
treated cross-over trials as parallel trials and included them in the
review up to the point of cross-over, i.e. first-phase data only.
In the analysis of quality of life outcomes, we converted Minnesota
Living with Heart Failure Questionnaire (MLHFQ) scores to negative
values in order to include these in a meta-analysis with other
measures on diJerent scales using the standardised mean
diJerence.
Dealing with missing data
We attempted to contact the authors of 27 studies (describing
30 independent trials) by email for clarification of methods
(randomisation, allocation concealment, and blinding), potential
overlapping of studies, and/or requests for additional data. We
failed to establish contact with the authors of 16 studies (17
independent trials) by email (Ang 2008; Bartunek 2012; Erbs 2005;
Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Mathiasen 2015;
Nasseri 2012; Patel 2015; Perin 2011; Perin 2012a; Perin 2012b;
Pokushalov 2010; Santoso 2014; Tse 2007; Wang 2010; Yao 2008;
Zhao 2008), and the authors of one study initially responded but did
not reply to subsequent emails (Jimenez-Quevedo 2011).
We are grateful to the authors of 10 studies (12 independent trials)
who responded to our emails as follows:
• Assmus 2006: results were reported for a pooled randomised
cohort and a non-randomised pilot study cohort; the authors
provided full clinical and surrogate outcome data for the
randomised cohort alone, as well as details of the method of
randomisation used;
• Assmus 2013: we received clarification of analysis sample sizes
and confidence intervals for mean change in NYHA;
• Hendrikx 2006: we received leM ventricular end-systolic volume
(LVESV) and end-diastolic volume (LVEDV) data (as only LVESV/
LVEDV index values were reported) (see previous version of this
review);
• Hu 2011: the authors confirmed overlap of multiple publications
and provided mean change from baseline data for exercise
capacity, LVEF, and other surrogate outcome measures (see
previous version of this review);
• Mozid 2014_IC; Mozid 2014_IM: results were reported pooled
across intervention arms; the authors provided mortality, MI,
rehospitalisation and arrhythmia rates, and mean NYHA and CCS
baseline, follow-up, and change from baseline values separately
for each randomised arm of the trial;
• Hamshere 2015_IC; Hamshere 2015_IM: this study was
published in abstract form only with limited presentation
of results. The authors kindly provided data for mortality,
morbidity, NYHA class, and CCS class;
• Patel 2005: we received clarification of randomisation methods;
• Patila 2014: we received mean (rather than reported median)
values for LVEF and NYHA class;
• Trifunovic 2015: LVEF data were reported graphically; the
authors provided the actual data used to generate the graphs;
• Turan 2011: a discrepancy in brain natriuretic peptide data
between papers was resolved; overlap of multiple publications
was confirmed.
Assessment of reporting biases
Although we made every eJort to identify unpublished studies,
we assessed publication bias for the primary outcome of mortality
using a funnel plot and with a formal test for publication bias using
Egger's test for asymmetry (Egger 1987), implemented with the
statistical soMware programme R v2.14.1 (R Core Team 2013). We
accept that asymmetry, one cause of which may be publication
bias, is diJicult to detect with the small numbers of studies (i.e.
fewer than 10) oMen encountered in systematic reviews.
Data synthesis
We undertook meta-analyses using Review Manager 5,
employing random-eJects models throughout due to the
anticipated heterogeneity arising from diJerences in participant
characteristics, interventions, and duration of follow-up (Review
Manager 2014). This diJers from the previous version of the review,
in which fixed-eJect models were used for meta-analyses in the first
instance.
Although quantitative synthesis was the main method of analysis,
we incorporated insights from a qualitative evaluation of studies
for an overall interpretation of the data. We based conclusions
on patterns of results identified across clearly tabulated results
of included studies as well as summary measures, taking both
direction and magnitude of any mean eJect sizes from random-
eJects models into account.
We included all studies in the main analyses irrespective of
risk of bias and performed sensitivity analyses for risk of
selection, performance, and attrition bias as described in the
Sensitivity analysis section below. Periprocedural adverse events
were summarised for each trial in tabular form and evaluated
descriptively. We made no formal evaluation of the frequency of
periprocedural adverse events in each treatment group due to the
diJerences in definition and reporting of periprocedural adverse
events between studies.
Within each included trial, all participants were analysed in
the treatment groups to which they had been randomised. We
undertook an available-case analysis, including all participants
who were randomised to treatment and were included in the
analysis, irrespective of whether or not they had received their
randomised treatment.
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In two trials, no variation in NYHA class, in Trifunovic 2015, or CCS
class, in Perin 2012b, between participants within the treatment
group was observed (and hence the sample standard deviation was
zero). For these outcomes, we estimated the standard deviation by
that observed in the control group in order to incorporate these
data into the meta-analysis.
We constructed 'Summary of findings' tables using GRADEpro GDT
(GRADEpro GDT). We focused our summary of findings on long-term
follow-up of the primary outcome of mortality, morbidity (non-fatal
MI, rehospitalisation for HF, composite MACE, arrhythmias) and
the surrogate outcome of LVEF measured by magnetic resonance
imaging (MRI). We excluded studies with a high or unclear risk
of selection bias from random sequence generation from the
'Summary of findings' tables and from summary results presented
in the abstract. We made an assessment of the quality of the
evidence based on study design limitations, inconsistency of
results, indirectness of evidence, imprecision, and publication bias
as described in the GRADE handbook (Schünemann 2013), with
consideration of the optimal information size generated from trial
sequential analysis (TSA).
Trial sequential analysis
Cumulative meta-analyses may result in type I errors due to
an increased risk of random error arising from repeated testing
of accumulating data (Borm 2009; Hu 2007; Lan 2003). Trial
sequential analysis provides a method of adjusting the thresholds
for statistical significance while maintaining the overall desired
type I error rate (Wettersley 2008). These adjusted thresholds
are known as trial sequential monitoring boundaries (TSMBs).
If the cumulative Z-curve crosses the TSMB, then statistical
significance has been reached whilst maintaining the overall type
I error rate. Trial sequential analysis also provides a required
information size, the meta-analysis information size needed to
detect a statistically significant eJect with overall desired power
and type I error given a defined underlying model. We calculated
the required information size for the outcomes of all-cause
mortality (primary outcome), morbidity outcomes (non-fatal MI,
rehospitalisation for HF, composite MACE, and arrhythmias), and
LVEF at long-term follow-up using the TSA program (TSA 2011). For
dichotomous outcomes, the required information size was based
on a DerSimonian and Laird random-eJects model for a relative
risk reduction of 35% (equivalent to the reduced risk of mortality
associated with PCI, Hartwell 2005, and less than that associated
with CABG, Benedetto 2016). We acknowledge that this may be
an overestimation of the eJect of cell therapy, but as an arbitrary
value it provides a benchmark comparison. Small treatment eJects
will require a larger information size. We assumed an incidence
rate in the control group equal to that observed in our control
data. For LVEF and NYHA class, we calculated the information size
using a DerSimonian and Laird random-eJects model with a model
variance-based heterogeneity correction assuming an a priori
absolute mean diJerence in change from baseline values of 4%
(LVEF) or a mean diJerence of 1 (NYHA class). We excluded studies
with a high or unclear risk of selection bias from random sequence
generation from TSA. For outcomes demonstrating eJicacy of cell
therapy, cumulative Z-scores (i.e. the Z-statistics obtained aMer
sequential inclusion of each trial) were constructed and assessed
for significance against the trial sequential monitoring boundaries,
calculated using the O'Brien-Fleming β-spending function for a
reduced overall 5% type I error rate and 80% power.
Subgroup analysis and investigation of heterogeneity
A range of diJerent methods (MRI, leM ventricular angiography
(LVA), single-photon emission computed tomography (SPECT),
echocardiography, and radionuclide ventriculography (RNV)) were
used to measure LVEF across studies, with several studies reporting
LVEF as an outcome using more than one method of measurement.
The limitations of some of these methods are well known (Arnesen
2007). Consistent with the previous version of this review, we
subgrouped analyses of LVEF according to the measurement
method used.
We assessed the percentage of variability in eJect estimates due to
heterogeneity using the I2 statistic (Higgins 2002; Higgins 2003). We
performed pre-planned subgroup analysis for mortality (primary
outcome). For outcomes with substantial observed heterogeneity
(I2 ≥ 50%) in combined analyses (or separate analyses for outcomes
reported as standardised mean diJerence) and a minimum of
three studies in each subgroup, we investigated potential sources
of heterogeneity by performing the subgroup analyses described
below as exploratory analyses, and by visual inspection of forest
plots with consideration of individual trial characteristics (Higgins
2003). Where possible, we based subgroup analyses on combined
analyses of mean values at endpoint and mean change from
baseline values, consistent with the main analyses as described
in the Measures of treatment eJectsection above. We performed
subgroup analyses on all available trials irrespective of risk of bias.
Subgroup analysis considered the following factors:
1. mean dose of stem/progenitor cells administered (≤ 107, 107 to
108, or > 108);
2. route of cell administration (intramyocardial, intracoronary);
3. baseline cardiac function (mean baseline LVEF < 30%, 30% to
50%, or > 50%);
4. type of cell administered (mononuclear cells; circulating
progenitor cells; haematopoietic progenitor cells; and
mesenchymal stem cells);
5. participant diagnosis (chronic IHD; HF (secondary to IHD);
intractable/refractory angina), classified in consultation with a
clinical expert (AM);
6. use of co-interventions (PCI or CABG or shockwave administered
or not administered).
We regarded the last three subgroup comparisons listed above as
hypothesis-generating.
For trials with multiple active-intervention arms, in subgroup
analyses where the intervention arms were stratified across the
subgrouping strata, we used the single control group as the
comparator in each subgroup.
Sensitivity analysis
For the outcomes of mortality, non-fatal MI, rehospitalisation for
HF, composite major adverse clinical events, NYHA class, and LVEF
measured by MRI, we assessed results for sensitivity to risk of
selection bias (by excluding studies with a high or unclear risk
of bias from random sequence generation). We also assessed the
primary outcome of mortality for sensitivity to risk of attrition bias
(by excluding studies with a high or unclear risk of attrition bias) and
performance bias (by excluding studies with a high or unclear risk
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
of performance bias due to known lack of blinding of participants
and clinicians).
R E S U L T S
Description of studies
Results of the search
We identified a total of 20,646 references from the electronic
database searches. De-duplication and removal of all clearly
irrelevant references by the Information Specialist (CD) excluded
14,955 references. Initial screening of the remaining 5691 citations
against inclusion criteria excluded a further 5486 references. Of the
remaining 205 citations, we subsequently excluded 70 references
(describing 54 independent studies), as they did not fully meet
the inclusion criteria (see Excluded studies). Five further references
described four independent study protocols (see Ongoing studies).
Ten studies (12 references) were published in abstract form only,
and although they appeared to meet the inclusion criteria, they did
not contain suJicient data for inclusion; we have identified these
as Studies awaiting classification. The remaining 118 citations
describe a total of 38 independent RCTs (see Included studies).
A summary of study classification is displayed in a PRISMA flow
diagram (Figure 1).
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Figure 1.   PRISMA flow diagram.
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Searching of ongoing trial databases identified 1302 trial records.
De-duplication and removal of clearly irrelevant trials by the
Information Specialist (CD) excluded 949 records. Of the remaining
353 records, 22 described included studies and 31 were ongoing
trials that met the eligibility criteria and are shown in Ongoing
studies.
Included studies
Thirty-eight studies met the inclusion criteria for this review,
including a total of 1907 randomised participants (1114 bone
marrow-derived stem/progenitor cells and 793 controls) who
were assessed for the primary outcomes of the study. Sixteen
independent trials are new to this review update (Bartunek 2012;
Hamshere 2015_IC; Hamshere 2015_IM; Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Jimenez-Quevedo 2011; Mathiasen 2015;
Mozid 2014_IC; Mozid 2014_IM; Nasseri 2012; Patel 2015; Patila
2014; Santoso 2014; Trifunovic 2015; Wang 2014; Wang 2015),
representing an approximately 70% increase in the number of
included participants from the previous version of the review. One
study included in the original review was excluded in this update, as
the co-intervention of G-CSF administered to the cell therapy group
was not given to the control group (Kang 2006). See Table 1 for a
summary of study participants.
The mean age of participants ranged from 55 to 70 years, and
the proportion of men ranged from 50.9% to 100%. All trials
were presented as full journal articles, with the exception of
three trials that were published in the form of a conference
abstract (Hamshere 2015_IC; Hamshere 2015_IM; Wang 2014), and
two trials that reported additional long-term follow-up results
in abstract form only (Assmus 2013; Patel 2005). Nine studies
were multicentre trials (Bartunek 2012; Jimenez-Quevedo 2011;
Losordo 2007; Losordo 2011; Patel 2015; Perin 2011; Perin 2012a;
Santoso 2014; Tse 2007). Studies were based worldwide, including
China (Chen 2006; Hu 2011; Wang 2009; Wang 2010; Wang 2014;
Wang 2015; Yao 2008; Zhao 2008), Germany (Assmus 2006; Assmus
2013; Erbs 2005; Honold 2012; Nasseri 2012; Turan 2011), the
United States (Heldman 2014_BMMNC; Heldman 2014_BM-MSC;
Losordo 2007; Losordo 2011; Perin 2011; Perin 2012a; Perin 2012b),
the United Kingdom (Ang 2008; Hamshere 2015_IC; Hamshere
2015_IM; Mozid 2014_IC; Mozid 2014_IM), Spain (Jimenez-Quevedo
2011), Belgium (Hendrikx 2006), Denmark (Mathiasen 2015), the
Netherlands (Van Ramshorst 2009), Finland (Patila 2014), Serbia
(Trifunovic 2015), Russia (Pokushalov 2010), Argentina (Patel 2005),
Hong Kong/Australia (Tse 2007), Indonesia/China (Santoso 2014),
Belgium/Serbia/Switzerland (Bartunek 2012), and USA/Germany/
India (Patel 2015). Two studies included publications in Chinese
(Hu 2011; Wang 2009), which were translated into English for this
review.
Fourteen studies included participants with chronic IHD (Ang
2008; Assmus 2006; Assmus 2013; Chen 2006; Erbs 2005; Heldman
2014_BMMNC; Heldman 2014_BM-MSC; Hendrikx 2006; Honold
2012; Trifunovic 2015; Turan 2011; Wang 2014; Wang 2015; Yao
2008), normally defined as multivessel disease with persistent
ischaemia and at least 30 days from the last MI. Seventeen studies
included participants with CHF, defined as severe ischaemic HF and
postinfarction HF (secondary to IHD) (Bartunek 2012; Hamshere
2015_IC; Hamshere 2015_IM; Hu 2011; Mathiasen 2015; Mozid
2014_IC; Mozid 2014_IM; Nasseri 2012; Patel 2005; Patel 2015;
Patila 2014; Perin 2011; Perin 2012a; Perin 2012b; Pokushalov 2010;
Santoso 2014; Zhao 2008), and seven studies were of people with
intractable or refractory angina (Jimenez-Quevedo 2011; Losordo
2007; Losordo 2011; Tse 2007; Van Ramshorst 2009; Wang 2009;
Wang 2010). One trial also included people with non-ischaemic
heart disease (Patel 2015), but reported results separately so
that only participants with ischaemic disease are included in this
review. All trials maintained participants with a standard set of
drugs including aspirin, clopidogrel, heparin, blockers, statins,
angiotensin converting enzyme (ACE) inhibitors, nitrates, and/or
diuretics.
Duration of follow-up ranged from three months (Assmus 2006),
four months (Hendrikx 2006), six months (Ang 2008; Jimenez-
Quevedo 2011; Losordo 2007; Mathiasen 2015; Mozid 2014_IC;
Mozid 2014_IM; Nasseri 2012; Perin 2011; Perin 2012a; Perin 2012b;
Santoso 2014; Tse 2007; Van Ramshorst 2009; Wang 2009; Wang
2010; Wang 2014; Wang 2015; Yao 2008; Zhao 2008), 12 months
(Chen 2006; Hamshere 2015_IC; Hamshere 2015_IM; Heldman
2014_BMMNC; Heldman 2014_BM-MSC; Hu 2011; Losordo 2011;
Patel 2015; Patila 2014; Pokushalov 2010; Turan 2011), 15 months
(Erbs 2005), 24 months (Bartunek 2012) up to a median 45 (17)
months (Assmus 2013), 60 months (Honold 2012; Trifunovic 2015),
and 10 years (Patel 2005).
See Table 2 for a summary of study interventions. Twenty-seven
trials isolated the stem cells by bone marrow aspiration and
further separation of the mononuclear cells using density gradient
centrifugation (Ang 2008; Assmus 2006; Assmus 2013; Bartunek
2012; Chen 2006; Heldman 2014_BMMNC; Heldman 2014_BM-
MSC; Hendrikx 2006; Hu 2011; Mathiasen 2015; Nasseri 2012;
Patel 2005; Patila 2014; Perin 2011; Perin 2012a; Perin 2012b;
Pokushalov 2010; Santoso 2014; Trifunovic 2015; Tse 2007; Turan
2011; Van Ramshorst 2009; Wang 2009; Wang 2010; Wang 2015;
Yao 2008; Zhao 2008), and one trial isolated and concentrated
the mononuclear cell fraction (Patel 2015). Three of these trials
enriched the stem cell fraction in CD34-positive haematopoietic
progenitors by magnetic separation (Patel 2005; Wang 2009;
Wang 2010), whilst one trial enriched the stem cell fraction in
CD133-positive cells (Nasseri 2012), and one trial in aldehyde
dehydrogenase (ALDH)-positive haematopoietic progenitors (Perin
2012b). Three trials cultured the mononuclear cell population from
bone marrow ex vivo to enrich in mesenchymal progenitors (Chen
2006; Heldman 2014_BM-MSC; Mathiasen 2015), whereas one trial
cultured mononuclear cells and enriched them in cardiopoietic
cells by exposure to cardiopoietic factors (Bartunek 2012). In
one three-arm trial (Assmus 2006), bone marrow mononuclear
cells were compared with circulating progenitor cells (CPCs), and
with mononuclear cells isolated from venous peripheral blood.
In the CPC arm, cells were isolated from peripheral blood by
leukapheresis.
In five trials, bone marrow stem cells were mobilised into
circulation with granulocyte colony-stimulating factor (G-CSF) and
subsequently isolated from blood via leukapheresis (Erbs 2005;
Honold 2012; Jimenez-Quevedo 2011; Losordo 2007; Losordo
2011). Whilst previous trials reported severe but transient
complications associated with G-CSF treatment (Kang 2006),
a recent pilot study demonstrated that G-CSF can be safely
administered to people suJering from IHD as none of the
participants in this trial experienced the type of adverse events
previously associated with G-CSF treatment (Honold 2012). Two
of these trials further enriched the stem cell population in
CD34-positive progenitors by magnetic separation (Losordo 2007;
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Losordo 2011). Four trials mobilised bone marrow cells into
circulation with G-CSF and isolated bone marrow mononuclear
cells by density gradient centrifugation (Hamshere 2015_IC;
Hamshere 2015_IM; Mozid 2014_IC; Mozid 2014_IM). Finally, one
study administered CD133-postive cells, but reported no details of
cell isolation (Wang 2014).
All but six trials reported the mean (or median) dose of cells
administered (Hamshere 2015_IC; Hamshere 2015_IM; Heldman
2014_BMMNC; Heldman 2014_BM-MSC; Santoso 2014; Wang 2014).
The mean dose of bone marrow mononuclear cells administered
varied between 2 x 106 cells, in Perin 2011, and 8.4 x 108
cells, in Patila 2014, whilst bone marrow aspirate concentrate
was administered at a mean dose of 3.7 x 109 cells (Patel
2015). Mesenchymal progenitor cells were administered at mean
doses of between 5.0 x 106 cells, in Chen 2006, and 7.8 x 107
cells, in Mathiasen 2015, with one study administering 7.3 x 108
cardiopoietic cells (Bartunek 2012). Five studies that adminstered
CD34-positive cells gave mean doses of between 5.0 x 104 cells, in
Losordo 2007, and 5.6 x 107 cells, in Wang 2010, and included two
dose escalation studies comparing 5.0 x 104 cells, 1.0 x 105 cells, and
5.0 x 105 cells or 1.0 x 105 cells and 5.0 x 105 cells (Losordo 2007;
Losordo 2011). CD133-positive cells were administered at a median
dose of 5.1 x 106 cells, in Nasseri 2012, or at doses of between 2 and
3 x 107 cells (Jimenez-Quevedo 2011). The doses of ALDH-positive
cells averaged 2.96 x 106 cells (Perin 2012b). In the trial where bone
marrow mononuclear cells were compared to CPCs, the mean dose
of CPCs administered was between 2.9 x 106 cells, in Honold 2012,
and 2.2 x 107 cells (Assmus 2006).
Thirteen trials administered the treatment via a coronary artery
(intracoronarily (IC)) (Assmus 2006; Assmus 2013; Chen 2006;
Erbs 2005; Hamshere 2015_IC; Honold 2012; Hu 2011; Mozid
2014_IC; Patel 2015; Turan 2011; Wang 2009; Wang 2010; Yao
2008), whilst 24 trials delivered the treatment intramyocardially
(IM) (Bartunek 2012; Hamshere 2015_IM; Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Hendrikx 2006; Jimenez-Quevedo 2011;
Losordo 2007; Losordo 2011; Mathiasen 2015; Mozid 2014_IM;
Nasseri 2012; Patel 2005; Patila 2014; Perin 2011; Perin 2012a;
Perin 2012b; Pokushalov 2010; Santoso 2014; Trifunovic 2015; Tse
2007; Van Ramshorst 2009; Wang 2014; Wang 2015; Zhao 2008). Of
these 24 studies, 22 aided delivery of the treatment into the heart
muscle using electromechanical mapping of the heart. The other
two studies did not report whether the IM delivery of stem cells
was aided in any other way (Hendrikx 2006; Zhao 2008). One trial
included three treatment arms comparing IC and IM delivery of
stem cells with control (Ang 2008).
Apart from G-CSF, 17 studies administered co-interventions. In
nine studies, participants underwent coronary artery bypass graM
(CABG) (Ang 2008; Hendrikx 2006; Hu 2011; Nasseri 2012; Patel
2005; Patila 2014; Trifunovic 2015; Wang 2015; Zhao 2008), and
in seven studies, percutaneous coronary intervention (PCI) was
administered to all participants (Chen 2006; Erbs 2005; Turan 2011;
Wang 2009), or to a subset of participants (Assmus 2006; Honold
2012; Yao 2008). One study administered shockwave targeted to
the leM ventricular anterior wall at either high or low dose (Assmus
2013).
Twenty-five studies compared cell therapy with administration of
a placebo consisting of a cell-free solution, either a heparin saline
solution or a saline solution containing the participant's own serum
(Assmus 2013; Erbs 2005; Hamshere 2015_IC; Hamshere 2015_IM;
Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Hendrikx 2006;
Hu 2011; Losordo 2007; Losordo 2011; Mathiasen 2015; Mozid
2014_IC; Mozid 2014_IM; Nasseri 2012; Patila 2014; Perin 2012a;
Perin 2012b; Santoso 2014; Tse 2007; Van Ramshorst 2009; Wang
2010; Wang 2014; Wang 2015; Yao 2008; Zhao 2008); two further
studies used a simulated mock injection procedure for participants
in the control arm, but without administering a placebo solution
(Jimenez-Quevedo 2011; Perin 2011). The remaining 11 trials
compared treatment to no treatment (Ang 2008; Assmus 2006;
Bartunek 2012; Chen 2006; Honold 2012; Patel 2005; Patel 2015;
Pokushalov 2010; Trifunovic 2015; Turan 2011; Wang 2009).
Three studies included multiple comparisons involving two or three
intervention arms, including intracoronary versus intramyocardial
cell administration (Ang 2008), mononuclear cells versus circulating
progenitor cells (Assmus 2006), and high versus medium or low
(Losordo 2007), or high versus low cell dose (Losordo 2011).
We combined data for multiple intervention arms for the main
analyses, although we used individual intervention trial arms for
subgroup analyses where applicable. One three-arm trial was also
a cross-over study (Assmus 2006); we have included only data up to
the point of cross-over (three months) in this review.
One study described aortic cross-clamping during surgery with
clamp times exceeding 25 to 30 minutes (Hendrikx 2006). Aortic
cross-clamping isolates the systemic circulation during surgery
but causes ischaemia. Although increasing times of aortic cross-
clamping have been identified as a predictor of mortality, the eJect
of cross-clamping in this study was not as strong as might be
expected. This may be due to the fact that the cause of cardiac
damage is multifactorial, including coronary lesions.
All but one study published only in abstract form reported
the primary clinical outcome of mortality (Wang 2014). All but
three studies reported periprocedural adverse events (or lack of)
(Hamshere 2015_IC; Hamshere 2015_IM; Wang 2014), and a fourth
study reported adverse events for shockwave treatment but not
for cell therapy (Assmus 2013). See the Characteristics of included
studies tables for details of the included studies; see Table 3 for a
summary of the reporting of outcomes considered in this review.
Studies awaiting classification
Ten independent studies (12 references) met the eligibility criteria
for this review but reported insuJicient data for inclusion; these
studies are awaiting classification (see Characteristics of studies
awaiting classification).
Ongoing studies
We identified 28 ongoing trials described in five references and
31 ongoing trial records; see Characteristics of ongoing studies for
details.
Excluded studies
We excluded 54 studies (described by 70 references and 15 ongoing
trial records) from the review following full-text assessment
against the eligibility criteria (see Characteristics of excluded
studies tables). In summary, we excluded studies for the following
sequential reasons: 10 studies were of people with acute
myocardial infarction (AMI); 16 studies were single-arm trials; seven
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studies compared multiple interventions but with no control or
placebo arm; eight studies did not randomise participants to
treatment arm; two studies administered G-CSF to the intervention
arm but not the comparator group; one study measured outcomes
not relevant to this review; six studies were terminated or
withdrawn; one study included non-bone marrow-derived cells;
one study compared allogeneic cells with a control group; one
study was a literature review; and one study was performed in
animals.
Risk of bias in included studies
A summary of the risk of bias in individual studies is given below
and in Figure 2. Further details of our assessment of risk of bias
can been found in the Characteristics of included studies tables.
We considered only five trials to have a low risk of bias across
all domains (Jimenez-Quevedo 2011; Mathiasen 2015; Perin 2011;
Perin 2012a; Van Ramshorst 2009).
 
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
 
Allocation
Twenty-seven studies provided details of randomisation methods
with a low risk of bias from random sequence generation.
These methods included sequentially numbered, sealed envelopes
(Hendrikx 2006; Patila 2014; Van Ramshorst 2009), simple
randomisation table (Santoso 2014; Tse 2007), or randomisation
codes generated electronically (Assmus 2006; Assmus 2013;
Hamshere 2015_IC; Hamshere 2015_IM; Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Hu 2011; Mathiasen 2015; Mozid 2014_IC;
Mozid 2014_IM; Patel 2015; Perin 2012a; Perin 2012b; Pokushalov
2010; Zhao 2008), by a study statistician (Losordo 2007; Perin
2011), by picking a coloured ball (Patel 2005), or via a centralised
site-independent process (Bartunek 2012; Jimenez-Quevedo 2011;
Losordo 2011; Nasseri 2012). Of these, 15 studies described
appropriate methods of allocation concealment with a low risk
of bias (Assmus 2013; Bartunek 2012; Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Hendrikx 2006; Jimenez-Quevedo 2011;
Losordo 2011; Mathiasen 2015; Nasseri 2012; Patila 2014; Perin
2011; Perin 2012a; Santoso 2014; Tse 2007; Van Ramshorst 2009),
whilst in 12 studies allocation concealment was unclear (Assmus
2006; Hamshere 2015_IC; Hamshere 2015_IM; Hu 2011; Losordo
2007; Mozid 2014_IC; Mozid 2014_IM; Patel 2005; Patel 2015; Perin
2012b; Pokushalov 2010; Zhao 2008).
We found five trials in which no description was given as to
what methods were used to generate the random sequence to
be at unclear risk of selection bias (Ang 2008; Erbs 2005; Honold
2012; Trifunovic 2015; Turan 2011). The method of generation of
randomisation sequence was also not reported in six Chinese trials,
which we deemed to have a high risk of bias (Chen 2006; Wang 2009;
Wang 2010; Wang 2014; Wang 2015; Yao 2008).
Blinding
In 24 studies, participants randomised to the control group
received a placebo injection (Assmus 2013; Erbs 2005; Hamshere
2015_IC; Hamshere 2015_IM; Heldman 2014_BMMNC; Heldman
2014_BM-MSC; Hendrikx 2006; Hu 2011; Losordo 2007; Losordo
2011; Mathiasen 2015; Mozid 2014_IC; Mozid 2014_IM; Nasseri 2012;
Patila 2014; Perin 2012a; Perin 2012b; Santoso 2014; Tse 2007; Van
Ramshorst 2009; Wang 2010; Wang 2015; Yao 2008; Zhao 2008), with
all but one study reporting that the control group underwent bone
marrow aspiration (Mathiasen 2015); we judged these trials to be
at a low risk of performance bias. We deemed two additional trials
to have a low risk of performance bias, as although no placebo was
administered, participants in the control group underwent a sham
procedure (Jimenez-Quevedo 2011; Perin 2011).
We considered nine trials in which no placebo was administered
to have a high risk of performance bias (Ang 2008; Assmus 2006;
Bartunek 2012; Chen 2006; Honold 2012; Patel 2015; Pokushalov
2010; Trifunovic 2015; Turan 2011). Two trials were reported as
"double-blind" (Wang 2014), or as having blinded participants
(Patel 2005), but no details of a placebo were given; a third trial
reported no details of blinding (Wang 2009). We judged the risk of
performance bias in these trials to be unclear.
We assessed two trials as having a high risk of detection bias: one
was reported as an "open-label" trial with no details of blinding
given (Trifunovic 2015), and one trial reported that outcome
assessors were not blinded (Wang 2009). We judged two trials in
which which blinding of outcome assessors was not reported as
at unclear risk of detection bias (Chen 2006; Wang 2014). All other
trials reported the blinding of outcome assessors.
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Incomplete outcome data
One trial had a high risk of attrition bias (Bartunek 2012): 11
participants randomised to the cell therapy group were excluded
from the analyses as they did not receive the study intervention.
In the study report, these participants were analysed as part
of the control group (although in this review they have been
excluded). The risk of attrition bias was unclear in four studies in
which some participants were excluded from the analyses without
suJicient explanation (Ang 2008; Heldman 2014_BMMNC; Heldman
2014_BM-MSC; Honold 2012). We also attributed an unclear risk of
attrition bias to one study reported in abstract form only (Wang
2014). In all other trials, any withdrawals or losses to follow-up were
similar in both treatment arms with reasons for withdrawals fully
documented.
Selective reporting
We attributed a high risk of reporting bias to one study in which
results have only been published as a conference abstract (Wang
2014). Twenty-two trials were prospectively registered on a clinical
trial database. Of these, 13 studies reported all outcomes described
in the the trial protocol, with a low risk of reporting bias (Ang
2008; Assmus 2006; Assmus 2013; Hu 2011; Jimenez-Quevedo 2011;
Losordo 2011; Mathiasen 2015; Nasseri 2012; Patel 2015; Perin
2011; Perin 2012a; Perin 2012b; Van Ramshorst 2009), whilst in
seven studies, we observed some diJerences between outcomes
described in the study protocol and those reported. Specifically,
three studies reported results for additional outcomes (Heldman
2014_BMMNC; Heldman 2014_BM-MSC; Santoso 2014); two studies
were a pilot study report of secondary outcomes only (Mozid
2014_IC; Mozid 2014_IM); one study failed to report six-month
results as described in the protocol (Patila 2014); and in one
study, diJerent definitions of primary and secondary outcomes
were reported in the study protocol and the publication of results
(Bartunek 2012). We deemed the risk of reporting bias in these
seven studies to be unclear. For two trials reported in abstract form
only (Hamshere 2015_IC; Hamshere 2015_IM), we requested and
obtained data for all outcomes presented in the trial protocol from
the authors, therefore we judged these trials to be at low risk of
reporting bias.
We identified no prospectively registered trial protocol for the
remaining 15 trials, and although the results of all outcomes
described in the methods were reported, we judged the risk of
reporting bias to be unclear.
We identified no obvious asymmetry from a funnel plot for
mortality (Figure 3). In a regression test for asymmetry (Egger's
test), the model intercept was -0.02 (P = 0.90) at short-term follow-
up and -0.004 (P = 0.98) at long-term follow-up, with no evidence
of publication bias. However, of 28 identified ongoing trials, 11
trials (787 participants) were recorded as having been completed
or were due to have been completed in advance of our search date,
but we identified no publications for them and no study results
were posted on the trial database. We therefore cannot rule out the
possibility of publication bias.
 
Figure 3.   Funnel plot of comparison: 1 Stem cells versus no stem cells, outcome: 1.1 Mortality.
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Other potential sources of bias
Twenty-eight studies reported details of study funding or
sponsorship (Ang 2008; Assmus 2006; Assmus 2013; Bartunek
2012; Erbs 2005; Hamshere 2015_IC; Hamshere 2015_IM; Heldman
2014_BMMNC; Heldman 2014_BM-MSC; Hu 2011; Jimenez-
Quevedo 2011; Losordo 2007; Losordo 2011; Mathiasen 2015;
Mozid 2014_IC; Mozid 2014_IM; Nasseri 2012; Patel 2015; Patila
2014; Perin 2011; Perin 2012a; Perin 2012b; Santoso 2014; Tse
2007; Van Ramshorst 2009; Wang 2015; Yao 2008; Zhao 2008. The
majority of these studies were funded entirely by academic or
healthcare research grants, or both and received no commercial
sponsorship. Four studies acknowledged provision of equipment
(Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Losordo 2007;
Perin 2012a), and two studies acknowledged receipt of consultant
fees, from Biosense Webster, in Tse 2007, and Cook Medical
(Patel 2015). Four studies declared full commercial sponsorship:
from Aldagen (Perin 2012b), Baxter Healthcare (Losordo 2011),
Cardio3 BioSciences (Bartunek 2012), and Harvest Technologies
(Patel 2015), and nine studies declared partial commercial funding:
from Baxter Healthcare (Losordo 2007), Chugai Pharma UK and
the Cordis Corporation (Hamshere 2015_IC; Hamshere 2015_IM;
Mozid 2014_IC; Mozid 2014_IM), Miltenyi Biotec (Nasseri 2012), and
BioCardia (Heldman 2014_BMMNC; Heldman 2014_BM-MSC), and
an unrestricted grant from t2cure GmbH (Assmus 2013). We judged
all 13 studies that received some degree of commercial funding to
be at high risk of bias. The primary investigator in four included
trials is also an author of this review (Hamshere 2015_IC; Hamshere
2015_IM; Mozid 2014_IC; Mozid 2014_IM).
E>ects of interventions
See: Summary of findings for the main comparison Bone
marrow-derived cell therapy for people with chronic ischaemic
heart disease and congestive heart failure
An overview of results for the primary outcomes of mortality
and periprocedural adverse events, and for morbidity outcomes
(non-fatal MI, rehospitalisation for HF, arrhythmias, composite
major adverse clinical events) and LVEF measured by MRI is given
in Summary of findings for the main comparison. We excluded
quality of life and performance status outcomes since diJerent
measures are likely to be used for diJerent participant diagnoses,
and therefore fewer trials are likely to have reported each of these
outcomes.
In one study (Yao 2008), continuous measures were reported as
mean +/- standard deviation. However, visual inspection of the data
revealed that the standard deviations were considerably lower than
might be expected for all continuous outcomes. This study also
reported P values for statistical comparisons between the baseline
and follow-up data using paired t-tests. However, we could not
identify the reported significance values, either using the standard
deviations provided, or based on an assumption that the values
were in fact standard errors. We therefore could not verify or include
continuous data from this study.
Primary outcomes
Mortality
All but one study included mortality as an outcome (Wang 2014),
which was published in abstract form only (see Table 3; Table 4).
Of 33 studies that reported mortality rates during short-term follow-
up (< 12 months), 15 trials reported deaths (Ang 2008; Assmus 2006;
Assmus 2013; Hendrikx 2006; Hu 2011; Jimenez-Quevedo 2011;
Losordo 2011; Mathiasen 2015; Mozid 2014_IC; Mozid 2014_IM;
Nasseri 2012; Perin 2012a; Pokushalov 2010; Van Ramshorst 2009;
Zhao 2008), whilst the remaining 18 trials reported no deaths.
In all trials, over short-term follow-up, the mortality rate of 1.6%
(15/963) in participants who received cell therapy was lower than
that observed in participants who received no cells (4.0%, 27/674)
(risk ratio (RR) 0.48, 95% confidence interval (CI) 0.26 to 0.87;
participants = 1637; studies = 33; I2 = 0%) (Analysis 1.1). However, in
the subset of trials with a low risk of selection bias, the eJect of cell
therapy on short-term mortality was no longer seen (RR 0.69, 95%
CI 0.32 to 1.50; participants = 744; studies = 14; I2 = 0%) (Analysis
8.1). Similarly, no eJect of cell therapy on short-term mortality was
shown when studies with a high or unclear risk of performance bias
were excluded (RR 0.58, 95% CI 0.29 to 1.16; participants = 1216;
studies = 25; I2 = 0%) (Analysis 9.1). However, results appeared to be
robust to attrition bias (RR 0.48, 95% CI 0.26 to 0.89; participants =
1449; studies = 28; I2 = 0%) (Analysis 10.1).
Seven studies reported reasons for short-term mortality in
participants who had received cell therapy, which included
perforated oesophageal ulcer complicated by mediastinitis seven
days postoperatively (Hendrikx 2006), cardiogenic shock (Jimenez-
Quevedo 2011), death on day 158 shortly aMer surgery for intestinal
ischaemia (Mathiasen 2015), pump failure leading to death on
day 29 aMer therapy (Perin 2012a), myocardial ischaemia leading
to acute HF at 2.5 months (Van Ramshorst 2009), ventricular
fibrillation five hours postoperatively leading to death on day
three (Zhao 2008), and cerebral vessel accident during six-month
follow-up (Zhao 2008). Cause of death in one study was not
specified in detail but reported as "cardiac" in four participants
and "non-cardiac" in one participant (Assmus 2013). In participants
who did not receive cell therapy, reasons for short-term mortality
included multiple organ failure secondary to low cardiac output
syndrome (Hendrikx 2006), fatal MI at 3.5 months (Jimenez-
Quevedo 2011), death during injection (Losordo 2007), terminal
HF at day 182 (Mathiasen 2015), pneumonia, mediastinitis and
sepsis with death on day 22 (Nasseri 2012), candida sepsis on day
8 aMer leM ventricular failure (Nasseri 2012), and death reported
as "cardiac" (five participants) or "non-cardiac" (one participant)
(Assmus 2013).
Of the 21 studies reporting mortality over long-term follow-up (≥
12 months), 15 studies reported deaths (Assmus 2013; Bartunek
2012; Chen 2006; Erbs 2005; Heldman 2014_BM-MSC; Honold 2012;
Hu 2011; Losordo 2011; Nasseri 2012; Patel 2005; Patel 2015;
Pokushalov 2010; Santoso 2014; Trifunovic 2015; Tse 2007), with
a mortality rate of 4.8% (28/587) in participants who received cell
therapy compared with 15.4% (65/423) in those who received no
cells. Meta-analysis of all available trials showed that cell therapy
reduced the risk of long-term mortality (RR 0.38, 95% CI 0.25 to 0.58;
participants = 1010; studies = 21; I2 = 0%) (Analysis 1.1). Sensitivity
analyses restricted to those trials with a low risk of bias from
randomisation sequence generation and allocation concealment
showed that the reduced risk of mortality at long-term follow-up
in participants who received cell therapy was robust to selection
bias (RR 0.42, 95% CI 0.21 to 0.87; participants = 491; studies = 9;
I2 = 0%; low-quality evidence) (Analysis 8.1). Similarly, analysis of
the subset of trials that blinded participants and clinicians showed
that the eJect of cell therapy on long-term mortality was robust
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to performance bias (RR 0.43, 95% CI 0.21 to 0.86; participants =
624; studies = 13; I2 = 0%) (Analysis 9.1). The eJect of cell therapy
also remained when trials with a high or unclear risk of attrition
bias were excluded (RR 0.39, 95% CI 0.25 to 0.60; participants = 883;
studies = 17; I2 = 0%) (Analysis 10.1).
Eleven studies reported reasons for mortality at long-term follow-
up. In participants who received cell therapy, reported causes
of death were sepsis aMer elective cardiac transplant at 21
months (Bartunek 2012), lung cancer at seven months (Hu
2011), cerebrovascular haemorrhage at six years (Trifunovic 2015),
pulmonary malignancy at six years (Trifunovic 2015), HF or sudden
cardiac death, or both at 31 months (Nasseri 2012), cardiac
death on day 239 (Heldman 2014_BM-MSC), "sudden death" (Chen
2006), and death due to cardiac (three participants) or non-
cardiac causes (two participants) (Patel 2015). Reported deaths
in participants who did not receive cell therapy were due to
ventricular fibrillation, sudden death, and HF (two participants)
(Chen 2006), angina followed by sudden death secondary to AMI
(Erbs 2005), progressive HF (Honold 2012), AMI (Tse 2007), HF
deterioration (Bartunek 2012), sudden cardiac death (Bartunek
2012; Santoso 2014), systemic infection (Hu 2011), gastrointestinal
bleeding (Hu 2011), cardiac death on day 115 (Heldman 2014_BM-
MSC), HF and/or sudden cardiac death at 34 months (Nasseri
2012), "cardiac" death (Patel 2015), gastrointestinal bleeding from
carcinoma of the colon (Santoso 2014), and cardiac events in four
participants (Trifunovic 2015).
Subgroup analyses
Although primary analyses of mortality showed no evidence for
heterogeneity, values of I2 are known to be underestimated,
especially when there are few events or a limited number of studies
included in a meta-analysis (Huedo-Medina 2006; Ioannidis 2007).
We therefore performed prespecified subgroup analyses on the
primary outcome of mortality as described in the Methods section.
Tests for diJerences between subgroups revealed no diJerences
in mortality between treatment groups, either at short-term or
long-term follow-up when participants were grouped according
to cell dose (test for subgroup diJerences, short term: P = 0.23
(Analysis 2.1); long term: P = 0.29 (Analysis 2.2)), baseline cardiac
function (short term: P = 0.13 (Analysis 3.1); long term: P = 0.35
(Analysis 3.2)), route of cell administration (short term: P = 0.90
(Analysis 4.1); long term: P = 0.12 (Analysis 4.2)), cell type (short
term: P = 0.89 (Analysis 5.1); long term: P = 0.65 (Analysis 5.2)),
participant diagnosis (short term: P = 0.57 (Analysis 6.1); long term:
P = 0.29 (Analysis 6.2)), or use of co-interventions (short term: P
= 0.15 (Analysis 7.1); long term: P = 0.37 (Analysis 7.2)). Notably,
subgroup analysis by participant diagnosis revealed a lower risk
of long-term mortality associated with cell therapy in participants
irrespective of diagnosis: chronic ischaemic heart disease (CIHD)
(RR 0.52, 95% CI 0.27 to 0.99; participants = 389; studies = 9; I2 =
0%), HF secondary to IHD (RR 0.33, 95% CI 0.19 to 0.58; participants
= 401; studies = 9; I2 = 0%), and refractory angina (RR 0.11, 95%
CI 0.01 to 0.91; participants = 220; studies = 3; I2 = 0%) (Analysis
6.2), and irrespective of whether co-interventions were used (co-
interventions: RR 0.47, 95% CI 0.26 to 0.88; participants = 312;
studies = 6; I2 = 0%; no co-interventions: RR 0.32, 95% CI 0.19 to 0.56;
participants = 698; studies = 15; I2 = 0%) (Analysis 7.2).
Trial sequential analyses
In trial sequential analysis of long-term mortality, the cumulative Z-
curve crossed both the conventional threshold but not the adjusted
trial sequential monitoring boundary, which may be indicative of
an inflated type I error rate (see Figure 4). Furthermore, the existing
evidence, based on a total of 432 participants, falls considerably
short of the required information size of 1899, suggesting that the
apparent beneficial eJect of cell therapy on long-term mortality
based on the existing evidence lacks robustness.
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Figure 4.   Trial sequential analysis: Mortality at long-term follow-up (≥ 12 months). TSMB = trial sequential
monitoring boundary; horizontal red lines indicate conventional significance threshold.
 
Periprocedural adverse events
A summary of periprocedural adverse events in each study is
included in Table 5. All but three studies reported periprocedural
adverse events (or lack of) (Hamshere 2015_IC; Hamshere 2015_IM;
Wang 2014), and a fourth study reported adverse events for
shockwave treatment but not cell therapy (Assmus 2013).
Seven studies reported adverse events associated with the
administration of G-CSF. The most common reactions were bone
or muscular pain (Honold 2012; Jimenez-Quevedo 2011; Losordo
2011; Mozid 2014_IC; Mozid 2014_IM), headache (Erbs 2005; Honold
2012), and pyrexia (Erbs 2005; Mozid 2014_IC; Mozid 2014_IM).
Two studies reported increased frequency or severity of angina, or
both associated with G-CSF administration (Losordo 2007; Losordo
2011), and one study reported that two participants developed CHF
(Losordo 2011).
Reactions associated with bone marrow aspiration were rare:
only two studies reported participants with haematomas at the
bone marrow harvest site (Patel 2005; Patel 2015). Adverse events
during the mapping or injection procedure included ventricular
tachycardia in seven participants (three cell therapy (Bartunek
2012; Mathiasen 2015; Perin 2012a), three placebo (Losordo
2007; Perin 2012b), one unknown (Mozid 2014_IM)); ventricular
fibrillation in one control participant (Perin 2012b); atrial fibrillation
in one participant (Mozid 2014_IM); and the development of
transient complete heart block periprocedure requiring temporary
pacing only in one participant (Mozid 2014_IM).
Three cell therapy participants experienced transient pulmonary
oedema during injection of cells (Chen 2006); a thrombus
was observed in one participant on mapping catheter tip as
removed (Losordo 2011); and two participants experienced visual
disturbances: one reported double vision and dizziness during the
injection procedure (Mathiasen 2015), and one participant with
pre-existing ophthalmic migraines experienced blurred vision aMer
the intervention (Bartunek 2012). Two participants experienced
a myocardial perforation: one with haemothorax (successfully
treated) (Losordo 2011), and one resulting in cardiac tamponade
followed by death (Losordo 2011). One participant experienced
a limited retrograde catheter-related dissection of the abdominal
aorta (Perin 2012a).
Serious early postoperative adverse events were rare. In the
cell therapy group, one participant died on postoperative day 7
from a perforated oesophageal ulcer complicated my mediastinitis
(Hendrikx 2006); one participant developed refractory ventricular
fibrillation five hours postoperatively and died on day 3 (Zhao
2008); and one death was reported within 30 days of treatment
(cause of death not reported but not considered to be related
to cell therapy) (Ang 2008). Postprocedural transient leM bundle
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branch block (resolved in 24 hours) was seen in one participant
(Perin 2011); in-hospital MI occurred in one participant (Assmus
2006); one participant suJered a stroke on postoperative day
12 (Mathiasen 2015); and one participant developed ventricular
fibrillation on day 5 but was successfully resuscitated (Zhao
2008). In the control group, one participant died on day 5 from
multiorgan failure secondary to low cardiac output syndrome
(Hendrikx 2006); one participant died on day 8 aMer developing
Candida sepsis following leM ventricular failure (Nasseri 2012); one
participant died on day 22, no reason given (Nasseri 2012); one
participant died from suspected acute leM ventricular failure six
days aMer discharge (Mozid 2014_IM); and one participant died
within 30 days of treatment with no reason given (Ang 2008).
Postprocedural transient leM bundle branch block (resolved in 24
hours) was seen in one participant (Perin 2011); one participant
developed a pericardial eJusion two days aMer the procedure,
and pericardiocentesis was performed (Van Ramshorst 2009); and
ventricular arrhythmia was detected during monitoring in one
participant (Assmus 2006). Transient fever but no sepsis occurred
in one control participant (Perin 2011). One study reported
that two participants (unclear which treatment arm) experienced
neurological complications but recovered (Hu 2011).
We made no formal comparisons of periprocedural adverse events
due to diJerences in the definition and reporting of adverse events
between studies. We acknowledge that there may be a risk of
reporting bias for this outcome, as few studies clearly defined
periprocedural events.
Secondary outcomes
Morbidity
(a) Non-fatal myocardial infarction
Twenty studies reported infarction as an outcome at short-term
follow-up (see Table 3; Table 4) (Ang 2008; Assmus 2006; Hamshere
2015_IC; Hamshere 2015_IM; Honold 2012; Hu 2011; Jimenez-
Quevedo 2011; Losordo 2007; Mathiasen 2015; Mozid 2014_IC;
Mozid 2014_IM; Perin 2011; Perin 2012a; Perin 2012b; Tse 2007; Van
Ramshorst 2009; Wang 2009; Wang 2010; Yao 2008; Zhao 2008).
There was no evidence of a diJerence in the risk of non-fatal MI
between participants who received cell therapy and those who did
not (RR 0.60, 95% CI 0.17 to 2.15; participants = 881; studies = 20;
I2 = 0%) (Analysis 1.2), consistent with findings when studies were
restricted to those with a low risk of selection bias (RR 0.50, 95% CI
0.05 to 4.58; participants = 288; studies = 6; I2 = 0%) (Analysis 8.2).
Of the nine studies reporting infarction as an outcome at long-term
follow-up (Assmus 2013; Hamshere 2015_IC; Hamshere 2015_IM;
Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Honold 2012;
Losordo 2007; Losordo 2011; Patila 2014), meta-analysis showed
that cell therapy was associated with a lower risk of non-fatal MI
at long-term follow-up (RR 0.40, 95% CI 0.17 to 0.93; participants =
461; studies = 9; I2 = 0%) (Analysis 1.2). Sensitivity analysis showed
that the eJect of cell therapy was robust to risk of selection bias (RR
0.38, 95% CI 0.15 to 0.97; participants = 345; studies = 5; I2 = 0%)
(Analysis 8.2).
Trial sequential analysis
Trial sequential analysis applied to non-fatal MI at long-term
follow-up (Figure 5) showed that the cumulative Z-curve crossed
conventional significance thresholds but not the adjusted trial
sequential monitoring boundaries, which may be indicative of
an inflated type I error rate. Furthermore, the existing evidence
falls considerably short of the required information size of 2383,
suggesting that the apparent beneficial eJect of cell therapy on
non-fatal MI at long-term follow-up based on existing evidence
lacks robustness.
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Figure 5.   Trial sequential analysis: Non-fatal myocardial infarction at long-term follow-up (≥ 12 months). TSMB =
trial sequential monitoring boundary; horizontal red lines indicate conventional significance threshold.
 
(b) Rehospitalisation due to heart failure
Ten studies reported hospital readmission for HF at short-term
follow-up (see Table 3; Table 4) (Assmus 2006; Assmus 2013;
Hamshere 2015_IC; Hamshere 2015_IM; Honold 2012; Mathiasen
2015; Mozid 2014_IC; Mozid 2014_IM; Perin 2012a; Yao 2008).
In participants who received cell therapy, 21/297 (7.0%) were
rehospitalised for HF compared with 22/185 (11.9%) who did not,
with no evidence of a diJerence between groups (RR 0.63, 95% CI
0.36 to 1.12; participants = 482; studies = 10; I2 = 0%) (Analysis 1.3).
Of the 10 studies reporting this outcome at long-term follow-
up (Assmus 2013; Bartunek 2012; Hamshere 2015_IC; Hamshere
2015_IM; Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Honold
2012; Losordo 2011; Patel 2015; Patila 2014), incidences of
rehospitalisation occurred in 21/302 participants (7.0%) who
received cell therapy compared with 26/193 (13.5%) who did not
(RR 0.62, 95% CI 0.36 to 1.04; participants = 495; studies = 10; I2 =
0%) (Analysis 1.3).
In trials with a low risk of selection bias, sensitivity analysis showed
no eJect of cell therapy on rehospitalisation due to heart failure at
either short-term (RR 0.65, 95% CI 0.32 to 1.32; participants = 234;
studies = 3; I2 = 15%) or long-term follow-up (RR 0.63, 95% CI 0.36
to 1.09; participants = 375; studies = 6; I2 = 0%) (Analysis 8.3).
Trial sequential analysis
Trial sequential analysis applied to rehospitalisation due to HF
at long-term follow-up (Figure 6) showed that the cumulative Z-
curve crossed neither the conventional significance thresholds nor
the adjusted trial sequential monitoring boundaries. The existing
evidence from 345 participants falls considerably short of the
required information size of 1193 to draw reliable conclusions
about the eJect of cell therapy on rehospitalisation for HF.
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Figure 6.   Trial sequential analysis: Rehospitalisation due to heart failure at long-term follow-up (≥ 12 months).
TSMB = trial sequential monitoring boundary; horizontal red lines indicate conventional significance threshold.
 
(c) Incidence of arrhythmias
Twenty-four studies reported arrhythmias as an outcome at short-
term follow-up (see Table 3; Table 4), although one study reported
arrhythmias as the number of cumulative events rather than
incidence (Wang 2015), and another included nine participants in
the control group who were randomised to the treatment arm
(Bartunek 2012), and was therefore excluded from the analysis. In
trials that defined arrhythmia, the majority reported ventricular
arrhythmia (ventricular tachycardia or ventricular fibrillation); two
trials reported incidences of atrial fibrillation (Hu 2011; Mathiasen
2015). In the remaining 22 studies, 11 reported incidences of
arrhythmias (Assmus 2006; Hamshere 2015_IC; Hamshere 2015_IM;
Jimenez-Quevedo 2011; Losordo 2007; Mathiasen 2015; Mozid
2014_IM; Perin 2012b; Santoso 2014; Wang 2010; Zhao 2008).
Arrhythmias occurred in 11/550 participants (2.0%) who received
cell therapy compared with 12/409 (2.9%) who did not (RR 0.70, 95%
CI 0.33 to 1.45; participants = 959; studies = 22; I2 = 0%) (Analysis
1.4). In trials with a low risk of selection bias, sensitivity analysis
showed no eJect of cell therapy on incidence of arrhythmias at
short-term follow-up (RR 0.77, 95% CI 0.18 to 3.21; participants =
224; studies = 6; I2 = 0%) (Analysis 8.4).
Of five studies reporting incidences of arrhythmia at long-term
follow-up (Assmus 2013; Hamshere 2015_IC; Hamshere 2015_IM;
Hu 2011; Losordo 2007), 8/199 participants (4.0%) in the cell
therapy group experienced arrhythmias compared with 16/164
(9.8%) in the control group (RR 0.46, 95% CI 0.22 to 0.97;
participants = 363; studies = 7; I2 = 0%) (Analysis 1.4); this finding
occurred in one study with a low risk of selection bias (RR 0.42, 95%
CI 0.18 to 0.99; participants = 82; studies = 1; I2 = 0%) (Analysis 8.3).
Trial sequential analysis
Trial sequential analysis applied to incidence of arrhythmias at
long-term follow-up (Figure 7) showed that the cumulative Z-curve
from a single trial with a low risk of selection bias crossed the
conventional significance thresholds but not the adjusted trial
sequential monitoring boundaries. The evidence from this single
trial of 82 participants falls considerably short of the required
information size of 461 to draw reliable conclusions about the eJect
of cell therapy on incidence of arrhythmias.
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Figure 7.   Trial sequential analysis: Arrhythmias at long-term follow-up (≥ 12 months). TSMB = trial sequential
monitoring boundary; horizontal red lines indicate conventional significance threshold.
 
(d) Composite measure of mortality, non-fatal MI, and
rehospitalisation for HF
Nine studies reported composite measures of major adverse
clinical events, defined here as mortality, non-fatal MI, and
rehospitalisation for HF (see Table 3; Table 4), of which
seven reported the composite of mortality, non-fatal MI, and
rehospitalisation for HF (Assmus 2006; Assmus 2013; Hamshere
2015_IC; Hamshere 2015_IM; Heldman 2014_BMMNC; Heldman
2014_BM-MSC; Hu 2011; Mozid 2014_IC; Mozid 2014_IM). One
study defined composite major adverse clinical events (MACE)
as cardiovascular death, non-fatal MI, ischaemic stroke, need for
revascularisation, and procedure-related complications (Jimenez-
Quevedo 2011), and another reported the composite of death,
MI, urgent revascularisation, worsening HF, and acute coronary
syndrome (Losordo 2011); we excluded these studies from
analyses. There was no evidence of a diJerence between treatment
arms at either short-term (RR 0.51, 95% CI 0.18 to 1.42; participants
= 288; studies = 8; I2 = 0%) or long-term follow-up (RR 0.68, 95% CI
0.41 to 1.12; participants = 201; studies = 5; I2 = 0%) (Analysis 1.5).
These findings were consistent with those from sensitivity analyses
of studies with a low risk of selection bias at long-term follow-up
(RR 0.64, 95% CI 0.38 to 1.08; participants = 141; studies = 3; I2 = 0%)
(Analysis 8.5). No studies at low risk of selection bias reported this
outcome.
Trial sequential analysis
Trial sequential analysis applied to the composite measure of MACE
at long-term follow-up (Figure 8) showed that the cumulative Z-
curve crossed neither the conventional significance thresholds nor
the adjusted trial sequential monitoring boundaries. The existing
evidence from 141 participants falls considerably short of the
required information size of 431 to draw reliable conclusions about
the eJect of cell therapy on rehospitalisation for HF.
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Figure 8.   Trial sequential analysis: Composite MACE at long-term follow-up (≥ 12 months). TSMB = trial sequential
monitoring boundary; horizontal red lines indicate conventional significance threshold.
 
Quality of life
(a) Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Seven studies reported MLHFQ scores as a measure of quality of
life (Bartunek 2012; Heldman 2014_BMMNC; Heldman 2014_BM-
MSC; Nasseri 2012; Patel 2015; Perin 2011; Pokushalov 2010),
although one study reported results graphically as the percentage
of participants showing improvement or deterioration (Bartunek
2012), another reported summary results only (Patel 2015), and in
a third study, it was unclear whether mean or median values were
reported (Nasseri 2012) (see Table 3; Table 6).
At short-term follow-up, two studies reported MLHFQ values at
endpoint (Perin 2011; Pokushalov 2010), and two reported mean
change from baseline values (Heldman 2014_BMMNC; Heldman
2014_BM-MSC). Combined analysis showed that quality of life
measured by the MLHFQ was higher in participants who had
received cell therapy than in those who had not (mean diJerence
(MD) -18.96, 95% CI -31.97 to -5.94; participants = 197; studies
= 4; I2 = 68%) (Analysis 1.6). All but one of these studies also
reported MLHFQ at long-term follow-up (Perin 2011), but there
was insuJicient evidence to show that the diJerence observed at
short-term follow-up was maintained over long-term follow-up (MD
-17.80, 95% CI -39.87 to 4.26; participants = 151; studies = 3; I2 = 93%)
(Analysis 1.7).
The number of studies reporting this outcome precluded further
investigation of the substantial observed heterogeneity at both
short-term and long-term follow-up through subgroup analyses.
(b) Seattle Angina Questionnaire (SAQ)
Five studies reported quality of life measured by the SAQ (Jimenez-
Quevedo 2011; Losordo 2007; Losordo 2011; Mathiasen 2015;
Van Ramshorst 2009), although two studies presented results
graphically (Losordo 2007; Mathiasen 2015), and one reported
median values (Jimenez-Quevedo 2011) (see Table 3; Table 6).
Evidence from two studies that reported mean change from
baseline values found a higher quality of life associated with cell
therapy (MD 9.34, 95% CI 2.62 to 16.07; participants = 211; studies
= 2; I2 = 16%) (Analysis 1.8) (Losordo 2011; Van Ramshorst 2009). A
single study reporting mean change in SAQ values from baseline at
long-term follow-up found no diJerence between treatment arms
(Losordo 2011).
Other reported measures of quality of life included the 36-Item
Short Form Health Survey (SF-36) physical and mental scores (Perin
2011), SF-36 (eight dimensions) (Patila 2014), and the Kansas City
Cardiomyopathy Questionnaire (Mathiasen 2015).
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(c) Angina frequency
Seven studies measured angina frequency, which has been shown
to be strongly associated with health-related quality of life
outcomes in people with chronic heart disease (Arnold 2014), and
can therefore be considered a surrogate measure of quality of life.
Angina frequency was reported as the number of episodes per
day (Pokushalov 2010), per week (Losordo 2007; Losordo 2011;
Mathiasen 2015; Wang 2009; Wang 2010), or per month (Jimenez-
Quevedo 2011) (see Table 3; Table 6). One study reported median
values at endpoint (Jimenez-Quevedo 2011), and another reported
results graphically (Mathiasen 2015). Meta-analysis of four studies
reporting angina frequency at follow-up showed that participants
who received cell therapy experienced fewer episodes of angina
per week than the control group (MD -6.96, 95% CI -11.99 to
-1.93; participants = 396; studies = 4; I2 = 44%), although we
observed no diJerence in three studies reporting mean change
from baseline values (MD -1.77, 95% CI -14.61 to 11.08; participants
= 167; studies = 3; I2 = 76%) (Analysis 1.9). There were insuJicient
studies to explore potential reasons for the substantial observed
heterogeneity through subgroup analyses.
Only one study reported angina frequency at long-term follow-
up; this study reported fewer angina episodes associated with cell
therapy (Pokushalov 2010).
Performance status
(a) New York Heart Association (NYHA) classification
Twenty-three studies reported NYHA classification at short-term
follow-up (see Table 3; Table 6). Two studies reported results
graphically (Bartunek 2012; Mathiasen 2015); one study reported
the number of participants in NYHA class III or IV (Ang 2008);
two studies only reported summary results (Santoso 2014; Wang
2014); and in one study there was only one participant in the
control group (Mozid 2014_IC); we have therefore excluded these
studies from meta-analysis. In 17 studies reporting mean NYHA
class at short-term follow-up (Assmus 2006; Assmus 2013; Chen
2006; Hamshere 2015_IC; Hamshere 2015_IM; Honold 2012; Mozid
2014_IM; Nasseri 2012; Patel 2005; Perin 2011; Perin 2012a;
Perin 2012b; Pokushalov 2010; Trifunovic 2015; Tse 2007; Turan
2011; Zhao 2008), combined meta-analysis of mean change from
baseline and endpoint values showed cell therapy to be associated
with a lower NYHA classification (MD -0.44, 95% CI -0.84 to
-0.05; participants = 741; studies = 17; I2 = 97%). This was also
demonstrated in the analysis of endpoint values only (MD -0.42,
95% CI -0.84 to -0.00; participants = 658; studies = 16; I2 = 97%),
but not in four studies that reported mean change from baseline
values (MD -0.56, 95% CI -1.49 to 0.36; participants = 239; studies
= 4; I2 = 95%) (Analysis 1.10). Sensitivity analysis omitting those
studies with a high or unclear risk of selection bias indicated that
the diJerence in NYHA class between treatment groups in favour of
cell therapy may be subject to selection bias (MD -0.26, 95% CI -0.59
to 0.07; participants = 277; studies = 5; I2 = 79%) (Analysis 8.6).
Eleven studies reported NYHA class at long-term follow-up,
although two studies only reported the number of participants
who improved or worsened (Heldman 2014_BMMNC; Heldman
2014_BM-MSC). Meta-analysis of nine studies showed that a lower
NYHA class was associated with cell therapy (MD -0.81, 95% CI -1.23
to -0.39; participants = 346; studies = 9; I2 = 93%) (Analysis 1.11)
(Chen 2006; Hamshere 2015_IC; Hamshere 2015_IM; Honold 2012;
Patel 2015; Patila 2014; Pokushalov 2010; Trifunovic 2015; Turan
2011). This improvement in NYHA class associated with cell therapy
was demonstrated in one study with a low risk of selection bias (MD
-2.20, 95% CI -2.70 to -1.70; participants = 39; studies = 1; I2 = 0%)
(Analysis 8.7).
Subgroup analyses
In view of the high level of heterogeneity across studies measuring
NYHA class at both short- and long-term follow-up, we conducted
exploratory subgroup analyses. At short-term follow-up, tests for
subgroup diJerences showed no diJerence in the eJect of cell
therapy on NYHA class between studies grouped according to cell
dose (P = 0.69) (Analysis 2.3), baseline cardiac function (P = 0.86)
(Analysis 3.3), route of cell administration (P = 0.75) (Analysis 4.3),
cell type (P = 0.95) (Analysis 5.3), participant diagnosis (P = 0.91)
(Analysis 6.3), or use of co-interventions (P = 0.62) (Analysis 7.3).
Visual inspection of forest plots revealed two study outliers at short-
term follow-up (Patel 2005; Pokushalov 2010); however, substantial
heterogeneity (I2 = 80%) remained when these two studies were
omitted from the analysis.
At long-term follow-up, the number of studies reporting NYHA
classification precluded subgroup analysis by cell dose or cell type.
We observed no diJerences from tests of subgroup diJerences
when participants were grouped according to baseline cardiac
function (P = 0.51) (Analysis 3.4), route of cell administration (P
= 0.21) (Analysis 4.4), or participant diagnosis (P = 0.41) (Analysis
6.4). Of note, the mean NYHA class was significantly lower both in
participants with CIHD (MD -0.66, 95% CI -0.91 to -0.42; participants
= 105; studies = 3; I2 = 0%) and participants with HF secondary to
IHD (MD -0.92, 95% CI -1.47 to -0.37; participants = 241; studies = 6;
I2 = 93%) when compared to the respective control groups (Analysis
6.4).
Trial sequential analysis
Trial sequential analysis of NYHA class at short-term follow-up
showed that the cumulative Z-curve did not cross the threshold
for significance despite exceeding the information size of 522
participants required to detect a mean diJerence in NYHA class of 1.
However, the required information size to detect a small diJerence
would be substantially higher (e.g. 2025 participants would be
required to detect a mean diJerence in NYHA class between groups
of 0.5). Over long-term follow-up, the cumulative Z-curve crossed
the adjusted trials sequential monitoring boundaries, although the
required information size of 380 to detect a diJerence between
groups of 1 was not reached. Further evidence is required before
this result can been considered robust.
(b) Canadian Cardiovascular Society (CCS) angina classification
Twenty studies reported CCS angina classification (see Table
3; Table 6). However, mean values at follow-up or as change
from baseline values were not available in seven studies: one
reported median values (Jimenez-Quevedo 2011); one reported
results graphically (Mathiasen 2015); one reported the number of
participants with CCS class greater than 2 (Ang 2008); one reported
the percentage of participants who changed CCS class (Losordo
2011); two reported results pooled across multiple trial arms (Mozid
2014_IC; Mozid 2014_IM); and one reported summary results only
(Patel 2015).
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At short-term follow-up, combined meta-analysis of 13 studies
found no diJerence in mean CCS class at follow-up between
participants who had received cell therapy and those who had not
(MD -0.43, 95% CI -0.92 to 0.06; participants = 608; studies = 13; I2
= 94%) (Analysis 1.12). Similarly, there was no diJerence between
treatment arms at long-term follow-up in three studies (all of which
reported mean CCS class at endpoint) (MD -0.58, 95% CI -2.04 to
0.88; participants = 142; studies = 3; I2 = 99%) (Analysis 1.13).
Subgroup analyses
We observed substantial heterogeneity at short- and long-term
follow-up. Exploratory subgroup analyses of CCS class at short-
term follow-up revealed no diJerences between studies grouped
according to cell dose (P = 0.64) (Analysis 2.4), baseline cardiac
function (P = 0.82) (Analysis 3.5), route of cell administration (P =
0.50) (Analysis 4.5), cell type (P = 0.79) (Analysis 5.4), or participant
diagnosis (P = 0.27) (Analysis 6.5). Although we observed no
diJerence in CCS class between treatment groups at short-term
follow-up overall, subgroup analysis showed that in five studies of
refractory angina (Losordo 2007; Tse 2007; Van Ramshorst 2009;
Wang 2009; Wang 2010), a higher CCS class was observed in
participants who had received cell therapy compared with those
who had not (MD -0.78, 95% CI -1.44 to -0.11; participants = 245;
studies = 5; I2 = 74%) (Analysis 6.5).
(c) Exercise capacity
Twenty-one studies reported exercise capacity (see Table 3; Table
6). Measures of exercise capacity included an exercise tolerance test
measured as metabolic equivalents, in Chen 2006 and Jimenez-
Quevedo 2011, or as time in minutes (Losordo 2007; Wang 2009;
Wang 2010), seconds (Losordo 2011), log seconds (Tse 2007),
or unspecified (Jimenez-Quevedo 2011); a bicycle test measured
as maximum O2 update, in Erbs 2005 and Honold 2012, or by
workload (Van Ramshorst 2009); and by a five-minute, in Wang
2014, or six-minute walk test measured as distance (Bartunek
2012; Heldman 2014_BMMNC; Heldman 2014_BM-MSC; Hu 2011;
Mathiasen 2015; Nasseri 2012; Perin 2012a; Pokushalov 2010;
Santoso 2014; Trifunovic 2015). All but five trials reported either
mean values at follow-up or mean change from baseline values.
One study reported data as median values (Jimenez-Quevedo
2011); one reported results graphically (Mathiasen 2015); two
reported summary descriptive results only (Santoso 2014; Wang
2014); and in one study it was unclear whether mean or median
values were reported (Nasseri 2012).
We have described results for exercise capacity using the
standardised mean diJerence, allowing outcomes of diJerent
measurement scales to be combined in a meta-analysis. This
method of analysis does not allow mean change from baseline and
endpoint data to be combined, and we therefore have presented
separate analyses of mean change from baseline and endpoint
data.
In 11 studies that reported exercise capacity as mean values at
follow-up (Bartunek 2012; Chen 2006; Erbs 2005; Honold 2012; Hu
2011; Perin 2012a; Pokushalov 2010; Trifunovic 2015; Tse 2007;
Van Ramshorst 2009; Wang 2010), participants who received cell
therapy showed a greater exercise capacity than those who did
not (standardised mean diJerence (SMD) 0.56, 95% CI 0.19 to 0.93;
participants = 563; studies = 11; I2 = 75%). Similarly, meta-analysis
of nine studies with mean change from baseline values showed
greater performance levels associated with cell therapy (SMD 0.33,
95% CI 0.05 to 0.61; participants = 535; studies = 9; I2 = 52%)
(Analysis 1.14) (Heldman 2014_BMMNC; Heldman 2014_BM-MSC;
Hu 2011; Losordo 2007; Losordo 2011; Tse 2007; Van Ramshorst
2009; Wang 2009; Wang 2010).
We also saw the diJerence in performance levels between
participants who had received cell therapy and the control group
at long-term follow-up, in five studies that reported mean values at
endpoint (SMD 1.14, 95% CI 0.04 to 2.25; participants = 178; studies
= 5; I2 = 89%) (Chen 2006; Erbs 2005; Honold 2012; Pokushalov
2010; Trifunovic 2015), and in three studies with mean change
from baseline values (SMD 0.34, 95% CI 0.07 to 0.62; participants =
227; studies = 3; I2 = 0%) (Analysis 1.15) (Heldman 2014_BMMNC;
Heldman 2014_BM-MSC; Losordo 2011).
Subgroup analyses
We investigated the substantial observed heterogeneity at short-
term follow-up through exploratory subgroup analysis. Tests for
subgroup diJerences found no diJerences in measures of exercise
performance at follow-up between studies grouped according to
cell dose (P = 0.72) (Analysis 2.5), baseline cardiac function (P = 0.31)
(Analysis 3.6), route of cell administration (P = 0.21) (Analysis 4.6), or
participant diagnosis (P = 0.40) (Analysis 6.6). The number of studies
reporting exercise capacity was insuJicient to perform subgroup
analysis according to the type of cells infused.
Le ventricular ejection fraction (LVEF)
In order to limit possible heterogeneity, we have subgrouped trials
reporting LVEF by the method of measurement. Results are shown
in forest plots for the combined analyses of mean change from
baseline and endpoint values as well as separately, as described
in the Methods section. Baseline LVEF values for each trial are
given in Table 7 for each method of measurement reported. One
study measured LVEF by either single-photon emission computed
tomography (SPECT) or echocardiography and was therefore
excluded from the analyses (Patel 2005).
(a) Magnetic resonance imaging (MRI)
FiMeen studies reported LVEF measured by MRI at short-term
follow-up, although two studies reported summary results only
(Hamshere 2015_IC; Hamshere 2015_IM), and we excluded one
study, Yao 2008, from analysis due to data inconsistencies as
described above (Ang 2008; Assmus 2013; Erbs 2005; Hendrikx 2006;
Honold 2012; Hu 2011; Mathiasen 2015; Nasseri 2012; Santoso 2014;
Tse 2007; Van Ramshorst 2009; Wang 2014). Meta-analysis showed
that cell therapy was associated with improved LVEF at short-term
follow-up (MD 2.92, 95% CI 1.03 to 4.82; participants = 439; studies
= 12; I2 = 64%). This was also demonstrated in separate analyses of
nine studies with mean change from baseline data (MD 4.05, 95% CI
2.55 to 5.55; participants = 308; studies = 9; I2 = 33%), but not in 10
studies that reported mean LVEF values at follow-up (MD 3.01, 95%
CI -0.05 to 6.07; participants = 352; studies = 10; I2 = 59%) (Analysis
1.16).
Sensitivity analysis excluding studies with a high or unclear
risk of selection bias confirmed the improved LVEF observed in
participants who had received cell therapy compared with those
who had not (MD 2.92, 95% CI 0.67 to 5.17; participants = 249;
studies = 7; I2 = 63%) (Analysis 8.8).
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Six studies reported LVEF measured by MRI at long-term follow-up,
although two reported results graphically (Heldman 2014_BMMNC;
Heldman 2014_BM-MSC). Meta-analysis of the remaining four
studies showed cell therapy to be associated with higher LVEF
values (combined analysis: MD 4.38, 95% CI 0.82 to 7.93;
participants = 110; studies = 4; I2 = 17%) (Erbs 2005; Honold 2012; Hu
2011; Patila 2014), although this was not demonstrated in separate
analyses of mean LVEF at endpoint and mean change from baseline
values (Analysis 1.17), and was not found in one study with a low
risk of selection bias (MD -1.60, 95% CI -8.70 to 5.50; participants =
25; studies = 1; I2 = 0%) (Analysis 8.9).
Subgroup analyses
In view of the substantial heterogeneity observed at short-term
follow-up, we performed exploratory subgroup analyses. Tests for
subgroup diJerences revealed no diJerences between subgroups
defined by cell dose (P = 0.08) (Analysis 2.6), baseline cardiac
function (P = 0.38) (Analysis 3.7), route of cell administration (P =
0.46) (Analysis 4.7), cell type (P = 0.95) (Analysis 6.7), or use of co-
interventions (P = 0.42) (Analysis 7.4).
Trial sequential analysis
Trial sequential analysis of LVEF at long-term follow-up based on
evidence from a single trial with low risk of selection bias showed
that the cumulative Z-curve crossed neither the conventional
threshold nor the adjusted trials sequential monitoring boundaries
(Figure 9). The available evidence from 25 participants falls
considerably short of the required information size of 322
participants.
 
Figure 9.   Trial sequential analysis: LeO ventricular ejection fraction measured by MRI at long-term follow-up (≥
12 months). TSMB = trial sequential monitoring boundary; horizontal red lines indicate conventional significance
threshold.
 
(b) Echocardiography
Twelve studies reported LVEF measured by echocardiography
at short-term follow-up, although one reported median values
(Jimenez-Quevedo 2011), and two studies, Nasseri 2012 and
Patel 2015, reported results graphically (Bartunek 2012; Jimenez-
Quevedo 2011; Nasseri 2012; Patel 2015; Perin 2011; Perin 2012a;
Perin 2012b; Pokushalov 2010; Trifunovic 2015; Van Ramshorst
2009; Wang 2015; Zhao 2008). Meta-analysis of nine studies showed
cell therapy to be associated with LVEF (combined analysis: MD
5.71, 95% CI 4.29 to 7.13; participants = 470; studies = 9; I2 = 28%)
(Analysis 1.18). This was also observed in separate analyses of mean
LVEF values at follow-up (MD 5.16, 95% CI 2.87 to 7.44; participants
= 388; studies = 8; I2 = 64%) and mean change from baseline values
(MD 3.47, 95% CI 1.59 to 5.34; participants = 161; studies = 3; I2 = 0%)
(Analysis 1.18).
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At long-term follow-up, five studies reported LVEF measured by
echocardiography, although one reported results graphically (Patel
2015), and one did not report any measures of variation (Patel
2005). Meta-analysis of three studies showed that the improvement
in LVEF associated with cell therapy extended to long-term follow-
up (MD 7.96, 95% CI 6.39 to 9.54; participants = 154; studies = 3; I2
= 6%) (Analysis 1.19).
(c) Single-photon emission computed tomography (SPECT)
Five studies reported LVEF measured by SPECT at short-term
follow-up (Chen 2006; Jimenez-Quevedo 2011; Patel 2015; Perin
2011; Van Ramshorst 2009), although one study reported median
values (Jimenez-Quevedo 2011). Meta-analysis of the remaining
four studies showed cell therapy to be associated with improved
LVEF when measured by SPECT (MD 5.22, 95% CI 2.60 to 7.85;
participants = 145; studies = 4; I2 = 0%) (Analysis 1.20). Only two
studies reported LVEF measured by SPECT at long-term follow-
up (Chen 2006; Van Ramshorst 2009): we observed no diJerence
in LVEF between participants who had received cell therapy and
controls (MD 0.28, 95% CI -2.48 to 3.03; participants = 88; studies =
2; I2 = 0%) (Analysis 1.21).
(d) LeO ventricular (LV) angiography
Seven studies reported LVEF measured by LV angiography (Assmus
2006; Assmus 2013; Honold 2012; Jimenez-Quevedo 2011; Perin
2011; Perin 2012b; Turan 2011), although one study reported
median values (Jimenez-Quevedo 2011). Meta-analysis showed
that cell therapy improved LVEF at short-term follow-up (MD 2.00,
95% CI 0.53 to 3.46; participants = 250; studies = 6; I2 = 33%). We
observed this result in separate analysis of both mean LVEF at
follow-up (MD 3.18, 95% CI 0.39 to 5.97; participants = 265; studies =
6; I2 = 7%) and mean change in LVEF from baseline (MD 1.72, 95% CI
0.50 to 2.95; participants = 181; studies = 4; I2 = 18%) (Analysis 1.22).
Only one study reported LVEF measured by LV angiography at long-
term follow-up (Turan 2011): this study found higher LVEF values at
long-term follow-up in participants who had received cell therapy
compared with those who had not (MD 6.00, 95% CI 0.81 to 11.19;
participants = 49; studies = 1; I2 = 0%) (Analysis 1.23).
D I S C U S S I O N
Mortality rates following MI have decreased in recent years due to
state-of-the-art revascularisation procedures and optimal medical
care (Hartwell 2005). Consequently, the incidence of HF secondary
to IHD is increasing. RCTs involving the administration of cell
therapies as adjunctive therapies to revascularisation for patients
with chronic IHD and HF have developed over the last 15 years
(for review see Afzal 2015; Fisher 2014; Jeevanantham 2012). We
have updated the original version of this review (Fisher 2014),
incorporating data from 15 new trials to increase the quality of
available evidence and draw more robust conclusions.
Trials compared cell therapy to no cells (control or placebo) and
administered standard primary interventions consisting of medical
therapy only or medical therapy and revascularisation (PCI or
CABG) or shockwave. Included participants were diagnosed with
chronic IHD, generally including chronic symptoms of ischaemia
that persisted for at least 30 days since the last MI, HF secondary
to IHD, or refractory angina. Cell type and dose administered and
route of administration are detailed in Table 2. All trials reported
short-term follow-up of between three and six months, and 17 trials
reported follow-up of 12 months and longer. We defined mortality
and adverse events as primary outcomes and morbidity, composite
measure of mortality, non-fatal MI, and rehospitalisation for HF;
performance status; health-related quality of life measures; and
LVEF as secondary outcomes.
Summary of main results
This update includes 38 RCTs with a total of 1907 participants
(1114 cell therapy, 793 no cell therapy). We have drawn the main
conclusions of this version of the review from those studies with a
low risk of selection bias; they are as follows.
1. We found low-quality evidence that cell therapy reduces the
risk of all-cause mortality at long-term follow-up in people with
CIHD, HF secondary to IHD, and refractory angina. However,
trial sequential analysis showed that this result may be subject
to an inflated type I error rate. The available evidence has not
met the overall number of participants required to draw robust
conclusions (the information size); a further large trial of around
1899 participants is required before this result can be considered
robust and conclusive.
2. Periprocedural adverse events were infrequent, and serious
adverse events were rare.
3. Analysis of morbidity produced low-quality evidence that
cell therapy may reduce the risk of both non-fatal MI and
arrhythmias at long-term follow-up. However, as for mortality,
these findings may be subject to an inflated type I error rate. Trial
sequential analysis showed that the available evidence has not
met the number of participants (2383 for non-fatal MI and 461 for
arrhythmias) required to draw robust conclusions. The current
evidence does not support a beneficial eJect of cell therapy on
rehospitalisation for HF or morbidity defined as a composite
measure of mortality, non-fatal MI, and rehospitalisation for HF.
4. In studies with a low risk of selection bias, we found no eJect of
cell therapy for either mortality or morbidity outcomes at short-
term follow-up.
5. Cell therapy is associated with an improvement in LVEF
measured by MRI at short-term follow-up, but not at long-term
follow-up. Trial sequential analysis of LVEF at long-term follow-
up showed that the evidence is not robust, as the meta-analysis
did not reach the required information size of 322 participants.
6. Quality of life and performance status outcomes were
infrequently reported, oMen with diJerent measures used for
diJerent participant diagnoses, and with limitations in reporting
(e.g. diJerent summary measures reported, results reported
graphically), minimising the data available for formal meta-
analysis, therefore results should be interpreted with caution.
7. Subgroup analyses found no evidence for diJerences in the
eJect of cell therapy between subgroups when studies were
grouped according to cell dose, route of cell administration, cell
type, participant diagnosis, or use of co-interventions. Notably,
cell therapy was eJective on long-term mortality irrespective
of participant diagnosis (CIHD, HF secondary to IHD, refractory
angina) and irrespective of whether co-interventions were used.
Overall completeness and applicability of evidence
We found low-quality evidence that cell therapy is associated with
a reduced risk of mortality over long-term follow-up, although
more evidence is required before this finding can been considered
robust. The number of studies reporting morbidity outcomes was
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generally low. There was evidence that cell therapy reduces the
risk of non-fatal MI and arrhythmias during long-term follow-up,
but meta-analyses were underpowered due to the number of
included studies (and participants), as well as the low number of
observed events. Composite measures of mortality and morbidity
are infrequently reported, despite the increased statistical power
obtained from such measures.
We detected no diJerences between diJerent cell types, doses, or
routes of administration. This contrasts with a recent systematic
review that found evidence of greater eJicacy associated with
more than 50 million cells in a combined analysis of trials
of both AMI and IHD (Afzal 2015), although it should be said
that the subgroup analyses performed here were considerably
underpowered to detect subgroup eJects, with few studies in each
group. Notably, subgroup analysis by participant diagnosis showed
that cell therapy appears to reduce the risk of long-term mortality
in people with the following diagnoses: chronic IHD, HF secondary
to IHD, and refractory angina, and is also eJective both in people
who are given co-interventions (PCI, CABG, or shockwave) and in
those who receive no such co-interventions.
We have included trial sequential analysis in the present update
of this systematic review. We acknowledge that the assumption of
a relative risk reduction in mortality of 35% is arbitrary and only
compares with the eJect size associated with revascularisation
using PCI. This may indeed seem optimistic, considering the
expectation that cell therapies may have a more modest eJect.
However, if we consider a relative risk reduction in mortality of 25%
as an acceptable clinically relevant eJect (Yusuf 2002), clearly the
required meta-analysis information size will increase.
This systematic review and meta-analysis aimed at evaluating
the clinical eJect of cell therapies in IHD and HF because these
outcomes are more likely to be free of risk of performance bias.
However, this review also reports changes in LVEF as a surrogate for
heart function. Although a great majority of included trials report
LVEF as an outcome measure, its use as surrogate for heart function
is questionable in the setting of heart failure. Changes in LV volumes
(LVESV and LVEDV) may be more meaningful measures to assess
the eJect of these therapies on heart function. Future trials and
future updates of this systematic review should report changes in
LV volume in preference to LVEF.
Quality of the evidence
Although the summary of findings is promising, we deemed the
quality of the available evidence as low for all outcomes. The
included studies were small: only three studies included more
than 100 participants in total, and the majority were considerably
smaller, leading to a risk of small-study bias and spuriously
inflated eJect sizes. Furthermore, where pooling of trial results was
possible, meta-analytical findings were based on small numbers
of events (e.g. 93 deaths out of 1010 participants, 22 non-fatal
MIs out of 461 participants, 47 rehospitalisations for HF out of
495 participants over long-term follow-up), with the composite
measure of mortality, non-fatal MI, and rehospitalisation for HF
reported in only five studies.
We have conducted subgroup analyses as defined in the protocol
of the review. However, results from subgroup analyses should be
considered with caution, as the number of studies in each subgroup
and the number of events were reduced even further.
The GRADE approach aims to evaluate the quality of the evidence
for each major outcome. It also takes into consideration results
from the trial sequential analyses (see Summary of findings for the
main comparison). For the outcomes of mortality, morbidity, and
LVEF, we deemed the quality of the evidence as generally low due to
imprecision, as the required information size had not been reached.
We further downgraded quality due to the risk of bias from a lack of
blinding, a high attrition rate, and commercial sponsorship of some
studies.
Overall, the results of this systematic review should be interpreted
with caution, as it appears that for most outcomes the meta-
analyses were underpowered to detect the expected treatment
eJect. Larger, adequately powered studies are needed to confirm
these results. As suggested by trial sequential analyses, a further
trial of approximately 700 participants with long-term mortality
data may be needed to reach the required information size of 1899
participants based on a relative risk reduction of 35%. Similarly, the
number of participants with long-term follow-up of LVEF measured
by MRI (currently only 25 participants in one study with a low risk
of selection bias) falls considerably short of the information size
required to detect an improvement in LVEF of 4% (322 participants).
Potential biases in the review process
This systematic review was based on a comprehensive search
strategy. We undertook formal tests for publication bias for
the primary outcome of mortality and found no evidence of
asymmetry, but we accept that the possibility of publication and
reporting bias cannot be ruled out completely. There was a risk of
small-study bias, as all included studies were small (as discussed
above), which could lead to spurious inflated results.
Risk of bias was present in the included trials, as summarised
in Figure 2. We assessed the robustness of results for outcomes
that showed evidence of a beneficial eJect of cell therapy through
sensitivity analyses, restricting analyses to those studies with a low
risk of selection, performance, and attrition bias. Our summary of
findings and conclusions are based only on those studies with a low
risk of selection bias.
The reporting and analysis of multiple outcomes considered in
this review could increase the likelihood of observing type I
(false positives) or type II (false negatives) random errors due to
multiple testing. In order to reduce the chance of observing random
errors, we have applied trial sequential analysis to major outcome
measures and have reported the information size required to give
robust and conclusive findings.
Finally, although the review authors have limited the selection
of studies to those administering bone marrow-derived cells,
variation remains in the type of cells utilised among the various
clinical trials (e.g. bone marrow mononuclear cells, bone marrow
mesenchymal stromal cells), which may be a potential source of
bias.
Agreements and disagreements with other studies or
reviews
In this Cochrane review update we have focused on the outcomes
of mortality and periprocedural adverse events. Our results suggest
that cell therapy may reduce the risk of long-term mortality
in people with IHD and congestive HF and that there are no
major adverse events associated with the treatment. This is in
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agreement with the original version of the review, Fisher 2014,
and other previous systematic reviews (Fisher 2015b; Wen 2011;
Xu 2014). However, our data is discordant with results obtained
in systematic reviews and meta-analysis where cell therapies have
been administered to people with AMI (de Jong 2014; Delewi 2014;
Fisher 2015a; Gyöngyösi 2015). This suggests that people with
chronic IHD or HF, or both may benefit more from such treatments
than AMI patients.
The eJicacy of cell therapy in reducing LVEF is consistent with
the findings of a recent review of 11 systematic reviews of cell
therapy, which reported that the mean diJerence in change from
baseline LVEF between treatment groups (random-eJects) ranged
from 2.6% to 5.6% across the included systematic reviews, and that
meta-analytical results were broadly similar irrespective of how
follow-up was defined and which patient population was studied
(Harvey 2015). However, in a recent trial sequential analysis of HF
trials (Fisher 2016), no diJerence in LVEF was observed between
treatment arms, and the available evidence led us to reject the
hypothesis of a mean diJerence in change from baseline LVEF of 4%
between treatment arms in this patient cohort.
These apparently conflicting results are certainly intriguing. Could
the eJect of cell therapy be reduced in the presence of co-
interventions? Of the eight trials included in the trial sequential
analysis of LVEF (Fisher 2016), all but two (accounting for over
70% of the analysed participants) administered co-interventions
(CABG: 4 trials, PCI: 1 trial, shockwave: 1 trial), whereas in the
current review, these co-interventions were only administered in 11
out of 39 studies (28.5% of participants). Meta-analyses of people
with HF with no option for revascularisation and refractory angina
have reported significantly improved LVEF associated with cell
therapy (Fisher 2013; Khan 2016). Here, we found no evidence for
subgroup diJerences in the eJect of cell therapy on outcomes
between studies that administered co-interventions and those that
did not, although the subgroup analyses here were considerably
underpowered, and it is worth noting that the estimated eJect size
for both mortality and LVEF was smaller in participants who had
received co-interventions. We regard this possible explanation as
hypothesis-generating, and potential diJerences in the eJicacy of
cell therapy between studies that administer co-interventions and
those that do not should be considered in the design of future trials
and systematic reviews.
Limitations of the review
Our conclusions are based on evidence that is of low quality due
to the lack of precision for the majority of reported outcomes and
possible small-study bias, as well as risk of bias due to lack of
blinding, high levels of attrition, and commercially funded trials.
The information size derived from trial sequential analyses for key
outcomes showed that meta-analyses are currently considerably
underpowered, and further large randomised trials are needed
before findings can been considered to be robust and conclusive.
The aim of this review was to assess the eJect of cell therapies on
main clinical outcomes, because these are less likely to be aJected
by risk of performance bias (blinding). We have assessed all-cause
mortality. Our predefined outcomes did not include cardiac-related
mortality; this will be considered as an outcome in future updates
of the review.
We have summarised any periprocedural adverse events reported
in individual studies descriptively and concluded that serious
periprocedural adverse events are rare. A formal assessment
of cumulative adverse events related to cell therapy, both
periprocedurally and over long-term follow-up, is beyond the scope
of this review.
In summary, the results of this review may be clinically relevant,
but the evidence for the reduction in the number of deaths
with cell treatment relative to controls needs to be confirmed
in larger clinical trials. To this end, the first Phase II/III and
Phase III clinical trials for severe IHD (NCT00362388; NCT00747708;
NCT01727063), HF (NCT01768702), and refractory angina are
currently ongoing (NCT01508910). Research should also focus on a
better understanding of the best types of cells to use and why some
people respond to treatment and others do not.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review and meta-analysis provides evidence for a reduction
in all-cause mortality at both short- and long-term follow-up (12
months and over) when cell therapy is administered to people
with chronic ischaemic heart disease or congestive heart failure.
However, we deemed the quality of evidence as low, and results
need to be confirmed in larger, appropriately powered randomised
clinical trials with appropriate generation and concealment of
allocation sequence and blinding of participants, clinicians, and
outcome assessors before cell-based treatment for these patients
can be developed as clinical practice.
Implications for research
The results of this systematic review should be confirmed in
large, adequately powered randomised controlled trials assessing
the clinical relevance of the treatment. All future clinical trials
should be prospectively registered and conducted appropriately
to minimise the risk of bias in all domains (e.g. appropriate
methods of randomisation, blinding, and reporting). It is important
that published trials include all variables and outcomes and that
deviations from the protocol are well documented and reported.
Outcome measures should be standardised (e.g. quality of life
outcome measures). In order to detect meaningful eJects on
mortality or hospitalisation due to worsening heart failure, trials
should include follow-up of longer than six months, as 20% of
people diagnosed with heart failure die in the first year, and up to
50% in the five years following diagnosis (Go 2014). These meta-
analyses are underpowered to detect clinically relevant treatment
eJects on mortality (e.g. relative risk reduction in mortality lower
than 35%). Currently, the number of participants included in these
meta-analyses falls considerably short of the required information
size, suggesting that double or triple that number may be required.
Future research should also focus on a better understanding of the
cell therapies used (e.g. mononuclear cells, circulating progenitor
cells, mesenchymal stem cells, or haematopoietic progenitor cells)
and their mechanism of action, particularly in the presence of
co-interventions. Additionally, patient-dependent outcomes need
to be more thoroughly investigated to ascertain and distinguish
between responders and non-responders, and to be able to tailor
autologous, allogeneic, or modified cell therapies to each patient
group.
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Characteristics of included studies [ordered by study ID]
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: British Heart Foundation (grant PG04050)
Study setting: Leicester, UK
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: Intramyocardial BMSC (IM): 21; intracoronary BMSC
(IC): 21; Controls: 21
Number (N) of participants analysed (primary outcome) in each arm: 17 IM, 16 IC, 15 C
Participants Description: Chronic IHD (aged 18 to 80 years; presence of at least 1 chronic, irreversible myocardial
scar; elective cardiac surgery).
Ang 2008 
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Age distribution (SD) in each arm: IM: 64.7 (8.7) years; IC: 62.1 (8.7) years; Controls: 61.3 (8.3) years.
Sex (% male) in each arm: IM: 71.4%; IC: 90.5%; Controls: 90%.
Number of diseased vessels: n/r (multivessel).
Time from symptom onset to initial treatment: At least 6 weeks.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arms: BMSC-IM or BMSC-IC
Type of stem cells: Mononuclear cells administered intramyocardially (IM) or intracoronarily (IC)
Summary of stem cell isolation and type and route of delivery: Bone marrow aspiration followed by den-
sity gradient centrifugation to enrich in mononuclear cells, infused via the coronary artery (IC) or inject-
ed into the myocardium (IM)
Dose of stem cells: 8.6 (5.6) x 107 cells (IM); 11.5 (73) x 107 cells (IC)
Timing of stem cell procedure: Concomitant to CABG
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; no placebo or sham procedure)
Co-intervention: CABG
Outcomes Primary outcome:
Improvement in contractile function of treated scar areas at 6 months.
Secondary outcomes:
Global leM ventricular functions at 6 months (infarct size, global end-diastolic volume and end-systolic
volume, and improvement in stroke volume and LVEF).
Additional outcomes: Postoperative complications, troponin I levels within 24 hours of surgery, and
clinical evaluation (assessment of functional status and adverse events).
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was described as randomised, but the method of randomisation was
not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was administered; participants and clinicians were not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Physicians treating the participants during the postoperative period and the
investigators performing the examinations and interpreting the results were
blind to which group participants had been assigned.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 2 controls (2/21) were excluded from analysis of mortality and morbidity (1x
withdrawal before surgery, 1x deemed unsuitable for follow-up). 12 partici-
pants were lost to follow-up (4 IM, 4 IC, 3 controls), and 2 died within 30 days.
MRI was performed in 33 participants, of which 4 were “not suitable for accu-
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rate analysis”. However, MRI results were only reported for 25 participants;
this discrepancy was unexplained.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00560742) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Ang 2008  (Continued)
 
 
Methods Type of study: Cross-over RCT
Type of publication: Full paper
Source of funding: Supported by the Deutsche ForschungsGemeinschaft (FOR 501-1: WA 146/2-1), Fon-
dation Leducq Transatlantic Network of Excellence for Cardiac Regeneration, European Union Euro-
pean Vascular Genomics Network (LSHM-CT-2003-503254), and Alfried Krupp StiMung.
Study setting: Frankfurt, Germany
Number of centres: 1
Length of follow-up: 3 months
Number (N) of participants randomised to each arm: BMSC: 28; CPC: 24; Controls: 23
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 24; CPC: 19, Controls: 18
Participants Description: Chronic IHD (aged 18 to 80 years; MI at least 3 months previously; well-demarcated region
of leM ventricular dysfunction and a patent infarct-related artery).
Age distribution in each arm: BMSC: 59 ± 12 years; CPC: 54 ± 12 years; Controls: 61 ± 9 years.
Sex (% male) in each arm: BMSC: 89%; CPC: 79%; Controls: 100%.
Number of diseased vessels: BMSC: 1 (n = 7), 2 (n = 13), 3 (n = 8); CPC: 1 (n = 7), 2 (n = 4), 3 (n = 12); Con-
trols: 1 (n = 2), 2 (n = 9), 3 (n = 12).
Time from symptom onset to initial treatment: Previous MI at least 3 months earlier. 100% participants
with previous MI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC or CPC
Type of stem cells: Mononuclear cells or circulating progenitor cells
Summary of stem cell isolation and type and route of delivery: BMSC: 50 mL of bone marrow aspirate was
obtained under local anaesthesia on the morning of cell transplantation. Mononuclear cells were iso-
lated by Ficoll-gradient centrifugation. CPC: Mononuclear cell fraction was isolated by Ficoll-gradient
centrifugation of 270 mL of venous blood and cultured for 3 days ex vivo. Cells were delivered intra-
coronarily in both arms of the trial.
Dose of stem cells: BMSC arm: 2.05 ± 1.1 x 108 mononuclear cells. On average less than 1% were CD34-
positive cells. CPC arm: 2.2 ± 1.1 x 107 mononuclear cells. No measure of CD34-positive cells in this frac-
tion.
Timing of stem cell procedure: At least 3 months after last MI. In some cases concomitant PCI.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; no placebo or sham procedure)
Co-intervention: Standard medical therapy; PCI (in 27% of participants)
Outcomes Primary outcome:
Change in global leM ventricular function (measured by quantitative leM ventricular angiography).
Secondary outcomes:
1. Quantitative parameters of regional leM ventricular function of the target area
2. Changes in leM ventricular volumes
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3. Functional status as assessed by NYHA classification
4. Event-free survival (defined as freedom from death, MI, stroke, or rehospitalisation for worsening HF)
after 4 months' follow-up
Outcome assessment points: Baseline and 3 months.
Method(s) of outcome measurement: LV angiography and MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed using computerised simple random allocation
with known N. No blockwise randomisation was performed.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was administered; participants and clinicians were not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quantitative analysis of angiograms and MRI images was performed by an in-
vestigator who was blinded to the individual participant's treatment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants were included in the analysis of mortality and morbidity. 14
participants (4x cell therapy, 5x CPC, 5x controls) were excluded from MRI/an-
giography and functional status at follow-up, with reasons given for all exclu-
sions.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00289822) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Assmus 2006  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper; abstract (long-term follow-up)
Source of funding: Supported by an unrestricted grant to the Goethe University Frankfurt from t2cure
GmbH.
Study setting: Langen, Germany
Number of centres: 1
Length of follow-up: 45.7 (17) months
Number (N) of participants randomised to each arm: BMSC: 43 (22 LD (low-dose shockwave), 21 HD
(high-dose shockwave)); Controls: 39 (20 LD, 19 HD)
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 41 (21 LD, 20 HD); Controls:
38 (19 LD, 19 HD)
Participants Description: Chronic ischaemic HF (aged 18 to 80 years; anterior MI occurring 3 months or more prior
to inclusion and stable chronic postinfarction HF defined by LVEF less than 50% or symptoms of NYHA
class II or greater; a patent vessel supplying the target region).
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Age distribution in each arm: BMSC: 65 (12) (LD), 58 (11) (HD); Controls: 60 (10) (LD), 63 (10) (HD).
Sex (% male) in each arm: BMSC: 77% (LD), 86% (HD); Controls: 80% (LD), 90% (HD).
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: Not reported.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL of bone marrow was aspirated in-
to heparin-containing syringes from the iliac crest under local anaesthesia. Mononuclear cells were iso-
lated and enriched with the use of Ficoll-Hypaque centrifugation procedures. The cell suspension con-
sisted of a heterogeneous cell population including hematopoietic, mesenchymal, and other progen-
itor cells. The cells were suspended in 10 mL of X-VIVO 10 medium, including 2 mL of the participant's
own serum.
Dose of stem cells: 123 (69) x 106 (HD), 150 (77) x 106 (LD).
Timing of stem cell procedure: 24 hours following shockwave.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; 10 mL of X-VIVO 10 medium, including 2 mL of the partici-
pant's own serum).
Co-intervention: Shockwave (HD or LD)
Outcomes Primary outcome:
Improvement in global LVEF on quantitative LV angiography at 4 months' follow-up.
Secondary outcomes:
1. Global LV volumes, regional LV function, and late enhancement volume measured by MRI at 4 months
and 1 year
2. NYHA class at 4 months
3. NT BNP levels at 4 months
4. Major adverse clinical events (death, model of death, rehospitalisation for worsening HF, recurrent MI,
ventricular tachycardia, revascularisation, and stroke) at 4 months
5. Quality of life at 4 months
Outcome assessment points: Baseline, 4 months, and mean 45.7 (17) months (clinical outcomes only).
Method(s) of outcome measurement: LV angiography; MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed by a simple random allocation using a comput-
er list with known N. No blockwise randomisation was performed.
Allocation concealment
(selection bias)
Low risk Randomisation codes were generated at the cell-processing centre for the en-
tire study cohort.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The trial was reported as double-blind. All participants underwent BM aspi-
ration, and the control group received a placebo. Participants were blinded;
blinding of clinicians was not specifically reported.
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Investigators were blinded for the intracoronary infusion of the study medica-
tion.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity. All participants were included in angiography analyses on an inten-
tion-to-treat basis. MRI was performed in a subset of participants (15 cell ther-
apy and 12 controls).
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00326989) were reported.
Other bias High risk Supported by an unrestricted grant from t2cure GmbH. No other sources of
bias were reported or identified.
Assmus 2013  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Cardio3 BioSciences
Study setting: Belgium, Serbia, Switzerland
Number of centres: 9 (Belgium, Serbia, Switzerland)
Length of follow-up: 2 years
Number (N) of participants randomised to each arm: BMSC: 32; Controls: 15
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 21; Controls: 15
Participants Description: IHD (aged 18 to 75 years; stable HF population with a history of MI; baseline LVEF 15% to
40%; ischaemic event at least 2 months prior to recruitment; optimally managed and revascularised).
Age distribution in each arm: BMSC: 55.3 (SE 10.4) years; Controls: 58.7 (SE 8.2) years
Sex (% male) in each arm: BMSC: 90.5%; Controls: 86.7%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: time from infarction to cell delivery, mean 1540 (range
192 to 7515) days.
Statistically significant baseline imbalances between the groups? None
Interventions Intervention arm: BMSC
Type of stem cells: Cardiopoietic cells (mesenchymal stem cells)
Summary of stem cell isolation and type and route of delivery: Human BM was harvested from the iliac
crest, cultured at 37°C/5% CO2 in 175 cm2 flasks to purify MSCs. After 24 h, nonadherent BM and cellular
debris were discarded, and adherent MSCs were washed with PBS solution. A 1-to-1 passage was per-
formed to dissociate colony-forming units and allow for expansion for up to 6 days in a culture medium
supplemented with 5% human pooled platelet lysate media to generate a monolayer whereby 50 x 106
cells were obtained. Lineage specification was achieved by MSC exposure to a cardiogenic cocktail reg-
imen triggering expression and nuclear translocation of cardiac transcription factors while maintain-
ing clonal proliferation. Passage P1 marked the start of cardiogenic cocktail treatment in which cells
were cultured for 5 days in 5% platelet lysate-supplemented high glucose medium containing cardio-
genic growth factors (TGF-b, BMP-4, Activin A, FGF-2, cardiotrophin, a-thrombin, diaminopyrimidine).
Cell density was 4000 cells/cm2 during MSC culture and 1500 cells/cm2 during cardiopoietic induction.
Passage P2/P3 marked the end of the cardiogenic cocktail treatment followed by expansion to yield
600 to 1200 x 106 cells. Harvest involved trypsinisation and concentration in a preservation solution.
Cells were centrally manufactured in a GMP facility. Cells packaged for transportation were transplant-
ed within 72 h of derivation.
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Dose of stem cells: mean 733 x 106 (range 605 x 1168 x 106) cells
Timing of stem cell procedure: BM harvest - 24 hrs - (P0) (up to 6 days) - P1 (5 days cell culture) - 4 to 6
weeks.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; no placebo or sham procedure)
Co-intervention: Standard medical therapy
Outcomes Primary outcome:
Changes in LVEF at 6 months
Note: Main study publication reports primary endpoint as feasibility and safety at 2-year follow-up (Bar-
tunek 2012).
Secondary outcomes:
1. 6-min walking distance (6 months, 1 and 2 years)
2. Quality of life (6 months, 1 and 2 years)
3. All-cause mortality (at each follow-up)
4. Cardiovascular events (at each follow-up)
Note: Main study publication reports secondary endpoints as including cardiac structure and function
(Bartunek 2012).
Outcome assessment points: Baseline, 6 months, and 2 years (clinical outcomes only).
Method(s) of outcome measurement: Echocardiography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was conducted through a site-independent, centralised
process after exclusion of participants that did not meet the inclusion criteria.
Allocation concealment
(selection bias)
Low risk Allocation concealment was not fully described, but randomisation was con-
ducted in a site-independent manner through a centralised process.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was administered; neither participants nor clinicians were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk An independent core laboratory masked to study arm assignment and
chronology of clinical evaluation provided data analysis.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 11 participants in the cell therapy group were excluded from analysis (2x clin-
ical inclusion criteira not met; 2x BM inclusion criteria not met; 5x cell release
inclusion criteria not met; 2x cell growth inclusion criteria not met). In prima-
ry analyses described in the paper, these participants were analysed as part of
the control group (although they are excluded from analysis in the results of
this review). All other randomised participants were included in all analyses.
Selective reporting (re-
porting bias)
Unclear risk The study protocol (NCT00810238) defined the primary outcome as change in
LVEF at 6 months, whereas the study publication defined the primary outcome
as feasibility and safety at 2 years. Follow-up of exercise capacity and quality
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of life at 1 and 2 years was also defined as an outcome according to the trial
protocol but was not reported. All other outcomes described in the trial proto-
col were reported in results.
Other bias High risk This study received commercial funding from Cardio3 BioSciences, although
the authors reported that they had no relationships relevant to the contents of
the paper to disclose. No other sources of bias were reported or identified.
Bartunek 2012  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported
Study setting: China
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 24; Controls: 24
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 22; Controls: 23
Participants Description: Severe ischaemic HF (isolated, chronic, total, or subtotal occluded LAD due to previous an-
terior wall infarction untreated by either thrombolysis or primary PCI; reversible perfusion defect de-
tectable by SPECT; LVEF < 40%).
Age distribution in each arm: BMSC: 59.3 ± 6.8 years; Controls: 57.8 ± 7.2 years.
Sex (% male) in each arm: BMSC: 88%; Controls: 92%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: 14 days following successful PCI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mesenchymal stem cells
Summary of stem cell isolation and type and route of delivery: 60 mL of autologous bone marrow were
aspirated under local anaesthesia from the ilium of all participants during the morning of the 8th day
after the PCI procedure and then cultured for 7 days. BM mesenchymal stem cells were harvested and
washed 3 to 4 times with heparinised saline. 2 hours before transplantation, the stem cell suspension
was mixed with heparin, filtered, and prepared for implantation. Cell viability was > 92%.
Dose of stem cells: 5 x 106 cells
Timing of stem cell procedure: 14 days following successful PCI and 7 days after bone marrow aspira-
tion.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no placebo).
Co-intervention: PCI
Outcomes Primary outcome:
None reported.
Secondary outcomes:
Reversible defects, metabolic equivalents, exercise, LVEF, NYHA, mortality.
Outcome assessment points: Baseline and 12 months.
Method(s) of outcome measurement: SPECT
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was used; neither participants nor clinicians were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding of outcome assessors was not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 cell therapy participants and 1 control were excluded from all analyses due
to failed PCI. All remaining participants were included in the analysis of mor-
tality and morbidity; all surviving participants were included in the analysis of
LVEF, NYHA class, and exercise tolerance at follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Chen 2006  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported by Heart Center Leipzig GmbH, University of Leipzig.
Study setting: Leipzig, Germany
Number of centres: 1
Length of follow-up: 15 months
Number (N) of participants randomised to each arm: BMSC: 14; Controls: 14
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 12; Controls: 11
Participants Description: Chronic total artery occlusion with clinical signs of myocardial ischaemia and local wall
motion abnormalities.
Age distribution in each arm: BMSC: 63 ± 7 years; Controls: 61 ± 9 years.
Sex (% male) in each arm: BMSC: 71%; Controls: 86%.
Number of diseased vessels: BMSC: 1 (n = 8), 2 (n = 4), 3 (n = 2); Control arm: 1 (n = 6), 2 (n = 5), 3 (n = 3).
Time from symptom onset to initial treatment: Complete total obstruction defined as an obstruction of a
native coronary artery for more than 30 days with no luminal continuity and with TIMI flow grade 0 or 1.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Circulating progenitor cells
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Summary of stem cell isolation and type and route of delivery: All participants subcutaneously injected
twice a day with filgrastim (G-CSF, 300 mcg) over 4 days to increase the amount of CPC in the blood. At
day 4, 400 mL of venous blood were collected from all participants, MNC were purified and ex vivo-cul-
tured for 4 days in endothelial-specific medium to select CPC. MNC were isolated from 400 mL of ve-
nous blood by density gradient centrifugation (Histopaque-1077). Immediately after isolation, total
MNC were plated on gelatin-coated cell culture flasks with a cell density of 1 x 106 cells/cm2. Cells were
maintained for 4 days in endothelial basal medium supplemented with EGM SingleQuots and 10% hu-
man serum, collected from each individual participant. Additionally, the cell culture medium was sup-
plemented with ascorbic acid (final concentration 75 ng/mL) and hydrocortisone (0.2 mcg/mL). After 4
days of culture, non-adherent cells were removed by a thorough washing with PBS, and the adherent
cells were detached with trypsin/EDTA. The collected cells were washed twice with PBS containing 2
mmol/L EDTA and resuspended in a final volume of 20 mL physiological sodium chloride supplement-
ed with 10% autologous participant serum. Cells were administered intracoronarily.
Dose of stem cells: 69 ± 14 x 106 CPC (range 22 x 106 to 200 x 106).
Timing of stem cell procedure: 10 ± 1 days following successful recanalisation.
G-CSF details: 300 mg of G-CSF administered for 4 days to all participants.
Comparator arm: G-CSF + placebo (BM aspiration; cell-free serum solution).
Co-intervention: PCI
Outcomes Primary outcomes:
LV function
Secondary outcomes:
Assessment of coronary endothelial function, myocardial viability (number of myocardial segments
with hibernation), regional wall motion, LV mass (myocardial mass; infarct size). Clinical outcomes,
restenosis, coronary endothelium function, myocardial viability, number of hibernating segments in
myocardium.
Outcome assessment points: Baseline, 3 and 15 months.
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was described as randomised, but the method of randomisation was
not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk G-CSF was administered and blood was taken from all participants. Control
participants received a placebo. Participants and clinicians were blinded to
treatment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Image analysis assessors remained blinded after the results at 3 months' fol-
low-up. Other assessors were blinded to 3 months only.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 1 cell therapy participant and 2 controls were excluded from all analyses (1x
reocclusion of target vessel, 2x withdrawal of consent). MRI was performed in
23 participants (12 cell therapy, 11 controls) at 3 months and 22 participants
(12 cell therapy and 10 controls) at 15 months.
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Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Erbs 2005  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: National Institute of Health Research (UK), Heart Cells Foundation, Barts and The
London Charity, Chugai Pharma UK, and Cordis Corporation
Study setting: London, UK
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 15; Controls: 15
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 15; Controls: 15
Participants Description: Advanced HF (NYHA class II-IV; optimal medical therapy and device therapy with no further
treatment options).
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL BM was obtained from the poste-
rior iliac crest. The BMSC fraction was obtained from the BM samples, and cells were resuspended in
10 mL autologous serum. All samples were maintained at room temperature for the entire procedure.
Following arterial access, a weight-adjusted (70 IU/kg) bolus dose of unfractionated heparin was ad-
ministered. A coronary angiogram was performed to expose the largest possible area of the leM ventri-
cle to the injectate via the intact coronary circulation. The total 10 mL volume of injectate was divided
equally and injected down patent coronary arteries or graMs, or both through an over-the-wire balloon
catheter (Medtronic, Galway, Ireland). The balloon was inflated at low pressure to occlude blood flow,
while the appropriate volume of injectate was delivered distally over 3 minutes. This procedure was re-
peated in the remaining target vessels.
Dose of stem cells: n/r
Timing of stem cell procedure: n/r
G-CSF details: 10 ug/kg/day for 5 days
Comparator arm: G-CSF + placebo (BM aspiration; 10 mL autologous serum)
Co-intervention: standard medical therapy
Outcomes Primary outcomes:
Change in global LVEF from baseline (12 months)
Secondary outcomes:
Change in quality of life (6 and 12 months), NT-proBNP (6 months); major adverse cardiac events (12
months), change in NYHA class (12 months), change in CCS class (12 months).
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Outcome assessment points: Baseline, 6 and 12 months.
Method(s) of outcome measurement: NYHA class; MRI, computed tomography
Notes Outcome data for this trial were obtained directly from the study authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were enrolled in a 1:1 computer-generated randomisation list.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants received G-CSF, underwent bone marrow aspiration, and re-
ceived a placebo infusion. Blinding of clinicians was not specifically reported,
but the trial was described as "double-blind".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The endpoints of NYHA and CCS classifications were measured by an investiga-
tor blinded to the participant's treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity on an intention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk Information for all outcomes requested from the authors was provided.
Other bias High risk Partially sponsored by Chugai Pharma UK and the Cordis Corporation. The pri-
mary investigator of this trial is an author of this Cochrane review. No other
sources of bias were reported or identified.
Hamshere 2015_IC  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: National Institute of Health Research (UK), Heart Cells Foundation, Barts and The
London Charity, Chugai Pharma UK, and Cordis Corporation
Study setting: London, UK
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 15; Controls: 15
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 15; Controls: 15
Participants Description: Advanced HF (NYHA class II-IV; optimal medical therapy and device therapy with no further
treatment options).
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
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Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL BM was obtained from the posteri-
or iliac crest. The BMSC fraction was obtained from the BM samples and cells were resuspended in 10
mL autologous serum. All samples were maintained at room temperature for the entire procedure. Af-
ter femoral arterial access, a weight-adjusted (70 IU/kg) bolus dose of heparin was administered. Par-
ticipants underwent leM ventricular electromechanical mapping using NOGA XP Cardiac Navigation
System (Biologics Delivery Systems Group, Cordis Corporation, CA, USA) and direct intramyocardial in-
jection with a MyoStar injection catheter. The number of sampling points for the mapping procedure
varied between 86 and 110. The target areas for injection were the border zones around the scar tissue
based on voltage criteria obtained using the NOGA map (areas greater than 6.9 mV). Areas of the my-
ocardium with a wall thickness of < 5 mm were avoided. The total 2 mL volume of injectate was divided
and delivered equally to 10 target areas at approximately 1-centimetre intervals.
Dose of stem cells: n/r
Timing of stem cell procedure: n/r
G-CSF details: 10 ug/kg/day for 5 days
Comparator arm: G-CSF + placebo (BM aspiration; 2 mL autologous serum)
Co-intervention: standard medical therapy
Outcomes Primary outcomes:
Change in global LVEF from baseline (12 months)
Secondary outcomes:
Change in quality of life (6 and 12 months), NT-proBNP (6 months); major adverse cardiac events (12
months), change in NYHA class (12 months), change in CCS class (12 months).
Outcome assessment points: Baseline, 6 and 12 months.
Method(s) of outcome measurement: NYHA class; MRI, computed tomography
Notes Outcome data for this trial were obtained directly from the study authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were enrolled in a 1:1 computer-generated randomisation list.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants received G-CSF, underwent bone marrow aspiration, and re-
ceived a placebo infusion. Blinding of clinicians was not specifically reported,
but the trial was described as "double-blind".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The endpoints of NYHA and CCS classifications were measured by an investiga-
tor blinded to the participant's treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity on an intention-to-treat basis.
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Selective reporting (re-
porting bias)
Low risk Information for all outcomes requested from the authors was provided.
Other bias High risk Partially sponsored by Chugai Pharma UK and the Cordis Corporation. The pri-
mary investigator of this trial is an author of this Cochrane review. No other
sources of bias were reported or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Partially funded by the Interdisciplinary Stem Cell Institute, Miller School of Medi-
cine, BioCardia, and grant U54HL081028 from the National Heart, Lung, and Blood Institute Specialized
Centers for Cell-Based Therapy. Helical infusion catheters were provided by BioCardia Inc and one trial
investigator (J. Hare) was supported by grants from the National Institutes of Health.
Study setting: Florida, USA
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BM-MSC: 22; Controls: 11
Number (N) of participants analysed (primary outcome) in each arm: BM-MSC: 19; Controls: 11
Participants Description: Chronic MI and LV dysfunction (aged 21 to 90 years; ischaemic cardiomyopathy with LV dys-
function resulting from chronic MI, as documented by confirmed coronary artery disease with a cor-
responding area of myocardial akinesis, dyskinesis, or severe hypokinesis and had LVEF < 50% with-
in 6 months of screening while taking maximally tolerated doses of beta-adrenergic blocking and an-
giotensin-converting enzyme or angiotensin II receptor blocking drugs and not during or recently after
an ischaemic event).
Age distribution in each arm: BM-MSC: 57.1 (10.6) years; Controls: 60.0 (12.0) years
Sex (% male) in each arm: BM-MSC: 94.7%; Controls: 90.9%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? Significantly higher baseline stroke
volume in participants who had received MSC compared with placebo.
Interventions Intervention arm: BMSC
Type of stem cells: Mesenchymal stem cells
Summary of stem cell isolation and type and route of delivery: All participants had bone marrow harvest-
ed. MSC were cultured from bone marrow aspirates. Delivery was by injection at 10 LV sites using TESI
during leM heart catheterisation using the helical infusion catheter (BioCardia). Injections were target-
ed to encircle the border zone of a chronically infarcted myocardial territory and defined by MRI and CT
imaging, echocardiography, and well-pacified biplane leM ventriculography.
Dose of stem cells: n/r
Timing of stem cell procedure: 4 to 6 weeks from BM aspiration to cell administration.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; vehicle placebo)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
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Incidence of treatment-emergent serious adverse events (defined as composite of death, non-fatal MI,
stroke, hospitalisation for worsening HF, cardiac perforation, pericardial tamponade, ventricular ar-
rhythmias > 15 sec, or with haemodynamic compromise or atrial fibrillation) at 1 month
Secondary outcomes:
1. Serial troponin values (every 12 hours for the first 48 hours postcatheterisation)
2. Serial creatine kinase values (every 12 hours for the first 48 hours postcatheterisation)
3. Incidence of major adverse cardiac events (MACE) (defined as the composite incidence of (1) death,
(2) hospitalisation for HF, or (3) non-fatal recurrent MI) at 12 months
4. Ectopic tissue formation (12 months)
5. Number of deaths at 12 months
6. Change from baseline in distance walked in 6 minutes (12 months)
7. Change from baseline in the MLHFQ total score (12 months)
8. Change from baseline in scar mass as a fraction of leM ventricle mass by cardiac MRI or CT (12 months)
Additional outcomes:
Infarct size, regional wall motion at the sites of study agent injection, global LV size and function, exer-
cise peak O2 consumption, NYHA class, quality of life measured at 3 and 6 months
Outcome assessment points: Baseline, 3 and 6 months (quality of life only), 12 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An electronic data entry system was used for randomisation. Participants
were randomised to the MSC or BMMNC group, and further randomised within
groups to cell therapy or placebo.
Allocation concealment
(selection bias)
Low risk Participants were randomised (unblinded) to the MSC or BMMNC group. Par-
ticipants were further randomised (blinded) within groups to cell therapy or
placebo.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM harvest, and control participants received a
placebo. Neither participants nor clinicians were aware of treatment alloca-
tion.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Preparation and administration of the study product was blinded to investiga-
tors outside the cell-processing laboratory.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 3 cell therapy participants were excluded from the analysis of mortality and
morbidity (2x withdrew consent, 1x cell-processing failure). MRI analysis in-
cluded 16 cell therapy participants and 17 controls (BMSC and MSC control
groups combined); missing data were unexplained.
Selective reporting (re-
porting bias)
Unclear risk All outcomes reported in the trial protocol (NCT00768066) were reported;
some additional outcomes were reported in the publication of results.
Other bias High risk Received partial funding from BioCardia. No other sources of bias were report-
ed or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Partially funded by the Interdisciplinary Stem Cell Institute, Miller School of Medi-
cine, BioCardia, and grant U54HL081028 from the National Heart, Lung, and Blood Institute Specialized
Centers for Cell-Based Therapy. Helical infusion catheters were provided by BioCardia Inc and one trial
investigator (J. Hare) was supported by grants from the National Institutes of Health.
Study setting: Florida, USA
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 22; Controls: 10
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 19; Controls: 10
Participants Description: Chronic MI and LV dysfunction (aged 21 to 90 years; ischaemic cardiomyopathy with LV dys-
function resulting from chronic MI, as documented by confirmed coronary artery disease with a cor-
responding area of myocardial akinesis, dyskinesis, or severe hypokinesis and had LVEF < 50% with-
in 6 months of screening while taking maximally tolerated doses of beta-adrenergic blocking and an-
giotensin-converting enzyme or angiotensin II receptor blocking drugs and not during or recently after
an ischaemic event).
Age distribution in each arm: BMSC: 61.1 (8.4) years; Controls: 61.3 (9.0) years
Sex (% male) in each arm: BMSC: 89.5%; Controls: 100%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: All participants underwent BM aspiration
from the iliac crest. BMMNC were prepared by centrifugation of whole BM against a low-density gradi-
ent using Ficoll-Paque PREMIUM according to manufacturer's protocol. Cells were collected at the in-
terface. Delivery was by injection at 10 LV sites using TESI during leM heart catheterisation using the he-
lical infusion catheter (BioCardia). Injections were targeted to encircle the border zone of a chronically
infarcted myocardial territory and defined by MRI and CT imaging, echocardiography, and well-pacified
biplane leM ventriculography.
Dose of stem cells: n/r
Timing of stem cell procedure: 4 to 6 weeks from BM aspiration to cell administration.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; vehicle placebo)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Incidence of treatment-emergent serious adverse events (defined as composite of death, non-fatal MI,
stroke, hospitalisation for worsening HF, cardiac perforation, pericardial tamponade, ventricular ar-
rhythmias > 15 sec, or with haemodynamic compromise or atrial fibrillation) at 1 month
Secondary outcomes:
1. Serial troponin values (every 12 hours for the first 48 hours postcatheterisation)
2. Serial creatine kinase values (every 12 hours for the first 48 hours postcatheterisation)
3. Incidence of the major adverse cardiac events (MACE) (defined as the composite incidence of (1) death,
(2) hospitalisation for HF, or (3) non-fatal recurrent MI) at 12 months
4. Ectopic tissue formation (12 months)
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5. Number of deaths at 12 months
6. Change from baseline in distance walked in 6 minutes (12 months)
7. Change from baseline in MLHFQ total score (12 months)
8. Change from baseline in scar mass as a fraction of leM ventricle mass by cardiac MRI or CT (12 months)
Additional outcomes:
Infarct size, regional wall motion at the sites of study agent injection, global LV size and function, exer-
cise peak O2 consumption, NYHA class, quality of life measured at 3 and 6 months
Outcome assessment points: Baseline, 3 and 6 months (quality of life only), 12 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An electronic data entry system was used for randomisation. Participants
were randomised to the MSC or BMMNC group, and further randomised within
groups to cell therapy or placebo.
Allocation concealment
(selection bias)
Low risk Participants were randomised (unblinded) to the MSC or BMMNC group. Par-
ticipants were further randomised (blinded) within groups to cell therapy or
placebo.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM harvest, and control participants received a
placebo. Neither participants nor clinicians were aware of treatment alloca-
tion.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Preparation and administration of the study product was blinded to investiga-
tors outside the cell-processing laboratory.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 3 cell therapy participants were excluded from the analysis of mortality and
morbidity (2x withdrew consent, 1x ineligible before BM aspiration). MRI analy-
sis included 16 cell therapy participants and 17 controls (BMSC and MSC con-
trol groups combined); missing data were unexplained.
Selective reporting (re-
porting bias)
Unclear risk All outcomes reported in the trial protocol (NCT00768066) were reported;
some additional outcomes were reported in the publication of results.
Other bias High risk Received partial funding from BioCardia. No other sources of bias were report-
ed or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported
Study setting: Hasselt, Belgium
Number of centres: 1
Length of follow-up: 4 months
Number (N) of participants randomised to each arm: BMSC: 11; Controls: 12
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Number (N) of participants analysed (primary outcome) in each arm: BMSC: 10; Controls: 10
Participants Description: Elective CABG surgery; transmural MI on ECG and akinesia or dyskinesia in part of the leM
ventricle as shown by angiography.
Age distribution in each arm: BMSC: 63.2 ± 8.5 years; Controls: 66.8 ± 9.2 years.
Sex (% male) in each arm: BMSC: 100%; Controls: 70%.
Number of diseased vessels: BMSC: 1 (n = 0), 2 (n = 2), 3 (n = 8); Controls: 1 (n = 1), 2 (n = 2), 3 (n = 7).
Time from symptom onset to initial treatment: BMSC arm: 217 (162) days and control arm: 213 (145) days
between occurrence of MI and time of CABG (and treatment).
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 40 mL of bone marrow was aspirated un-
der local anaesthesia from the participant's iliac crest, the day before surgery. BMSC were immediate-
ly isolated by density gradient centrifugation using Lymphoprep. Isolated cells were washed twice with
saline and subsequently resuspended in X-VIVO 15 medium (Cambrex) supplemented with 2% autolo-
gous serum. This cell suspension was transferred to Teflon bags at a concentration of approximately 1
x 106 cells/mL for overnight cultivation. The next day cells were harvested and washed 3 times before fi-
nally being suspended in 10 mL heparinised saline. 10 mL of cell suspension were injected into the bor-
der zone of the infarct with 29-gauge myoinjector syringes containing 0.5 mL of cell suspension. Multi-
ple punctures were performed with prevent needles to make injections parallel to the epicardium and
avoid delivery of cells into the ventricular cavity.
Dose of stem cells: 60.25 (31.35) x 106 cells with > 95% viability and over 73% recovery. Containing
1.42% (0.99%) CD34-positive cells and 76.37 (44.47) CFU-GM/105 mononuclear cells.
Timing of stem cell procedure: Approximately 24 hours following bone marrow aspiration; 217 (162)
days post-AMI.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; heparinised saline)
Co-intervention: CABG
Outcomes Primary outcomes:
Global LVEF change and regional wall-thickening changes in the infarct area.
Secondary outcomes:
Changes in metabolic activity measured by thallium scintigraphy.
Outcome assessment points: Baseline, postoperative (9 to 14 days), and 4 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation (1:1) was carried out using sequentially numbered, sealed en-
velopes.
Allocation concealment
(selection bias)
Low risk Sealed envelopes were used.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both treatment groups underwent BM aspiration: the BM group had bone
marrow isolated the day before surgery from the iliac crest, and the control
group had bone marrow aspirated from the sternum during the operation.
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Controls received a placebo. Both participants and the surgeon were unaware
of whether cells or only saline was injected.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Cardiac MR images were analysed by an investigator blinded to treatment as-
signment. For thallium scintigraphy, 2 investigators independently analysed
data and were blinded to treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity. 3 participants (1x cell therapy and 1x control) were excluded from
MRI analysis (2x death, 1x acute psychiatric illness).
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Hendrikx 2006  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported
Study setting: Frankfurt/Main, Germany
Number of centres: 1
Length of follow-up: 60 months
Number (N) of participants randomised to each arm: BMSC: 23; Controls: 10
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 23; Controls: 9
Participants Description: Coronary artery disease (aged > 18 years; previous MI at least 3 months prior to cell therapy
and well demarcated LV regional wall motion abnormality; receiving constant state-of-the-art pharma-
cotherapy for at least 3 months prior to enrolment).
Age distribution in each arm: BMSC: 53.4 ± 12.3 years; Controls: 58.8 ± 7.3 years.
Sex (% male) in each arm: BMSC: 82%; Controls: 100%.
Number of diseased vessels: BMSC: 1 (n = 10), 2 (n = 6), 3 (n = 6); Controls: 1 (n = 4), 2 (n = 2), 3 (n = 4).
Time from symptom onset to initial treatment: At least 3 months from previous MI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Circulating progenitor cells.
Summary of stem cell isolation and type and route of delivery: G-CSF was administered to the partici-
pants for 5 days. 270 mL of peripheral blood was drawn. Mononuclear cells were isolated using a Ficoll
gradient centrifugation, and cells were resuspended in X-VIVO 15 medium with 1 ng/mL carrier-free hu-
man recombinant VEGF, atorvastatin, and 20% human serum drawn from each individual participant.
Cells were cultured ex vivo for 4 days to enrich in endothelial progenitor cells (uptake of LDL).
Dose of stem cells: 29 ± 12 x 106. 
Timing of stem cell procedure: % days following G-SCF administration and 4 days following bone mar-
row aspiration and cell culture.
G-CSF details: 5 ug/kg/day (first 12 participants) or 10 ug/kg/day (20 participants) for 5 days.
Comparator arm: G-CSF + control (no BM aspiration, no placebo)
Co-intervention: Standard medical therapy; PCI (in 33% of participants)
Outcomes Primary outcomes:
Honold 2012 
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
71
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Safety and efficacy.
Secondary outcomes:
Global and regional LV function and volumes after 3 months, determined by both LV angiography and
MRI. Clinical parameters like functional NYHA class, cardiopulmonary exercise testing, and NT-proBNP
serum levels were obtained during a 5-year follow-up period.
Outcome assessment points: Baseline and 3, 12, 60 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was described as randomised, but the method of randomisation was
not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of clinicians and participants was not specifically reported, but no
placebo was administered to the control group.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk MRI independent observers were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All randomised participants were included in the analysis of mortality and
morbidity, although 1 participant randomised to (but who did not receive) cell
therapy was analysed in the control group. Angiography was carried out at fol-
low-up in 26 participants (21 cell therapy, 5 controls). MRI was performed in a
subset of participants (9 cell therapy, 4 controls).
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Honold 2012  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Key project in the National Science and Technology Pillar programme during the
11th 5-year plan period (2006BAJ01A09), basic scientific research fund of the National Scientific Insti-
tute 2009-2011.
Study setting: Beijing, China
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 31; Controls: 29
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 31; Controls: 28
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Participants Description: Chronic HF (aged 18 to 75 years; at least 3 months since last MI; severe ischaemic cardiomy-
opathy with LVEF < 30% by MRI and suitable for CABG; no evidence of surviving myocardium in the in-
farct area, as shown by SPECT and LV angiography; without LV aneurysm or valvular diseases requiring
surgical intervention).
Age distribution in each arm: BMSC: 56.6 ± 9.7 years; Controls: 58.3 ± 8.9 years.
Sex (% male) in each arm: 93.3% (both arms pooled).
Number of diseased vessels: BMSC: 3; Controls: 3.
Time from symptom onset to initial treatment: At least 3 months from last MI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: After anaesthesia but before CABG, 60
mL of BM was aspirated from the participant's iliac crest and diluted with normal saline solution. The
mononuclear cells were isolated using Ficoll density gradient centrifugation according to good manu-
facturing practice regulations and resuspended in 10 mL of saline solution. The cell suspension was fil-
tered by a 70-micrometre cell strainer before transplantation. The cells were counted under a light mi-
croscope, and the viability was assessed by trypan blue dye. The final suspension of BMMNC contained
107 mL MNC. Cells were delivered via the grafted vessel (saphenous vein graM).
Dose of stem cells: Mean 13.17 ± 10.66 x 107.
Timing of stem cell procedure: Within 24 hours and during CABG.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; mixture of 8 mL of saline solution and 2 mL of the partici-
pant's own serum)
Co-intervention: CABG
Outcomes Primary outcomes:
Changes in LVEF from baseline to 6 months' follow-up.
Secondary outcomes:
None reported.
Additional outcomes:
LVEDV index (MRI; echocardiograpy); LVESV index (MRI); wall motion score index (echocardiography);
perfusion score (SPECT), 6-min walking test, and BNP value.
Outcome assessment points: Baseline, 6 and 12 months
Method(s) of outcome measurement: MRI; echocardiography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A randomisation table was generated by statistical software.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
Low risk All participants underwent BM harvest, and control participants received a
placebo. The study processes were blinded to surgeons and participants.
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The study processes were blinded to investigators who were responsible for
participant assessments.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants were included in the analysis of mortality and morbidity; 1
control participant did not attend follow-up at 6 months. MRI at 12 months
included 25 participants in each group. Echocardiography at 12 months in-
cluded 42 participants (24 cell therapy and 18 controls); missing data were ex-
plained.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00395811) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Hu 2011  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Funded by an independent research grant from the Spanish National Ministry of
Health and Social Policy (Direccion general de Terapias Avanzadas y Transplante) and an unrestricted
grant from Mutua Madrileña Foundation.
Study setting: Spain
Number of centres: 3 (Madrid, Barcelona, Logrono)
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 19; Controls: 9
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 19; Controls: 9
Participants Description: Refractory angina (CCS class II-IV; optimal medical therapy; not suitable for surgical/percu-
taneous revascularisation; and with reversible perfusion defect measured by SPECT).
Age distribution in each arm: BMSC: median 70 years; Controls: median 58.2 years
Sex (% male) in each arm: BMSC: 78.9%; Controls: 100%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r (no AMI within preceding 3 months)
Statistically significant baseline imbalances between the groups? Median age significantly higher in
treated group.
Interventions Intervention arm: G-CSF; BMSC
Type of stem cells: CD133+ progenitor cells from mobilised peripheral blood
Summary of stem cell isolation and type and route of delivery: All participants underwent leukaphere-
sis to isolate the mononuclear fraction from the peripheral blood. Only those participants allocated to
the cell group CD133+ PC were isolated by immunomagnetic selection with CliniMACS cell separation
system (Miltenyi Biotec, Bergisch-Gladback, Germany). Sterility tests (Gram stain and culture) were per-
formed on the final cell preparation. The cells were suspended in normal saline and concentrated in 3
mL for the injection.
Dose of stem cells: 20 to 30 × 106 cells
Timing of stem cell procedure: At last 5 days after G-CSF.
G-CSF details: 5 μg/kg per 12 hours for 4 days
Comparator arm: Control (BM aspiration; sham procedure but no placebo administered)
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Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Major adverse cardiac and cerebrovascular events, defined as cardiovascular death, non-fatal MI,
ischaemic stroke, need for revascularisation, or procedure-related complications (pericardial effu-
sion/cardiac tamponade, vascular complications, and sustained ventricular arrhythmias) at 6, 12, and
24 months.
Secondary outcomes:
Efficacy of the transendocardial injection of PC CD133+ assessed by means of the following variables:
the change in the myocardial perfusion defect as measured by SPECT, symptom-limited treadmill test,
quality of life, CCS angina classification, and antianginal medication requirement.
Outcome assessment points: Baseline, 6 months
Method(s) of outcome measurement: Echocardiography, SPECT, LV angiography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A centralised telephone randomisation was performed using a computer-gen-
erated code before the index procedure.
Allocation concealment
(selection bias)
Low risk Randomisation was performed using a centralised telephone procedure.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both groups were treated with G-CSF, underwent an apheresis and electro-
mechanical mapping; however, transendocardial injections were not per-
formed in the control group but were simulated to keep the participant and all
the investigators except the 2 operators who performed the injections blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk A blinded investigator analysed angiograms with the use of a computer-based
system. All the analyses were centralised in an independent core laboratory
blinded to the randomisation. All investigators except 2 operators who per-
formed the injections were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants were included in the analysis of all outcomes on an inten-
tion-to-treat basis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00694642) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Jimenez-Quevedo 2011  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported in part by National Institutes of Health grants and by a grant from Baxter
Healthcare. Biosense Webster provided the mapping and injection catheters for this study at no extra
cost.
Study setting: USA
Number of centres: n/r (multicentre)
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Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC-high dose (HD): 6; BMSC-medium dose (MD):
6; BMSC-low dose (LD): 6; and Controls: 6
Number (N) of participants analysed (primary outcome) in each arm: BMSC-HD: 6; BMSC-MD: 6; BMSC-LD:
6; and Controls: 6
Participants Description: Chronic refractory angina (aged > 21 years; CCS class III–IV; optimal medical therapy; not
suitable for revascularisation; ischaemia on nuclear perfusion imaging, to complete at least 1 minute
but no more than 6 mins of a standard Bruce protocol, and to experience angina/angina equivalent
during the baseline exercise test).
Age distribution in each arm: Mean 62.4 (range 48 to 84 years) for all groups.
Sex (% male) in each arm: 80% for all arms.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: Not reported, not applicable.
Statistically significant baseline imbalances between the groups? None reported.
Interventions Intervention arm: G-CSF, BMSC at low dose, medium dose, or high dose.
Type of stem cells: CD34+ cells from mobilised peripheral blood.
Summary of stem cell isolation and type and route of delivery: Leukoapheresis was performed on the 5th
day for collection of mononuclear cells. The cells were stored overnight at 4°C, and the following morn-
ing the CD34+ fraction was purified on a commercially available device (Isolex 300i, Baxter Healthcare)
according to manufacturer's instructions. Cells were then subjected to testing and were required to
meet lot-release criteria. Once passed, the participants underwent NOGA electromechanical mapping
and intramyocardial injection of CD34+ cells suspended in saline plus 5% autologous serum, versus cell
diluent using the NOGA MyoStar catheter. The dose was divided into 10 injections of 0.2 mL per injec-
tion.
Dose of stem cells: 5 x 104 CD34 cells/kg (LD); 1 x 105 CD34 cells/kg (MD); 5 x 105 CD34 cells/kg (HD).
Timing of stem cell procedure: On day 6 following G-CSF administration and within 24 hours of cell isola-
tion.
G-CSF details: G-CSF was given to all participants at 5 μg/kg for 4 to 5 days.
Comparator arm: G-CSF; placebo (BM aspiration; saline (0.9% sodium chloride) with 5% autologous
plasma).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes: Not reported.
Secondary outcomes: Safety analysis (AEs), efficacy (angina frequency, NTG use, exercise tolerance, CCS
class, SPECT perfusion imaging, quality of life testing).
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: Angina frequency and CCS angina class
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation codes were established by the study statistician.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
Low risk All participants were administered G-CSF prior to treatment and had CD34+
cells collected. Controls received a placebo solution in a syringe that was iden-
tical for all treatment arms.
Losordo 2007  (Continued)
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
76
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Randomisation codes were only revealed to the stem cell laboratory techni-
cian responsible for separating the cells into aliquots or preparing the placebo
material.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias High risk Partially funded by a grant from Baxter Healthcare. No other sources of bias
were reported or identified.
Losordo 2007  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Baxter Healthcare sponsored the study and was responsible for the conduct of the
investigation, with oversight provided by the principal investigator and the scientific advisory board.
Study setting: USA
Number of centres: 26
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC-low dose (LD): 56; BMSC-high dose (HD): 56;
Controls: 56
Number (N) of participants analysed (primary outcome) in each arm: BMSC-LD: 55; BMSC-HD: 56; Con-
trols: 56
Participants Description: Chronic refractory angina (aged 21 to 80 years; CCS class III–IV; optimum medical man-
agement; not suitable for revascularisation; SPECT imaging to document the presence of reversible
ischaemia; patients required to walk a minimum of 3 mins but no longer than 10 mins on a modified
Bruce protocol exercise tolerance test and had to experience angina or their angina equivalent during
exercise testing.
Age distribution in each arm: BMSC-LD: 61.3 (9.1) years; BMSC-HD: 59.8 ± 9.2 years; Controls: 61.8 ± 8.5
years.
Sex (% male) in each arm: BMSC-LD: 83.6%; BMSC-HD: 87.5%; Controls: 89.3%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: At least 40 days from previous MI.
Statistically significant baseline imbalances between the groups? Cardiovascular risk factors (HTN,
smoking, DM); angina episodes per week.
Interventions Intervention arm: G-CSF, BMSC at low dose or high dose.
Type of stem cells: CD34+ cells from mobilised peripheral blood.
Summary of stem cell isolation and type and route of delivery: On day 5 leukapheresis was performed.
The following day mononuclear cells were collected and CD34+ cells enriched using a commercially
available device (Isolex 300im) magnetic cell separation system. Cell suspension with > 70% viability
and > 50% CD34+ cells were given at 2 doses of body weight with a maximum of 100 kg. Cell suspension
was diluted in saline (0.9% sodium chloride) with 5% autologous plasma. Cells were injected into the
myocardium. The injection was performed by NOGA mapping and at 10 sites (0.2 cm3/site) using a NO-
GA MyoStar catheter.
Dose of stem cells: 1 x 105 CD34 cells/kg (LD) or 5 x 105 CD34 cells/kg (HD).
Timing of stem cell procedure: At least 3 months following MI.
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G-CSF details: G-CSF was given to all participants at 5 μg/kg for 4 to 5 days.
Comparator arm: G-CSF; placebo (BM aspiration; saline (0.9% sodium chloride) with 5% autologous
plasma).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Angina frequency 6 months after treatment.
Secondary outcomes:
None reported in study protocol.
Additional outcomes:
Efficacy endpoints including exercise tolerance testing; use of antianginal medication; CCS functional
class; health-related QOL (Seattle Angina Questionnaire, SF-36, Dyspnea Questionnaire, EQ-5D); com-
bined rate of MACE, SPECT, cardiac MRI (in a substudy). Safety endpoints including adverse event re-
porting, chest X-ray, and echocardiology and laboratory screening.
Outcome assessment points: Baseline, 6 and 12 months
Method(s) of outcome measurement: CCS functional class
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly assigned to 1 of 3 treatment groups via a tele-
phone call-in and an interactive voice-response system.
Allocation concealment
(selection bias)
Low risk The cell-processing laboratory at each centre was responsible for making the
randomisation call and preparing the CD34+ cells or control injection accord-
ingly.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants were administered G-CSF prior to treatment and had CD34+
cells collected. Controls received a placebo solution in a syringe that was iden-
tical for both treatment arms.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk An independent committee conducted the analysis. All study personnel re-
mained blinded until the end of the study.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in analyses at follow-up on an in-
tention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00300053) were reported.
Other bias High risk Baxter Healthcare sponsored the study and was responsible for the conduct of
the investigation. No other sources of bias were reported or identified.
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Type of publication: Full paper
Source of funding: Supported by the Arvid Nilsson's Foundation, Aase and Ejnar Danielsen's Founda-
tion, Agustinus Foundation, the Research Foundation at Rigshospitalet, Axel Muusfeldt Foundation, Eva
and Henry Fraenkel's Foundation, Gangsted Foundation, Vera and Fleming Westerberg's Foundation,
Jeppe and Ovita Juhl's Foundation, Sophus and Astrid Jacobsen Foundation.
Study setting: Copenhagen, Denmark
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 40; Controls: 20
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 40; Controls: 20
Participants Description: Severe ischaemic HF (aged 30 to 80 years; optimal medical therapy with no change in med-
ication for 2 months; no revascularisation options, LVEF < 45%; NYHA class II-III).
Age distribution in each arm: BMSC: 66.1 (7.7) years; Controls: 64.2 (10.6) years
Sex (% male) in each arm: BMSC: 90%; Controls: 70%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mesenchymal stem cells
Summary of stem cell isolation and type and route of delivery: A total of 50 mL bone marrow aspirate was
obtained from the iliac crest by needle aspiration under local anaesthesia. The marrow sample was di-
luted 1:2 with PBS. MNC were harvested by gradient centrifugation on lymphoprep (density 1077 g/
cm3), then primary cell cultures were established by seeding 2 × 107 BMMNC using a T75 culture flask in
complete medium (DMEM low glucose (1 g/L) with 25 mM HEPES and L-Glutamine, 1% penicillin/strep-
tomycin and 10% fetal bovine serum). The cells were incubated at 37°C in humid air with 5% CO2. The
medium was changed 5 days after plating and subsequently every 3 or 4 days. After 2, 3, 4, and 5 weeks
of cultivation, cells were harvested. Mesenchymal stromal cells were successfully culture expanded
under good manufacturing practice conditions for 46.9 + 10.5 days. Participants were treated with the
number of cells reached after 2 passages.
Dose of stem cells: mean 77.5 (67.9) x 10e6
Timing of stem cell procedure: Mesenchymal stromal cells were successfully culture expanded under
good manufacturing practice conditions for 46.9 (10.5) days following BM aspiration.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; PBS mixed with a drop of the participant’s blood to maintain
blinded appearance of placebo solution).
Co-intervention: Standard medical therapy
Outcomes Primary outcome:
Changes in LVESV at 6 months' follow-up
Secondary outcome:
Clinical improvements at 6 and 12 months
Note: the main study publication reports secondary outcomes as LVEDV, LVEF, SV, cardiac output, LV
myocardial mass, wall thickness, wall thickening, scar volume, NYHA class, CCS class, 6MWT, weekly
angina attacks and weekly use of nitroglycerine, biomarkers, the Seattle Angina Questionnaire and
Kansas City Cardiomyopathy Questionnaire, and safety (Mathiasen 2015).
Outcome assessment points: Baseline, 6 months
Method(s) of outcome measurement: MRI; computed tomography
Notes  
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were enrolled in a 2:1 computer-generated randomisation list
blocks of 6.
Allocation concealment
(selection bias)
Low risk The randomisation list was generated by a person unrelated to the study
group.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The trial investigators, study nurses, and participants were blinded to treat-
ment allocation. To maintain blinding, a drop of the participant's blood was
mixed into the syringe containing MSC or placebo by the stem cell laboratory
to make the MSC solution and placebo identical.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The trial investigators and experienced physicians who performed the MRI
analyses were blinded to treatment allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in all analyses at follow-up on an
intention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00644410) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Mathiasen 2015  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: National Institute of Health Research (UK), Heart Cells Foundation, Barts and The
London Charity, Chugai Pharma UK, and Cordis Corporation.
Study setting: London, UK
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 14; Controls: 2
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 14; Controls: 2
Participants Description: Advanced HF (NYHA class II-IV; optimal medical therapy and device therapy with no further
treatment options).
Age distribution in each arm: Mean 70 (10) years
Sex (% male) in each arm: 94%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: Duration since last MI: 11 (7) years
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL BM was obtained from the poste-
rior iliac crest. The BMSC fraction was obtained from the BM samples, and cells were resuspended in
10 mL autologous serum. All samples were maintained at room temperature for the entire procedure.
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Following arterial access, a weight-adjusted (70 IU/kg) bolus dose of unfractionated heparin was ad-
ministered. A coronary angiogram was performed to expose the largest possible area of the leM ventri-
cle to the injectate via the intact coronary circulation. The total 10 mL volume of injectate was divided
equally and injected down patent coronary arteries or graMs, or both through an over-the-wire balloon
catheter (Medtronic, Galway, Ireland). The balloon was inflated at low pressure to occlude blood flow,
while the appropriate volume of injectate was delivered distally over 3 minutes. This procedure was re-
peated in the remaining target vessels.
Dose of stem cells: Mean 8.6 (11.0) x 107
Timing of stem cell procedure: n/r
G-CSF details: 10 ug/kg/day for 5 days
Comparator arm: G-CSF + placebo (BM aspiration; 10 mL autologous serum)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
None (change in global LVEF from baseline (12 months) is a primary outcome in the main REGENER-
ATE-IHD trial but not included in the pilot study)
Secondary outcomes:
Change in quality of life (6 and 12 months); NT-proBNP (6 months); major adverse cardiac events (12
months); change in NYHA class (12 months)
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: NYHA class; MRI, computed tomography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were enrolled in a 1:1 computer-generated randomisation list.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants received G-CSF, underwent bone marrow aspiration, and re-
ceived a placebo infusion. Blinding of clinicians was not specifically reported,
but the trial was described as "double-blind".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The endpoints of NYHA and CCS classifications were measured by an investiga-
tor blinded to the participant's treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity on an intention-to-treat basis.
Selective reporting (re-
porting bias)
Unclear risk This is a pilot study report that only reports 6-month follow-up of the sec-
ondary outcomes described in the protocol (NCT00747708).
Other bias High risk Partially sponsored by Chugai Pharma UK and the Cordis Corporation. The pri-
mary investigator of this trial is an author of this Cochrane review. No other
sources of bias were reported or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: National Institute of Health Research (UK), Heart Cells Foundation, Barts and The
London Charity, Chugai Pharma UK, and Cordis Corporation.
Study setting: London, UK
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 10; Controls: 8
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 10; Controls: 8
Participants Description: Advanced HF (NYHA class II-IV; optimal medical therapy and device therapy with no further
treatment options).
Age distribution in each arm: Mean 64 (9) years
Sex (% male) in each arm: 100%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: Duration since last MI: 7 (5) years
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: G-CSF + BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL BM was obtained from the posteri-
or iliac crest. The BMSC fraction was obtained from the BM samples, and cells were resuspended in 10
mL autologous serum. All samples were maintained at room temperature for the entire procedure. Af-
ter femoral arterial access, a weight-adjusted (70 IU/kg) bolus dose of heparin was administered. Par-
ticipants underwent leM ventricular electromechanical mapping using NOGA XP Cardiac Navigation
System (Biologics Delivery Systems Group, Cordis Corporation, CA, USA) and direct intramyocardial in-
jection with a MyoStar injection catheter. The number of sampling points for the mapping procedure
varied between 86 and 110. The target areas for injection were the border zones around the scar tissue
based on voltage criteria obtained using the NOGA map (areas greater than 6.9 mV). Areas of the my-
ocardium with a wall thickness of < 5 mm were avoided. The total 2 mL volume of injectate was divided
and delivered equally to 10 target areas at approximately 1-centimetre intervals.
Dose of stem cells: Mean 5.2 (5.3) x 107
Timing of stem cell procedure: n/r
G-CSF details: 10 ug/kg/day for 5 days
Comparator arm: G-CSF + placebo (BM aspiration; 2 mL autologous serum)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
None (change in global LVEF from baseline (12 months) is a primary outcome in the main REGENER-
ATE-IHD trial but not included in the pilot study)
Secondary outcomes:
Change in quality of life (6 and 12 months); NT-proBNP (6 months); major adverse cardiac events (12
months); change in NYHA class (12 months)
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: NYHA class; MRI, computed tomography
Notes  
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were enrolled in a 1:1 computer-generated randomisation list.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants received G-CSF, underwent bone marrow aspiration, and re-
ceived a placebo infusion. Blinding of clinicians was not specifically reported,
but the trial was described as "double-blind".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The endpoints of NYHA and CCS classifications were measured by an investiga-
tor blinded to the participant's treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity on an intention-to-treat basis.
Selective reporting (re-
porting bias)
Unclear risk This is a pilot study report that only reports 6-month follow-up of the sec-
ondary outcomes described in the protocol (NCT00747708).
Other bias High risk Partially sponsored by Chugai Pharma UK and the Cordis Corporation. The pri-
mary investigator of this trial is an author of this Cochrane review. No other
sources of bias were reported or identified.
Mozid 2014_IM  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported in part by Miltenyi Biotec and by the German Bundesministerium fur Bil-
dung und Forschung.
Study setting: Berlin, Germany
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 30; Controls: 30
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 28; Controls: 26
Participants Description: Chronic IHD (indication for CABG surgery; reduced global LVEF by transthoracic echocar-
diography at rest (LVEF ≤ 35); presence of akinetic or hypokinetic and hypoperfused LV myocardium on
MRI for defining the target area).
Age distribution in each arm: BMSC: 61.9 (7.3) years; Controls: 62.7 (10.6) years
Sex (% male) in each arm: BMSC: 93%; Controls: 97%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: Duration since last MI: BMSC: 2.6 months (range 17 days
to 17.1 years); Controls: 1.5 months (range 14 days to 28.5 years).
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: CD133+ progenitor cells
Summary of stem cell isolation and type and route of delivery: All participants underwent BM aspiration
from the leM posterior iliac crest with local anaesthesia and analgosedation. An average BM volume
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of 196 +/- 28 mL was harvested and diluted with 20 mL saline solution containing 1000 U heparin. The
BM solution was filtered, transferred into a plastic bag, and washed with PBS/EDTA solution contain-
ing 0.5% human serum albumin. This cell suspension was incubated with human IgG 5% as blocking
reagent, labelled with 7.5mL reconstituted CD133 MicroBeads, murine anti-human CD133 monoclonal
antibodies conjugated to superparamagnetic iron dextran particles. Then CD133+ cells were separat-
ed using the CliniMACS Magnetic Separation device. The enriched cell fraction was reconstituted with
13 mL saline containing 10% autologous serum. Samples were drawn for cell numbers, purity, viability,
and proof of sterility. Finally, cells were aliquoted into 1-millilitre syringes and stored at 4°C without he-
parin.
Dose of stem cells: Median 5.1 (IQR 3.0 to 9.1) x 106 CD133+ cells
Timing of stem cell procedure: 36 hours after BM aspiration
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; isotonic sodium chloride solution containing 10% autolo-
gous serum)
Co-intervention: CABG
Outcomes Primary outcomes:
LVEF at rest, measured 6 months' postoperatively by MRI.
Secondary outcomes:
1. Change in LVEF compared with preoperatively and early postoperatively
2. Regional contractility in the area of interest
3. Physical exercise capacity determined by 6-minute walk test
4. Perfusion in the AOI
5. Change in LV dimensions
6. NYHA and CCS class
7. MLHFQ
8. Death, MI, or need for reintervention during follow-up
Post-hoc outcome:
Infarct scar size.
Outcome assessment points: Baseline, 6 months
Method(s) of outcome measurement: MRI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was conducted in the cell preparation facility. Group allocation
was performed according to a predefined non-block-wise 1:1 randomisation
plan.
Allocation concealment
(selection bias)
Low risk The randomisation plan was accessible only to the external cell processing
team that prepared the cell product or placebo.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent bone marrow aspiration. Syringes were prepared
with either cells or placebo solution, and an ID number was added so that par-
ticipants, the surgical team, and all investigators were unaware of treatment
allocation.
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Syringes were prepared with either cells or placebo solution, and an ID num-
ber was added so that participants, the surgical team, and all investigators
were unaware of treatment allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity (3x cell therapy and 1x control were excluded from exercise testing).
In MRI analysis, the number of withdrawals was low (treatment: 2/30 vs con-
trol: 4/30), and reasons for exclusion were given. 4 participants (3 cell therapy,
1 control) did not undergo exercise tests.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00462774) were reported. One
post-hoc outcome was clearly defined as such.
Other bias High risk Supported in part by Miltenyi Biotec and the German Bundesministerium
fur Bildung und Forshcung. Two authors received lecture fees from Miltenyi
Biotec. No other sources of bias were reported or identified.
Nasseri 2012  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper (6 months); abstract (10 years)
Source of funding: Not reported.
Study setting: Rosario, Argentina
Number of centres: 1
Length of follow-up: 10 years
Number (N) of participants randomised to each arm: BMSC: 10, Controls: 10 (pilot study); BMSC: 25, Con-
trols: 25 (long-term follow-up)
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 10, Control: 10 (pilot study);
BMSC: 25, Controls: 25 (long-term follow-up)
Participants Description: Ischaemic HF (LVEF < 35% by echocardiography and multiplanar cardiac catheterisation;
NYHA class III or IV; requiring revascularisation, undergoing oJ-pump CABG).
Age distribution in each arm: BMSC arm: 64.8 ± 7.1 years old; Control arm: 63.6 ± 5.2 years old (pilot
study data).
Sex (% male) in each arm: BMSC arm: 80%; Control arm: 80% (pilot study data).
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: At least 7 days after the last MI, all participants had histo-
ry of MI and revascularisation by PCI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: CD34+ progenitor cells
Summary of stem cell isolation and type and route of delivery: Bone marrow was harvested from the iliac
bone in a sterile fashion after achievement of general anaesthesia. A special multihold harvest needle
with a 60-millilitre syringe was designed to minimise the anaesthetic time. It was introduced into the ili-
ac bone between both posterior iliac spines at both sides. 500 mL to 600 mL of BM with a minimal num-
ber of puncture sites was harvested. At least 250 mL BM must have been harvested to continue with the
protocol. Harvested BM was placed in a blood bag with 10,000 U of heparin sulfate and 400 μm of lysine
acetylsalicylate to avoid platelet clumping. The BM was filtered on a 500-micrometre filter followed by
a 200-micrometre filter. The resulting solution was mixed with hydroethylstarch 6%. The supernatant
was centrifuged at 400 g for 15 mins. The cellular pellet was resuspended in PBS. The cell solution was
mixed 3:1 with a solution of 155 mmol/L ammonium chloride, 10 mmol/L potassium bicarbonate, and
0.1 mmol/L EDTA and set for 5 mins at room temperature. The solution was then centrifuged at 400 g
for 10 mins. The pellet was washed with PBS and resuspended. The cell suspension was placed over Fi-
coll-Paque (1.077 density) 4:1 and centrifuged at 400 g for 30 mins. The upper layer was aspirated, leav-
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ing the mononuclear cell layer at the interphase. The interphase cells were transferred to a new coni-
cal tube with PBS and centrifuged at 300 g for 10 mins. The supernatant was completely removed, and
the cell pellet was resuspended in PBS. Cell counts were performed, and the magnetic labelling with
Isolex 300i was performed to obtain an enriched product of at least 70% CD34+ cells. The resulting cell
solution was resuspended in 30 mL of the participant's own plasma and 10,000 U of heparin sulphate.
30 mL of cell preparation was delivered in 1 mL aliquots over a 2-second period. The injections into the
myocardium were spaced 1 cm apart and spaced to avoid coronary vessels. Injections were 3 mm to 5
mm in depth.
Dose of stem cells: Median 22 x 106 CD34+ cells.
Timing of stem cell procedure: At least 7 days following last MI.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration, no placebo)
Co-intervention: CABG
Outcomes Primary outcomes: Not reported.
Secondary outcomes: Global LVEF, LVEDV, NYHA class (6 months only), arrhythmias (6 months) only.
Outcome assessment points: Baseline and 1, 3, and 6 months; 1, 5, and 10 years
Method(s) of outcome measurement: SPECT; echocardiography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A person who did not participate in the trial had the choice of picking a
coloured ball (red = BMSC arm; blue = control arm).
Allocation concealment
(selection bias)
Unclear risk The person undertaking the randomisation procedure did not participate in
the trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Clinicians were not blinded. The authors report that participants were blind-
ed, although the control group did not undergo bone marrow aspiration and
no placebo was used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The reviewers of imaging studies (cardiologists) were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
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Source of funding: Funded by Harvest Technologies, Plymouth, MA. One study investigator (A. Patel) has
"compensated honoraria" from Cook Medical Inc.
Study setting: Utah and California, USA; Rostock and Berlin, Germany; and Grugoan, India
Number of centres: 5
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 24; Controls: 6
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 22; Controls: 6
Participants Description: CHF (aged > 18 years; LVEF < 40% by contrast echocardiography, NYHA class III or IV, stable
with standard medical therapy for at least 1 month before screening, and a life expectancy of 6 months
or longer).
Age distribution in each arm: BMSC: 58.5 (12.7) years; Controls: 52.7 (8.5) years.
Sex (% male) in each arm: BMSC: 91.7%; Controls: 100%.
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r (at least 7 days since last MI).
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Bone marrow cell concentrate
Summary of stem cell isolation and type and route of delivery: Approximately 240 mL of bone marrow
was aspirated from the posterior iliac crest. The samples was concentrated to a volume of 60 mL over
15 mins using the Harvest Bone Marrow Aspirate Concentrate System (from Harvest Technologies, Ply-
mouth, MA). The concentrate comprised mononuclear cells. Retrograde delivery through the coronary
sinus, accessed via the right femoral vein using a 7F 8 mm x 40 mm balloon catheter (Cook Medical Inc)
under fluoroscopic guidance. The 60 mL of BM concentrate was infused continuously over a 5-minute
period. The balloon was kept inflated for 10 min afterwards to allow the migration of cells into the car-
diac tissue.
Dose of stem cells: Mean 3.7 (0.9) x 109 nucleated cells.
Timing of stem cell procedure: 29 (14) minutes from venous access.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; no placebo)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Number of participants with adverse events as a measure of safety and tolerability (12 months)
Secondary outcomes:
To assess the effect of the infusion of bone marrow nucleated cells on the clinical course of angina as
measured by QOL questionnaire, MLHFQ, NYHA and CCS classification, and SPECT (12 months)
Assess the effect of the infusion of bone marrow nucleated cells on the clinical course of HF (12
months)
Outcome assessment points: Baseline; 1, 3, 6, and 12 months
Method(s) of outcome measurement: SPECT, NYHA class, CCS class, MLHFQ
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Electronic randomisation" was performed.
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Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was used; neither participants nor clinicians were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All imaging and follow-up information was blinded to the reviewers.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk With the exception of 2 early withdrawals with reasons clearly defined, all ran-
domised participants were included in the analysis of mortality and morbidity
on an intention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT01299324) were reported.
Other bias High risk Commercially sponsored study (funded by Harvest Technologies). No other
sources of bias were reported or identified.
Patel 2015  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported by the Heart Research Foundation, the Academy of Finland and govern-
ment subsidies for medical research block grants.
Study setting: Helsinki, Finland
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 20; Controls: 19
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 18; Controls: 17
Participants Description: Ischaemic HF (aged 18 to 75 years; managed by optimal medical care; undergoing CABG;
LVEF between 15% and 45%; NYHA class II-IV HF symptoms).
Age distribution in each arm: BMSC: median 65 (IQR 57 to 73) years; Controls: median 64 (IQR 58 to 70)
years.
Sex (% male) in each arm: BMSC: 94.7%; Controls: 95%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: After anaesthesia induction, 100 mL of BM
aspirated from each participant's posterior iliac crests was collected into a sterile bag containing he-
parin (final concentration 20 units/mL). The aliquots were filtered and density-gradient centrifuged (Fi-
coll-Paque PREMIUM; GE Healthcare Bio-Sciences AB; COBE 2991 Cell Processing Centrifuge) to obtain
the mononuclear cell traction, according to standard methods. The cells were washed with medium
199 containing human serum albumin 0.5% and heparin (20 unit/mL) and finally suspended in 6 mL of
the same medium. The cell suspension was divided into six 1-millilitre syringes for each participant in
the treatment group. After BM aspiration, standard CABG operation was performed under cardiac ar-
rest, cardiopulmonary bypass, cardioplegia protection, and mild hypothermia. After completion of by-
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pass anastomoses, each participant received, under cardiac arrest, 15 to 20 0.2 mL injections into the
infarction border area through a small 24G needle into sites chosen before surgery using imaging da-
ta. Injection procedure was carefully photographed during each surgery, and segments injected were
specified in participants' documentation for analysis.
Dose of stem cells: Median 8.4 (range 5.2 to 13.5) x 108 cells
Timing of stem cell procedure: n/r
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; vehicle medium)
Co-intervention: CABG
Outcomes Primary outcomes:
Change in LVEF after 1-year follow-up measured by MRI (12 months)
Secondary outcomes:
Changes in any other cardiac parameters as measured by echocardiography, MRI, or PET ischaemia
area (6 months; 1 year)
Change in plasma concentrations of proBNP (6 months; 1 year)
Primary hospitalisation or days stayed in hospital
Correlation between pericardial fluid growth factor concentrations and leM ventricular function im-
provement (up to 1 year)
Correlation between autologous cardiac stem cell quality and leM ventricular function improvement (6
months; 1 year)
Outcome assessment points: Baseline, 1 week, 1 year.
Method(s) of outcome measurement: MRI, PET
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Before examination, numbered randomisation envelopes were sealed by stem
cell laboratory personnel blinded to other participants. After delivery of the
BM harvest to the stem cell laboratory, randomisation of each participant was
done at the time of operation.
Allocation concealment
(selection bias)
Low risk Numbered, sealed envelopes were prepared by the stem cell laboratory before
examinations.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent bone marrow aspiration, and the control group re-
ceived a placebo. Syringes containing cell therapy or placebo were masked us-
ing a non-transparent tape.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk 1 investigator analysed all MRI imaging data in a random order. Areas of scar
and ischaemic myocardium were assessed by 2 study-blind, experienced nu-
clear medicine physicians.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity. The number of withdrawals from MRI analysis was low (treatment:
2/20 vs control: 2/19), and reasons for withdrawals were reported in detail.
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Selective reporting (re-
porting bias)
Unclear risk All outcomes reported in the trial protocol (NCT00418418) were reported, al-
though results were reported for 12 months only and not at 6 months as speci-
fied in the trial protocol.
Other bias Low risk No other sources of bias were reported or identified.
Patila 2014  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: No extramural funding was used to support this work; the authors have no disclo-
sures, no funding, and no relationship with industry to report.
Study setting: Texas and Minneapolis, USA
Number of centres: 2
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 20; Controls: 10
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 20; Controls: 10
Participants Description: Ischaemic HF (functional class III or IV (angina) and/or HF symptoms (NYHA) on maximal
medical therapy; chronic CAD with a reversible perfusion defect ≥ 7% (SPECT); LVEF < 40%; MVO2 < 21
mL/kg/min; ineligible for percutaneous or surgical revascularisation).
Age distribution in each arm: BMSC: 56.3 ± 8.6 years; Controls: 60.5 ± 6.4 years.
Sex (% male) in each arm: BMSC: 50%; Controls: 80%.
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: 50 mL of BM was aspirated from the pos-
terior iliac crest, approximately 4 hours before the cells were injected into the heart. Mononuclear cells
were isolated using a density gradient centrifugation, washed in heparinised saline containing 5% hu-
man serum albumin and passed through a mesh. 3 x 107 cells were resuspended in 3 mL saline contain-
ing serum albumin (5%). 3 mL were preserved for further studies. 3 hours after bone marrow aspiration,
participants underwent an electromechanical mapping to select myocardial segments for cell injec-
tion. Cells were injected into viable myocardium (> 6.9 mV unipolar voltage). Electromechanical maps
comprised an average of 87 ± 16 points. Each injection of 2 million cells was delivered in a volume of 0.2
mL. Participants received an average of 15 cell injections in a mean of 6 ± 1 segments.
Dose of stem cells: 2 x 106 cells.
Timing of stem cell procedure: Within 24 hours of harvesting the bone marrow.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; sham procedure performed but no placebo administered).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Safety of cell injections at 3 time points: i) early safety (periprocedural and up to 2 weeks); ii) 3 months;
and iii) 6 months: major adverse events (hospitalisation, arrhythmia, exacerbation of CHF, acute coro-
nary syndrome, MI, stroke, or death).
Secondary outcomes:
1. CCS angina score (baseline, 3 months, 6 months)
2. NYHA classification (baseline, 3 months, 6 months)
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3. Myocardial oxygen consumption (baseline, 3 months, 6 months)
4. Ejection fraction measured by echocardiography (baseline, 3 months, 6 months)
5. Minute ventilation - CO2 production relationship (VE/VCO2 slope) (baseline, 3 months)
6. Wall motion score index measured by echocardiography (baseline, 3 months)
7. LVEF measured by SPECT (baseline, 3 months, 6 months)
8. LVEF measured by angiography (baseline, 6 months)
9. LVEDV and LVESV (baseline and 6 months)
10.Endocardial unipolar voltages (UPV) (baseline, 6 months)
11.Linear local shortening (baseline, 6 months)
Outcome assessment points: Baseline, 3 and 6 months
Method(s) of outcome measurement: Not applicable.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation tables were prepared by the statistical department.
Allocation concealment
(selection bias)
Low risk Numbered, sealed envelopes were used.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Clinicians were not blinded, but participants received a simulated mock injec-
tion procedure (although it was unclear whether BM aspiration was undertak-
en in control group).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Efficacy studies were read by an independent, blinded investigator. Blinding
was maintained until the end of the assessment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00203203) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Perin 2011  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: NHLBI under co-operative agreement 5 U01 HL087318-04. In part by NHLBI contracts
N01-HB37164 and HHSN268201000008C awarded to the Molecular and Cellular Therapeutics Facili-
ty, University of Minnesota and NO1-HB-37163 and HHSN268201000007C awarded to the Cell Process-
ing Facility, Baylor College of Medicine and National Center for Research Resources CTSA grant UL1
TR000064 awarded to the University of Florida. The CCTRN also acknowledges its industry partners,
BioSafe, Biologics Delivery Systems Group, and Cordis Corporation for their contributions of equip-
ment and technical support during the conduct of the trial. (Full details and conflict of interest declara-
tions in the paper.)
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Study setting: USA
Number of centres: 5
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 61; Controls: 31
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 54; Controls: 28
Participants Description: Chronic IHD (aged > 18 years; clinically stable coronary artery disease, LVEF ≤ 45%, limiting
angina (CCS class II-IV) and/or CHF (NYHA class II-III), a perfusion defect by SPECT, and no revascularisa-
tion options while receiving guideline-based medical therapy).
Age distribution in each arm: BMSC: 63.95 ± 10.90 years; Controls: 62.32 ± 8.25 years.
Sex (% male) in each arm: BMSC: 86.89%; Controls: 93.65%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: Not reported.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Approximately 80 mL to 100 mL of BM
was aspirated from the iliac crest using standard techniques. The aspirate was processed using Ficoll
with a closed, automated cell processing system (Sepax). Composition of CD34 and CD133 cells was
determined by flow cytometry. Cells passed stipulated lot release criteria, included viability (> 70%)
and sterility. The target dose was 100 x 106 total BMC. The BMC final product was suspended in nor-
mal saline containing 5% human serum albumin and adjusted to a concentration of 100 x 106 cells in 3
mL distributed into three 1-millilitre syringes. The placebo group received a cell-free suspension in the
same volume. Mean (SD) volume of BM harvested was 93.7 (8.3) mL. Total dose of 100 x 106 contained
an average of 2.6% of CD34 cells and 1.2% of CD133 cells. Cells were delivered by intramyocardial injec-
tion. The cell-containing or cell-free preparation was delivered to viable myocardial regions identified
during electromechanical mapping of the LV endocardial surface (NOGA).
Dose of stem cells: 100 x 106 BMSC.
Timing of stem cell procedure: Within 12 hours of cell harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; cell-free suspension in the same volume).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
1. Change in LVESV (baseline, 6 months)
2. Change in maximal oxygen consumption (baseline, 6 months)
3. Change in reversible defect size on SPECT (baseline, 6 months)
Secondary outcomes:
1. Regional wall motion by MRI (baseline, 6 months)
2. Regional blood flow improvement by MRI (baseline, 6 months)
3. Regional wall motion by echocardiography (baseline, 6 months)
4. Clinical improvement in CCS classification (baseline, 6 months)
5. Clinical improvement in NYHA classification (baseline, 6 months)
6. Number of participants with a decrease in antianginal medication (baseline, 6 months)
7. Exercise time and level (6MWT) (baseline, 6 months)
8. Serum BNP levels in participants with CHF (baseline, 6 months)
9. LV diastolic dimension measured by echocardiography (baseline, 6 months)
10.Incidence of a major adverse cardiac event (baseline, 6 months)
11.Reduction in fixed perfusion defect via SPECT (baseline, 6 months)
Outcome assessment points: Baseline and 6 months
Perin 2012a  (Continued)
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
92
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Method(s) of outcome measurement: Echocardiography and SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was computer generated and used variable block sizes of 6 or
9, randomly selected and stratified by centre.
Allocation concealment
(selection bias)
Low risk Treatment assignment was masked to all but 1 designated cell-processing
team member at each centre not involved in participant care.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration, and the control group received a
placebo injection. All caregivers and participants were masked to treatment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The study was described as “double-blind”. Major adverse clinical events were
assessed by 2 independent cardiologists not affiliated with any clinical site and
masked to treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity outcomes. Reasons for loss to follow-up and withdrawals from
echocardiography and SPECT analysis were given, with similar attrition rates
in both treatment arms.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00824005) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Perin 2012a  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: "This work was supported solely by Aldagen, Inc, Durham, NC".
Study setting: Texas, USA
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 10; Controls: 10
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 10; Controls: 10
Participants Description: Advanced ischaemic HF (CCS class II-IV angina or NYHA class II-III HF; optimal medical ther-
apy, LVEF < 45% by echocardiography; presence of a reversible perfusion defect on SPECT, ineligible for
percutaneous or surgical revascularisation).
Age distribution in each arm: BMSC: 58.2 ± 6.1 years; Controls: 57.8 ± 5.5 years.
Sex (% male) in each arm: BMSC: 90%; Controls: 80%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: At least 1 month from the last MI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: ALDH+ cells
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Summary of stem cell isolation and type and route of delivery: 100 mL (± 20) BM was harvested from the
iliac crest under local anaesthesia unless institutional guidelines required general anaesthesia. Bone
marrow cells were depleted of CD15 and glycophorin-A-expressing cells using immunomagnetic beads
(EasySep). The cells were reacted with ALDH substrate and ALDH bright (+) cells were isolated using a
cell sorter (MoFlo or FACSAria). After centrifugation, the cells were resuspended in 3.5 mL 5% pharma-
ceutical grade human serum albumin. The final products were transferred to a 3-millilitre fluorinated
ethylene propylene bag with a needles entry port. ALDH (+) cells were administered intramyocardially
via a NOGA MyoStar catheter. Cells comprised a mean of 0.74% (0.28%) of the nucleared BM cells in the
unprocessed aspirates from participants (median 0.73%, range 0.35% to 1.16%). Cell injections were
targeted at areas of the myocardium identified as ischaemic or SPECT and as viable by EMM.
Dose of stem cells: 15 injections in a volume of 0.2 mL per injection. Mean number of nucleated cells ad-
ministered to the treatment group was 2.94 ± 1.58 x 106 cells (median 2.78 x 106, range 0.53 to 5.42 x
106). When the total cell doses were corrected for the proportion of ALDH (+) cells in the cell product,
the mean number of ALDH (+) cells administered to the cell treatment group was 2.37 ± 1.31 x 106 (me-
dian 2.27 x 106, range 0.35 to 4.42 x 106).
Timing of stem cell procedure: Products manufactured at Aldagen were administered within 50 to 55
hours of BM aspiration, whereas those produced locally at the University of Texas were administered
within 30 to 36 hours of aspiration.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; 5% albumin).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Safety (combined early and late adverse events) (baseline, 6 months)
Secondary outcomes:
1. NYHA classification (baseline, 6 months)
2. CCS score (baseline, 6 months)
3. EF measured by echocardiography (baseline, 6 months)
4. LVESV; LVEDV (baseline, 6 months)
5. Wall motion score index measured by echocardiography (baseline, 6 months)
6. Myocardial oxygen consumption (baseline, 6 months)
7. Total severity score (stress, rest, and reversible) (baseline, 6 months)
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated randomised sequence was used.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Control participants underwent an identical bone marrow harvest procedure,
including insertion of the needle, except that BM was not aspirated. Control
participants received transendocardial injections of placebo solution instead
of cell preparation. All personnel involved were blinded. Personnel involved in
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the harvesting procedure acted independently of the study team, thus main-
taining blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The trial was described as “double-blind”. Two blinded, independent echocar-
diologists reviewed the echocardiograms, and the average of the 2 readings
was reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (NCT00314366) were reported.
Other bias High risk This work was supported solely by Aldagen Inc, Durham, NC. No other sources
of bias were reported or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported.
Study setting: Russia
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 55; Controls: 54
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 49; Controls: 33 at the end of
study
Participants Description: Chronic MI and end-stage chronic HF (history of MI > 12 months before enrolment and fixed
perfusion defect on technetium-99m tetrofosmin SPECT; clinical symptoms of HF; ineligible for revas-
cularisation; LVEF < 35% as determined by 2-dimensional echocardiography).
Age distribution in each arm: BMSC: 61 ± 9 years; Controls: 62 ± 5 years.
Sex (% male) in each arm: BMSC: 87%; Controls: 85%.
Number of diseased vessels: BMSC: 1 (n = 2), 2 (n = 1), 3 (n = 52); Controls: 1 (n = 3), 2 (n = 3), 3 (n = 48).
Time from symptom onset to initial treatment: History of MI > 12 months before enrolment.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: On the day of surgery, BM was aspirated
from the iliac crest under local anaesthesia by the standard technique. BMMNC were isolated by Ficoll
density gradient centrifugation. 3 washing steps were performed, and the cells were resuspended in
heparinised saline for further use. Cell viability was tested by trypan blue (exclusion method) and es-
timated at more than 98% for each transplant. Intramyocardial injection. Non-fluroscopic mapping
with the NOGA system via femoral artery access and retrograde aortic approach using a 7-Fr NOGA-Star
catheter. An area of interest located by technetium-99m tetrofosmin SPECT was delineated in detail by
means of NOGA mapping, including ischaemic but viable myocardium. Immediately before injection,
the catheter was positioned perpendicularly to endocardium with excellent loop stability and the ex-
tension of the needle to induce premature ventricular contraction. 10 successive intramyocardial injec-
tions (roughly 0.2 mL each) were administered into the infarction border zone.
Dose of stem cells: 41 ± 16 x 106 BMSC, with 2.5 (1.6)% being CD34-positive cells.
Timing of stem cell procedure: Within 24 hours after cell harvesting.
G-CSF details: No G-CSF administered.
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Comparator arm: Control (no BM aspiration or placebo administration reported).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes: Efficacy of the intramyocardial injection of autologous bone marrow mononuclear
cells, measured by change in myocardial perfusion defects at rest and under pharmacological stress.
Secondary outcomes: Safety of the intramyocardial BMMNC therapy, quality of life, CCS angina class,
NYHA functional class, LV functions, life-threatening arrhythmias, mortality between 2 groups, NOGA
change in voltage assessed by NOGA follow-up endocardial mapping.
Outcome assessment points: Baseline, 6 and 12 months
Method(s) of outcome measurement: SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was carried out using an electronic system.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo was administered; participants and clinicians were not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk SPECT imaging was carried out though consensus by 2 readers blinded to the
type of study and clinical data. Other blinding was not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes (oth-
er than deaths prior to follow-up).
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Pokushalov 2010  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported by the S.K. Yee Medical Foundation Grant (208207); Research Grant Coun-
cil of Hong Kong: General Research Fund (no. HKU 780110M); the Collaborative Research Fund (HKU 8/
CRF/09); and Theme Based Research Scheme (T12-705/11).
Study setting: Jakarta (Indonesia) and Hong Kong (China)
Number of centres: 2
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 19; Controls: 9
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 19; Controls: 9
Santoso 2014 
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Participants Description: Advanced ischaemic HF (NYHA class III or IV; HF refractory to conventional medical thera-
py not eligible for conventional percutaneous or surgical revascularisation; existence of 1 or 2 coronary
territories of viable, ischaemic myocardium as documented by dipyridamole single-photon emission
computed tomographic perfusion study; and LVEF < 40% measured by transthoracic echocardiogram).
Age distribution in each arm: BMSC: 58 (5.9) years; Controls: 60 (5.6) years
Sex (% male) in each arm: BMSC: 95%; Controls: 100%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: At least 3 months since last MI.
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: On the day of the procedure, BMC were
harvested from every participant by an experienced haematologist via posterior iliac crest punc-
ture under local anaesthetic. A total of 80 mL to 100 mL of BM blood was aspirated, and an adequate
trephine biopsy was performed. Mononuclear cells were isolated by Ficoll density gradient centrifuga-
tion. Bone marrow cells were washed twice in PBS, resuspended in PBS enriched with 10% autologous
plasma to 100 × 106 mononuclear cells/mL, and returned directly to cardiac catheterisation laborato-
ry for use. In the preparation for the control group, BM cells were not included in the final suspension,
which comprised merely phosphate-buJered saline with 10% autologous plasma. Bone marrow sus-
pensions were tested by flow cytometry (Elite, Beckman Coulter, Fullerton, CA, USA) with directly con-
jugated antibodies. Cells administered by electromechanical mapping and endocardial injection (e.g.
NOGA system).
Dose of stem cells: n/r
Timing of stem cell procedure: At least 3 to 4 hours after BM harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; PBS with 10% autologous plasma).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Change in LVEF from baseline to 6 months' follow-up measured by MRI
Secondary outcomes:
Changes in exercise duration and MVO2 (treadmill modified Bruce protocol) (baseline and 6 months)
Note: main study publication reports secondary endpoints as changes in NYHA classification, LVESV, LV
infarct and peri-infarct ischaemic volume, and exercise performance (6MWT) (Santoso 2014).
Outcome assessment points: Baseline, 6 months; mean 23 (8) months (mortality only)
Method(s) of outcome measurement: MRI, NYHA, 6MWT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation codes were generated using a randomisation table; randomi-
sation was constrained, stratified by study centre.
Allocation concealment
(selection bias)
Low risk Randomisation was conducted via a system of sealed and numbered en-
velopes provided to each investigation centre.
Santoso 2014  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Bone marrow cells were harvested from all participants. The control group re-
ceived an identical final suspension but without cells. After randomisation,
participants were blinded to the study processes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk After randomisation, investigators who were responsible for participant as-
sessment were blinded to study processes.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes on
an intention-to-treat basis.
Selective reporting (re-
porting bias)
Unclear risk All outcomes reported in the trial protocol (NCT01150175) were reported; ad-
ditional outcomes were reported in the publication of results.
Other bias Low risk No other sources of bias were reported or identified.
Santoso 2014  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: n/r
Study setting: Belgrade, Serbia
Number of centres: 1
Length of follow-up: median 5 years (IQR 2.5 to 7.5)
Number (N) of participants randomised to each arm: BMSC: 15; Controls: 15
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 15; Controls: 15
Participants Description: IHD (aged 35 to 72 years; scheduled for CABG surgery due to LAD occlusion or multivessel
coronary disease; previous MI older than 30 days; established diagnosis of ischaemic cardiomyopathy
with LVEF < 40% and in the NYHA III-IV functional class, full medical treatment for HF).
Age distribution in each arm: BMSC: 53.8 (10.1) years; Controls: 60 (6.8) years.
Sex (% male) in each arm: BMSC: 93.3%; Controls: 93.3%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: Duration since last MI, BMSC: mean 3.2 (range 6 to 12)
months; Controls: mean 3.07 (range 6 to 12) months
Statistically significant baseline imbalances between the groups? Significantly higher hypercholestero-
laemia in BMSC group than in control group.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Bone marrow was obtained by multiple
aspirations from the posterior iliac crest in the amount of 150 mL, mixed with 25 mL of heparinised
saline and transferred into a sterile bag. The BMMNC fraction was isolated by gradient centrifugation.
All procedures from harvesting to cell injection were performed in a closed-circuit system using ster-
ile connection equipment with a sterile plastic bag system designated for cell transplantation in pre-
operative conditions. After finishing revascularisation with LIMA to LAD and sufficient number of au-
tovenous aortocoronary bypass graMs to achieve total targeted revascularisation (either “on pump” or
“oJ pump”, and if “on pump” when heart resumed its function from cardiopulmonary bypass), intramy-
ocardial injection of BMMNC was carried out with a 1-millilitre insulin syringe through a 27-gauge nee-
dle. Bone marrow mononuclear cells injection was targeted into the hypocontractile peri-infarcted vi-
able myocardium visually identified and performed transepicardially in 30- to 45-degree manner by
Trifunovic 2015 
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multiple injections (17.5 (3.8) injections) injecting 0.2 mL to 0.5 mL in each injection to a final volume of
5.7 (1.5) mL.
Dose of stem cells: Mean 70.7 (32.4) x 106 cells
Timing of stem cell procedure: n/r
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration, no placebo).
Co-intervention: CABG
Outcomes Primary outcomes:
Postoperative functional capacity and cardiac-related mortality in the median follow-up of 5 years.
Secondary outcomes:
Cardiovascular mortality, NYHA, 6MWT, LVEF, perfusion defect; BNP levels.
Outcome assessment points: Baseline, 2 and 4 months, 1 year and subsequent years (clinical f/up); pre-
operatively and 6 months and at 2-year intervals (SPECT) or at each follow-up visit (echocardiography);
baseline, 6 months and yearly (exercise capacity). Median follow-up 5 years (range 2.5 to 7.5 years).
Method(s) of outcome measurement: SPECT, echocardiography, 6MWT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was described as randomised, but the method of randomisation was
not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk This was an open-label trial; no blinding was carried out.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The heart team consisting of an interventional cardiologist/radiologist, heart
surgeon, and clinical cardiologist evaluated coronary angiography and all clin-
ical and imaging data and made decisions on coronary revascularisation and
stem cell implantation. This was an open-label trial; no blinding was reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: This study was partially supported by the Sun Chieh Yeh Heart Foundation Fund; S K
Ye Medical Foundation Grant (project no 203217), and The Research Grants Council of Hong Kong (HKU
7357/02M). Two authors received consultant fee from Biosense Webster, CA, USA. All other authors de-
clare that they have no conflict of interest.
Study setting: Hong Kong (China) and Newcastle (Australia)
Number of centres: 2
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 19; Controls: 9
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 19; Controls: 9
Participants Description: Refractory angina (CCS class III or IV; no conventional percutaneous or surgical revascular-
isation option; ability to complete > 3 min but < 10 min of treadmill exercise using modified Bruce pro-
tocol, and 1 or 2 coronary territories of viable, ischaemic myocardium as documented by dipyridamole
SPECT perfusion study).
Age distribution in each arm: BMSC: 65.2 ± 8.3 years; Controls: 68.9 ± 6.3 years.
Sex (% male) in each arm: BMSC: 79%; Controls: 88%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: Not reported.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Bone marrow was harvested via posteri-
or iliac crest puncture under local anaesthesia. A total of 40 mL of BM blood was aspirated, and an ad-
equate trephine biopsy was performed. Bone marrow mononuclear cells were isolated by Ficoll densi-
ty gradient centrifugation. Bone marrow cells were washed twice in phosphate-buJered saline, resus-
pended in phosphate-buJered saline enriched with 10% autologous plasma to either 1 or 2 x 107 MNC/
mL and returned directly to cardiac catheterisation laboratory for use. Bone marrow suspensions were
tested by flow cytometry with directly conjugated antibodies against CD34. Intramyocardial injection.
Non-fluoroscopic LV electromechanical mapping (NOGA) to identify the foci of ischaemic myocardium.
During the procedure, systemic anticoagulation was achieved with intravenous heparin to maintain an
activated clotting time of 250 to 300 s throughout the procedure. The targeted injection regions were
selected by matching the area of ischaemic myocardium identified by SPECT. After completion of the
LV electromechanical mapping, the mapping catheter was replaced by a modified mapping catheter in-
corporated with a 27G needle at the tip that could be used for direct endomyocardial injection.
Dose of stem cells: 1.5 x 107 BMMNC.
Timing of stem cell procedure: Within 3 to 4 hours from cell harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; 8 to 12 injections of 0.1 mL of phosphate buJered saline with
10% autologous serum).
Co-intervention: CABG
Outcomes Primary outcomes: Change from baseline in total exercise time on a modified Bruce protocol at 6
months' follow-up.
Secondary outcomes: Changes in LVEF, NYHA, and CCS angina classification and sum of different scores
on SPECT, global LVEF, LVEDV and LVESV by MRI.
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: SPECT and MRI
Notes  
Risk of bias
Tse 2007 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed using a randomisation table and was con-
strained, stratified by the study centre.
Allocation concealment
(selection bias)
Low risk Sealed, numbered envelopes were provided by the study centre (centralised)
to each investigational centre.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All randomised participants underwent BM aspiration, and the control group
received a placebo injection. After randomisation, the study processes were
blinded to participants. No details were given of the blinding of clinicians.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk After randomisation, the study processes were blinded to study co-ordinators
and investigators responsible for participants' assessment. Blinding was main-
tained until the end of the study.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes on
an intention-to-treat basis.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Tse 2007  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported
Study setting: Germany
Number of centres: 1
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: BMSC: 38; Controls: 18
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 33; Controls: 16
Participants Description: IHD (aged 18 to 80 years; documented MI at least 3 months previously; clear-cut demarcat-
ed region of leM ventricular dysfunction with an open infarct-related coronary artery at the time of stem
cell therapy).
Age distribution in each arm: BMSC: 62 ± 10 years old; Controls: 60 ± 9 years old.
Sex (% male) in each arm: BMSC: 52.6%; Controls: 55.6%.
Number of diseased vessels: BMSC: 1.5 ± 0.5; Controls: 2.0 ± 0.6.
Time from symptom onset to initial treatment: Transmural MI 28 ± 14 months before treatment.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC.
Type of stem cells: Mononuclear cells.
Summary of stem cell isolation and type and route of delivery: 120 mL bone marrow was aspirated from
the participant's own iliac crest, mononuclear cells were isolated using Harvest BMAC System (Ger-
many) (most likely by density gradient centrifugation) and concentrated into 20 mL of cell suspension.
Cell transplantation was performed via the coronary artery using 4 fractional infusions parallel to bal-
loon inflation over 2 to 4 mins of 5 mL cell suspension. Cells were infused directly into the infarcted
Turan 2011 
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artery via an angioplasty balloon catheter that was inflated at a low pressure and was located within
the previously stented coronary artery. Intracoronary infusion. This prevented back flow of cells and
produced stop flow beyond the site of balloon inflation to facilitate high-pressure infiltration of cells
into the infarcted zone with prolonged contact time for cellular migration. After undergoing arterial
puncture, all participants received 7500 to 10,000 units of heparin. 
Dose of stem cells: 99 x 106 (± 25) mononuclear cells.
Timing of stem cell procedure: Within 24 hours from cell harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration; no placebo administered).
Co-intervention: PCI
Outcomes Primary outcomes: Change in global EF as well as the size of infarcted area measured by leM ventricu-
lography.
Secondary outcomes: Functional activity of BMSC immediately pre-procedure and 3, 6, and 12 months
after procedure; functional status assessed by NYHA classification and brain natriuretic peptide level in
peripheral blood in both groups.
Outcome assessment points: Baseline, 3 and 12 months
Method(s) of outcome measurement: LeM ventriculography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The trial was described as randomised, but the method of randomisation was
not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants in the control group did not undergo BM aspiration, and no place-
bo was administered. Blinding was not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Haemodynamic investigations and laboratory results were obtained indepen-
dently by 2 investigators.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of mortality and
morbidity outcomes; 7 participants (5x cell therapy, 2x controls) were exclud-
ed from LVEF and functional capacity at follow-up due to restenosis.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Turan 2011  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
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Source of funding: This study is an academia-initiated exploratory Phase II study. No external sponsor
was involved in study design, data collection, data analysis, data interpretation, or writing of the re-
port. No external funding was applicable for this study.
Study setting: Leiden, the Netherlands
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 25; Controls: 25
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 25; Controls: 25
Participants Description: Severe angina (CCS class II-IV, myocardial ischaemia in at least 1 myocardial segment on
Tc099m tetrofosmin SPECT, ineligible for CABG or PCI).
Age distribution in each arm: BMSC: 64 ± 8 years; Controls: 62 ± 9 years.
Sex (% male) in each arm: BMSC: 92%; Controls: 80%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: At least 6 months from the last MI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Bone marrow was aspirated from the iliac
crest under local anaesthesia and placed in a heparinised Hanks balanced salt solution. The MNC were
isolated using Ficoll density gradient centrifugation, washed in phosphate-buJered saline with 0.5%
human serum albumin and resuspended in phosphate-buJered saline with 0.5% human serum albu-
min. The final suspension of BMMNC contained 40 x 102 mL. The filtered bone marrow was checked
for the presence of clots, and the BM cell population was analysed by fluorescence-activated cell sort-
ing using anti-CD34 and anti-CD35 antibodies. Intramyocardial injection. During cell isolation and ran-
domisation, a 3D electromechanical map of the LV was obtained using the NOGA system. The ischaemic
regions on SPECT were visually matched with the 3D electromechanical map based on anatomical
landmarks including LV long axis, position of apex, mitral valve area, aortic valve location, and basal in-
feroseptal point. Cross-referencing was also performed using fluoroscopic identification of anterior,
septal, lateral, and inferior orientations.
Dose of stem cells: The cell suspension contained 98 ± 6 x 106 BM cells with a cell viability of 98% (1%)
and a CD34+ cell fraction of 2.4% (0.9%).
Timing of stem cell procedure: Within 2 hours of BM aspiration.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; sodium chloride 0.9% with 0.5% human serum albumin).
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
Change in myocardial perfusion (SPECT) at 3 months' follow-up relative to baseline.
Secondary outcomes:
1. Angina frequency
2. CCS score
3. Quality of life
4. Exercise capacity
5. Change in LVEF at 3 months
6. Regional myocardial function on a segmental base at 3 months
7. Occurrence of arrhythmias
8. Pericardial effusion greater than 5 mm (echocardiography)
9. Myocardial damage
10.Severe inflammation
Van Ramshorst 2009  (Continued)
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Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was carried out using sequentially numbered, sealed en-
velopes provided by the Department of Medical Statistics and Bioinformatics.
A block size of 4 was used without further stratification.
Allocation concealment
(selection bias)
Low risk Sequentially numbered, sealed envelopes were used.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration, and the control group received a
placebo injection; participants were unaware of group assignment. A blinded
syringe with either cell suspension or placebo was used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Participants, study co-ordinators, and investigators involved in participant as-
sessments were unaware of group assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes on
an intention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial protocol (ISRCTN58194927) were reported.
Other bias Low risk No other sources of bias were reported or identified.
Van Ramshorst 2009  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Not reported.
Study setting: Beijing, China
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 16; Controls: 16
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 16; Controls: 16
Participants Description: Angina (no AMI in the month prior to transplantation).
Age distribution in each arm: BMSC: 60.6 years; Controls: 60 years.
Sex (% male) in each arm: BMSC: 56.25%; Controls: 63.25%.
Number of diseased vessels: Not reported.
Time from symptom onset to initial treatment: At least 1 month from the last AMI.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Wang 2009 
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Type of stem cells: CD34+ progenitor cells
Summary of stem cell isolation and type and route of delivery: 150 mL of BM was aspirated from the iliac
crest. CD34+ cells were enriched by a cell separation device under GMP conditions. CD34+ cells were re-
suspended in normal saline and kept at room temperature. Cells were transported to the catheterisa-
tion lab. Cells were delivered using a microcatheter following PCI.
Dose of stem cells: 1.0 - 6.1 x 106 CD34+ cells.
Timing of stem cell procedure: Unclear, not reported.
G-CSF details: No G-CSF administered.
Comparator arm: Control (no BM aspiration, no placebo administered).
Co-intervention: PCI
Outcomes Primary outcomes: Not reported.
Secondary outcomes: Myocardial perfusion defect area, wall motion, angina frequency change, nitrate
triglycerine dose change, angina classification by CCS class.
Outcome assessment points: Baseline and 6 months.
Method(s) of outcome measurement: SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding of clinicians and participants was not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome assessors were not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Wang 2009  (Continued)
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Type of publication: Full paper
Source of funding: Not reported.
Study setting: China
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Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 56; Controls: 56
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 56; Controls: 56
Participants Description: Intractable angina (aged > 30 years; diffuse triple-vessel disease; CCS class III or IV; opti-
mal medical therapy and considered ineligible for revascularisation, no ischaemia or nuclear perfusion
imaging according to the Bruce protocol; angina experienced during baseline exercise test).
Age distribution in each arm: BMSC: 42 to 80 years; Controls: 43 to 80 years.
Sex (% male) in each arm: BMSC: 51.79%; Controls: 50%.
Number of diseased vessels: 3
Time from symptom onset to initial treatment: Not reported.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: CD34+ progenitor cells
Summary of stem cell isolation and type and route of delivery: 120 mL to 150 mL bone marrow aspirates
from the posterior iliac crest were obtained from all participants. CD34+ cells were isolated by labelling
with the appropriate CD34 antibody and separating them magnetically using a CliniMACS (Miltenyi
Biotec). CD34+ cells were resuspended in 15 mL of saline + human serum albumin. Only the saline + hu-
man serum albumin was infused in the control group, using the same protocol as in the BMSC group.
The cells were infused into the coronary artery using a GE Innova 2000 DSA with 3000 units of heparin.
Approximately 1 to 2 hours after cell separation, 10 mL of cells and 5 mL of saline were infused into the
leM coronary artery and right coronary artery separately by an over-the-wire balloon.
Dose of stem cells: 5.6 ± 2.3 x 107 CD34 cells.
Timing of stem cell procedure: Within 2 hours of cell harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; saline + human serum albumin)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes: Safety (mortality and morbidities).
Secondary outcomes: Arrythmias, angina frequency, nitroglycerine use, exercise tolerance, CCS class,
perfusion effect or myocardial perfusion.
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: Treadmill test, CCS class
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration, and the control group received a
placebo injection. Participants were unaware of the treatment received. Blind-
ing of clinicians was not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All researchers were unaware of the treatments.
Wang 2010  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Wang 2010  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Conference abstract
Source of funding: Not reported.
Study setting: Guangzhou, China
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 35; Controls: 35
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 35; Controls: 35
Participants Description: Chronic IHD (impaired LV function: LVEF < 35%).
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Statistically significant baseline imbalances between the groups? None reported.
Interventions Intervention arm: BMSC
Type of stem cells: CD133+ progenitor cells
Summary of stem cell isolation and type and route of delivery: Injection of cells into the non-transmural
hypokinetic infract border zone. No further details reported.
Dose of stem cells: n/r
Timing of stem cell procedure: n/r
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration not reported; no further details)
Co-intervention: Standard medical therapy
Outcomes Primary outcomes:
LVEF measured by cMRI.
Secondary outcomes:
5-min walk test; NYHA, regional wall motion, scar mass, LVESV, LVEDV.
Outcome assessment points: Baseline, 6 months
Method(s) of outcome measurement: MRI, NYHA class, 5-min walk test
Notes  
Risk of bias
Wang 2014 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The trial was reported as "double-blind", but no details of blinding were re-
ported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The trial was reported as "double-blind", but no details of blinding were re-
ported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No withdrawals were reported in this conference abstract.
Selective reporting (re-
porting bias)
High risk All outcomes mentioned in the methods were reported in the results, although
selective reporting would be considered likely in this conference abstract. No
prospectively registered or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Wang 2014  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Supported by funding from the Major Project of Clinical Advanced Technology from
PLA (2010gxjs002 to H.W.) and funded in part by the National Natural Science Foundation of China
(30960379 to J.H.)
Study setting: Shenyang, China
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 45; Controls: 45
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 45; Controls: 45
Participants Description: Chronic MI (multivessel disease; admitted for elective OPCAB surgery at least 4 weeks after
a cardiac infarction).
Age distribution in each arm: BMSC: 61.4 (7.45) years; Controls: 62.9 (6.93) years.
Sex (% male) in each arm: BMSC: 82%; Controls: 78%.
Number of diseased vessels: n/r (multivessel)
Time from symptom onset to initial treatment: Duration since last MI, mean 18.2 (16.8) months (BMSC) or
20.1 (19.0) months (Controls).
Statistically significant baseline imbalances between the groups? None.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Bone marrow aspiration (100 mL) took
place from the sternum of all participants. Bone marrow mononuclear cells were isolated by gradient
centrifugation using Lymphoprep, washed twice with saline, and resuspended in 2 mL of heparinised
Wang 2015 
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saline. The 2 mL suspension or an equivalent volume of saline was injected with 8 punctures from a 22-
gauge Myjector syringe at the border zone of the infarct scar after finishing the revascularisation of the
infarct-related area. In cases where the infarct border could not be visualised, the cells were injected in
an area of myocardium that corresponded to the perfusion defect on SPECT or scintigraphy. The injec-
tions were made parallel to the epicardium to avoid leakage of cells or delivery into the ventricular cav-
ity, and depth was controlled with a plate stabiliser.
Dose of stem cells: mean 5.21 (0.44) x 108 cells
Timing of stem cell procedure: n/r
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration, saline solution)
Co-intervention: CABG
Outcomes Primary outcomes:
Incidence of emergent adverse events within the follow-up period (6 months).
Secondary outcomes:
LVEF, wall motion score index, LVEDV/LVESV, LVEDD/LVESD, arrhythmias, atrial fibrillation, non-sus-
tained ventricular tachycardia, ventricular premature beats, sustained ventricular tachycardia, tro-
ponin T levels.
Outcome assessment points: Baseline, 6 months
Method(s) of outcome measurement: Echocardiography
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration and received cells or a placebo in-
jection. The surgeon performing the OPCAB and injections was unaware of
whether the light-resistant syringe contained saline or BMC.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All preoperative baseline and follow-up echocardiography was performed by
an experienced cardiologist blinded to treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Wang 2015  (Continued)
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Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: This work was supported by Shanghai Scientific Research Fund (06DJ14001), Pro-
gram for Shanghai Outstanding Medical Academic Leader (LJ06008), and National Key Program
(2006CB943704).
Study setting: Shanghai, China
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 24; Controls: 23
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 24; Controls: 23
Participants Description: IHD (aged < 75 years; history of transmural MI and revascularisation plus stent implanta-
tion at least 6 months earlier; patent infarct-related artery at the time of stem cell transplantation).
Age distribution in each arm: BMSC: 54.8 ± 11.5 years; Controls: 56.3 ± 7.9 years.
Sex (% male) in each arm: BMSC: 96%; Controls: 96%.
Number of diseased vessels: BMSC: 1 (67%), 2 (29%), 3 (4%); Controls: 1 (70%), 2 (26%), 3 (4%).
Time from symptom onset to initial treatment: At least 6 months from last MI. 13 ± 8 months before entry
into study.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: Bone marrow (95 (20) mL) was collected
under local anaesthesia from the posterior superior iliac spine. Bone marrow cells were isolated and
enriched with the use of Ficoll-Hypaque gradient centrifugation procedures. Bone marrow aspirates
were diluted with 0.9% sodium chloride (1:5), and mononuclear cells were isolated by density gradient
centrifugation using Ficoll (800 g x 25 mins). Mononuclear cells were washed (800 g x 5 mins) 3 times
with phosphate-buJered saline and then resuspended in 16 mL of heparin-treated plasma at a den-
sity of 2.4 (1.2 x 107) cells/mL at room temperature. Before intracoronary injection, the mononuclear
cells were filtered (Falcon) and counted. These cells were used for therapy. To ensure that a certain %
of stem cells was present in the infused MNC, a 1 mL suspension was subjected to FACS analysis after
incubation with anti-human monoclonal antibodies: anti-human CD34 conjugated with FITC, or CD133
antibodies conjugated with APC. The FACS analysis revealed that 2.4% (0.9%) of BMC was positive for
CD34, and 0.75% (0.2%) was positive for CD133. Intracoronary infusion. An over-the-wire angioplasty
balloon catheter was inserted into the stent previously implanted during the acute reperfusion proce-
dure. The balloon was inflated with low pressure (2 atm to 4 atm) to completely block blood flow for 2
mins; this was repeated 5 times. During each balloon inflation, 3 mL of BMC suspensions was infused
distal to the occluding balloon into the infarct-related artery.
Dose of stem cells: 7.2 x 107 cells.
Timing of stem cell procedure: Within 6 hours after bone marrow puncture.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (0.9% sodium chloride containing heparin). Unclear whether BM aspiration
was performed.
Co-intervention: Standard medical therapy, PCI (in 30% of participants)
Outcomes Primary outcomes: Improvement of LV function.
Secondary outcomes: LVEF, LVED diameter, LVES diameter (echocardiography).
LVEF, LVESV, LVEDV, infarct size (MRI).
Myocardial perfusion (SPECT); mortality and morbidities.
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: Echocardiography, MRI, and SPECT
Notes  
Risk of bias
Yao 2008 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk This Chinese trial was described as randomised, but the method of randomisa-
tion was not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment was not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration, and the control group received a
placebo injection. Blinding of clinicians was not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors (MRI, echocardiography, SPECT) were blinded to the as-
signed therapy.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up.
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Yao 2008  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Full paper
Source of funding: Shanghai Medical Development Research Fund, Grant Number 2000I-2D002
Study setting: Shanghai, China
Number of centres: 1
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: BMSC: 18; Controls: 18
Number (N) of participants analysed (primary outcome) in each arm: BMSC: 18; Controls: 18
Participants Description: Ischaemic HF (aged 18 to 75 years; admitted for elective CABG; history of transmural old MI
with akinesis or dyskinesis of the leM ventricle shown by echocardiography; multivessel disease with a
reversible perfusion defect detected by SPECT; LVEF less than 40%).
Age distribution in each arm: BMSC: 60.3 ± 10.4 years; Controls: 59.1 ± 15.7 years.
Sex (% male) in each arm: BMSC: 83.3%; Controls: 83.3%.
Number of diseased vessels: multivessel, 2 or more
Time from symptom onset to initial treatment: Not reported.
Statistically significant baseline imbalances between the groups? No.
Interventions Intervention arm: BMSC
Type of stem cells: Mononuclear cells
Summary of stem cell isolation and type and route of delivery: After heparinisation and median sternoto-
my, BM (about 30 mL) was aspirated from the sternum by a special suction appliance in both groups.
The BMMNC were immediately isolated by density gradient centrifugation using Ficoll. Isolated cells
were washed twice with heparinised saline and subsequently resuspended in 5 mL saline. The cells
were counted and the viability was assessed by trypan blue dye exclusion. The cell suspension was fil-
Zhao 2008 
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tered by a 70-micron cell strainer before transplantation. During CABG, intramyocardial injection in and
around the infarct area at 10 points (approximately 0.5 mL per injection) with a 29-gauge syringe.
Dose of stem cells: 6.59 ± 5.12 x 108 (cell viability 96.48% ± 3.10%).
Timing of stem cell procedure: Within 24 hours following cell harvest.
G-CSF details: No G-CSF administered.
Comparator arm: Placebo (BM aspiration; saline).
Co-intervention: CABG
Outcomes Primary outcomes: Death, MI, and recurrence of HF.
Secondary outcomes: Echo: infarction wall thickness; infarction wall motion velocity; LVEDD/LVESD;
global LVEF; LV shortening fraction; mitral valve regurgitation.
SPECT: LV SRS; infarcted area SRS; clinical parameters; NYHA, CCS classification; 24-hour Holter analy-
sis.
Outcome assessment points: Baseline and 6 months
Method(s) of outcome measurement: Echocardiography and SPECT
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was achieved using a computer-generated sequence of ran-
dom numbers.
Allocation concealment
(selection bias)
Unclear risk No method of allocation concealment was reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants underwent BM aspiration, and the control group received a
placebo injection. Blinding of clinicians was not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The results were analysed by 2 independent, experienced observers; investiga-
tors (echocardiography, SPECT) were blinded to the randomisation scheme.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analysis of all outcomes at
follow-up (other than deaths).
Selective reporting (re-
porting bias)
Unclear risk All outcomes mentioned in the methods were reported in the results, although
it would be difficult to rule out selective reporting. No prospectively registered
or published trial protocol was identified.
Other bias Low risk No other sources of bias were reported or identified.
Zhao 2008  (Continued)
6MWT: 6-minute walk test
AEs: adverse events
ALDH: aldehyde dehydrogenase
AMI: acute myocardial infarction
AOI: area of interest
APC: allophycocyanin
BM: bone marrow
BMC: bone marrow cells
BMMNC: bone marrow mononuclear cells
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BMSC: bone marrow stem cells
BNP: brain natriuretic peptide
CABG: coronary artery bypass graMing
CAD: coronary artery disease
CCS: Canadian Cardiovascular Society
CCTRN: Cardiovascular Cell Therapy Research Network
CFU-GM: colony forming unit-granulocyte macrophage
CHF: congestive heart failure
cMRI: cardiovascular magnetic resonance imaging
CPC: circulating progenitor cells
CT: computed tomography
DM: diabetes mellitus
ECG: electrocardiogram
EDTA: ethylenediaminetetraacetic acid
EF: ejection fraction
EMM: electromechanical mapping
EPC: endothelial progenitor cells
FACS: fluorescence-activated cell sorting
FITC: fluorescein isothiocyanate
G-CSF: granulocyte colony-stimulating factor
GMP: good manufacturing practices
HF: heart failure
HTN: hypertension
IC: intracoronarily
IgG: immunoglobulin G
IHD: ischaemic heart disease
IM: intramyocardial
IQR: interquartile range
LAD: leM anterior descending
LDL: low-density lipoprotein
LIMA: leM internal mammary artery
LV: leM ventricular
LVEDD: leM ventricular end-diastolic diameter
LVEDV: leM ventricular end-diastolic volume
LVEF: leM ventricular ejection fraction
LVESD: leM ventricular end-systolic diameter
LVESV: leM ventricular end-systolic volume
MACE: major adverse clinical events
MI: myocardial infarction
MLHFQ: Minnesota Living with Heart Failure Questionnaire
MNC: mononuclear cells
MRI: magnetic resonance imaging
MSC: mesenchymal stem cells
MVO2: myocardial oxygen consumption
NHLBI: National Heart, Lung, and Blood Institute
n/r: not reported
NTG: nitroglycerine
NT-proBNP: N-terminal pro b-type natriuretic peptide
NYHA: New York Heart Association
OPCAB: oJ-pump coronary artery bypass
PBS: phosphate-buJered saline
PBSC: peripheral blood stem cell
PC: progenitor cells
PCI: percutaneous coronary intervention
PET: positron emission tomography
QOL: quality of life
RCT: randomised controlled trial
SD: standard deviation
SE: standard error
SF-36: 13-Item Short Form Health Survey
SPECT: single-photon emission computed tomography
SRS: segmental resting score
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
113
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
SV: stroke volume
STEMI: ST elevation myocardial infarction
TIMI: Thrombolysis In Myocardial Infarction
VEGF: vascular endothelial growth factor
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ascheim 2014 RCT of allogeneic mesenchymal precursor cells.
Assmann 2014 Single-arm trial of CD133+ in ischaemic cardiomyopathy, no control arm included.
Beeres 2006 Single-arm substudy of BMMNC in refractory angina and chronic myocardial ischaemia, no control
arm included.
Beeres 2007 Single-arm trial of BMMNC in chronic ischaemia, no control arm included.
Beeres 2007a Single-arm trial of BMMNC in chronic myocardial infarction and severe leM ventricular dysfunction,
no control arm included.
Beeres 2007b Review of imaging techniques for cardiac stem cell therapy.
Bittencourt 2008 Single-arm trial of BMSC in severe coronary artery disease, no control arm included.
Bolli 2011 RCT of cardiac stem cells in ischaemic cardiomyopathy, no BMSC administered.
Chang 2006 RCT of peripheral blood stem cells in AMI.
Charwat 2010 Randomised trial of early versus late administration of BMMNC in AMI.
Chen 2014 RCT of G-CSF-mobilised PBSC in heart failure; G-CSF was not administered to the control group.
Chin 2010 Single-arm trial of autologous MSC in end-stage dilated cardiomyopathy.
EUCTR2006-005628-17-ES RCT of BMMNC in people with AMI.
EUCTR2009-017924-18-NL A follow-on study of people with refractory angina and documented ischaemia who received bone
marrow-derived cells in 2 previous trials, no control arm included.
Fuchs 2004 Single-arm trial of bone marrow cells in advanced ischaemic heart disease, no control arm includ-
ed.
Gu 2011 Non-randomised trial of single or repeated infusion of PBSC and G-CSF compared with a control
group in refractory ischaemic heart failure.
Haack-Sorensen 2013 A single-arm trial of autologous MSC in stable coronary artery disease and refractory angina, no
control arm included.
Jimenez-Quevedo 2008 A comparison of outcomes in diabetic/non-diabetic patients with end-stage heart failure who re-
ceived BMMNC in a previous trial.
Kang 2006 RCT of G-CSF-mobilised PBSC in people with acute and old myocardial infarction; G-CSF was not
administered to the control group.
Kang 2006b RCT of G-CSF-mobilised PBSC in people with acute myocardial infarction.
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
114
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Karantalis 2014 RCT of autologous MSC in people undergoing CABG; trial suspended due to low accrual and no con-
trol participants included.
Koestering 2005 Non-randomised trial of BMMNC in chronic coronary artery disease.
Lai 2009 RCT of autologous MSC in people undergoing CABG; study of cardiac enzyme outcomes measured
within 24 to 48 hours of treatment, which are not relevant to this review. No further publications
have been identified.
Lee 2015 RCT of CD34+ in end-stage diffuse coronary artery disease comparing 2 cell doses, no control arm
included.
Makkar 2011 RCT of cardiosphere-derived cells in AMI.
Mann 2015 A follow-on single-arm substudy of 3 previous cell therapy trials, no control group included.
Maroto 2010 RCT of BMMNC in sub-acute myocardial infarction (within 15 days).
Maureira 2012 Although this study was described as randomised, the 7 participants in each treatment arm (14 in
total) were matched by age and sex.
Mocini 2006 Non-randomised study of BMSC in AMI.
Nagaya 2007 Non-randomised study of BMMSC for severe chronic heart failure.
NCT00285454 Study withdrawn prior to enrolment.
NCT00289822 Trial terminated (reason not given), no relevant publications identified.
NCT00362388 Trial terminated (reason not given), no relevant publications identified.
NCT01074099 Trial terminated due to pilot study resulting in changes to protocol and new study required.
NCT01337011 RCT of intramyocardial versus intracoronary administration of enriched CD133+ cells, no control
arm included.
NCT01666132 Trial terminated after phase I due to slow recruitment.
NCT01693042 RCT of single versus repeated administration of BMMNC in chronic postinfarction HF, no control
arm included.
NCT01721902 Trial terminated due to lack of recruitment, no relevant publications identified.
Perin 2003 Non-randomised controlled trial of BMMNC in chronic ischaemic heart failure.
Peruga 2009 Non-randomised trial of BMMNC in AMI.
Poglajen 2013 Single-arm trial of CD34+ cell in ischaemic cardiomyopathy.
Pokushalov 2011 Randomised cross-over trial of cardiac resynchronisation and BMMNC in ischaemic heart failure, no
control arm included.
Premer 2014 Randomised trial of autologous versus allogeneic MSC in dilated cardiomyopathy.
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Study Reason for exclusion
Qin 2015 RCT of cardiosphere-derived cells for heart regeneration after myocardial infarction; no bone mar-
row-derived cells were administered.
Rivas-Plata 2010 Non-RCT of BMMNC in people with heart failure.
Shen 2007 Pre-clinical animal study of BMMSC after AMI.
Stamm 2007a Non-randomised trial of CD133+ cells in chronic ischaemic heart disease.
Suncion 2014 A single-arm substudy of the POSEIDON (Prevention of Contrast Renal Injury with Different Hydra-
tion Strategies) trial, no control arm.
Takehara 2012 A single-arm trial of autologous human cardiac-derived stem cells in ischaemic cardiomyopathy.
Tuma 2010 A comparison of outcomes in people with ischaemic and non-ischaemic heart failure who received
CD34+ and MSC.
Tuma 2011 A single-arm trial of BMMNC in refractory angina.
Vicario 2004 A single-arm trial of autologous unfractionated bone marrow in refractory angina.
Vrtovec 2015 A comparison of the effects of CD34+ cell therapy in ischaemic and non-ischaemic HF, no control
arm included.
Wang 2006 Non-randomised trial of BMMNC in AMI.
AMI: acute myocardial infarction
BMMNC: bone marrow mononuclear cells
BMMSC: bone marrow mesenchymal stem cells
BMSC: bone marrow stem cells
CABG: coronary artery bypass graMing
G-CSF: granulocyte colony-stimulating factor
MSC: mesenchymal stem cells
PBSC: peripheral blood stem cell
RCT: randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: Tehran, Iran
Number of centres: n/r
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: n/r
Number (N) of participants analysed (primary outcome) in each arm: 10 (cell therapy), 10 (controls)
Participants Description: Ischaemic cardiomyopathy and low global ejection fraction (< 35%)
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Ahmadi 2010 
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Statistically significant baseline imbalances between the groups? n/r
Interventions Intervention arm: CABG + intramyocardial mesenchymal/CD133+ stem cells
Type of cells: Intramyocardial mesenchymal/CD133+ stem cells
Dose of cells: n/r
Timing of stem cell procedure: Bone marrow was harvested from iliac crest 2 weeks prior to surgery,
and purified expanded mesenchymal/CD133+ stem/progenitor cells were injected in the ischaemic
border zone of the heart during CABG.
Comparator arm: CABG only
Outcomes LV function, wall motion score index, mortality, morbidities
Outcome assessment points: Baseline, 6 months
Method of measurement: Echocardiography
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Ahmadi 2010  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: n/r
Number of centres: n/r
Length of follow-up: 35 months
Number (N) of participants randomised to each arm: n/r (total 27)
Number (N) of participants analysed (primary outcome) in each arm: n/r
Participants Description: Severe ischaemic HF undergoing CABG
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm 1: CABG + BMMSC
Intervention arm 2: CABG + recycling stem cells
Type of cells: BMMNC
Dose of cells: n/r
Timing of stem cell procedure: Cells were injected in the border zone of the infarcted myocardium.
Comparator arm: CABG
Ahmadi 2015 
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Outcomes Morbidy, mortality, LVEF wall motion score index.
Outcome assessment points: Baseline, 36 months
Method of measurement: Echocardiography
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Ahmadi 2015  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: Italy
Number of centres: n/r
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: n/r (total 37 randomised 1:1)
Number (N) of participants analysed (primary outcome) in each arm: n/r (total 16)
Participants Description: Ischaemic cardiomyopathy (acute transmural MI less than 6 months prior to admission
and LVEF lower than 35%).
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: < 6 months prior to admission
Interventions Intervention arm: CABG + BMMNC
Type of cells: BMMNC
Dose of cells: n/r
Timing of stem cell procedure: Bone marrow mononuclear cells were isolated from bone marrow as-
pirates and injected intramyocardially during cardiac surgery (CABG).
Comparator arm: CABG + placebo
Outcomes Periprocedural adverse events, mortality, LVEF and LV volumes; flow cytometry measures
Outcome assessment points: 6 and 12 months
Method of measurement: Not reported.
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Cuzzola 2007 
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Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: Buenos Aires, Argentina
Number of centres: n/r
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: n/r
Number (N) of participants analysed (primary outcome) in each arm: 7 cell therapy, 8 controls
Participants Description: Chronic MI with patent infarct-related artery, extensive necrosis, no development of is-
chaemia, and impaired ventricular function.
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: < 3 months
Interventions Intervention arm: BMSC
Type of cells CD34+ and CD133+ cells
Dose of cells: 4 - 10 x 106
Timing of stem cell procedure: Bone marrow aspiration, with filter and cell processing to obtain
CD34+ and CD133+, and latter intracoronary injection of this preparation through the infarct-relat-
ed artery.
Comparator arm: Control (optimal medical therapy)
Outcomes Major cardiovascular events, rehospitalisation, target vessel revascularisation, LVEF, myocardial
perfusion (summed rest score)
Outcome assessment points: Baseline, 12 months
Method of measurement: Radioisotopic ventriculography
Notes Participants are from the chronic branch of the "RECUPERAR" study. To our knowledge, this tri-
al has published in abstract form only with insufficient reporting of methodology to determine
whether this substudy is randomised. Should further publications be identified confirming this, the
study will be incorporated into future updates to this review.
Grynberg 2008 
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: China
Number of centres: n/r
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Length of follow-up: 12 months
Number (N) of participants randomised to each arm: n/r (110 in total)
Number (N) of participants analysed (primary outcome) in each arm: 42x cell therapy (assumed 68
controls)
Participants Description: Ischaemic HF with LVEF < 45%
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: BMSC
Type of cells: Mononuclear cells
Dose of cells: 8.6 x 108
Timing of stem cell procedure: Cells or placebo were injected intraoperatively into the MI border
area.
Comparator arm: Placebo (no details)
Outcomes Myocardial scar size, LVEF, cell viability, wall thickening
Outcome assessment points: Baseline, 12 months
Method of measurement: MRI, PET
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Jie 2014  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: Moscow, Russia
Number of centres: n/r
Length of follow-up: 6 months
Number (N) of participants randomised to each arm: n/r
Number (N) of participants analysed (primary outcome) in each arm: n/r (total 50 participants)
Participants Description: Chronic HF patients in NYHA class III-IV (24 participants with ischaemic dilated car-
diomyopathy and 26 participants with idiopathic dilated cardiomyopathy)
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Kakuchaya 2011 
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Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: BMSC
Type of cells: CD133+
Dose of cells: n/r
Timing of stem cell procedure: CD133+ were obtained by CliniMACS technology of magnetic separa-
tion.
Comparator arm: Placebo
Outcomes LVEF, LV volumes, LV mass
Outcome assessment points: Baseline, 6 months
Method of measurement: SPECT
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Kakuchaya 2011  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: Beijing, China
Number of centres: n/r
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: n/r
Number (N) of participants analysed (primary outcome) in each arm: n/r (50 in total)
Participants Description: Old MI
Age distribution in each arm: total: 57.48 ± 7.98 years
Sex (% male) in each arm: total: 94%
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: CABG + BMSC
Type of cells: BMMNC
Dose of cells: n/r
Timing of stem cell procedure: No details of cell isolation or cell delivery method reported.
Comparator arm: CABG + placebo
Outcomes LVEF, LV volumes, cardiac output, cardiac index, cardiac mass, infarct size
Outcome assessment points: Baseline, 12 months
Minjie 2011 
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Method of measurement: MRI
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Minjie 2011  (Continued)
 
 
Methods Type of study: Controlled trial (unclear whether randomised)
Type of publication: Abstract
Source of funding: n/r
Study setting: Yazd, Iran
Number of centres: n/r
Length of follow-up: n/r
Number (N) of participants randomised to each arm: n/r (15 recruited in total)
Number (N) of participants analysed (primary outcome) in each arm: n/r
Participants Description: Severe ischaemic cardiomyopathy requiring CABG
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: CABG + BMSC
Type of cells: BMSC
Dose of cells: median 5 x 107 (SD 1 x 106) cells
Timing of stem cell procedure: No details given.
Comparator arm: CABG + placebo
Outcomes Periprocedural adverse events, angina frequency, LVEF, LV volumes, wall motion
Outcome assessment points: n/r
Method of measurement: n/r
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Pourrajab 2013 
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Stefanelli 2015 
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
122
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study setting: Modena, Italy
Number of centres: n/r
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: 19x BMSC, 11x controls
Number (N) of participants analysed (primary outcome) in each arm: 10x BMSC, controls n/r
Participants Description: Ischaemic HF
Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: LV restoration + BMSC
Type of cells: BMMNC
Dose of cells: 5 cm3 to 8 cm3
Timing of stem cell procedure: Mononuclear cells were derived from the sternal bone marrow and
processed in a sterile mini-lab before injection by direct visualisation into the infarcted areas of the
myocardium before LV reconstruction.
Comparator arm: LV restoration only
Outcomes Mortality, rehospitalisation, change in LVEF diameter, change in LVEF and NYHA, change in infarct-
ed area
Outcome assessment points: Baseline, 6 and 12 months
Method of measurement: Echocardiography, PET
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Stefanelli 2015  (Continued)
 
 
Methods Type of study: Parallel RCT
Type of publication: Abstract
Source of funding: n/r
Study setting: St Petersburg, Russia
Number of centres: n/r
Length of follow-up: 12 months
Number (N) of participants randomised to each arm: 18x BMMSC, 38x BMMNC, 13x controls
Number (N) of participants analysed (primary outcome) in each arm: 8x BMMSC, 38x BMMNC, 13x
controls
Participants Description: Non-acute IHD
Zverev 2006 
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Age distribution in each arm: n/r
Sex (% male) in each arm: n/r
Number of diseased vessels: n/r
Time from symptom onset to initial treatment: n/r
Interventions Intervention arm: BMMSC or BMMNC
Type of cells: BMMSC or BMMNC
Dose of cells: 12 x 108 cells
Timing of stem cell procedure: Mesenchymal stem cells were isolated from bone marrow and cul-
tured in vitro. Bone marrow mononuclear cells were also isolated from bone marrow. Cells were
delivered via the coronary artery.
Comparator arm: Placebo
Outcomes Angina episodes, nitroglycerine consumption, myocardial viability and perfusion, LVEF
Outcome assessment points: Baseline, 6, 9, and 12 months
Method of measurement: PET, SPECT, echocardiography
Notes To our knowledge, this trial has published in abstract form only with insufficient data reporting for
inclusion. Should further publications be identified, this study will be incorporated into future up-
dates to this review.
Zverev 2006  (Continued)
AMI: acute myocardial infarction
BMMNC: bone marrow mononuclear cells
BMMSC: bone marrow mesenchymal stem cells
BMSC: bone marrow stem cells
BNP: brain natriuretic peptide
CABG: coronary artery bypass graMing
CCS: Canadian Cardiovascular Society
CPC: circulating progenitor cells
EPC: endothelial progenitor cells
G-CSF: granulocyte colony-stimulating factor
HF: heart failure
IC: intracoronary
IM: intramyocardial
LV: leM ventricular
LVEF: leM ventricular ejection fraction
LVEDV: leM ventricular end-diastolic volume
LVESV: leM ventricular end-systolic volume
MACE: major adverse clinical events
MI: myocardial infarction
MRI: magnetic resonance imaging
MSC: mesenchymal stem cells
MVO2: myocardial oxygen consumption
NYHA: New York Heart Association
PCI: percutaneous coronary intervention
PET: positron emission tomography
RCT: randomised controlled trial
SD: standard deviation
SPECT: single-photon emission computed tomography
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Trial name or title Injection of autologous bone marrow cells into damaged myocardium of no-option patients with
ischaemic heart failure: a randomised placebo controlled trial - cell therapy for ischaemic heart
failure
Methods A randomised, double-blind, cross-over, placebo-controlled trial
Participants Ischaemic HF:
1. Ischaemic HF NYHA class III or IV despite optimal pharmacological and non-pharmacological ther-
apy.
2. No candidate for (repeat) surgery (revascularisation, valve repair, or ventricular reconstruction).
3. No candidate for (repeat) percutaneous revascularisation.
4. Optimal resynchronisation therapy, or no candidate for resynchronisation therapy.
5. Male or female > 18 and < 75 years old.
6. Life expectancy more than 6 months.
7. Able to perform an exercise tolerance test prior to therapy.
8. Able and willing to undergo all the tests used in this protocol including the travelling involved.
9. Written informed consent.
Interventions Intervention arm: Intracardiac administration of bone marrow mononuclear cells
Comparator arm: Intracardiac administration of placebo
Outcomes Primary outcomes:
1. LeM ventricular global ejection fraction as assessed by gated SPECT.
2. LV regional wall motion by echocardiography.
3. FDG-SPECT for assessment of viability and hibernation.
4. Myocardial innervation imaging (MIBG-SPECT) for assessment of myocardial innervation.
5. Exercise capacity by bicycle exercise testing with VO2 measurement.
6. Quality of life assessed using the MLHFQ.
Secondary outcomes:
Safety (incidence of arrhythmias via Holter monitoring, inflammation and myocardial damage)
Starting date July 2010
Contact information None identified.
Notes Planned enrolment: 64
Estimated completion date: The status of this trial is "completed", but no publications have been
identified.
EUCTR2009-016364-36-NL 
 
 
Trial name or title Bone-marrow derived stem cell transplantation in patients undergoing leM ventricular restoration
surgery for dilated ischaemic end-stage heart failure: a randomised blinded controlled trial (Trans-
ACT 2)
Methods A double-blind, randomised, placebo-controlled trial
Participants End-stage HF:
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1. Previous anterior MI (with evidence of large surgically excludible scar at cardiac MRI).
2. Significant LV dilation (LVESV index greater than or equal to 60 mL/m2).
3. LVEF less than or equal to 35%.
4. NYHA class III/IV and 1 episode of CHF requiring medical attention.
5. Elective leM ventricular restoration surgery indicated.
6. Elective CABG indicated to bypass stenoses or occlusions of coronary arteries.
7. Participant aged ≥ 16 and < 80 years old, either sex.
Interventions Intervention arm: Surgical ventricular restoration and transplantation of autologous CD133+
Comparator arm: Surgical ventricular restoration and injection of placebo, i.e. autologous plasma
Outcomes Primary outcome:
Regional LV thickening of the 'affected' segments 6 months after surgery.
Secondary outcomes:
1. Mid-term generic and cardiac-specific health status and quality of life, measured at baseline and
6 months' follow-up.
2. End-systolic volume and stroke volume quantified by cardiac MRI, measured at baseline (3 to 5
days postoperatively), and 6 months' follow-up.
3. Myocardial injury throughout the duration of the study by measuring troponin I levels (24 hours
preoperatively; surgery; 4, 12, 24 hours postoperatively; 6 weeks' and 6 months' follow-up).
Starting date August 2009
Contact information University of Bristol, Bristol Royal Infirmary. Contact: Mr R Ascione (r.ascione@bristol.ac.uk)
Notes Planned enrolment: 40
Estimated completion date: The status of this trial is "completed", but no publications have been
identified.
ISRCTN71717097  (Continued)
 
 
Trial name or title A pilot study to evaluate the efficacy of combined transplantation of progenitor cells and coronary
artery bypass grafting (TOPCABG)
Methods RCT
Participants Participants undergoing CABG
Interventions Intervention arm: Stem cells (5 participants)
Comparator arm: Heparinised saline (5 participants)
Outcomes Primary outcome: To show improvements in myocardial function, regional wall motion, and my-
ocardial perfusion.
Starting date January 2004
Contact information Southampton University Hospitals NHS Trust, Level D, East Wing, Southampton General Hospital,
Tremona Road, Southampton, UK SO16 6YD. Contact: Mr D Varghese (dvarghese@btinternet.com)
Notes Planned enrolment: 10
ISRCTN75217135 
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Estimated completion date: The status of this trial is "completed", but no publications have been
identified.
ISRCTN75217135  (Continued)
 
 
Trial name or title Bypass surgery with stem cell therapy in chronic ischemic cardiopathy
Methods A phase II, parallel, randomised, single-blind (participant) controlled study
Participants IHD:
1. Aged 18 to 75 years.
2. Chronic IHD.
3. LVESV > 140 mL.
4. Poor global contractile function (LVEF < 40%).
5. Substantial amount of residual viability (> 30% of leM ventricle).
Interventions Intervention arm: Surgical revascularisation associated with autologous bone marrow-derived
stem cells injection in viable territories.
Comparator arm: Surgical revascularisation alone.
Outcomes Primary outcome: Evolution of leM ventricular volumes and contractility.
Secondary outcome: Functional status.
Starting date May 2008
Contact information Departments of Cardiac Surgery, Cardiology and Radiology, University Hospital, Clermont-Ferrand,
France (Principal Investigator: Dr J Lipiecki. Contact: Patrick Lacarin (placarin@chu-clermontfer-
rand.fr)
Notes Planned enrolment: 12
Estimated completion date: June 2011
The status of this trial is "completed", but no publications have been identified.
NCT00690209 
 
 
Trial name or title Phase II combination stem cell therapy for the treatment of severe coronary ischemia (CI)
Methods A phase II, randomised, placebo-controlled, safety/efficacy study
Participants Severe coronary ischaemia:
1. Age 18 to 80.
2. Men or women.
3. Angina pectoris: CCS class III or IV or symptoms consistent with angina equivalent (dyspnoea) CCS
class III or IV (Functional Class).
4. Chronic coronary artery disease in at least 1 epicardial vessel with stenosis > 70% by coronary
angiography within the last 6 months.
5. Stable medical therapy for at least 1 month.
6. Reversible perfusion defects by SPECT.
NCT00790764 
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7. Not a candidate for coronary artery bypass surgery due to poor targets or small vessels and not
a candidate for percutaneous intervention due to small vessels or unreachable coronary lesions
due to complicated anatomy.
Interventions Enrolled individuals (60) will be divided into 2 treatment groups for the infusion of the cell/placebo
product:
1. Intervention arm A: 30 individuals, including patients and placebo controls, will receive the prod-
uct by intracoronary infusion.
2. Intervention arm B: 30 individuals, including patients and placebo controls, will receive the prod-
uct by transendocardial injections.
In turn, each treatment group will consist of 2 subgroups of individuals that will receive the infu-
sion of 1 of the 2 doses established of the cell product:
1. In subgroup 1, 10 individuals will receive the 'low dose' of the cell product, and 5 individuals will
receive the placebo product.
2. In subgroup 2, 10 individuals will receive the 'high dose' of the cell product, and 5 individuals will
receive the placebo product.
For the cell product, proper aliquots of each cell type will be taken to fulfil the doses established for
this protocol. The 2 aliquots will be mixed and resuspended to a final volume of 3 mL in the "final
suspension medium", which consists of Dulbecco's Phosphate BuJered Saline, containing 5% HSA.
For placebo, 3 mL of the "final suspension medium", which consists of Dulbecco's Phosphate
BuJered Saline, containing 5% HSA will be transferred to a 5-millilitre syringe.
Outcomes Primary outcome: Safety as measured by laboratory assessments, ECG, and temperature (2 weeks).
Secondary outcome: Efficacy as measured by SPECT scan, MUGA scan, and 2D echocardiogram (6
months).
Starting date November 2008
Contact information TCA Cellular Therapy, Covington, LA, United States, 70433 (Principal Investigator: Dr Patrick
Lacarin)
Notes Planned enrolment: 60
Estimated completion date: November 2011
This study has suspended participant recruitment due to lack of funding.
NCT00790764  (Continued)
 
 
Trial name or title Intramyocardial delivery of autologous bone marrow
Methods A phase II, parallel, randomised, double-blind (participant, investigator), safety/efficacy study
Participants Refractory angina:
1. Participants > 21 years old.
2. Participants with functional class (CCS) III or IV angina.
3. Participants with LVEF < 30%.
4. Attempted 'best' tolerated medical therapy.
5. Clinical signs and symptoms of myocardial ischaemia with reversible ischaemia on perfusion
imaging.
6. Participant deemed to be a poor candidate or at high surgical risk.
NCT00820586 
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7. Participant must be able to complete a minimum of 2 minutes but no more than 10 minutes ex-
ercise test (Bruce protocol).
8. Participant (or their legal guardian) understands the nature of the procedure and provides written
consent prior to the procedure.
9. Participant is willing to comply with specified follow-up evaluations.
10.Participant must develop angina and a horizontal or down-sloping ST segment depression of < 1
mm during exercise, compared to pre-exercise ST segment, 80 ms from the J point or moderate
angina with or without the above ST segment changes.
Angiographic inclusion criteria:
1. Severe obstruction (lumen diameter stenosis > 70%) in a coronary or surgical conduit believed to
be solely or partially responsible for angina and myocardial ischaemia.
2. At least 1 coronary or surgical conduit with < 70% diameter stenosis.
3. Poor candidate for PCI of treatment zone.
4. Poor candidates for surgical revascularisation procedures, such as inadequate target coronary
anatomy or lack of potential surgical conduits.
Interventions Intervention arm: Direct intramyocardial percutaneous delivery of autologous total bone mar-
row-derived total mononuclear cells or selected CD34+ bone marrow-derived cells.
Comparator arm: Not specified.
Outcomes Primary outcome:
Incidence of MACE, defined as a combined endpoint of death, acute MI (Q wave and non-Q wave),
revascularisation procedures (percutaneous or surgical), and periprocedural complications (i.e.
leM ventricular perforation with haemodynamic consequences requiring pericardiocentesis, and
stroke) (1/3/6/12 months).
Secondary outcomes:
1. Change in CCS angina classification score from baseline (12 months).
2. Changes in the quality of life, as assessed according to the Seattle Angina Questionnaire.
3. Change in exercise duration and exercise tolerance using standardised treadmill exercise testing
from baseline (6/12 months).
4. Cumulative number of hospitalisations for coronary ischaemia and CHF (12 months).
5. SPECT changes in global and regional radionuclide perfusion at rest, peak stress, and redistribu-
tion from baseline (1/6/12 months).
6. Change in angiographic collateral score (6 months).
7. Change in global and regional myocardial contractility (assessed by echocardiography) from
baseline (6/12 months).
Starting date January 2009
Contact information Antonio Colombo, Director of Invasive Cardiology Unit, IRCCS San Raffaele, Milan, Italy
Notes Planned enrolment: 13
Estimated completion date: February 2012
This study has suspended participant recruitment due to lack of further funding support.
NCT00820586  (Continued)
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Trial name or title Intramyocardial transplantation of bone marrow stem cells in addition to coronary artery bypass
graM (CABG) surgery (PERFECT)
Methods A phase III, randomised, parallel, double-blind (participant, caregiver, investigator, outcomes as-
sessor) efficacy study
Participants Chronic ischaemic coronary artery disease:
1. Coronary artery disease after MI with indication for CABG surgery.
2. Currently reduced global LVEF assessed at site by cardiac MRI at rest (25% ≤ LVEF ≤ 50%).
3. Presence of a localised akinetic/hypokinetic/hypoperfused area of LV myocardium for defining
the target area.
4. Informed consent of the participant.
5. Aged ≥ 18 and < 80 years.
6. Not pregnant and do not plan to become pregnant during the study. Women with childbearing
potential must provide a negative pregnancy test within 1 to 7 days before operation and must be
using oral or injectable contraception (non-childbearing potential is defined as postmenopausal
for at least 1 year or surgical sterilisation or hysterectomy at least 3 months before study start).
Interventions Intervention arm: Intramyocardial injection of 5 mL CD133+ cells (0.5 - 5 x 106 cells) suspended in
physiological saline + 10% autologous serum intramyocardially during CABG surgery.
Comparator arm: Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum
intramyocardially during CABG surgery.
Outcomes Primary outcome:
LVEF at rest, measured by MRI (6 months).
Secondary outcomes:
1. Change in LVEF as assessed by MRI and echocardiography (early postoperatively and 6 months).
2. Regional contractility in the AOI/change in LVESD, LVEDD as assessed by echocardiography (early
postoperatively (discharge), 6 months).
3. Physical exercise capacity determined by 6-minute walk test (early postoperatively (discharge),
6 months).
4. NYHA and CCS class (early postoperatively (discharge), 6 months).
5. MACE (cardiac death, MI, secondary intervention/reoperation, ventricular arrhythmia) (6 months).
6. QOL score: MLHFQ, SF-36, EQ-5D (3 months, 6 months).
Starting date July 2009
Contact information University of Rostock, Germany, 18057 (Principal Investigator: Dr G Steinhoff (gustav.steinhof-
f@med.uni-rostock.de))
Notes Planned enrolment: 142
Estimated completion date: December 2013
The status of this trial is "terminated"; no further details are provided, and no publications have
been identified.
NCT00950274 
 
 
Trial name or title IMPACT-CABG trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG
(IMPACT-CABG)
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Methods A phase II, parallel, randomised, double-blind (participant, caregiver, investigator, outcomes asses-
sor), placebo-controlled safety/efficacy study
Participants Myocardial infarct; HF:
1. Age ≥ 18 and ≤ 75 years.
2. People with severe chronic ischaemic cardiomyopathy manifested by CCS class II or greater angi-
na or NYHA class II or greater, or both, and who have undergone diagnostic coronary angiography
demonstrating ≥ 70% diameter narrowing of at least 2 major coronary arteries or branches or ≥
50% diameter narrowing of the leM main coronary artery.
3. A significant leM ventricular systolic dysfunction evaluated by echocardiography or LV angiogra-
phy (LVEF ≤ 45% but ≥ 25%) due to prior MI. This area of leM ventricular dysfunction should be aki-
netic or severely hypokinetic, not dyskinetic or aneurysmal, when assessed by echocardiography
or LV angiogram. This territory should be irrigated by 1 or a branch of the 3 major vascular territo-
ries (i.e. right coronary artery, leM circumflex, or leM anterior descending artery distribution) that
will be bypassed during the surgical procedure.
4. No contraindications or exclusions (see below).
5. Willingness to participate and ability to provide informed consent.
Interventions Intervention arm: Autologous CD133+ stem cells (total 2 mL with 10 to 15 injections) injected into
the myocardium.
Comparator arm: Placebo solution containing plasma injected into the myocardium.
Outcomes Primary outcomes:
1. Freedom from MACE: cardiac death, myocardial infarct, repeat coronary bypass grafting or per-
cutaneous intervention of bypassed artery (6 months).
2. Freedom from major arrhythmia: sustained ventricular tachycardia or survived sudden death (6
months).
Secondary outcomes:
1. Regional myocardial perfusion and function assessed by magnetic resonance scans (6 months).
2. Device performance endpoint: feasibility to produce from 100 mL of bone marrow aspiration a
final cell product that contains a target CD133+ cells higher than 0.5 million with a purity superior
to 30% and a recovery superior to 10% (baseline).
3. Symptom severity and quality of life after CABG surgery (6 months).
Starting date December 2009
Contact information Centre de recherche du CHUM (CRCHUM), Montreal, Quebec, Canada, H2W 1T8 (Principal Inves-
tigators: Dr N Noiseux, Dr S Mansour, Dr D-C Roy). Contact: Nicolas Noiseux, MD, MSc, FRCSC,
(noiseuxn@videotron.ca)
Notes Planned enrolment: 20
Estimated completion date: July 2013
The recruitment status of this study is unknown because the information has not been recently ver-
ified.
NCT01033617  (Continued)
 
 
Trial name or title Prospective, controlled and randomized clinical trial on cardiac cell regeneration with laser and au-
tologous bone marrow stem cells, in patients with coronary disease and refractory angina
NCT01214499 
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Methods A phase II, randomised, single-blind (outcome assessor), parallel safety/efficacy study
Participants Coronary disease and refractory angina:
1. Aged > 18 years of age.
2. At least 1 area of myocardial ischaemia or chronic MI of the leM ventricle demonstrated by any
imaging technique not amenable to conventional revascularisation and angina refractory to med-
ical treatment.
3. LVEF > 25% measured in the 6 months prior to the procedure.
4. Participants must be mentally competent to give consent for inclusion in the clinical trial.
Interventions Intervention arm: Transmyocardial revascularisation with Holmium YAG laser plus the participant's
own stem cells extracted from bone marrow.
Comparator arm: Transmyocardial revascularisation with Holmium YAG laser.
Outcomes Primary outcome:
NYHA classification for angina (12 months).
Secondary outcomes:
1. The demographic, intra-operative, and postoperative variables (12 months).
2. Percentage of ischaemic area (SPECT) and maximum effort capacity before the occurrence of the
angina (12 months).
3. LVEF, LVESV, LVEDV will be examined through an echocardiogram and a pre- and postoperative
cardiac magnetic resonance imaging study (12 months).
4. The EQ-5D (standardised instrument for use as a measure of health outcome) will be completed
by the participant for the subjective assessment of quality of life (12 months).
Starting date October 2010
Contact information Cardiovascular Surgery Service, Hospital Universitario de La Princesa, Madrid, Spain, 28006 (Princi-
pal Investigator: Dr GR Copa (guillermo_reyes_copa@yahoo.es))
Notes Planned enrolment: 20
Estimated completion date: October 2012
The recruitment status of this study is unknown because the information has not been recently ver-
ified.
NCT01214499  (Continued)
 
 
Trial name or title Cell therapy in patients with chronic ischemic heart disease undergoing cardiac surgery
Methods A phase I/II, randomised, double-blind (participant, caregiver), parallel safety/efficacy study
Participants Severe, chronic ischaemic disease:
1. Aged between 18 and 75 years.
2. Scheduled to undergo CABG.
3. At least 3 months since last episode of MI.
4. Echocardiogram-assessed LVEF between 15% and 40% (Simpson's rule).
5. Abnormal wall motion of at least 1 segment due to prior MI shown by echocardiography or leM
ventriculography.
6. Abnormal myocardial perfusion in infarcted area by SPECT.
NCT01267331 
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7. Willingness to participate and ability to provide written informed consent.
Interventions Intervention arm: Direct intramyocardial injection of autologous bone marrow mononuclear cells
during CABG.
Comparator arm: Between 10 and 15 placebo injections consisting of saline and 5% HSA during
CABG.
Outcomes Primary outcome:
Major adverse cardiac events (6 months)
Secondary outcomes:
LeM ventricular function (global function, regional myocardial perfusion, and function assessed by
magnetic resonance imaging and echocardiogram) (6 months)
Starting date December 2010
Contact information Chinese PLA General Hospital, Beijing, China (Principal Investigator: Dr C Gao (gaochq301@ya-
hoo.com) and Dr L Zhang (drzhanglin@gmail.com))
Notes Planned enrolment: 60
Estimated completion date: June 2013
The recruitment status of this study is unknown because the information has not been recently ver-
ified.
NCT01267331  (Continued)
 
 
Trial name or title Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Is-
chemia (IMPI)
Methods A phase I, parallel, randomised, double-blind (participant, caregiver, investigator) safety/efficacy
study
Participants Ischaemic HF:
1. Participants with coronary artery disease and HF NYHA class II-III.
2. MI > 6 months before the study.
3. LVEF < 35%.
4. Absence of indication to coronary revascularisation.
5. Optimal pharmacological therapy no less than 8 weeks.
6. Heart transplantation is contraindicated.
7. Participants with implantable cardioverter-defibrillator or cardiac resynchronisation therapy de-
fibrillator.
8. Participants giving informed consent.
Interventions Intervention arm: Intramyocardial multiple precision injection of bone marrow mononuclear cells.
Comparator arm: Intramyocardial multiple precision injection with placebo.
Outcomes Primary outcome: Change in global LVEF and regional wall motion score index (6/12 months).
Secondary outcomes: Incidence of the major adverse cardiac events (6/12 months).
Starting date May 2011
NCT01354678 
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Contact information Almazov Federal Center of Heart, Blood and Endocrinology (Principal Investigator: Prof EV
Shlyakhto). Contact: Prof DS Lebedev (lebedevdmitry@mail.ru); Prof OM Moiseeva (moiseeva@al-
mazovcentre.ru)
Notes Planned enrolment: 30
Estimated completion date: May 2015
This study is marked as ongoing but is not currently recruiting participants.
First identified publication in Russian (Shlyakhto 2013) confirmed by translator as early report of
safety in 1 participant.
NCT01354678  (Continued)
 
 
Trial name or title IMPACT-CABG trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coro-
nary Artery Bypass Grafting
Methods A phase II, randomised, parallel, double-blind (participant, caregiver, investigator, outcomes asses-
sor) safety/efficacy study
Participants Chronic ischaemic cardiomyopathy:
1. Age ≥ 18 and ≤ 75 years.
2. People with severe chronic ischaemic cardiomyopathy manifested by CCS class II or greater angi-
na or NYHA class II or greater dyspnoea, or both, AND who have undergone diagnostic coronary
angiography demonstrating ≥ 70% diameter narrowing of at least 2 major coronary arteries or
branches or ≥ 50% diameter narrowing of the leM main coronary artery.
3. Significant leM ventricular systolic dysfunction evaluated by echocardiography or LV angiography
(LVEF ≤ 45% but ≥ 25%) due to a prior MI. This area of leM ventricular dysfunction should be akinetic
or severely hypokinetic, not dyskinetic or aneurysmal, when assessed by echocardiography or LV
angiogram.
4. No contraindications or exclusions.
5. Willingness to participate and ability to provide informed consent.
Interventions Intervention arm: Autologous CD133+ stem cells injected into the mycardium.
Comparator arm: Placebo (saline solution containing autologous plasma without CD133+).
Outcomes Primary outcomes:
1. Freedom from major adverse cardiac event at 6 months (cardiac death, myocardial infarct, repeat
coronary bypass grafting or percutaneous intervention of bypassed artery).
2. Freedom from major arrhythmia at 6 months (sustained ventricular tachycardia or survived sud-
den death).
Secondary outcomes:
1. Regional myocardial perfusion and function assessed by magnetic resonance scans.
2. Global ventricular function assessed by echocardiographic measures of ejection fraction.
3. Relief of symptom severity after CABG surgery.
4. Device performance endpoint.
5. Feasibility to produce from 100 mL of bone marrow aspiration a final cell product that contains a
target CD133+ cells higher than 0.5 million with a purity superior to 30% and a recovery superior
to 10%.
6. Quality of life after CABG surgery.
NCT01467232 
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Starting date September 2011
Contact information Terrence M Yau, MD, Peter Munk Cardiac Center/University Health Network, Toronto, Ontario,
Canada, M5G 2C4
Notes Planned enrolment: 20
Estimated completion date: October 2015
This study is marked as completed, but no publications have been identified.
NCT01467232  (Continued)
 
 
Trial name or title Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving
Exercise Capacity in Subjects With Refractory Angina (RENEW)
Methods A phase III, randomised, parallel, double-blind (participant, investigator) safety/efficacy study
Participants Refractory angina and chronic myocardial ischaemia:
1. Men or women aged 21 to 80 years at the time of signing the informed consent.
2. Participants with CCS class III or IV chronic refractory angina.
3. Participants without control of their angina symptoms despite maximal tolerated doses of an-
tiangina drugs. Participants must be on optimal therapy for their angina and have been on a stable
antianginal medication regimen for at least 4 weeks before signing the informed consent form.
4. Participants with obstructive coronary disease unsuitable for conventional revascularisation due
to unsuitable anatomy or comorbidity as determined at the site and confirmed by an independent
adjudication committee.
5. Participants must have evidence of inducible myocardial ischaemia.
6. Participants must experience angina episodes.
7. Participants must be able to complete 2 exercise tolerance tests on the treadmill within 3 weeks
of randomisation.
8. If a woman of childbearing potential, she must not be pregnant and must agree to employ ade-
quate birth control measures for the duration of the study.
Interventions Intervention arm: Targeted intramyocardial delivery of 1 x 105 Auto-CD34+ cells after G-CSF mobili-
sation and apheresis.
Comparator arm: Targeted intramyocardial delivery of placebo after G-CSF mobilisation and
apheresis.
Outcomes Primary outcome:
Change from baseline in total exercise time on exercise tolerance test using the modified Bruce
protocol (12 months).
Secondary outcomes:
1. Angina frequency (episodes per week) (3/6/12 months).
2. Change from baseline in total exercise time on exercise tolerance test (6 months).
3. Incidence of MACE and other serious adverse events in all participants (24 months).
Starting date April 2012
Contact information Baxter Healthcare Corporation (Study Director: Dr A Nada). Contact: Lauren Davis, Clinical Project
Manager (lauren.davis@ppdi.com)
NCT01508910 
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
135
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Notes Planned enrolment: 291
Estimated completion date: June 2016
This study is marked as completed, but no publications have been identified.
NCT01508910  (Continued)
 
 
Trial name or title Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy (ISCIC)
Methods A phase I, randomised, parallel, open-label safety/efficacy study
Participants Ischaemic cardiomyopathy:
1. People with ischaemic cardiomyopathy and HF NYHA class II-IV.
2. MI > 6 months before the study.
3. LVEF < 35%.
4. Absence of effect of coronary revascularisation during 6 months.
5. Optimal pharmacological therapy no less than 8 weeks.
6. Heart transplantation is contraindicated.
7. Participants with implantable cardioverter-defibrillator or cardiac resynchronisation therapy de-
fibrillator.
8. Participants giving informed consent.
Interventions Intervention arm: Intramyocardial implantation of peripheral mononuclear cells with CD34+ stem
cells in participant with ischaemic cardiomyopathy after preparatory course of shockwave therapy.
Comparator arm: Cardiospec shockwave therapy only.
Outcomes Primary outcomes:
Change in global LVEF and regional wall motion score index (6/12 months).
Secondary outcomes:
Incidence of MACE (6/12 months).
Starting date January 2012
Contact information Odessa Regional Clinical Hospital, Odessa, Ukraine, 65025 (Principal Investigator: Prof II Karpenko
(arcard2@gmail.com))
Notes Planned enrolment: 50
Estimated completion date: January 2016
The recruitment status of this study is unknown because the information has not been recently ver-
ified.
NCT01615250 
 
 
Trial name or title Intracardiac CD133+ cells in patients with no-option resistant angina (RegentVsel)
Methods A phase II, randomised, parallel, double-blind (participant, investigator) efficacy study
NCT01660581 
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Participants Stable angina:
1. Stable angina CCS II-IV despite maximum pharmacotherapy for at least 2 weeks since last med-
ications change.
2. Presence of ≥ 1 myocardial segment with ischaemia features in Tc-99m SPECT.
3. Participants disqualified from revascularisation procedures by Heart Team.
4. Aged over 18 and less than 75 years old.
5. Person must provide written informed consent for participation in study.
Interventions Intervention arm: Intramyocardial injection (electromechanical mapping based) of autological
CD133+ cells, isolated from bone marrow.
Comparator arm: Intramyocardial injection (electromechanical mapping based) of placebo (0.9%
sodium chloride plus 0.5% solution of participant's serum).
Outcomes Primary outcome:
Myocardial perfusion change (4 months).
Secondary outcomes:
1. Global and segmental contractility change and myocardial perfusion change (MRI: 4 months;
echocardiography: 4/12 months).
2. Exercise tolerance (4/12 months).
3. Occurrence of symptomatic angina (1/4/6/12 months).
4. Quality of life (1/4/6/12 months).
5. Occurrence of ventricular arrhythmia (1/4/6/12 months).
6. Occurrence of in-stent restenosis and progression of atherosclerotic lesions in remained coronary
artery segments (4 months).
Starting date June 2012
Contact information Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca, Katowice-Ochojec, Silesian, Poland, 40-635
(Principal Investigator: Prof W Wojakowski (wojtek.wojakowski@gmail.com))
Notes Planned enrolment: 60
Estimated completion date: June 2014
This study is currently recruiting participants.
NCT01660581  (Continued)
 
 
Trial name or title Intracoronary autologous mesenchymal stem cells implantation in patients with ischemic dilated
cardiomyopathy
Methods A phase II, randomised, parallel, open-label efficacy study
Participants Ischaemic dilated cardiomyopathy:
1. Aged between 35 and 75 years.
2. Diagnosed as having ischaemic cardiomyopathy confirmed by previous coronary angiogram
showing significant coronary artery disease > 70% or history of previous MI.
3. Myocardial infarction event occurred 6 months or longer from time of screening.
4. LeM ventricular ejection fraction of ≤ 40% by echocardiogram or cardiac MRI.
NCT01720888 
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Interventions Intervention arm: Intracoronary implantation of autologous bone marrow-derived mesenchymal
stem cells.
Comparator arm: Control (optimal medical therapy).
Outcomes Primary outcome:
Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation
(measured at 1, 3, 6, 9, and 12 months).
Secondary outcomes:
1. Changes in functional status (12 months).
2. Improvement in other LV parameters as assessed by echocardiogram and cardiovascular magnet-
ic resonance (1, 3, 6, 9, 12 months).
3. Resolution of scar tissue volume/area on cardiac MRI (6, 12 months).
4. Change in serum NT-proBNP level (1, 6, 12 months).
5. Freedom from major adverse cardiac events as defined by MI, hospitalisation for angina, MI or HF,
or death (all-cause mortality) (1, 3, 6, 9, 12 months).
Other outcomes:
1. No periprocedural complications (1, 3, 6, 9, 12 months).
2. Significant improvement in overall leM ventricular function (12 months).
3. Resolution of scar tissue (6, 12 months).
4. Reduction of major adverse cardiac events (1, 3, 6, 9, 12 months).
Starting date July 2012
Contact information Oteh Maskon, MB Bch (Principal Investigator), UKM Medical Centre, Cheras, Kuala Lumpur,
Malaysia, 56000
Notes Planned enrolment: 80
Estimated completion date: December 2015
This study is ongoing but not recruiting participants.
NCT01720888  (Continued)
 
 
Trial name or title Cell therapy in severe chronic ischemic heart disease (MiHeart)
Methods A phase II/III, randomised, parallel, double-blind (participant, investigator) safety/efficacy study
Participants Chronic IHD:
1. Symptoms of angina or angina equivalent.
2. Documented coronary artery disease (invasive angiography).
3. Documented myocardial ischaemia (stress echo, cardiac scintigraphy, or MRI).
4. Unsuitable for complete myocardial revascularisation (PCI or CABG) OR even if a complete proce-
dure is feasible, it is anticipated that myocardial perfusion may not be restored due to poor distal
beds.
Interventions Intervention arm: Intramyocardial injection of autologous bone marrow-derived cells.
Comparator arm: Saline injection.
NCT01727063 
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Outcomes Primary outcome:
Increase in myocardial perfusion assessed by MRI (1/6/12 months).
Secondary outcomes:
1. Improvement in LV function assessed by MRI (1/6/12 months).
2. Improvement in angina functional class determined using the CCS classification (1/6/12 months).
Starting date January 2006
Contact information Heart Institute, Sao Paulo, SP, Brazil 05403-000 (Principal Investigator: Prof LHW Gowdak). Contact:
Meyrielli A Vieira (meyri.vieira@incor.usp.br); Prof LHW Gowdak (luis.gowdak@incor.usp.br)
Notes Planned enrolment: 200
Estimated completion date: July 2013
The recruitment status of this study is unknown because the information has not been recently ver-
ified.
NCT01727063  (Continued)
 
 
Trial name or title Transplantation of autologous cardiac stem cells in ischemic heart failure
Methods A phase II, randomised, parallel, double-blind (participant, investigator) safety/efficacy study
Participants Ischaemic HF:
1. EF ≤ 40 (by echocardiography).
2. Not responding to standard therapies for HF for over 1 month.
3. NYHA class III or greater.
4. MI due to coronary artery atherosclerotic disease.
5. An area of regional dysfunction, i.e. hypokinetic, akinetic, or dyskinetic (echocardiography or
MRI).
6. No HIV/viral hepatitis.
7. Normal liver function (SGPT < 3 times the upper reference range).
8. No or controlled diabetes (glycated haemoglobin < 8.5%).
9. Ability to provide informed consent and follow-up with protocol procedures.
Interventions Intervention arm: Autologous cardiac stem cell intracoronary injection.
Comparator arm: Placebo (no details).
Outcomes Primary outcomes:
Rate of mortality, arrhythmia, and hospitalisation at 18 months.
Secondary outcomes:
1. Ejection fraction changes (18 months).
2. NT-proBNP changes (18 months).
3. NYHA functional class (18 months).
4. 6-minute walk test (18 months).
Starting date December 2013
NCT01758406 
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Contact information Hoda Madani, MD (Principal Investigator), Royan Institute, Tehran, Iran. Contact: Nasser Aghdami,
MD, PhD +982123562000 ext 504 (nasser.aghdami@royaninstitute.org)
Notes Planned enrolment: 50
Estimated completion date: December 2017
This study is currently recruiting participants.
NCT01758406  (Continued)
 
 
Trial name or title Safety and efficacy of autologous cardiopoietic cells for treatment of ischemic heart failure
(CHART-1)
Methods A phase III, randomised, parallel, double-blind (participant, outcomes assessor) safety/efficacy
study
Participants Ischaemic HF:
1. Age ≥ 18 and < 80 years.
2. Systolic dysfunction with LVEF ≤ 30% as assessed by echocardiography.
3. Ischaemic HF without known need for revascularisation.
4. MLHFQ score > 30.
5. Ability to perform a 6-minute walk test > 100 m and ≤ 400 m.
6. History of hospitalisation for HF within 12 months prior to screening.
7. NYHA class III or IV despite optimal standard of care or INTERMACS class 4, 5, 6, or 7.
8. Use of ACE inhibitor and/or ARB and beta blocker for at least 3 months prior to screening visit,
unless intolerant or contraindicated.
9. Stable dosing of ACE inhibitor, ARB, beta blocker, aldosterone blocker, and diuretics for at least 1
month prior to screening visit, defined as ≤ 50% change in total dose of each agent.
10.Willing and able to give written informed consent.
Interventions Intervention arm: Injection of C3BS-CQR-1 cardiopoietic cells using the C-Cath injection catheter.
Comparator arm: Mimic injection procedure through insertion of a sham catheter. No injection ac-
tually performed.
Outcomes Primary outcome:
Efficacy between groups post-index procedure: change between groups from baseline in a hier-
archical composite outcome comprising, from most- to least-severe outcome, days to death from
any cause, number of worsening of HF events, change in score for the MLHFQ (10-point deteriora-
tion, no meaningful change, 10-point improvement), change in 6-minute walk distance (40 m dete-
rioration, no meaningful change, 40 m improvement), and change in LVESV (15 mL deterioration,
no meaningful change, 15 mL improvement) and LVEF (4% absolute deterioration, no meaningful
change, 4% absolute improvement) (39 weeks).
Secondary outcomes:
1. Efficacy (time to all-cause mortality, time to worsening of HF, and time to aborted sudden death)
and safety (number and cause of deaths and readmissions, number of cardiac transplantations,
number of MIs, number of strokes, incidence of serious AEs and non-serious AEs) between groups
post-index procedure (52/104 weeks).
2. Efficacy and safety between groups post-index procedure (time to all-cause mortality, time to car-
diovascular mortality, and rate of worsening HF requiring outpatient IV therapy for HF or readmis-
sion for HF, and other) (39/52 weeks post-index).
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Starting date November 2012
Contact information Multicentre study: Cardio3 BioSciences (Study Chairs: Dr A Terzic, Mayo Clinic, Division of Cardio-
vascular Diseases, Rochester, MN, USA and Dr J Bartunek, OLV Ziekenhuiz Aalst, Belgium). Contact:
Dr Christian Homsy (chomsy@c3bs.com)
Notes Planned enrolment: 240
Estimated completion date: March 2017
This study is ongoing but not recruiting participants.
NCT01768702  (Continued)
 
 
Trial name or title Intracoronary infusion of mononuclear cells autologous bone marrow in patients with chronic
coronary occlusion and ventricular dysfunction, previously revascularized
Methods Open-label randomised controlled trial
Participants Chronic coronary artery occlusion:
1. People of both sexes with atherosclerotic coronary disease and chronic occlusions older than 3
months in which successful recanalisation was achieved, medicated stents implanted, and where
it persists despite ventricular dysfunction.
2. Age between 18 and 80 years.
3. The baseline ventricular function recanalisation catheterisation (performed approximately 3
months earlier) should be less than 45% ejection fraction.
4. The ejection fraction of the person should remain below 45% in the MRI performed at 3 months
of recanalisation.
Interventions Intervention arm: Bone marrow mononuclear cells by intra-arterial administration.
Comparator arm: Control (no placebo).
Outcomes Primary outcome:
Change in ejection fraction measured by MRI between inclusion and 6 months' follow-up.
Secondary outcomes:
1. Changes in NYHA functional grade between groups.
2. Possible cardiac events during follow-up (death, MI, repeat revascularisation).
3. Need for hospitalisation or major arrhythmias.
4. Changes in global and segmental leM ventricular function.
Starting date November 2013
Contact information None identified.
Notes Planned enrolment: 66
Estimated completion date: May 2017
This study is currently recruiting participants.
NCT02022514 
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Trial name or title Autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease
(TAMIS)
Methods A phase III, randomised, parallel, single-blind (investigator) efficacy study
Participants Coronary heart disease:
1. Men and women from 18 to 80 years.
2. People with angina pectoris III-IV functional class.
3. People signed informed consent.
Interventions Intervention arm 1: Bone marrow mononuclear cells (intramyocardial).
Intervention arm 2: Bone marrow mononuclear cells (intramyocardial and intracoronary).
Comparator arm: Placebo (intramyocardial administration of 0.9% sodium chloride 0.2 mL).
Outcomes Primary outcome:
All-cause mortality associated with the progression of basic disease (60 months).
Secondary outcomes:
Quality of life (12 months).
Other outcomes:
1. Percentage of functioning graMs in participants with implantation of autologous bone marrow
mononuclear cells (60 months).
2. Estimation of efficiency: (i) assessment of myocardial perfusion and metabolism (before and af-
ter treatment); (ii) evaluation of systolic and diastolic myocardial function; (iii) speckle tracking
echocardiography; (iv) patency of graMs within a specified time of treatment (angiography); (v)
dependence and duration of positive clinical effect on the amount of injected cell material; (vi)
evaluation of the quality of life (Minnesota questionnaire, Seattle questionnaire, SF-36 question-
naire).
Starting date February 2013
Contact information Alexander S Nemkov, MD, PhD (Principal Investigator), First Pavlov State Medical University of St
Petersburg, St Petersburg, Russia, 197089 (nemk_as@mail.ru)
Notes Planned enrolment: 100
Estimated completion date: February 2018
This study is ongoing but not recruiting participants.
NCT02059512 
 
 
Trial name or title Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) trial
Methods A phase III, randomised, parallel, double-blind (participant, caregiver, investigator, outcomes as-
sessor) safety/efficacy study
Participants Advanced chronic ischaemic HF:
1. Age ≥ 18 and < 80 years.
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2. Chronic HF, NYHA class II or greater, without need for revascularisation.
3. Systolic dysfunction with LVEF ≤ 35%.
4. Total MLHFQ score > 30.
5. 6-minute walk test distance > 100 m and < 400 m.
6. Hospitalisation or outpatient with intravenous therapy for HF within the previous 12 months.
7. Stable medical regimen, including ACE inhibitor or ARB, or both; beta blocker, aldosterone blocker
and diuretic for at least 1 month.
8. Willing and able to give written informed consent.
Interventions Intervention arm: BM-derived mesenchymal cardiopoietic cells (C3BR-CQR-1) using intramyocardial
injection.
Comparator arm: Control (standard of care with sham procedure).
Outcomes Primary outcome:
6-minute walk test at 39 weeks' postprocedure.
Secondary outcomes:
None reported.
Starting date December 2014
Contact information Celyad (formerly named Cardio3 BioSciences)
Notes Planned enrolment: 240
Estimated completion date: August 2018
This study is not yet open for participant recruitment.
NCT02317458  (Continued)
 
 
Trial name or title Safety & efficacy of intramyocardial injection of mesenchymal precursor cells on myocardial func-
tion in LVAD recipients
Methods A phase II, randomised, parallel, double-blind (participant, caregiver, investigator, outcomes asses-
sor) safety/efficacy study
Participants LeM ventricular assist device recipients:
1. Age 18 years or older.
2. If the participant or partner is of childbearing potential, he or she must be willing to use adequate
contraception (hormonal or barrier method or abstinence) from the time of screening and for a
period of at least 16 weeks after procedure.
3. Female participants of childbearing potential must have a negative serum pregnancy test at
screening.
4. Admitted to the clinical center at the time of randomisation.
5. Clinical indication and accepted candidate for implantation of an FDA-approved (US sites only)
or Health Canada-approved (Canadian sites only) implantable, non-pulsatile LVAD as a bridge to
transplantation or for destination therapy.
Interventions Intervention arm: Mensenchymal precursor cells (intramyocardial injection).
NCT02362646 
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Comparator arm: Placebo (50% Alpha-Minimum Essential Medium/42.5% ProFreeze NAO Freeze
Medium/7.5% DMSO)
Outcomes Primary outcomes:
1. Functional status (6 months).
2. Adverse events (12 months).
Secondary outcomes:
1. Physiologic assessments (12 months).
2. Histopathological assessments of myocardial tissue (12 months).
3. Overall survival (12 months).
4. Change in quality of life (6, 12 months).
5. Hopkins Verbal Learning Test (3, 12 months).
6. Trail Making Tests A and B (3, 12 months).
7. Medical College of Georgia (MCG) complex figures (3, 12 months).
8. Digit span (3, 12 months).
9. Digit symbol substitution test (3, 12 months).
10.Controlled Oral Word Association Test (3, 12 months).
11.Length of hospital stay (12 months).
12.Hospitalisations (12 months).
13.Hospital costs (12 months).
14.Functional status (12 months).
Starting date July 2015
Contact information Michael Bowdish, MD (Principal Investigator), University of Southern California, Los Angeles, Cal-
ifornia, United States, 90033 (michael.bowdish@med.usc.edu); Joseph Woo, MD (Principal Inves-
tigator), Stanford University School of Medicine, Stanford, California, United States, 94305 (jos-
woo@stanford.edu)
Notes Planned enrolment: 120
Estimated completion date: August 2016
This study is currently recruiting participants.
NCT02362646  (Continued)
 
 
Trial name or title CardiAMP Heart Failure Trial
Methods A phase III, randomised, parallel, double-blind (participant, outcome assessor) safety/efficacy
study
Participants Post-MI HF:
1. Older than 21 and younger than 90 years of age.
2. NYHA class II or III.
3. Diagnosis of chronic ischaemic leM ventricular dysfunction secondary to MI.
4. Have an ejection fraction ≥ 20% and ≤ 40%.
5. On stable evidence-based medical and device therapy for HF or postinfarction leM ventricular dys-
function, per the 2013 ACC/AHA heart failure guidelines, for at least 3 months prior to randomisa-
tion.
6. Cell potency assay score of 3, as determined by the Cell Analysis Core Lab results.
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7. Provide written informed consent.
Interventions Intervention arm: Autologous CardiAMP cell therapy.
Comparator arm: Placement of an introducer and performance of LV gram only.
Outcomes Primary outcome:
Change in 6-minute walk distance at 12 months from baseline.
Secondary outcomes:
1. Overall survival as a non-inferiority outcome (12 months).
2. Freedom from MACE (composite of all-cause death, hospitalisation for worsening HF, non-fatal
MI, [LVAD], or heart transplantation) as a non-inferiority outcome (12 months).
3. Change in quality of life as measured by MLHFQ as a superiority outcome (12 months).
4. Time to first MACE as a superiority outcome (12 months).
5. Overall survival as a superiority outcome (12 months).
6. Survival at 2 years.
7. HF death (12 months).
8. Treatment-emergent serious adverse event at 30 days.
9. HF hospitalisation (12 months).
10.All-cause hospitalisation (12 months).
11.Days alive out of hospital (12 months).
12.Freedom from serious adverse events (12 months).
13.NYHA Functional Class (12 months).
14.6-minute walk distance repeated measure analysis (12 months).
15.Echocardiographic measures of change in ejection fraction, leM ventricular end-systolic and end-
diastolic volumes, leM ventricular end-systolic and end-diastolic dimensions, mitral regurgitation
(composite) (baseline).
16.Technical success defined as successful delivery of ABM MNC, at the time of the procedure.
Starting date January 2016
Contact information Cheryl Wong Po Foo, BioCardia Inc (Email info@biocardia.com). Principal Investigators: Carl
Pepine, University of Florida and Amish Raval, University of Wisconsin
Notes Planned enrolment: 250
Estimated completion date: April 2019
This study is not yet open for participant recruitment.
NCT02438306  (Continued)
 
 
Trial name or title Administration of mesenchymal stem cells in patients with chronic ischemic cardiomyopathy
(MESAMI2)
Methods A phase II, randomised, parallel, double-blind (participant, investigator) efficacy study
Participants Chronic ischaemic cardiomyopathy and leM ventricular dysfunction:
1. Aged 18 to 75 years.
2. Signed the informed consent.
3. Chronic, stable ischaemic cardiomyopathy for at least 1 month with a NYHA class II-IV or angina
pectoris CCS class III or IV, or both.
NCT02462330 
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4. Not a candidate for revascularisation by coronary artery bypass surgery or angioplasty.
5. LeM ventricular function ≤ 45%.
6. Presence of ischaemia or myocardial viability on the myocardial perfusion imaging.
7. VO2 max ≤ 20 mL/min/kg.
8. Optimal medical therapy.
9. Optimal interventional therapy (implantable cardioverter defibrillator, effort rehabilitation).
Interventions Intervention arm: BMMSC (isolated and cultured during 17 ± 2 days by the French Blood Establish-
ment; administered by intramyocardial injections of MSC using the electromechanical NOGA-XP
system).
Comparator arm: Human albumin 4%.
Outcomes Primary outcome:
Change in VO2max (or peak VO2) before injection and at 3 months' postinjection.
Secondary outcomes:
1. LeM ventricular viability (3 and 12 months).
2. Change in NYHA/CCS class (3 and 12 months).
3. Change on quality of life test score (3 and 12 months).
4. Change in VO2max (or peak VO2) at 3 and 12 months postinjection.
5. 6-minute walk test (3 and 12 months).
6. Volume of myocardium and measurement of ejection fraction (echocardiography) (3 and 12
months).
7. Myocardial perfusion imaging (3 and 12 months).
Other outcomes:
1. Adverse event related to cell administration (12 months).
2. Complication related to cell administration (12 months).
3. Control of the implantable cardioverter defibrillator (12 months).
4. Analysis of major cardiovascular events (12 months).
Starting date June 2015
Contact information Jerome Roncalli, MD, PhD (Principal Investigator), Cardiology Department of Rangueil Hospital,
Toulouse, France, 31059 (roncalli.j@chu-toulouse.fr)
Notes Planned enrolment: 90
Estimated completion date: May 2017
This study is currently recruiting participants.
NCT02462330  (Continued)
 
 
Trial name or title Combination of mesenchymal and c-kit+ cardiac stem cells as regenerative therapy for heart failure
(CONCERT-HF)
Methods A phase II, randomised, parallel, double-blind (participant, caregiver, investigator, outcomes asses-
sor) safety/efficacy study
Participants Ischaemic cardiomyopathy:
NCT02501811 
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1. ≥ 21 and < 80 years of age.
2. Documented coronary artery disease with evidence of myocardial injury, LV dysfunction, and clin-
ical evidence of HF.
3. "Detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any
subendocardial involvement by cMRI.
4. EF ≤ 40% by cMRI.
5. Receiving guideline-driven medical therapy for HF at stable and tolerated doses for ≥ 1 month
prior to consent. For beta-blockade, "stable" is defined as no greater than a 50% reduction in dose
or no more than a 100% increase in dose.
6. Candidate for cardiac catheterisation.
7. NYHA class II or III HF symptoms.
8. If a female of childbearing potential, be willing to use one form of birth control for the duration of
the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection.
Interventions Intervention arm 1: 15 transendocardial injections of 0.4 mL BMMSC administered to the leM ventri-
cle via NOGA MyoStar injection catheter (single procedure) (target dose 150 million MSC).
Intervention arm 2: 15 transendocardial injections of 0.4 mL cardiac stem cells (c-kit+ cells) adminis-
tered to the leM ventricle via NOGA MyoStar injection catheter (single procedure) (target dose 5 mil-
lion CSC).
Intervention arm 3: Combo: 15 transendocardial injections of 0.4 mL MSC administered to the leM
ventricle via NOGA MyoStar injection catheter (single procedure) and 15 transendocardial injec-
tions of 0.4 mL CSC administered to the leM ventricle via NOGA MyoStar injection catheter (single
procedure) (target dose 150 million MSC and 5 million CSC).
Comparator arm: 15 transendocardial injections of 0.4 mL placebo (Plasma-Lyte A) administered to
the leM ventricle via NOGA MyoStar injection catheter (single procedure).
Outcomes Primary outcomes:
1. Change in LVEF as measured by cMRI (12 months).
2. Change in global strain (HARP MRI) as measured by cMRI (12 months).
3. Change in regional strain (HARP MRI) as measured by cMRI (12 months).
4. Change in LeM Ventricular End-Diastolic Volume Index (LVEDVI) as measured by cMRI (12 months).
5. Change in LeM Ventricular End-Systolic Volume Index (LVESVI) as measured by cMRI (12 months).
6. Change in LeM Ventricular Sphericity Index as measured by cMRI (12 months).
7. Change in infarct/scar volume (delayed enhancement MRI) as measured by cMRI (12 months).
8. Change in maximal oxygen consumption (VO2 max) as measured by treadmill (12 months).
9. Change in exercise tolerance as measured by the 6-minute walk test (12 months).
10.Change in MLHFQ score (12 months).
11.Incidence rate of MACE (12 months).
12.Cumulative days alive and out of hospital (12 months).
13.Change in NT-proBNP as measured by blood draw (12 months).
Secondary outcomes:
1. Change in LVEF as measured by cMRI (6 months).
2. Change in global strain (HARP MRI) as measured by cMRI (6 months).
3. Change in regional strain (HARP MRI) as measured by cMRI (6 months).
4. Change in LeM Ventricular End-Diastolic Volume Index (LVEDVI) as measured by cMRI (6 months).
5. Change in LeM Ventricular End-Systolic Volume Index (LVESVI) as measured by cMRI (6 months).
6. Change in LeM Ventricular Sphericity Index as measured by cMRI (6 months).
7. Change in infarct/scar volume (delayed enhancement MRI) as measured by cMRI (6 months).
8. Change in maximal oxygen consumption (VO2 max) as measured by treadmill (6 months).
9. Change in exercise tolerance as measured by the 6-minute walk test (6 months).
NCT02501811  (Continued)
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10.Change in MLHFQ score (6 months).
11.Incidence rate of MACE (6 months).
12.Cumulative days alive and out of hospital (6 months).
13.Change in NT-proBNP as measured by blood draw (6 months).
Other outcomes:
1. Change in LVEF as measured by cMRI (6 to 12 months).
2. Change in global strain (HARP MRI) as measured by cMRI (6 to 12 months).
3. Change in regional strain (HARP MRI) as measured by cMRI (6 to 12 months).
4. Change in LeM Ventricular End-Diastolic Volume Index (LVEDVI) as measured by cMRI (6 to 12
months).
5. Change in LeM Ventricular End-Systolic Volume Index (LVESVI) as measured by cMRI (6 to 12
months).
6. Change in LeM Ventricular Sphericity Index as measured by cMRI (6 to 12 months).
7. Change in infarct/scar volume (delayed enhancement MRI) as measured by cMRI (6 to 12 months).
8. Change in maximal oxygen consumption (VO2 max) as measured by treadmill (6 to 12 months).
9. Change in exercise tolerance as measured by the 6-minute walk test (6 to 12 months).
10.Change in MLHFQ score (6 to 12 months).
11.The difference in the incident rate of MACE (6 to 12 months).
12.The difference in the cumulative days alive and out of hospital (6 to 12 months).
13.Change in NT-proBNP as measured by blood draw (6 to 12 months).
Starting date October 2015
Contact information The University of Texas Health Science Center, Houston, TX, United States; National Heart, Lung,
and Blood Institute. Contact: Rachel Vojvodic, MPH (Rachel.W.Vojvodic@uth.tmc.edu); Lemuel
Moye, MD, PhD (Lemmoye@msn.com)
Notes Planned enrolment: 144
Estimated completion date: February 2019
This study is currently recruiting participants.
NCT02501811  (Continued)
 
 
Trial name or title The Transendocardial Autologous Cells (hMSC or hMSC and hCSC) in Ischemic Heart Failure Trial
(TAC-HFT II)
Methods A phase I/II, randomised, parallel, single-blind (participant) safety/efficacy study
Participants Chronic ischaemic leM ventricular dysfunction and HF secondary to MI:
1. ≥ 21 and < 90 years of age.
2. Provide written informed consent.
3. Diagnosis of chronic ischaemic leM ventricular dysfunction secondary to MI as defined by the fol-
lowing: Screening MRI must show an area of akinesis, dyskinesis, or severe hypokinesis associated
with evidence of myocardial scarring based on delayed hyperenhancement following gadolinium
infusion.
4. Been treated with appropriate maximal medical therapy for HF or postinfarction leM ventricular
dysfunction. For beta-blockade, the person must have been on a stable dose of a clinically appro-
priate beta-blocker for 3 months. For angiotensin-converting enzyme inhibition, the person must
have been on a stable dose of a clinically appropriate agent for 1 month.
5. Candidate for cardiac catheterisation.
NCT02503280 
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6. Ejection fraction ≤ 50% by gated blood pool scan, 2-dimensional echocardiogram, cardiac MRI, or
leM ventriculogram within the prior 6 months and not in the setting of a recent ischaemic event.
Interventions Treatment arm 1: Autologous hMSC: 40 million cells/mL delivered in 0.5 mL injection volumes times
10 injections for a total of 2 x 108 (200 million) hMSC.
Treatment arm 2: Autologous hMSC PLUS autologous c-kit hCSC: mixture of 39.8 million hMSC and
0.2 million c-kit hCSC/mL delivered in 0.5 mL injection volumes times 10 injections for a total of
1.99 x 108 (199 million) hMSC and 1 million c-kit hCSC.
Comparator arm: Placebo (10 0.5 mL injections of phosphate-buJered saline and 1% human serum
albumin).
Outcomes Primary outcomes:
1. Incidence of any TE-SAEs 1 month postcatherisation.
2. Incidence (at 1 month postcatheterisation) of any TE-SAEs, defined as the composite of: death,
non-fatal MI, stroke, hospitalisation for worsening HF, cardiac perforation, pericardial tampon-
ade, sustained ventricular arrhythmias (characterised by ventricular arrhythmias lasting longer
than 15 seconds or with haemodynamic compromise), or atrial fibrillation.
Secondary outcomes:
1. Treatment emergent adverse event rates (6 and 12 months).
2. Ectopic tissue formation (6 and 12 months).
3. 48-hour ambulatory electrocardiogram recordings (6 and 12 months).
4. Urinalysis results changes postcatheterisation (6 and 12 months).
5. Clinical chemistry values postcatheterisation (6 and 12 months).
6. Pulmonary function - forced expiratory volume in 1 second (FEV1) results.
7. Serial troponin I values (every 12 hours for first 48 hours post-cardiac catheterisation).
8. Creatine kinase-MB values (every 12 hours for first 48 hours post-cardiac catheterisation).
9. Post-cardiac catheterisation echocardiogram (6 and 12 months).
10.MRI measures of infarct scar size (6 and 12 months).
11.Echocardiographic measures of infarct scar size (6 and 12 months).
12.LeM regional and global ventricular function (6 and 12 months).
13.Global ventricular function (6 and 12 months).
14.Tissue perfusion measured by MRI (6 and 12 months).
15.Peak oxygen consumption (peak VO2) (by treadmill determination) (6 and 12 months).
16.6-minute walk test (6 and 12 months).
17.NYHA Functional Class (6 and 12 months).
18.MLHFQ (6 and 12 months).
19.Incidence of MACE (6 and 12 months).
20.Incidence of MACE, defined as the composite incidence of death, hospitalisation for worsening
HF, or non-fatal recurrent MI (6 and 12 months).
Starting date March 2020
Contact information ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States, 33136. Principal
Investigator: Joshua M Hare, MD. Contact: Darcy L DiFede (DDIFEDE@MED.MIAMI.EDU)
Notes Planned enrolment: 55
Estimated completion date: March 2030
This study is not yet open for participant recruitment.
NCT02503280  (Continued)
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Trial name or title Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease
(TPAABPIHD)
Methods A phase I/II, randomised, parallel, double-blind (participant, outcome assessor) safety/efficacy
study
Participants IHD:
1. Under 75 years of age.
2. Clinical diagnosis of AMI, chronic MI, and ischaemic cardiomyopathy.
3. NYHA grade III-IV, LVEF 25% to 50%.
4. No infection diseases including hepatitis B virus, hepatitis C virus, syphilis, and AIDS.
5. No psychiatric illnesses and speaking dysfunction.
6. Informed consent.
Interventions Intervention arm 1: Autologous BMMSC with hypoxia pre-condition and endothelial pre-induction.
Intervention arm 2: Autologous BMMSC without pre-condition.
Comparator: Standard therapy without autologous BMMSC infusion.
Outcomes Primary outcome: LVEF at 12 months.
Secondary outcomes: None reported.
Starting date November 2015
Contact information Academy Military Medical Science, China; Sun Yat-sen University. Contact: Xuetao Pei, MD, PhD (AM-
MS0906@163.com); Junnian Zhou, PhD (zhoujunnian@scrm.org.cn)
Notes Planned enrolment: 200
Estimated completion date: December 2017
This study is not yet open for participant recruitment.
NCT02504437 
ABM MNC: autologous bone marrow mononuclear cell
ACE: angiotensin converting enzyme
AEs: adverse events
ACC/AHA: American College of Cardiology/American Heart Association
AICD: automatic implantable cardioverter defibrillator
AMI: acute myocardial infarction
AOI:
ARB: angiotensin receptor blocker
AST: aspartate transaminase
BMAC: bone marrow aspirate concentrate
BMMNC: bone marrow mononuclear cells
BMMSC: bone marrow mesenchymal stem cells
BMSC: bone marrow stem cells
BNP: brain natriuretic peptide
CABG: coronary artery bypass graMing
CCS: Canadian Cardiovascular Society
CHF: congestive heart failure
CMR: cardiac magnetic resonance
cMRI: cardiovascular magnetic resonance imaging
CPC: circulating progenitor cells
CSC: cardiac stem cells
DMSO: dimethyl sulfoxide
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ECG: electrocardiogram
EDTA: ethylene-diamine-tetraacetic acid
EF: ejection fraction
EPC: endothelial progenitor cells
FDA: US Food and Drug Administration
G-CSF: granulocyte-colony stimulating factor
HARP: harmonic phase
HcG: human chorionic gonadotrophin
hCSC: human cardiac stem cells
HF: heart failure
hMSC: human mesenchymal stem cells
HSA: human serum albumin
IC: intracoronary
IHD: ischaemic heart disease
IM: intramuscular
INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support
IV: intravenous
LV: leM ventricular
LVAD: leM ventricular assist device
LVEDD: leM ventricular end-diastolic diameter
LVEDV: leM ventricular end-diastolic volume
LVEF: leM ventricular ejection fraction
LVESD: leM ventricular end-systolic diameter
LVESV: leM ventricular end-systolic volume
MACE: major adverse clinical events
MI: myocardial infarction
MLHFQ: Minnesota Living with Heart Failure Questionnaire
MRI: magnetic resonance imaging
MSC: mesenchymal stem cells
MUGA: multigated radionuclide angiography
MVO2: myocardial oxygen consumption
NT-proBNP: N-terminal pro b-type natriuretic peptide
NYHA: New York Heart Association
PCI: percutaneous coronary intervention
QOL: quality of life
PET: positron emission tomography
RCT: randomised controlled trial
SF-36: 13-Item Short Form Health Survey
SGOT: serum aspartic aminotransferase
SGPT: serum glutamate pyruvate transaminase
SPECT: single-photon emission computed tomography
TE-SAEs: treatment emergent serious adverse events
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Comparison 1.   Cells versus no cells
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause) 37   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Short term follow-up (< 12 months) 33 1637 Risk Ratio (M-H, Random,
95% CI)
0.48 [0.26, 0.87]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.2 Long term follow-up (≥ 12 months) 21 1010 Risk Ratio (M-H, Random,
95% CI)
0.38 [0.25, 0.58]
2 Non-fatal myocardial infarction 25   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Short term follow-up (< 12 months) 20 881 Risk Ratio (M-H, Random,
95% CI)
0.60 [0.17, 2.15]
2.2 Long term follow-up (≥ 12 months) 9 461 Risk Ratio (M-H, Random,
95% CI)
0.40 [0.17, 0.93]
3 Rehospitalisation due to heart failure 16   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Short term follow-up (< 12 months) 10 482 Risk Ratio (M-H, Random,
95% CI)
0.63 [0.36, 1.12]
3.2 Long term follow-up (≥ 12 months) 10 495 Risk Ratio (M-H, Random,
95% CI)
0.62 [0.36, 1.04]
4 Arrhythmias 24   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 Short term follow-up (< 12 months) 22 959 Risk Ratio (M-H, Random,
95% CI)
0.70 [0.33, 1.45]
4.2 Long term follow-up (≥ 12 months) 7 363 Risk Ratio (M-H, Random,
95% CI)
0.46 [0.22, 0.97]
5 Composite MACE 9   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 Short term follow-up (< 12 months) 8 288 Risk Ratio (M-H, Random,
95% CI)
0.51 [0.18, 1.42]
5.2 Long term follow-up (≥ 12 months) 5 201 Risk Ratio (M-H, Random,
95% CI)
0.68 [0.41, 1.12]
6 MLHFQ: short term follow-up (< 12 months) 4   Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 Mean value at endpoint 2 125 Mean Difference (IV, Random,
95% CI)
-29.52 [-33.76, -25.27]
6.2 Mean change from baseline 2 72 Mean Difference (IV, Random,
95% CI)
-9.07 [-22.09, 3.95]
6.3 Combined 4 197 Mean Difference (IV, Random,
95% CI)
-18.96 [-31.97, -5.94]
7 MLHFQ: long term follow-up (≥ 12 months) 3   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7.1 Mean value at endpoint 1 82 Mean Difference (IV, Random,
95% CI)
-36.5 [-42.21, -30.79]
7.2 Mean change from baseline 2 69 Mean Difference (IV, Random,
95% CI)
-7.63 [-16.35, 1.09]
7.3 Combined 3 151 Mean Difference (IV, Random,
95% CI)
-17.80 [-39.87, 4.26]
8 Seattle Angina Questionnaire: short term fol-
low-up (< 12 months)
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
8.1 Mean value at endpoint 1 49 Mean Difference (IV, Random,
95% CI)
5.0 [-3.21, 13.21]
8.2 Mean change from baseline 2 211 Mean Difference (IV, Random,
95% CI)
9.34 [2.62, 16.07]
8.3 Combined 2 211 Mean Difference (IV, Random,
95% CI)
9.34 [2.62, 16.07]
9 Angina episodes per week: short term fol-
low-up (< 12 months)
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
9.1 Mean value at endpoint 4 396 Mean Difference (IV, Random,
95% CI)
-6.96 [-11.99, -1.93]
9.2 Mean change from baseline 3 167 Mean Difference (IV, Random,
95% CI)
-1.77 [-14.61, 11.08]
9.3 Combined 5 428 Mean Difference (IV, Random,
95% CI)
-5.11 [-11.30, 1.09]
10 NYHA classification: short-term follow-up (<
12 months)
17   Mean Difference (IV, Random,
95% CI)
Subtotals only
10.1 Mean value at endpoint 16 658 Mean Difference (IV, Random,
95% CI)
-0.42 [-0.84, -0.00]
10.2 Mean change from baseline 4 239 Mean Difference (IV, Random,
95% CI)
-0.56 [-1.49, 0.36]
10.3 Combined 17 741 Mean Difference (IV, Random,
95% CI)
-0.44 [-0.84, -0.05]
11 NYHA classification: long term follow-up (≥
12 months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
11.1 Mean value at endpoint 9 346 Mean Difference (IV, Random,
95% CI)
-0.57 [-1.03, -0.10]
11.2 Mean change from baseline 1 39 Mean Difference (IV, Random,
95% CI)
-2.2 [-2.70, -1.70]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
11.3 Combined 9 346 Mean Difference (IV, Random,
95% CI)
-0.81 [-1.23, -0.39]
12 CCS class: short term follow-up (< 12
months)
13   Mean Difference (IV, Random,
95% CI)
Subtotals only
12.1 Mean value at endpoint 10 486 Mean Difference (IV, Random,
95% CI)
-0.32 [-0.82, 0.18]
12.2 Mean change from baseline 6 318 Mean Difference (IV, Random,
95% CI)
-0.62 [-1.40, 0.17]
12.3 Combined 13 608 Mean Difference (IV, Random,
95% CI)
-0.43 [-0.92, 0.06]
13 CCS class: long term follow-up (≥ 12 months) 3   Mean Difference (IV, Random,
95% CI)
Subtotals only
13.1 Mean value at endpoint 3 142 Mean Difference (IV, Random,
95% CI)
-0.58 [-2.04, 0.88]
14 Exercise capacity: short term follow-up (< 12
months)
16   Std. Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
14.1 Mean value at endpoint 11 563 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.56 [0.19, 0.93]
14.2 Mean change from baseline 9 535 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.33 [0.05, 0.61]
15 Exercise capacity: long term follow-up (≥ 12
months)
8   Std. Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
15.1 Mean value at endpoint 5 178 Std. Mean Difference (IV, Ran-
dom, 95% CI)
1.14 [0.04, 2.25]
15.2 Mean change from baseline 3 227 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.34 [0.07, 0.62]
16 LVEF (%) measured by MRI: short term fol-
low-up (< 12 months)
12   Mean Difference (IV, Random,
95% CI)
Subtotals only
16.1 Mean value at endpoint 10 352 Mean Difference (IV, Random,
95% CI)
3.01 [-0.05, 6.07]
16.2 Mean change from baseline 9 308 Mean Difference (IV, Random,
95% CI)
4.05 [2.55, 5.55]
16.3 Combined 12 439 Mean Difference (IV, Random,
95% CI)
2.92 [1.03, 4.82]
17 LVEF (%) measured by MRI: long term fol-
low-up (≥ 12 months)
4   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
17.1 Mean value at endpoint 4 110 Mean Difference (IV, Random,
95% CI)
2.37 [-1.54, 6.29]
17.2 Mean change from baseline 3 97 Mean Difference (IV, Random,
95% CI)
3.83 [-0.42, 8.08]
17.3 Combined 4 110 Mean Difference (IV, Random,
95% CI)
4.38 [0.82, 7.93]
18 LVEF (%) measured by echocardiography:
short term follow-up (< 12 months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
18.1 Mean value at endpoint 8 388 Mean Difference (IV, Random,
95% CI)
5.16 [2.87, 7.44]
18.2 Mean change from baseline 3 161 Mean Difference (IV, Random,
95% CI)
3.47 [1.59, 5.34]
18.3 Combined 9 470 Mean Difference (IV, Random,
95% CI)
5.71 [4.29, 7.13]
19 LVEF (%) measured by echocardiography:
long term follow-up (≥ 12 months)
3   Mean Difference (IV, Random,
95% CI)
Subtotals only
19.1 Mean value at endpoint 3 154 Mean Difference (IV, Random,
95% CI)
7.69 [6.47, 8.92]
19.2 Mean change from baseline 1 82 Mean Difference (IV, Random,
95% CI)
6.1 [-1.27, 13.47]
19.3 Combined 3 154 Mean Difference (IV, Random,
95% CI)
7.96 [6.39, 9.54]
20 LVEF (%) measured by SPECT: short term fol-
low-up (< 12 months)
4   Mean Difference (IV, Random,
95% CI)
Subtotals only
20.1 Mean value at endpoint 4 145 Mean Difference (IV, Random,
95% CI)
2.41 [-2.65, 7.46]
20.2 Mean change from baseline 1 30 Mean Difference (IV, Random,
95% CI)
-2.3 [-17.33, 12.73]
20.3 Combined 4 145 Mean Difference (IV, Random,
95% CI)
5.22 [2.60, 7.85]
21 LVEF (%) measured by SPECT: long term fol-
low-up (≥ 12 months)
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
21.1 Mean value at endpoint 2 88 Mean Difference (IV, Random,
95% CI)
0.37 [-2.30, 3.04]
21.2 Mean change from baseline 1 49 Mean Difference (IV, Random,
95% CI)
4.0 [-6.48, 14.48]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
21.3 Combined 2 88 Mean Difference (IV, Random,
95% CI)
0.28 [-2.48, 3.03]
22 LVEF (%) measured by LV angiography: short
term follow-up (< 12 months)
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
22.1 Mean value at endpoint 6 265 Mean Difference (IV, Random,
95% CI)
3.18 [0.39, 5.97]
22.2 Mean change from baseline 4 181 Mean Difference (IV, Random,
95% CI)
1.72 [0.50, 2.95]
22.3 Combined 6 250 Mean Difference (IV, Random,
95% CI)
2.00 [0.53, 3.46]
23 LVEF (%) measured by LV angiography: long
term follow-up (≥ 12 months)
1   Mean Difference (IV, Random,
95% CI)
Subtotals only
23.1 Mean value at endpoint 1 49 Mean Difference (IV, Random,
95% CI)
6.0 [0.81, 11.19]
 
 
Analysis 1.1.   Comparison 1 Cells versus no cells, Outcome 1 Mortality (all-cause).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Short term follow-up (< 12 months)  
Ang 2008 1/42 1/19 4.87% 0.45[0.03,6.86]
Assmus 2006 0/52 1/23 3.59% 0.15[0.01,3.57]
Assmus 2013 5/43 6/39 29.47% 0.76[0.25,2.28]
Bartunek 2012 0/21 0/15   Not estimable
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 5.13% 1.09[0.08,15.41]
Honold 2012 0/23 0/9   Not estimable
Hu 2011 0/31 1/29 3.6% 0.31[0.01,7.38]
Jimenez-Quevedo 2011 1/19 1/9 5.1% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 3.55% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 4.86% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 4.13% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 4.49% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 4.01% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 3.58% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pokushalov 2010 2/55 8/54 15.92% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Van Ramshorst 2009 1/25 0/25 3.62% 3[0.13,70.3]
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 2/18 0/18 4.08% 5[0.26,97.37]
Subtotal (95% CI) 963 674 100% 0.48[0.26,0.87]
Total events: 15 (Cells), 27 (No cells)  
Heterogeneity: Tau2=0; Chi2=10, df=14(P=0.76); I2=0%  
Test for overall effect: Z=2.41(P=0.02)  
   
1.1.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 8/39 18.23% 0.68[0.26,1.79]
Bartunek 2012 1/21 2/15 3.19% 0.36[0.04,3.59]
Chen 2006 2/22 4/23 6.7% 0.52[0.11,2.57]
Erbs 2005 0/13 1/12 1.76% 0.31[0.01,6.94]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 1/19 1/11 2.38% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Honold 2012 0/23 1/9 1.75% 0.14[0.01,3.13]
Hu 2011 1/31 2/29 3.09% 0.47[0.04,4.89]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 1.96% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 3.49% 0.33[0.04,3.03]
Patel 2005 3/25 10/25 12.53% 0.3[0.09,0.96]
Patel 2015 5/22 2/6 9.07% 0.68[0.17,2.68]
Patila 2014 0/13 0/17   Not estimable
Pokushalov 2010 6/55 21/54 24.93% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 1.97% 0.1[0.01,1.89]
Trifunovic 2015 2/15 4/15 7.18% 0.5[0.11,2.33]
Tse 2007 0/19 1/9 1.76% 0.17[0.01,3.73]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 587 423 100% 0.38[0.25,0.58]
Total events: 28 (Cells), 65 (No cells)  
Heterogeneity: Tau2=0; Chi2=6, df=14(P=0.97); I2=0%  
Test for overall effect: Z=4.55(P<0.0001)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 1.2.   Comparison 1 Cells versus no cells, Outcome 2 Non-fatal myocardial infarction.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Short term follow-up (< 12 months)  
Ang 2008 0/42 0/19   Not estimable
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Assmus 2006 1/52 0/23 16.34% 1.36[0.06,32.15]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Honold 2012 0/23 1/9 16.87% 0.14[0.01,3.13]
Hu 2011 0/31 0/29   Not estimable
Jimenez-Quevedo 2011 0/19 0/9   Not estimable
Losordo 2007 0/18 0/6   Not estimable
Mathiasen 2015 0/40 0/20   Not estimable
Mozid 2014_IC 0/14 0/2   Not estimable
Mozid 2014_IM 0/10 0/8   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 16.26% 1.55[0.06,36.94]
Perin 2012b 1/10 0/10 17.14% 3[0.14,65.9]
Tse 2007 0/19 1/9 16.92% 0.17[0.01,3.73]
Van Ramshorst 2009 0/25 0/25   Not estimable
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Yao 2008 0/24 1/23 16.47% 0.32[0.01,7.48]
Zhao 2008 0/18 0/18   Not estimable
Subtotal (95% CI) 528 353 100% 0.6[0.17,2.15]
Total events: 3 (Cells), 3 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.3, df=5(P=0.65); I2=0%  
Test for overall effect: Z=0.79(P=0.43)  
   
1.2.2 Long term follow-up (≥ 12 months)  
Assmus 2013 1/43 4/39 15.12% 0.23[0.03,1.94]
Hamshere 2015_IC 1/15 0/15 7.15% 3[0.13,68.26]
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 0/22 0/11   Not estimable
Heldman 2014_BMMNC 0/22 0/10   Not estimable
Honold 2012 1/23 2/9 13.5% 0.2[0.02,1.9]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 6/112 7/56 64.23% 0.43[0.15,1.22]
Patila 2014 0/13 0/17   Not estimable
Subtotal (95% CI) 283 178 100% 0.4[0.17,0.93]
Total events: 9 (Cells), 13 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.27, df=3(P=0.52); I2=0%  
Test for overall effect: Z=2.14(P=0.03)  
Favours cell therapy 1000.01 100.1 1 Favours no cell therapy
 
 
Analysis 1.3.   Comparison 1 Cells versus no cells, Outcome 3 Rehospitalisation due to heart failure.
Study or subgroup Cells No Cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Short term follow-up (< 12 months)  
Assmus 2006 1/52 1/23 4.32% 0.44[0.03,6.77]
Assmus 2013 8/43 11/39 50.14% 0.66[0.3,1.47]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 1/15 1/15 4.49% 1[0.07,14.55]
Favours cell therapy 100.1 50.2 20.5 1 Favours no cell therapy
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Study or subgroup Cells No Cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Honold 2012 0/23 0/9   Not estimable
Mathiasen 2015 6/40 2/20 14.15% 1.5[0.33,6.77]
Mozid 2014_IC 1/14 0/2 3.69% 0.6[0.03,11.47]
Mozid 2014_IM 0/10 0/8   Not estimable
Perin 2012a 3/61 5/31 17.28% 0.3[0.08,1.19]
Yao 2008 1/24 2/23 5.92% 0.48[0.05,4.93]
Subtotal (95% CI) 297 185 100% 0.63[0.36,1.12]
Total events: 21 (Cells), 22 (No Cells)  
Heterogeneity: Tau2=0; Chi2=2.6, df=6(P=0.86); I2=0%  
Test for overall effect: Z=1.57(P=0.12)  
   
1.3.2 Long term follow-up (≥ 12 months)  
Assmus 2013 8/43 13/39 46.67% 0.56[0.26,1.2]
Bartunek 2012 6/21 4/15 23.62% 1.07[0.36,3.15]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 1/15 1/15 3.83% 1[0.07,14.55]
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 1/10 2.83% 0.18[0.01,4.13]
Honold 2012 0/23 2/9 3.16% 0.08[0,1.58]
Losordo 2011 3/112 4/56 12.83% 0.38[0.09,1.62]
Patel 2015 2/22 0/6 3.23% 1.52[0.08,28.11]
Patila 2014 1/13 1/17 3.83% 1.31[0.09,19]
Subtotal (95% CI) 302 193 100% 0.62[0.36,1.04]
Total events: 21 (Cells), 26 (No Cells)  
Heterogeneity: Tau2=0; Chi2=4.71, df=7(P=0.7); I2=0%  
Test for overall effect: Z=1.81(P=0.07)  
Favours cell therapy 100.1 50.2 20.5 1 Favours no cell therapy
 
 
Analysis 1.4.   Comparison 1 Cells versus no cells, Outcome 4 Arrhythmias.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Short term follow-up (< 12 months)  
Ang 2008 0/42 0/19   Not estimable
Assmus 2006 0/52 1/23 5.41% 0.15[0.01,3.57]
Chen 2006 0/22 0/23   Not estimable
Hamshere 2015_IC 0/15 1/15 5.54% 0.33[0.01,7.58]
Hamshere 2015_IM 0/15 1/15 5.54% 0.33[0.01,7.58]
Hu 2011 0/31 0/29   Not estimable
Jimenez-Quevedo 2011 1/19 1/9 7.67% 0.47[0.03,6.74]
Losordo 2007 0/18 1/6 5.7% 0.12[0.01,2.67]
Mathiasen 2015 3/40 1/20 11.19% 1.5[0.17,13.52]
Mozid 2014_IC 0/14 0/2   Not estimable
Mozid 2014_IM 2/10 2/8 18.18% 0.8[0.14,4.49]
Patel 2005 0/10 0/10   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012b 3/10 2/10 22.24% 1.5[0.32,7.14]
Pokushalov 2010 0/55 0/54   Not estimable
Santoso 2014 1/19 1/9 7.67% 0.47[0.03,6.74]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 0/25 0/25   Not estimable
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 1/56 5.35% 0.33[0.01,8.01]
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 1/18 0/18 5.5% 3[0.13,69.09]
Subtotal (95% CI) 550 409 100% 0.7[0.33,1.45]
Total events: 11 (Cells), 12 (No cells)  
Heterogeneity: Tau2=0; Chi2=5.18, df=10(P=0.88); I2=0%  
Test for overall effect: Z=0.96(P=0.34)  
   
1.4.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 13/39 74.93% 0.42[0.18,0.99]
Hamshere 2015_IC 1/15 1/15 7.82% 1[0.07,14.55]
Hamshere 2015_IM 0/15 1/15 5.74% 0.33[0.01,7.58]
Hu 2011 1/31 0/29 5.61% 2.81[0.12,66.4]
Losordo 2007 0/18 1/6 5.9% 0.12[0.01,2.67]
Patel 2015 0/22 0/6   Not estimable
Pokushalov 2010 0/55 0/54   Not estimable
Subtotal (95% CI) 199 164 100% 0.46[0.22,0.97]
Total events: 8 (Cells), 16 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.38, df=4(P=0.67); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 1.5.   Comparison 1 Cells versus no cells, Outcome 5 Composite MACE.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Short term follow-up (< 12 months)  
Assmus 2006 1/52 1/23 14% 0.44[0.03,6.77]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 1/15 1/15 14.53% 1[0.07,14.55]
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hu 2011 3/31 4/29 52.49% 0.7[0.17,2.87]
Mozid 2014_IC 1/14 1/2 18.98% 0.14[0.01,1.49]
Mozid 2014_IM 0/10 0/8   Not estimable
Subtotal (95% CI) 175 113 100% 0.51[0.18,1.42]
Total events: 6 (Cells), 7 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.64, df=3(P=0.65); I2=0%  
Test for overall effect: Z=1.29(P=0.2)  
   
1.5.2 Long term follow-up (≥ 12 months)  
Assmus 2013 14/43 19/39 87.71% 0.67[0.39,1.14]
Hamshere 2015_IC 1/15 0/15 2.59% 3[0.13,68.26]
Hamshere 2015_IM 1/15 1/15 3.53% 1[0.07,14.55]
Heldman 2014_BM-MSC 1/19 1/11 3.55% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 1/10 2.61% 0.18[0.01,4.13]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 111 90 100% 0.68[0.41,1.12]
Total events: 17 (Cells), 22 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.65, df=4(P=0.8); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 1.6.   Comparison 1 Cells versus no cells, Outcome 6 MLHFQ: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.6.1 Mean value at endpoint  
Perin 2011 17 41.6 (22.1) 9 61.8 (28.5) 3.94% -20.2[-41.58,1.18]
Pokushalov 2010 53 32.9 (8) 46 62.8 (13) 96.06% -29.9[-34.23,-25.57]
Subtotal *** 70   55   100% -29.52[-33.76,-25.27]
Heterogeneity: Tau2=0; Chi2=0.76, df=1(P=0.38); I2=0%  
Test for overall effect: Z=13.63(P<0.0001)  
   
1.6.2 Mean change from baseline  
Heldman 2014_BM-MSC 19 -11.6 (25.1) 19 -4.6 (32) 50.68% -7[-25.29,11.29]
Heldman 2014_BMMNC 15 -15.8 (23.1) 19 -4.6 (32) 49.32% -11.2[-29.74,7.34]
Subtotal *** 34   38   100% -9.07[-22.09,3.95]
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.37(P=0.17)  
   
1.6.3 Combined  
Heldman 2014_BM-MSC 19 -11.6 (25.1) 19 -4.6 (32) 22% -7[-25.29,11.29]
Heldman 2014_BMMNC 15 -15.8 (23.1) 19 -4.6 (32) 21.74% -11.2[-29.74,7.34]
Perin 2011 17 41.6 (22.1) 9 61.8 (28.5) 18.98% -20.2[-41.58,1.18]
Pokushalov 2010 53 32.9 (8) 46 62.8 (13) 37.29% -29.9[-34.23,-25.57]
Subtotal *** 104   93   100% -18.96[-31.97,-5.94]
Heterogeneity: Tau2=113.39; Chi2=9.42, df=3(P=0.02); I2=68.17%  
Test for overall effect: Z=2.85(P=0)  
Test for subgroup differences: Chi2=10.09, df=1 (P=0.01), I2=80.19%  
Favours cell therapy 10050-100 -50 0 Favours no cell therapy
 
 
Analysis 1.7.   Comparison 1 Cells versus no cells, Outcome 7 MLHFQ: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.7.1 Mean value at endpoint  
Pokushalov 2010 49 22.4 (6) 33 58.9 (16) 100% -36.5[-42.21,-30.79]
Subtotal *** 49   33   100% -36.5[-42.21,-30.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=12.53(P<0.0001)  
   
1.7.2 Mean change from baseline  
Heldman 2014_BM-MSC 16 -6.3 (16.3) 19 0.4 (20.5) 51.11% -6.7[-18.9,5.5]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heldman 2014_BMMNC 15 -8.2 (16.6) 19 0.4 (20.5) 48.89% -8.6[-21.07,3.87]
Subtotal *** 31   38   100% -7.63[-16.35,1.09]
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=1.71(P=0.09)  
   
1.7.3 Combined  
Heldman 2014_BM-MSC 16 -6.3 (16.3) 19 0.4 (20.5) 32.47% -6.7[-18.9,5.5]
Heldman 2014_BMMNC 15 -8.2 (16.6) 19 0.4 (20.5) 32.33% -8.6[-21.07,3.87]
Pokushalov 2010 49 22.4 (6) 33 58.9 (16) 35.2% -36.5[-42.21,-30.79]
Subtotal *** 80   71   100% -17.8[-39.87,4.26]
Heterogeneity: Tau2=351.45; Chi2=29.51, df=2(P<0.0001); I2=93.22%  
Test for overall effect: Z=1.58(P=0.11)  
Test for subgroup differences: Chi2=30.23, df=1 (P<0.0001), I2=93.38%  
Favours cell therapy 10050-100 -50 0 Favours no cell therapy
 
 
Analysis 1.8.   Comparison 1 Cells versus no cells, Outcome 8
Seattle Angina Questionnaire: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.8.1 Mean value at endpoint  
Van Ramshorst 2009 24 69 (12) 25 64 (17) 100% 5[-3.21,13.21]
Subtotal *** 24   25   100% 5[-3.21,13.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.19(P=0.23)  
   
1.8.2 Mean change from baseline  
Losordo 2011 109 27.6 (30.1) 53 13.8 (31.9) 37.22% 13.8[3.52,24.08]
Van Ramshorst 2009 24 13 (11.5) 25 6.3 (15.1) 62.78% 6.7[-0.8,14.2]
Subtotal *** 133   78   100% 9.34[2.62,16.07]
Heterogeneity: Tau2=4.13; Chi2=1.2, df=1(P=0.27); I2=16.4%  
Test for overall effect: Z=2.72(P=0.01)  
   
1.8.3 Combined  
Losordo 2011 109 27.6 (30.1) 53 13.8 (31.9) 37.22% 13.8[3.52,24.08]
Van Ramshorst 2009 24 13 (11.5) 25 6.3 (15.1) 62.78% 6.7[-0.8,14.2]
Subtotal *** 133   78   100% 9.34[2.62,16.07]
Heterogeneity: Tau2=4.13; Chi2=1.2, df=1(P=0.27); I2=16.4%  
Test for overall effect: Z=2.72(P=0.01)  
Test for subgroup differences: Chi2=0.8, df=1 (P=0.67), I2=0%  
Favours no cell therapy 10050-100 -50 0 Favours cell therapy
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Analysis 1.9.   Comparison 1 Cells versus no cells, Outcome 9
Angina episodes per week: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.9.1 Mean value at endpoint  
Losordo 2007 17 8.6 (10.3) 6 16 (19.3) 8.25% -7.4[-23.6,8.8]
Losordo 2011 109 7.6 (8.1) 53 10.9 (8.7) 48.87% -3.3[-6.09,-0.51]
Pokushalov 2010 53 7 (10.5) 46 19.6 (32.2) 18.26% -12.6[-22.33,-2.87]
Wang 2010 56 5.6 (15.7) 56 15.5 (24.7) 24.62% -9.9[-17.57,-2.23]
Subtotal *** 235   161   100% -6.96[-11.99,-1.93]
Heterogeneity: Tau2=11.44; Chi2=5.37, df=3(P=0.15); I2=44.18%  
Test for overall effect: Z=2.71(P=0.01)  
   
1.9.2 Mean change from baseline  
Losordo 2007 17 12.6 (18.2) 6 -4.5 (20.1) 23.86% 17.1[-1.16,35.36]
Wang 2009 16 -5.6 (9.3) 16 -2 (16.3) 37.29% -3.6[-12.8,5.6]
Wang 2010 56 -14.6 (29.9) 56 -3 (8.9) 38.85% -11.6[-19.77,-3.43]
Subtotal *** 89   78   100% -1.77[-14.61,11.08]
Heterogeneity: Tau2=93.21; Chi2=8.19, df=2(P=0.02); I2=75.57%  
Test for overall effect: Z=0.27(P=0.79)  
   
1.9.3 Combined  
Losordo 2007 17 12.6 (18.2) 6 -4.5 (20.1) 8.6% 17.1[-1.16,35.36]
Losordo 2011 109 7.6 (8.1) 53 10.9 (8.7) 31.95% -3.3[-6.09,-0.51]
Pokushalov 2010 53 7 (10.5) 46 19.6 (32.2) 18.54% -12.6[-22.33,-2.87]
Wang 2009 16 -5.6 (9.3) 16 -2 (16.3) 19.49% -3.6[-12.8,5.6]
Wang 2010 56 -14.6 (29.9) 56 -3 (8.9) 21.42% -11.6[-19.77,-3.43]
Subtotal *** 251   177   100% -5.11[-11.3,1.09]
Heterogeneity: Tau2=29.21; Chi2=11.65, df=4(P=0.02); I2=65.68%  
Test for overall effect: Z=1.62(P=0.11)  
Favours cell therapy 4020-40 -20 0 Favours no cell therapy
 
 
Analysis 1.10.   Comparison 1 Cells versus no cells, Outcome
10 NYHA classification: short-term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.10.1 Mean value at endpoint  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 6.13% -0.14[-0.61,0.33]
Assmus 2013 43 2 (0.7) 39 2.2 (0.8) 6.41% -0.2[-0.51,0.11]
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 6.3% -1.2[-1.58,-0.82]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 6.24% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 6.35% 0.2[-0.15,0.55]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 6% 0.11[-0.42,0.64]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 5.82% -0.3[-0.91,0.31]
Nasseri 2012 28 2 (0.7) 26 1.5 (0.7) 6.32% 0.54[0.17,0.91]
Patel 2005 10 0.7 (0.8) 10 2.7 (0.7) 5.72% -2[-2.66,-1.34]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 6.54% -0.6[-0.81,-0.39]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 6.33% 0.2[-0.16,0.56]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 6.63% -1.5[-1.56,-1.44]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 6.22% -0.27[-0.69,0.15]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 6.31% -0.38[-0.75,-0.01]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 6.29% -0.5[-0.88,-0.12]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 6.38% -0.8[-1.13,-0.47]
Subtotal *** 373   285   100% -0.42[-0.84,-0]
Heterogeneity: Tau2=0.69; Chi2=512.53, df=15(P<0.0001); I2=97.07%  
Test for overall effect: Z=1.98(P=0.05)  
   
1.10.2 Mean change from baseline  
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 25.29% -0.45[-0.82,-0.08]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 24.76% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 24.53% -2.1[-2.59,-1.61]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 25.42% -0.2[-0.55,0.15]
Subtotal *** 135   104   100% -0.56[-1.49,0.36]
Heterogeneity: Tau2=0.84; Chi2=61.48, df=3(P<0.0001); I2=95.12%  
Test for overall effect: Z=1.19(P=0.23)  
   
1.10.3 Combined  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 5.75% -0.14[-0.61,0.33]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 5.94% -0.45[-0.82,-0.08]
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 5.92% -1.2[-1.58,-0.82]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 5.86% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 5.97% 0.2[-0.15,0.55]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 5.62% 0.11[-0.42,0.64]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 5.44% -0.3[-0.91,0.31]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 5.78% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 5.71% -2.1[-2.59,-1.61]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 6.16% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 5.98% -0.2[-0.55,0.15]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 5.95% 0.2[-0.16,0.56]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 6.26% -1.5[-1.56,-1.44]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 5.84% -0.27[-0.69,0.15]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 5.93% -0.38[-0.75,-0.01]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 5.91% -0.5[-0.88,-0.12]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 6% -0.8[-1.13,-0.47]
Subtotal *** 427   314   100% -0.44[-0.84,-0.05]
Heterogeneity: Tau2=0.64; Chi2=495.64, df=16(P<0.0001); I2=96.77%  
Test for overall effect: Z=2.21(P=0.03)  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
 
 
Analysis 1.11.   Comparison 1 Cells versus no cells, Outcome
11 NYHA classification: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.11.1 Mean value at endpoint  
Chen 2006 20 1.4 (0.7) 19 2.4 (0.4) 11.79% -1[-1.36,-0.64]
Hamshere 2015_IC 15 2.1 (0.6) 15 2.4 (0.6) 11.36% -0.29[-0.73,0.15]
Hamshere 2015_IM 15 2.1 (0.7) 15 2.1 (0.6) 11.2% -0.01[-0.48,0.46]
Honold 2012 20 1.5 (0.8) 6 1.7 (0.8) 9.62% -0.25[-0.99,0.49]
Favours cell therapy 21-2 -1 0 Favours no cell therapy
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Patel 2015 17 1.8 (0.8) 4 2.3 (1) 7.89% -0.43[-1.45,0.59]
Patila 2014 20 1.3 (0.5) 19 1.4 (0.5) 11.98% -0.1[-0.41,0.21]
Pokushalov 2010 49 2.5 (0.1) 33 3.9 (0.1) 12.65% -1.4[-1.44,-1.36]
Trifunovic 2015 15 1.1 (0.3) 15 1.8 (0.7) 11.73% -0.73[-1.1,-0.36]
Turan 2011 33 1.6 (0.6) 16 2.3 (0.6) 11.78% -0.7[-1.06,-0.34]
Subtotal *** 204   142   100% -0.57[-1.03,-0.1]
Heterogeneity: Tau2=0.44; Chi2=156.24, df=8(P<0.0001); I2=94.88%  
Test for overall effect: Z=2.39(P=0.02)  
   
1.11.2 Mean change from baseline  
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 100% -2.2[-2.7,-1.7]
Subtotal *** 20   19   100% -2.2[-2.7,-1.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.58(P<0.0001)  
   
1.11.3 Combined  
Chen 2006 20 1.4 (0.7) 19 2.4 (0.4) 12.07% -1[-1.36,-0.64]
Hamshere 2015_IC 15 2.1 (0.6) 15 2.4 (0.6) 11.5% -0.29[-0.73,0.15]
Hamshere 2015_IM 15 2.1 (0.7) 15 2.1 (0.6) 11.3% -0.01[-0.48,0.46]
Honold 2012 20 1.5 (0.8) 6 1.7 (0.8) 9.37% -0.25[-0.99,0.49]
Patel 2015 17 1.8 (0.8) 4 2.3 (1) 7.41% -0.43[-1.45,0.59]
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 11.1% -2.2[-2.7,-1.7]
Pokushalov 2010 49 2.5 (0.1) 33 3.9 (0.1) 13.2% -1.4[-1.44,-1.36]
Trifunovic 2015 15 1.1 (0.3) 15 1.8 (0.7) 11.99% -0.73[-1.1,-0.36]
Turan 2011 33 1.6 (0.6) 16 2.3 (0.6) 12.05% -0.7[-1.06,-0.34]
Subtotal *** 204   142   100% -0.81[-1.23,-0.39]
Heterogeneity: Tau2=0.34; Chi2=107.59, df=8(P<0.0001); I2=92.56%  
Test for overall effect: Z=3.81(P=0)  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
 
 
Analysis 1.12.   Comparison 1 Cells versus no cells, Outcome 12 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.12.1 Mean value at endpoint  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 11.02% 0.14[-0.21,0.49]
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 11.01% 0.18[-0.17,0.53]
Nasseri 2012 28 0.7 (0.7) 26 0.5 (0.8) 10.87% 0.21[-0.18,0.6]
Perin 2011 20 1.8 (0.2) 10 2.6 (0.3) 11.43% -0.8[-1.01,-0.59]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 10.7% 0[-0.44,0.44]
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 11.36% -1.8[-2.04,-1.56]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 10.89% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 10.74% -0.3[-0.73,0.13]
Wang 2010 56 0.9 (7.5) 56 2.7 (20.2) 0.73% -1.8[-7.44,3.84]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 11.25% -0.03[-0.31,0.25]
Subtotal *** 256   230   100% -0.32[-0.82,0.18]
Heterogeneity: Tau2=0.56; Chi2=180.19, df=9(P<0.0001); I2=95.01%  
Test for overall effect: Z=1.27(P=0.2)  
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.12.2 Mean change from baseline  
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 13.52% -0.6[-2.03,0.83]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 21.39% 0.51[-0.1,1.12]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 18.75% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 23.25% -0.2[-0.58,0.18]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 19.57% -2[-2.8,-1.2]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 3.52% -1.6[-5.46,2.26]
Subtotal *** 182   136   100% -0.62[-1.4,0.17]
Heterogeneity: Tau2=0.65; Chi2=26.26, df=5(P<0.0001); I2=80.96%  
Test for overall effect: Z=1.54(P=0.12)  
   
1.12.3 Combined  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 8.86% 0.14[-0.21,0.49]
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 8.85% 0.18[-0.17,0.53]
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 5.21% -0.6[-2.03,0.83]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 8.12% 0.51[-0.1,1.12]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 7.16% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 8.8% -0.2[-0.58,0.18]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 8.64% 0[-0.44,0.44]
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 9.08% -1.8[-2.04,-1.56]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 8.77% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 8.67% -0.3[-0.73,0.13]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 7.46% -2[-2.8,-1.2]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 1.38% -1.6[-5.46,2.26]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 9.01% -0.03[-0.31,0.25]
Subtotal *** 334   274   100% -0.43[-0.92,0.06]
Heterogeneity: Tau2=0.68; Chi2=187.39, df=12(P<0.0001); I2=93.6%  
Test for overall effect: Z=1.71(P=0.09)  
Favours cell therapy 52.5-5 -2.5 0 Favours no cell therapy
 
 
Analysis 1.13.   Comparison 1 Cells versus no cells, Outcome 13 CCS class: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Mean value at endpoint  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.2 (0.4) 33.11% 0.19[-0.15,0.53]
Hamshere 2015_IM 15 1.1 (0.4) 15 1.2 (0.4) 33.34% -0.01[-0.27,0.25]
Pokushalov 2010 49 1.6 (0.4) 33 3.5 (0.4) 33.55% -1.9[-2.08,-1.72]
Subtotal *** 79   63   100% -0.58[-2.04,0.88]
Heterogeneity: Tau2=1.64; Chi2=199.92, df=2(P<0.0001); I2=99%  
Test for overall effect: Z=0.78(P=0.44)  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
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Analysis 1.14.   Comparison 1 Cells versus no cells, Outcome
14 Exercise capacity: short term follow-up (< 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.14.1 Mean value at endpoint  
Bartunek 2012 21 456 (142.8) 3 404 (97.5) 5.5% 0.36[-0.85,1.58]
Chen 2006 22 7 (3) 23 5 (2) 9.77% 0.77[0.17,1.38]
Erbs 2005 12 23.1 (5.8) 10 22.4 (4.7) 7.91% 0.13[-0.71,0.97]
Honold 2012 12 376 (198) 5 501 (175) 6.33% -0.62[-1.69,0.45]
Hu 2011 30 491 (47) 27 451 (66) 10.37% 0.69[0.16,1.23]
Perin 2012a 51 184 (407) 29 80 (415) 11.01% 0.25[-0.21,0.71]
Pokushalov 2010 53 325 (81) 46 211 (48) 10.99% 1.67[1.21,2.13]
Trifunovic 2015 15 435 (90) 15 315 (80) 8.16% 1.37[0.56,2.18]
Tse 2007 19 6.1 (0.5) 9 5.7 (0.7) 8.16% 0.54[-0.27,1.34]
Van Ramshorst 2009 24 116 (32) 25 103 (41) 10.13% 0.35[-0.22,0.91]
Wang 2010 56 8.9 (9.7) 56 6.8 (15.7) 11.68% 0.16[-0.21,0.53]
Subtotal *** 315   248   100% 0.56[0.19,0.93]
Heterogeneity: Tau2=0.27; Chi2=39.4, df=10(P<0.0001); I2=74.62%  
Test for overall effect: Z=2.94(P=0)  
   
1.14.2 Mean change from baseline  
Heldman 2014_BM-MSC 18 28.2 (34.9) 19 21.6 (41.9) 10.25% 0.17[-0.48,0.81]
Heldman 2014_BMMNC 15 -25.7 (87.3) 19 21.6 (41.9) 9.34% -0.7[-1.4,-0]
Hu 2011 30 44 (39) 27 16 (84) 12.6% 0.43[-0.1,0.96]
Losordo 2007 18 0.5 (1.3) 6 0.3 (2.1) 6.47% 0.13[-0.8,1.05]
Losordo 2011 109 124.4 (153) 53 69 (122) 17.36% 0.38[0.05,0.71]
Tse 2007 19 0.1 (0.3) 9 -0.2 (0.5) 7.37% 1.01[0.17,1.85]
Van Ramshorst 2009 24 9 (15.7) 25 2 (14.3) 11.72% 0.46[-0.11,1.03]
Wang 2009 16 2.4 (1) 16 0.8 (1.7) 8.56% 1.12[0.37,1.87]
Wang 2010 56 4.5 (9.7) 56 2.5 (15.7) 16.33% 0.15[-0.22,0.52]
Subtotal *** 305   230   100% 0.33[0.05,0.61]
Heterogeneity: Tau2=0.09; Chi2=16.81, df=8(P=0.03); I2=52.41%  
Test for overall effect: Z=2.33(P=0.02)  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 1.15.   Comparison 1 Cells versus no cells, Outcome 15 Exercise capacity: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 Mean value at endpoint  
Chen 2006 20 7 (2) 19 5 (3) 21.3% 0.77[0.12,1.43]
Erbs 2005 12 22.6 (7.9) 10 21.6 (4.7) 20.3% 0.14[-0.7,0.99]
Honold 2012 10 19 (19) 5 17 (8.9) 18.89% 0.11[-0.96,1.19]
Pokushalov 2010 49 359 (69) 33 196 (42) 21.49% 2.71[2.09,3.32]
Trifunovic 2015 15 520 (79) 5 343 (114) 18.01% 1.93[0.71,3.14]
Subtotal *** 106   72   100% 1.14[0.04,2.25]
Heterogeneity: Tau2=1.38; Chi2=35.67, df=4(P<0.0001); I2=88.79%  
Test for overall effect: Z=2.03(P=0.04)  
   
1.15.2 Mean change from baseline  
Heldman 2014_BM-MSC 16 32.6 (69.7) 19 6.1 (78.2) 16.79% 0.35[-0.32,1.02]
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Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heldman 2014_BMMNC 17 16.9 (60.5) 19 6.1 (78.2) 17.58% 0.15[-0.51,0.81]
Losordo 2011 106 121.5
(166.8)
50 58 (146) 65.63% 0.39[0.05,0.73]
Subtotal *** 139   88   100% 0.34[0.07,0.62]
Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%  
Test for overall effect: Z=2.45(P=0.01)  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 1.16.   Comparison 1 Cells versus no cells, Outcome 16
LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.16.1 Mean value at endpoint  
Ang 2008 18 28.6 (8.4) 7 22.3 (5.8) 11.03% 6.3[0.51,12.09]
Erbs 2005 12 57.7 (10.9) 11 55.8 (8.8) 8.04% 1.9[-6.17,9.97]
Hendrikx 2006 10 48.9 (9.5) 10 43.1 (10.9) 7.1% 5.8[-3.16,14.76]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 7.49% 7.5[-1.07,16.07]
Hu 2011 31 36.5 (11.8) 28 32.3 (10.3) 11.26% 4.2[-1.44,9.84]
Nasseri 2012 26 31 (7) 22 33 (8) 13.42% -2[-6.29,2.29]
Santoso 2014 19 25.7 (9.5) 9 29.4 (11.1) 7.66% -3.7[-12.12,4.72]
Tse 2007 18 55.6 (8.8) 8 45.3 (8.2) 9.34% 10.3[3.31,17.29]
Van Ramshorst 2009 22 59 (11) 18 53 (10) 9.97% 6[-0.52,12.52]
Wang 2014 35 33 (7) 35 35 (8) 14.69% -2[-5.52,1.52]
Subtotal *** 200   152   100% 3.01[-0.05,6.07]
Heterogeneity: Tau2=13.33; Chi2=21.88, df=9(P=0.01); I2=58.87%  
Test for overall effect: Z=1.93(P=0.05)  
   
1.16.2 Mean change from baseline  
Ang 2008 18 2.1 (4.8) 7 0.7 (4.2) 10.85% 1.4[-2.42,5.22]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 16.83% 3[0.31,5.69]
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 8.71% 6.7[2.26,11.14]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 3.39% 2.5[-5.26,10.26]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 7.58% 5.4[0.55,10.25]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 22.18% 6.3[4.3,8.3]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 6.54% -0.7[-6.01,4.61]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 5.81% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 18.12% 4[1.49,6.51]
Subtotal *** 185   123   100% 4.05[2.55,5.55]
Heterogeneity: Tau2=1.59; Chi2=11.92, df=8(P=0.15); I2=32.88%  
Test for overall effect: Z=5.29(P<0.0001)  
   
1.16.3 Combined  
Ang 2008 18 2.1 (4.8) 7 0.7 (4.2) 9.23% 1.4[-2.42,5.22]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 11.39% 3[0.31,5.69]
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 8.17% 6.7[2.26,11.14]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 4.25% 2.5[-5.26,10.26]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 3.68% 7.5[-1.07,16.07]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 7.51% 5.4[0.55,10.25]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 12.68% 6.3[4.3,8.3]
Nasseri 2012 26 31 (7) 22 33 (8) 8.41% -2[-6.29,2.29]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 6.84% -0.7[-6.01,4.61]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 6.32% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 11.74% 4[1.49,6.51]
Wang 2014 35 33 (7) 35 35 (8) 9.79% -2[-5.52,1.52]
Subtotal *** 255   184   100% 2.92[1.03,4.82]
Heterogeneity: Tau2=6.33; Chi2=30.55, df=11(P=0); I2=63.99%  
Test for overall effect: Z=3.02(P=0)  
Favours no cell therapy 2010-20 -10 0 Favours cell therapy
 
 
Analysis 1.17.   Comparison 1 Cells versus no cells, Outcome 17
LVEF (%) measured by MRI: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.17.1 Mean value at endpoint  
Erbs 2005 12 59 (10.9) 10 57.9 (8.7) 22.83% 1.1[-7.09,9.29]
Honold 2012 9 32.3 (10.9) 4 24.5 (7.5) 14.63% 7.8[-2.43,18.03]
Hu 2011 25 36.9 (12.3) 25 33 (10.2) 39.05% 3.9[-2.36,10.16]
Patila 2014 11 42.4 (9.1) 14 44.7 (11.5) 23.49% -2.3[-10.38,5.78]
Subtotal *** 57   53   100% 2.37[-1.54,6.29]
Heterogeneity: Tau2=0; Chi2=2.69, df=3(P=0.44); I2=0%  
Test for overall effect: Z=1.19(P=0.23)  
   
1.17.2 Mean change from baseline  
Erbs 2005 12 8 (9.1) 10 2.1 (2.7) 36.56% 5.9[0.49,11.31]
Hu 2011 25 13.5 (10.3) 25 8 (8.6) 37.82% 5.5[0.24,10.76]
Patila 2014 11 3.7 (9.7) 14 5.3 (8) 25.62% -1.6[-8.7,5.5]
Subtotal *** 48   49   100% 3.83[-0.42,8.08]
Heterogeneity: Tau2=5.23; Chi2=3.17, df=2(P=0.2); I2=36.95%  
Test for overall effect: Z=1.76(P=0.08)  
   
1.17.3 Combined  
Erbs 2005 12 8 (9.1) 10 2.1 (2.7) 33.04% 5.9[0.49,11.31]
Honold 2012 9 32.3 (10.9) 4 24.5 (7.5) 11.13% 7.8[-2.43,18.03]
Hu 2011 25 13.5 (10.3) 25 8 (8.6) 34.53% 5.5[0.24,10.76]
Patila 2014 11 3.7 (9.7) 14 5.3 (8) 21.3% -1.6[-8.7,5.5]
Subtotal *** 57   53   100% 4.38[0.82,7.93]
Heterogeneity: Tau2=2.34; Chi2=3.63, df=3(P=0.3); I2=17.33%  
Test for overall effect: Z=2.41(P=0.02)  
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Analysis 1.18.   Comparison 1 Cells versus no cells, Outcome 18 LVEF (%)
measured by echocardiography: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.18.1 Mean value at endpoint  
Bartunek 2012 21 34.5 (4.5) 15 28 (4.1) 16.14% 6.5[3.67,9.33]
Perin 2011 20 40 (5.4) 10 42 (5.4) 12.69% -2[-6.1,2.1]
Perin 2012b 10 36 (11.3) 10 34 (9.3) 4.89% 2[-7.07,11.07]
Pokushalov 2010 53 32.8 (6.2) 46 26.2 (6.1) 17.28% 6.6[4.17,9.03]
Trifunovic 2015 15 44.8 (5.5) 15 37.7 (7.4) 11.32% 7.1[2.43,11.77]
Van Ramshorst 2009 24 54 (7) 25 51 (7) 13.15% 3[-0.92,6.92]
Wang 2015 45 47.6 (6.3) 45 40.1 (7.4) 16.12% 7.5[4.66,10.34]
Zhao 2008 16 49.1 (9.7) 18 40.6 (8.4) 8.42% 8.5[2.36,14.64]
Subtotal *** 204   184   100% 5.16[2.87,7.44]
Heterogeneity: Tau2=6.32; Chi2=19.52, df=7(P=0.01); I2=64.13%  
Test for overall effect: Z=4.43(P<0.0001)  
   
1.18.2 Mean change from baseline  
Perin 2011 20 3 (37.9) 10 3 (8) 1.17% 0[-17.33,17.33]
Perin 2012a 54 1.4 (5.2) 28 -1.3 (5.1) 64% 2.7[0.36,5.04]
Van Ramshorst 2009 24 4 (4) 25 -1 (7) 34.83% 5[1.82,8.18]
Subtotal *** 98   63   100% 3.47[1.59,5.34]
Heterogeneity: Tau2=0; Chi2=1.46, df=2(P=0.48); I2=0%  
Test for overall effect: Z=3.63(P=0)  
   
1.18.3 Combined  
Bartunek 2012 21 34.5 (4.5) 15 28 (4.1) 15.95% 6.5[3.67,9.33]
Perin 2011 20 3 (37.9) 10 3 (8) 0.66% 0[-17.33,17.33]
Perin 2012a 54 1.4 (5.2) 28 -1.3 (5.1) 19.91% 2.7[0.36,5.04]
Perin 2012b 10 36 (11.3) 10 34 (9.3) 2.32% 2[-7.07,11.07]
Pokushalov 2010 53 32.8 (6.2) 46 26.2 (6.1) 19.15% 6.6[4.17,9.03]
Trifunovic 2015 15 44.8 (5.5) 15 37.7 (7.4) 7.64% 7.1[2.43,11.77]
Van Ramshorst 2009 24 4 (4) 25 -1 (7) 13.7% 5[1.82,8.18]
Wang 2015 45 47.6 (6.3) 45 40.1 (7.4) 15.88% 7.5[4.66,10.34]
Zhao 2008 16 49.1 (9.7) 18 40.6 (8.4) 4.77% 8.5[2.36,14.64]
Subtotal *** 258   212   100% 5.71[4.29,7.13]
Heterogeneity: Tau2=1.21; Chi2=11.04, df=8(P=0.2); I2=27.54%  
Test for overall effect: Z=7.87(P<0.0001)  
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Analysis 1.19.   Comparison 1 Cells versus no cells, Outcome 19 LVEF (%)
measured by echocardiography: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.19.1 Mean value at endpoint  
Hu 2011 24 49.1 (1.9) 18 41.4 (2.2) 58.82% 7.7[6.43,8.97]
Pokushalov 2010 49 32.3 (4.1) 33 25.2 (4.1) 35.61% 7.1[5.29,8.91]
Trifunovic 2015 15 45.3 (4.9) 15 33.9 (8.8) 5.58% 11.4[6.3,16.5]
Subtotal *** 88   66   100% 7.69[6.47,8.92]
Heterogeneity: Tau2=0.25; Chi2=2.44, df=2(P=0.3); I2=18.03%  
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=12.3(P<0.0001)  
   
1.19.2 Mean change from baseline  
Pokushalov 2010 49 4.5 (14.9) 33 -1.6 (17.8) 100% 6.1[-1.27,13.47]
Subtotal *** 49   33   100% 6.1[-1.27,13.47]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.1)  
   
1.19.3 Combined  
Hu 2011 24 49.1 (1.9) 18 41.4 (2.2) 86.46% 7.7[6.43,8.97]
Pokushalov 2010 49 4.5 (14.9) 33 -1.6 (17.8) 4.45% 6.1[-1.27,13.47]
Trifunovic 2015 15 45.3 (4.9) 15 33.9 (8.8) 9.08% 11.4[6.3,16.5]
Subtotal *** 88   66   100% 7.96[6.39,9.54]
Heterogeneity: Tau2=0.33; Chi2=2.13, df=2(P=0.34); I2=6.24%  
Test for overall effect: Z=9.93(P<0.0001)  
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Analysis 1.20.   Comparison 1 Cells versus no cells, Outcome 20
LVEF (%) measured by SPECT: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.20.1 Mean value at endpoint  
Chen 2006 22 37 (5) 23 31 (5) 42.17% 6[3.08,8.92]
Patel 2015 17 29.3 (6.7) 4 31.3 (14.3) 9.89% -2[-16.37,12.37]
Perin 2011 20 44 (13.4) 10 47.8 (7.5) 23.64% -3.8[-11.29,3.69]
Van Ramshorst 2009 24 57 (12) 25 53 (14) 24.3% 4[-3.29,11.29]
Subtotal *** 83   62   100% 2.41[-2.65,7.46]
Heterogeneity: Tau2=13.57; Chi2=6.53, df=3(P=0.09); I2=54.05%  
Test for overall effect: Z=0.93(P=0.35)  
   
1.20.2 Mean change from baseline  
Perin 2011 20 2.5 (30.7) 10 4.8 (10.8) 100% -2.3[-17.33,12.73]
Subtotal *** 20   10   100% -2.3[-17.33,12.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
   
1.20.3 Combined  
Chen 2006 22 37 (5) 23 31 (5) 80.66% 6[3.08,8.92]
Patel 2015 17 29.3 (6.7) 4 31.3 (14.3) 3.34% -2[-16.37,12.37]
Perin 2011 20 2.5 (30.7) 10 4.8 (10.8) 3.05% -2.3[-17.33,12.73]
Van Ramshorst 2009 24 57 (12) 25 53 (14) 12.96% 4[-3.29,11.29]
Subtotal *** 83   62   100% 5.22[2.6,7.85]
Heterogeneity: Tau2=0; Chi2=2.31, df=3(P=0.51); I2=0%  
Test for overall effect: Z=3.9(P<0.0001)  
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Analysis 1.21.   Comparison 1 Cells versus no cells, Outcome 21
LVEF (%) measured by SPECT: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.21.1 Mean value at endpoint  
Chen 2006 20 30 (4) 19 30 (5) 87.64% 0[-2.85,2.85]
Van Ramshorst 2009 24 56 (12) 25 53 (15) 12.36% 3[-4.59,10.59]
Subtotal *** 44   44   100% 0.37[-2.3,3.04]
Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%  
Test for overall effect: Z=0.27(P=0.79)  
   
1.21.2 Mean change from baseline  
Van Ramshorst 2009 24 3 (5.2) 25 -1 (26.2) 100% 4[-6.48,14.48]
Subtotal *** 24   25   100% 4[-6.48,14.48]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
   
1.21.3 Combined  
Chen 2006 20 30 (4) 19 30 (5) 93.11% 0[-2.85,2.85]
Van Ramshorst 2009 24 3 (5.2) 25 -1 (26.2) 6.89% 4[-6.48,14.48]
Subtotal *** 44   44   100% 0.28[-2.48,3.03]
Heterogeneity: Tau2=0; Chi2=0.52, df=1(P=0.47); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
Favours no cell therapy 2010-20 -10 0 Favours cell therapy
 
 
Analysis 1.22.   Comparison 1 Cells versus no cells, Outcome 22 LVEF
(%) measured by LV angiography: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.22.1 Mean value at endpoint  
Assmus 2006 43 41.2 (10.1) 18 42 (13) 15.96% -0.8[-7.52,5.92]
Assmus 2013 41 37.8 (12.6) 38 32.1 (12.6) 22.56% 5.7[0.14,11.26]
Honold 2012 21 38.9 (13.3) 5 39.2 (7.4) 9.98% -0.3[-8.93,8.33]
Perin 2011 20 42 (14.4) 10 40.9 (8.5) 10.94% 1.1[-7.12,9.32]
Perin 2012b 10 40.4 (15.8) 10 42.2 (7.6) 6.4% -1.8[-12.67,9.07]
Turan 2011 33 53 (8) 16 47 (7) 34.17% 6[1.62,10.38]
Subtotal *** 168   97   100% 3.18[0.39,5.97]
Heterogeneity: Tau2=0.93; Chi2=5.39, df=5(P=0.37); I2=7.27%  
Test for overall effect: Z=2.24(P=0.03)  
   
1.22.2 Mean change from baseline  
Assmus 2006 43 1.4 (3.5) 18 -1.2 (3) 36.61% 2.64[0.91,4.37]
Assmus 2013 33 3.2 (3.1) 31 1.3 (3.4) 40.94% 1.9[0.3,3.5]
Honold 2012 21 1.4 (4.4) 5 1.6 (1.7) 21.81% -0.2[-2.6,2.2]
Perin 2011 20 4.5 (16.2) 10 0.9 (22) 0.63% 3.6[-11.77,18.97]
Subtotal *** 117   64   100% 1.72[0.5,2.95]
Heterogeneity: Tau2=0.29; Chi2=3.64, df=3(P=0.3); I2=17.61%  
Test for overall effect: Z=2.76(P=0.01)  
   
1.22.3 Combined  
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Assmus 2006 43 1.4 (3.5) 18 -1.2 (3) 31.7% 2.64[0.91,4.37]
Assmus 2013 33 3.2 (3.1) 31 1.3 (3.4) 33.86% 1.9[0.3,3.5]
Honold 2012 21 1.4 (4.4) 5 1.6 (1.7) 22.47% -0.2[-2.6,2.2]
Perin 2011 20 4.5 (16.2) 10 0.9 (22) 0.89% 3.6[-11.77,18.97]
Perin 2012b 10 40.4 (15.8) 10 42.2 (7.6) 1.76% -1.8[-12.67,9.07]
Turan 2011 33 53 (8) 16 47 (7) 9.32% 6[1.62,10.38]
Subtotal *** 160   90   100% 2[0.53,3.46]
Heterogeneity: Tau2=0.98; Chi2=7.48, df=5(P=0.19); I2=33.13%  
Test for overall effect: Z=2.67(P=0.01)  
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Analysis 1.23.   Comparison 1 Cells versus no cells, Outcome 23 LVEF
(%) measured by LV angiography: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.23.1 Mean value at endpoint  
Turan 2011 33 52 (8) 16 46 (9) 100% 6[0.81,11.19]
Subtotal *** 33   16   100% 6[0.81,11.19]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.27(P=0.02)  
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Comparison 2.   Cell dose: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short term fol-
low-up (< 12 months)
30   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 < 107 cells 6 334 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.02, 1.63]
1.2 107 < 108 cells 18 771 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.15, 0.79]
1.3 ≥ 108 cells 8 487 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.35, 1.94]
2 Mortality (all-cause): long term fol-
low-up (≥ 12 months)
16   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 < 107 cells 4 297 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.10, 1.09]
2.2 107 < 108 cells 7 330 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.17, 0.53]
2.3 ≥ 108 cells 5 236 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.30, 1.26]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 NYHA classification: short term fol-
low-up (< 12 months)
15   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.1 < 107 cells 4 149 Mean Difference (IV, Random,
95% CI)
-0.29 [-0.94, 0.36]
3.2 107 < 108 cells 8 309 Mean Difference (IV, Random,
95% CI)
-0.65 [-1.22, -0.08]
3.3 ≥ 108 cells 4 241 Mean Difference (IV, Random,
95% CI)
-0.41 [-0.72, -0.11]
4 CCS class: short term follow-up (< 12
months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 < 107 cells 4 288 Mean Difference (IV, Random,
95% CI)
-0.87 [-1.92, 0.19]
4.2 107 < 108 cells 5 160 Mean Difference (IV, Random,
95% CI)
-0.54 [-1.40, 0.32]
5 Exercise capacity: short term follow-up
(< 12 months)
10   Std. Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 107 < 108 cells 7 357 Std. Mean Difference (IV, Random,
95% CI)
0.56 [-0.03, 1.14]
5.2 ≥ 108 cells 3 161 Std. Mean Difference (IV, Random,
95% CI)
0.43 [0.10, 0.77]
6 LVEF (%) measured by MRI: short term
follow-up (< 12 months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 107 < 108 cells 7 199 Mean Difference (IV, Random,
95% CI)
5.23 [3.91, 6.54]
6.2 ≥ 108 cells 3 101 Mean Difference (IV, Random,
95% CI)
2.37 [-0.92, 5.66]
 
 
Analysis 2.1.   Comparison 2 Cell dose: subgroup analysis, Outcome
1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 < 107 cells  
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 46.94% 0.17[0.01,4.06]
Nasseri 2012 0/30 2/30 53.06% 0.2[0.01,4]
Perin 2011 0/20 0/10   Not estimable
Perin 2012b 0/10 0/10   Not estimable
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Wang 2009 0/16 0/16   Not estimable
Subtotal (95% CI) 206 128 100% 0.18[0.02,1.63]
Total events: 0 (Cells), 3 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=1.52(P=0.13)  
   
2.1.2 107 < 108 cells  
Ang 2008 0/21 1/19 7.21% 0.3[0.01,7.02]
Assmus 2006 0/24 1/23 7.17% 0.32[0.01,7.48]
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hendrikx 2006 1/11 1/12 10.15% 1.09[0.08,15.41]
Honold 2012 0/23 0/9   Not estimable
Jimenez-Quevedo 2011 1/19 1/9 10.1% 0.47[0.03,6.74]
Mathiasen 2015 1/40 1/20 9.63% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 8.18% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 8.9% 0.12[0.01,1.98]
Patel 2005 0/10 0/10   Not estimable
Pokushalov 2010 2/55 8/54 31.51% 0.25[0.05,1.1]
Tse 2007 0/19 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Van Ramshorst 2009 1/25 0/25 7.16% 3[0.13,70.3]
Wang 2010 0/56 0/56   Not estimable
Yao 2008 0/24 0/23   Not estimable
Subtotal (95% CI) 432 339 100% 0.34[0.15,0.79]
Total events: 6 (Cells), 17 (No cells)  
Heterogeneity: Tau2=0; Chi2=4.62, df=8(P=0.8); I2=0%  
Test for overall effect: Z=2.5(P=0.01)  
   
2.1.3 ≥ 108 cells  
Ang 2008 1/21 1/19 10.01% 0.9[0.06,13.48]
Assmus 2006 0/28 1/23 7.34% 0.28[0.01,6.47]
Assmus 2013 5/43 6/39 59.81% 0.76[0.25,2.28]
Bartunek 2012 0/21 0/15   Not estimable
Hu 2011 0/31 1/29 7.3% 0.31[0.01,7.38]
Perin 2012a 1/61 0/31 7.26% 1.55[0.06,36.94]
Wang 2015 0/45 0/45   Not estimable
Zhao 2008 2/18 0/18 8.28% 5[0.26,97.37]
Subtotal (95% CI) 268 219 100% 0.83[0.35,1.94]
Total events: 9 (Cells), 9 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.43, df=5(P=0.79); I2=0%  
Test for overall effect: Z=0.44(P=0.66)  
Test for subgroup differences: Chi2=2.92, df=1 (P=0.23), I2=31.44%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
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Analysis 2.2.   Comparison 2 Cell dose: subgroup analysis, Outcome
2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 < 107 cells  
Chen 2006 2/22 4/23 55.11% 0.52[0.11,2.57]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 16.13% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 28.76% 0.33[0.04,3.03]
Subtotal (95% CI) 182 115 100% 0.33[0.1,1.09]
Total events: 3 (Cells), 10 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%  
Test for overall effect: Z=1.82(P=0.07)  
   
2.2.2 107 < 108 cells  
Erbs 2005 0/13 1/12 3.52% 0.31[0.01,6.94]
Honold 2012 0/23 1/9 3.51% 0.14[0.01,3.13]
Patel 2005 3/25 10/25 25.11% 0.3[0.09,0.96]
Pokushalov 2010 6/55 21/54 49.95% 0.28[0.12,0.64]
Trifunovic 2015 2/15 4/15 14.38% 0.5[0.11,2.33]
Tse 2007 0/19 1/9 3.52% 0.17[0.01,3.73]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 188 142 100% 0.3[0.17,0.53]
Total events: 11 (Cells), 38 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.82, df=5(P=0.98); I2=0%  
Test for overall effect: Z=4.07(P<0.0001)  
   
2.2.3 ≥ 108 cells  
Assmus 2013 6/43 8/39 54.28% 0.68[0.26,1.79]
Bartunek 2012 1/21 2/15 9.51% 0.36[0.04,3.59]
Hu 2011 1/31 2/29 9.19% 0.47[0.04,4.89]
Patel 2015 5/22 2/6 27.01% 0.68[0.17,2.68]
Patila 2014 0/13 0/17   Not estimable
Subtotal (95% CI) 130 106 100% 0.62[0.3,1.26]
Total events: 13 (Cells), 14 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.33, df=3(P=0.95); I2=0%  
Test for overall effect: Z=1.32(P=0.19)  
Test for subgroup differences: Chi2=2.5, df=1 (P=0.29), I2=19.91%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 2.3.   Comparison 2 Cell dose: subgroup analysis, Outcome
3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.3.1 < 107 cells  
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 24.77% -1.2[-1.58,-0.82]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 23.89% 0.48[0.02,0.94]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 26.36% -0.6[-0.81,-0.39]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 24.99% 0.2[-0.16,0.56]
Subtotal *** 80   69   100% -0.29[-0.94,0.36]
Favours no cell therapy 42-4 -2 0 Favours cell therapy
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0.41; Chi2=45.2, df=3(P<0.0001); I2=93.36%  
Test for overall effect: Z=0.88(P=0.38)  
   
2.3.2 107 < 108 cells  
Assmus 2006 19 1.9 (0.8) 18 2.1 (0.9) 12.05% -0.16[-0.71,0.39]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 12.14% 0.11[-0.42,0.64]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 11.73% -0.3[-0.91,0.31]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 12.33% -2.1[-2.59,-1.61]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 13.53% -1.5[-1.56,-1.44]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 12.62% -0.27[-0.69,0.15]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 12.82% -0.38[-0.75,-0.01]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 12.78% -0.5[-0.88,-0.12]
Subtotal *** 180   129   100% -0.65[-1.22,-0.08]
Heterogeneity: Tau2=0.63; Chi2=158.34, df=7(P<0.0001); I2=95.58%  
Test for overall effect: Z=2.22(P=0.03)  
   
2.3.3 ≥ 108 cells  
Assmus 2006 24 2 (0.7) 18 2.1 (0.9) 19.63% -0.12[-0.62,0.38]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 25.74% -0.45[-0.82,-0.08]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 26.95% -0.2[-0.55,0.15]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 27.68% -0.8[-1.13,-0.47]
Subtotal *** 137   104   100% -0.41[-0.72,-0.11]
Heterogeneity: Tau2=0.06; Chi2=7.94, df=3(P=0.05); I2=62.24%  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=0.74, df=1 (P=0.69), I2=0%  
Favours no cell therapy 42-4 -2 0 Favours cell therapy
 
 
Analysis 2.4.   Comparison 2 Cell dose: subgroup analysis, Outcome 4 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 < 107 cells  
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 31.97% -1.8[-2.04,-1.56]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 31.12% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 30.85% -0.3[-0.73,0.13]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 6.06% -1.6[-5.46,2.26]
Subtotal *** 152   136   100% -0.87[-1.92,0.19]
Heterogeneity: Tau2=0.89; Chi2=60.96, df=3(P<0.0001); I2=95.08%  
Test for overall effect: Z=1.61(P=0.11)  
   
2.4.2 107 < 108 cells  
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 14.71% -0.6[-2.03,0.83]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 22.01% 0.51[-0.1,1.12]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 19.65% -0.8[-1.68,0.08]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 23.23% 0[-0.44,0.44]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 20.39% -2[-2.8,-1.2]
Subtotal *** 92   68   100% -0.54[-1.4,0.32]
Heterogeneity: Tau2=0.78; Chi2=27.45, df=4(P<0.0001); I2=85.43%  
Test for overall effect: Z=1.23(P=0.22)  
Favours cell therapy 52.5-5 -2.5 0 Favours no cell therapy
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=0.22, df=1 (P=0.64), I2=0%  
Favours cell therapy 52.5-5 -2.5 0 Favours no cell therapy
 
 
Analysis 2.5.   Comparison 2 Cell dose: subgroup analysis,
Outcome 5 Exercise capacity: short term follow-up (< 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 107 < 108 cells  
Erbs 2005 12 23.1 (5.8) 10 22.4 (4.7) 13.19% 0.13[-0.71,0.97]
Honold 2012 12 376 (198) 5 501 (175) 11.3% -0.62[-1.69,0.45]
Pokushalov 2010 53 325 (81) 46 211 (48) 16.25% 1.67[1.21,2.13]
Trifunovic 2015 15 435 (90) 15 315 (80) 13.47% 1.37[0.56,2.18]
Tse 2007 19 6.1 (0.5) 9 5.7 (0.7) 13.47% 0.54[-0.27,1.34]
Van Ramshorst 2009 24 116 (32) 25 103 (41) 15.48% 0.35[-0.22,0.91]
Wang 2010 56 8.9 (9.7) 56 6.8 (15.7) 16.84% 0.16[-0.21,0.53]
Subtotal *** 191   166   100% 0.56[-0.03,1.14]
Heterogeneity: Tau2=0.5; Chi2=36.6, df=6(P<0.0001); I2=83.61%  
Test for overall effect: Z=1.85(P=0.06)  
   
2.5.2 ≥ 108 cells  
Bartunek 2012 21 456 (142.8) 3 404 (97.5) 7.59% 0.36[-0.85,1.58]
Hu 2011 30 491 (47) 27 451 (66) 38.92% 0.69[0.16,1.23]
Perin 2012a 51 184 (407) 29 80 (415) 53.49% 0.25[-0.21,0.71]
Subtotal *** 102   59   100% 0.43[0.1,0.77]
Heterogeneity: Tau2=0; Chi2=1.53, df=2(P=0.46); I2=0%  
Test for overall effect: Z=2.53(P=0.01)  
Test for subgroup differences: Chi2=0.13, df=1 (P=0.72), I2=0%  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 2.6.   Comparison 2 Cell dose: subgroup analysis, Outcome
6 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.6.1 107 < 108 cells  
Ang 2008 10 4.3 (4.3) 7 0.7 (4.2) 10.28% 3.6[-0.5,7.7]
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 8.76% 6.7[2.26,11.14]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 2.87% 2.5[-5.26,10.26]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 2.35% 7.5[-1.07,16.07]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 42.98% 6.3[4.3,8.3]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 5.3% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 27.46% 4[1.49,6.51]
Subtotal *** 121   78   100% 5.23[3.91,6.54]
Heterogeneity: Tau2=0; Chi2=3.94, df=6(P=0.68); I2=0%  
Test for overall effect: Z=7.8(P<0.0001)  
   
Favours no cell therapy 105-10 -5 0 Favours cell therapy
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.6.2 ≥ 108 cells  
Ang 2008 8 -0.5 (4.3) 7 0.7 (4.2) 29.98% -1.2[-5.51,3.11]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 43.66% 3[0.31,5.69]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 26.36% 5.4[0.55,10.25]
Subtotal *** 54   47   100% 2.37[-0.92,5.66]
Heterogeneity: Tau2=4.57; Chi2=4.34, df=2(P=0.11); I2=53.9%  
Test for overall effect: Z=1.41(P=0.16)  
Test for subgroup differences: Chi2=2.49, df=1 (P=0.11), I2=59.89%  
Favours no cell therapy 105-10 -5 0 Favours cell therapy
 
 
Comparison 3.   Baseline cardiac function: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short term fol-
low-up (< 12 months)
28   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 < 30% 11 508 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.09, 0.59]
1.2 30 - 50% 13 642 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.36, 2.11]
1.3 > 50% 4 271 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.11, 3.35]
2 Mortality (all-cause): long term fol-
low-up (≥ 12 months)
16   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 < 30% 9 426 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.20, 0.64]
2.2 30 - 50% 7 289 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.27, 1.21]
3 NYHA classification: short term fol-
low-up (< 12 months)
15   Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.1 < 30% 6 273 Mean Difference (IV, Random, 95%
CI)
-0.40 [-1.22, 0.43]
3.2 30 - 50% 9 420 Mean Difference (IV, Random, 95%
CI)
-0.32 [-0.54, -0.10]
4 NYHA classification: long term fol-
low-up (≥ 12 months)
9   Mean Difference (IV, Random, 95%
CI)
Subtotals only
4.1 < 30% 5 202 Mean Difference (IV, Random, 95%
CI)
-0.66 [-1.28, -0.04]
4.2 30 - 50% 4 144 Mean Difference (IV, Random, 95%
CI)
-0.98 [-1.72, -0.25]
5 CCS class: short term follow-up (< 12
months)
8   Mean Difference (IV, Random, 95%
CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5.1 < 30% 4 213 Mean Difference (IV, Random, 95%
CI)
-0.25 [-1.47, 0.97]
5.2 30 - 50% 4 150 Mean Difference (IV, Random, 95%
CI)
-0.11 [-0.31, 0.09]
6 Exercise capacity: short term fol-
low-up (< 12 months)
7   Std. Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 < 30% 4 225 Std. Mean Difference (IV, Random,
95% CI)
0.96 [0.37, 1.56]
6.2 30 - 50% 3 127 Std. Mean Difference (IV, Random,
95% CI)
0.38 [-0.57, 1.33]
7 LVEF (%) measured by MRI: short
term follow-up (< 12 months)
9   Mean Difference (IV, Random, 95%
CI)
Subtotals only
7.1 < 30% 6 290 Mean Difference (IV, Random, 95%
CI)
1.54 [-1.96, 5.03]
7.2 30 - 50% 3 60 Mean Difference (IV, Random, 95%
CI)
3.31 [0.88, 5.75]
 
 
Analysis 3.1.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 < 30%  
Ang 2008 1/42 1/19 11.62% 0.45[0.03,6.86]
Bartunek 2012 0/21 0/15   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hu 2011 0/31 1/29 8.59% 0.31[0.01,7.38]
Mathiasen 2015 1/40 1/20 11.61% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 9.86% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 10.73% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 9.57% 0.2[0.01,4]
Pokushalov 2010 2/55 8/54 38% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Subtotal (95% CI) 292 216 100% 0.23[0.09,0.59]
Total events: 4 (Cells), 17 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.5, df=6(P=0.96); I2=0%  
Test for overall effect: Z=3.08(P=0)  
   
3.1.2 30 - 50%  
Assmus 2006 0/52 1/23 7.84% 0.15[0.01,3.57]
Assmus 2013 5/43 6/39 64.28% 0.76[0.25,2.28]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 11.19% 1.09[0.08,15.41]
Honold 2012 0/23 0/9   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 7.8% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Turan 2011 0/38 0/18   Not estimable
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 2/18 0/18 8.9% 5[0.26,97.37]
Subtotal (95% CI) 383 259 100% 0.87[0.36,2.11]
Total events: 9 (Cells), 8 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.74, df=4(P=0.6); I2=0%  
Test for overall effect: Z=0.31(P=0.75)  
   
3.1.3 > 50%  
Erbs 2005 0/13 0/12   Not estimable
Jimenez-Quevedo 2011 1/19 1/9 41.59% 0.47[0.03,6.74]
Losordo 2011 0/112 1/56 28.92% 0.17[0.01,4.06]
Van Ramshorst 2009 1/25 0/25 29.49% 3[0.13,70.3]
Subtotal (95% CI) 169 102 100% 0.61[0.11,3.35]
Total events: 2 (Cells), 2 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.65, df=2(P=0.44); I2=0%  
Test for overall effect: Z=0.58(P=0.57)  
Test for subgroup differences: Chi2=4.14, df=1 (P=0.13), I2=51.64%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 3.2.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 < 30%  
Bartunek 2012 1/21 2/15 6.09% 0.36[0.04,3.59]
Chen 2006 2/22 4/23 12.77% 0.52[0.11,2.57]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hu 2011 1/31 2/29 5.89% 0.47[0.04,4.89]
Nasseri 2012 1/30 3/30 6.66% 0.33[0.04,3.03]
Patel 2015 5/22 2/6 17.3% 0.68[0.17,2.68]
Pokushalov 2010 6/55 21/54 47.53% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 3.75% 0.1[0.01,1.89]
Subtotal (95% CI) 230 196 100% 0.36[0.2,0.64]
Total events: 16 (Cells), 36 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.22, df=6(P=0.9); I2=0%  
Test for overall effect: Z=3.51(P=0)  
   
3.2.2 30 - 50%  
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Assmus 2013 6/43 8/39 61.71% 0.68[0.26,1.79]
Heldman 2014_BM-MSC 1/19 1/11 8.07% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Honold 2012 0/23 1/9 5.93% 0.14[0.01,3.13]
Patila 2014 0/13 0/17   Not estimable
Trifunovic 2015 2/15 4/15 24.29% 0.5[0.11,2.33]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 170 119 100% 0.57[0.27,1.21]
Total events: 9 (Cells), 14 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.95, df=3(P=0.81); I2=0%  
Test for overall effect: Z=1.47(P=0.14)  
Test for subgroup differences: Chi2=0.88, df=1 (P=0.35), I2=0%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 3.3.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.3.1 < 30%  
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 16.76% -1.2[-1.58,-0.82]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 16.65% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 16.86% 0.2[-0.15,0.55]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 15.85% -0.3[-0.91,0.31]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 16.5% 0.48[0.02,0.94]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 17.37% -1.5[-1.56,-1.44]
Subtotal *** 143   130   100% -0.4[-1.22,0.43]
Heterogeneity: Tau2=1.01; Chi2=213.34, df=5(P<0.0001); I2=97.66%  
Test for overall effect: Z=0.94(P=0.35)  
   
3.3.2 30 - 50%  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 9.38% -0.14[-0.61,0.33]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 11.28% -0.45[-0.82,-0.08]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 8.37% 0.11[-0.42,0.64]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 14.5% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 11.75% -0.2[-0.55,0.15]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 11.43% 0.2[-0.16,0.56]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 10.26% -0.27[-0.69,0.15]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 11.01% -0.5[-0.88,-0.12]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 12.02% -0.8[-1.13,-0.47]
Subtotal *** 255   165   100% -0.32[-0.54,-0.1]
Heterogeneity: Tau2=0.07; Chi2=26.48, df=8(P=0); I2=69.79%  
Test for overall effect: Z=2.88(P=0)  
Test for subgroup differences: Chi2=0.03, df=1 (P=0.86), I2=0%  
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Analysis 3.4.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 4 NYHA classification: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.4.1 < 30%  
Chen 2006 20 1.4 (0.7) 19 2.4 (0.4) 21.51% -1[-1.36,-0.64]
Hamshere 2015_IC 15 2.1 (0.6) 15 2.4 (0.6) 20.7% -0.29[-0.73,0.15]
Hamshere 2015_IM 15 2.1 (0.7) 15 2.1 (0.6) 20.4% -0.01[-0.48,0.46]
Patel 2015 17 1.8 (0.8) 4 2.3 (1) 14.27% -0.43[-1.45,0.59]
Pokushalov 2010 49 2.5 (0.1) 33 3.9 (0.1) 23.13% -1.4[-1.44,-1.36]
Subtotal *** 116   86   100% -0.66[-1.28,-0.04]
Heterogeneity: Tau2=0.43; Chi2=63.7, df=4(P<0.0001); I2=93.72%  
Test for overall effect: Z=2.09(P=0.04)  
   
3.4.2 30 - 50%  
Honold 2012 20 1.5 (0.8) 6 1.7 (0.8) 22.02% -0.25[-0.99,0.49]
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 25% -2.2[-2.7,-1.7]
Trifunovic 2015 15 1.1 (0.3) 15 1.8 (0.7) 26.44% -0.73[-1.1,-0.36]
Turan 2011 33 1.6 (0.6) 16 2.3 (0.6) 26.54% -0.7[-1.06,-0.34]
Subtotal *** 88   56   100% -0.98[-1.72,-0.25]
Heterogeneity: Tau2=0.49; Chi2=30.5, df=3(P<0.0001); I2=90.17%  
Test for overall effect: Z=2.64(P=0.01)  
Test for subgroup differences: Chi2=0.43, df=1 (P=0.51), I2=0%  
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Analysis 3.5.   Comparison 3 Baseline cardiac function: subgroup
analysis, Outcome 5 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.5.1 < 30%  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 25.18% 0.14[-0.21,0.49]
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 25.17% 0.18[-0.17,0.53]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 24.17% 0.51[-0.1,1.12]
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 25.47% -1.8[-2.04,-1.56]
Subtotal *** 111   102   100% -0.25[-1.47,0.97]
Heterogeneity: Tau2=1.51; Chi2=143.01, df=3(P<0.0001); I2=97.9%  
Test for overall effect: Z=0.41(P=0.68)  
   
3.5.2 30 - 50%  
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 5.21% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 27.2% -0.2[-0.58,0.18]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 20.32% 0[-0.44,0.44]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 47.27% -0.03[-0.31,0.25]
Subtotal *** 90   60   100% -0.11[-0.31,0.09]
Heterogeneity: Tau2=0; Chi2=3.14, df=3(P=0.37); I2=4.52%  
Test for overall effect: Z=1.07(P=0.28)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%  
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Analysis 3.6.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 6 Exercise capacity: short term follow-up (< 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.6.1 < 30%  
Bartunek 2012 21 456 (142.8) 3 404 (97.5) 14.56% 0.36[-0.85,1.58]
Chen 2006 22 7 (3) 23 5 (2) 26.7% 0.77[0.17,1.38]
Hu 2011 30 491 (47) 27 451 (66) 28.45% 0.69[0.16,1.23]
Pokushalov 2010 53 325 (81) 46 211 (48) 30.29% 1.67[1.21,2.13]
Subtotal *** 126   99   100% 0.96[0.37,1.56]
Heterogeneity: Tau2=0.25; Chi2=10.6, df=3(P=0.01); I2=71.69%  
Test for overall effect: Z=3.17(P=0)  
   
3.6.2 30 - 50%  
Honold 2012 12 376 (198) 5 501 (175) 27.86% -0.62[-1.69,0.45]
Perin 2012a 51 184 (407) 29 80 (415) 39.24% 0.25[-0.21,0.71]
Trifunovic 2015 15 435 (90) 15 315 (80) 32.9% 1.37[0.56,2.18]
Subtotal *** 78   49   100% 0.38[-0.57,1.33]
Heterogeneity: Tau2=0.54; Chi2=9.44, df=2(P=0.01); I2=78.82%  
Test for overall effect: Z=0.78(P=0.43)  
Test for subgroup differences: Chi2=1.05, df=1 (P=0.31), I2=4.72%  
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Analysis 3.7.   Comparison 3 Baseline cardiac function: subgroup analysis,
Outcome 7 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.7.1 < 30%  
Ang 2008 18 2.1 (4.8) 7 0.7 (4.2) 17% 1.4[-2.42,5.22]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 15.12% 5.4[0.55,10.25]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 19.93% 6.3[4.3,8.3]
Nasseri 2012 26 31 (7) 22 33 (8) 16.14% -2[-6.29,2.29]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 14.29% -0.7[-6.01,4.61]
Wang 2014 35 33 (7) 35 35 (8) 17.53% -2[-5.52,1.52]
Subtotal *** 169   121   100% 1.54[-1.96,5.03]
Heterogeneity: Tau2=14.93; Chi2=26.85, df=5(P<0.0001); I2=81.38%  
Test for overall effect: Z=0.86(P=0.39)  
   
3.7.2 30 - 50%  
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 82.05% 3[0.31,5.69]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 9.86% 2.5[-5.26,10.26]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 8.08% 7.5[-1.07,16.07]
Subtotal *** 34   26   100% 3.31[0.88,5.75]
Heterogeneity: Tau2=0; Chi2=1.01, df=2(P=0.6); I2=0%  
Test for overall effect: Z=2.67(P=0.01)  
Test for subgroup differences: Chi2=0.67, df=1 (P=0.41), I2=0%  
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Comparison 4.   Route of cell administration: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short term follow-up
(< 12 months)
33   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Intramyocardial 22 1049 Risk Ratio (M-H, Random, 95%
CI)
0.47 [0.21, 1.03]
1.2 Intracoronary 12 607 Risk Ratio (M-H, Random, 95%
CI)
0.51 [0.21, 1.23]
2 Mortality (all-cause): long term follow-up
(≥ 12 months)
21   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 Intramyocardial 13 652 Risk Ratio (M-H, Random, 95%
CI)
0.29 [0.17, 0.50]
2.2 Intracoronary 8 358 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.30, 1.09]
3 NYHA classification: short term follow-up
(< 12 months)
17   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.1 Intramyocardial 11 445 Mean Difference (IV, Random,
95% CI)
-0.48 [-0.99, 0.03]
3.2 Intracoronary 6 296 Mean Difference (IV, Random,
95% CI)
-0.38 [-0.76, 0.00]
4 NYHA classification: long term follow-up (≥
12 months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 Intramyocardial 4 181 Mean Difference (IV, Random,
95% CI)
-1.09 [-1.76, -0.41]
4.2 Intracoronary 5 165 Mean Difference (IV, Random,
95% CI)
-0.61 [-0.92, -0.30]
5 CCS class: short term follow-up (< 12
months)
13   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 Intramyocardial 10 434 Mean Difference (IV, Random,
95% CI)
-0.33 [-0.87, 0.22]
5.2 Intracoronary 3 174 Mean Difference (IV, Random,
95% CI)
-1.00 [-2.87, 0.86]
6 Exercise capacity: short term follow-up (<
12 months)
11   Std. Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
6.1 Intramyocardial 6 310 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.78 [0.19, 1.36]
6.2 Intracoronary 5 253 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.33 [-0.06, 0.72]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7 LVEF (%) measured by MRI: short term fol-
low-up (< 12 months)
12   Mean Difference (IV, Random,
95% CI)
Subtotals only
7.1 Intramyocardial 8 309 Mean Difference (IV, Random,
95% CI)
2.18 [-0.41, 4.77]
7.2 Intracoronary 5 137 Mean Difference (IV, Random,
95% CI)
3.72 [0.86, 6.57]
 
 
Analysis 4.1.   Comparison 4 Route of cell administration: subgroup analysis,
Outcome 1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Intramyocardial  
Ang 2008 0/21 1/19 6.28% 0.3[0.01,7.02]
Bartunek 2012 0/21 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 8.85% 1.09[0.08,15.41]
Jimenez-Quevedo 2011 1/19 1/9 8.8% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 6.12% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 8.39% 0.5[0.03,7.59]
Mozid 2014_IM 0/10 3/8 7.75% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 6.92% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 6.17% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Pokushalov 2010 2/55 8/54 27.46% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 1/25 0/25 6.24% 3[0.13,70.3]
Wang 2015 0/45 0/45   Not estimable
Zhao 2008 2/18 0/18 7.04% 5[0.26,97.37]
Subtotal (95% CI) 617 432 100% 0.47[0.21,1.03]
Total events: 9 (Cells), 18 (No cells)  
Heterogeneity: Tau2=0; Chi2=7.13, df=10(P=0.71); I2=0%  
Test for overall effect: Z=1.88(P=0.06)  
   
4.1.2 Intracoronary  
Ang 2008 1/21 1/19 10.78% 0.9[0.06,13.48]
Assmus 2006 0/52 1/23 7.86% 0.15[0.01,3.57]
Assmus 2013 5/43 6/39 64.45% 0.76[0.25,2.28]
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Honold 2012 0/23 0/9   Not estimable
Hu 2011 0/31 1/29 7.87% 0.31[0.01,7.38]
Mozid 2014_IC 0/14 1/2 9.04% 0.07[0,1.27]
Turan 2011 0/38 0/18   Not estimable
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Yao 2008 0/24 0/23   Not estimable
Subtotal (95% CI) 346 261 100% 0.51[0.21,1.23]
Total events: 6 (Cells), 10 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.15, df=4(P=0.53); I2=0%  
Test for overall effect: Z=1.49(P=0.14)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.9), I2=0%  
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Analysis 4.2.   Comparison 4 Route of cell administration: subgroup analysis,
Outcome 2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 Intramyocardial  
Bartunek 2012 1/21 2/15 5.38% 0.36[0.04,3.59]
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 1/19 1/11 4.01% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 3.3% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 5.88% 0.33[0.04,3.03]
Patel 2005 3/25 10/25 21.09% 0.3[0.09,0.96]
Patila 2014 0/13 0/17   Not estimable
Pokushalov 2010 6/55 21/54 41.97% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 3.31% 0.1[0.01,1.89]
Trifunovic 2015 2/15 4/15 12.09% 0.5[0.11,2.33]
Tse 2007 0/19 1/9 2.96% 0.17[0.01,3.73]
Subtotal (95% CI) 380 272 100% 0.29[0.17,0.5]
Total events: 14 (Cells), 47 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.3, df=8(P=0.97); I2=0%  
Test for overall effect: Z=4.5(P<0.0001)  
   
4.2.2 Intracoronary  
Assmus 2013 6/43 8/39 44.91% 0.68[0.26,1.79]
Chen 2006 2/22 4/23 16.49% 0.52[0.11,2.57]
Erbs 2005 0/13 1/12 4.33% 0.31[0.01,6.94]
Hamshere 2015_IC 0/15 0/15   Not estimable
Honold 2012 0/23 1/9 4.32% 0.14[0.01,3.13]
Hu 2011 1/31 2/29 7.61% 0.47[0.04,4.89]
Patel 2015 5/22 2/6 22.35% 0.68[0.17,2.68]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 207 151 100% 0.57[0.3,1.09]
Total events: 14 (Cells), 18 (No cells)  
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=1.19, df=5(P=0.95); I2=0%  
Test for overall effect: Z=1.69(P=0.09)  
Test for subgroup differences: Chi2=2.44, df=1 (P=0.12), I2=59.1%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 4.3.   Comparison 4 Route of cell administration: subgroup analysis,
Outcome 3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.3.1 Intramyocardial  
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 9.18% 0.2[-0.15,0.55]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 8.42% -0.3[-0.91,0.31]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 8.9% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 8.81% -2.1[-2.59,-1.61]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 9.44% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 9.19% -0.2[-0.55,0.15]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 9.15% 0.2[-0.16,0.56]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 9.58% -1.5[-1.56,-1.44]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 9% -0.27[-0.69,0.15]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 9.12% -0.38[-0.75,-0.01]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 9.22% -0.8[-1.13,-0.47]
Subtotal *** 251   194   100% -0.48[-0.99,0.03]
Heterogeneity: Tau2=0.7; Chi2=391.54, df=10(P<0.0001); I2=97.45%  
Test for overall effect: Z=1.86(P=0.06)  
   
4.3.2 Intracoronary  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 15.94% -0.14[-0.61,0.33]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 17.56% -0.45[-0.82,-0.08]
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 17.36% -1.2[-1.58,-0.82]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 16.84% 0[-0.42,0.42]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 14.95% 0.11[-0.42,0.64]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 17.34% -0.5[-0.88,-0.12]
Subtotal *** 176   120   100% -0.38[-0.76,0]
Heterogeneity: Tau2=0.18; Chi2=25.31, df=5(P=0); I2=80.24%  
Test for overall effect: Z=1.94(P=0.05)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
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Analysis 4.4.   Comparison 4 Route of cell administration: subgroup
analysis, Outcome 4 NYHA classification: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.4.1 Intramyocardial  
Hamshere 2015_IM 15 2.1 (0.7) 15 2.1 (0.6) 24.01% -0.01[-0.48,0.46]
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 23.66% -2.2[-2.7,-1.7]
Favours no cell therapy 21-2 -1 0 Favours cell therapy
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Pokushalov 2010 49 2.5 (0.1) 33 3.9 (0.1) 27.17% -1.4[-1.44,-1.36]
Trifunovic 2015 15 1.1 (0.3) 15 1.8 (0.7) 25.17% -0.73[-1.1,-0.36]
Subtotal *** 99   82   100% -1.09[-1.76,-0.41]
Heterogeneity: Tau2=0.44; Chi2=55.13, df=3(P<0.0001); I2=94.56%  
Test for overall effect: Z=3.15(P=0)  
   
4.4.2 Intracoronary  
Chen 2006 20 1.4 (0.7) 19 2.4 (0.4) 28.23% -1[-1.36,-0.64]
Hamshere 2015_IC 15 2.1 (0.6) 15 2.4 (0.6) 23.36% -0.29[-0.73,0.15]
Honold 2012 20 1.5 (0.8) 6 1.7 (0.8) 12.67% -0.25[-0.99,0.49]
Patel 2015 17 1.8 (0.8) 4 2.3 (1) 7.67% -0.43[-1.45,0.59]
Turan 2011 33 1.6 (0.6) 16 2.3 (0.6) 28.07% -0.7[-1.06,-0.34]
Subtotal *** 105   60   100% -0.61[-0.92,-0.3]
Heterogeneity: Tau2=0.06; Chi2=7.62, df=4(P=0.11); I2=47.48%  
Test for overall effect: Z=3.88(P=0)  
Test for subgroup differences: Chi2=1.57, df=1 (P=0.21), I2=36.33%  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 4.5.   Comparison 4 Route of cell administration: subgroup
analysis, Outcome 5 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.5.1 Intramyocardial  
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 10.74% 0.18[-0.17,0.53]
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 6.36% -0.6[-2.03,0.83]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 9.88% 0.51[-0.1,1.12]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 8.71% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 10.68% -0.2[-0.58,0.18]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 10.49% 0[-0.44,0.44]
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 11.02% -1.8[-2.04,-1.56]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 10.65% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 10.53% -0.3[-0.73,0.13]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 10.93% -0.03[-0.31,0.25]
Subtotal *** 247   187   100% -0.33[-0.87,0.22]
Heterogeneity: Tau2=0.69; Chi2=160.38, df=9(P<0.0001); I2=94.39%  
Test for overall effect: Z=1.18(P=0.24)  
   
4.5.2 Intracoronary  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 43.66% 0.14[-0.21,0.49]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 41.03% -2[-2.8,-1.2]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 15.31% -1.6[-5.46,2.26]
Subtotal *** 87   87   100% -1[-2.87,0.86]
Heterogeneity: Tau2=2.05; Chi2=23.66, df=2(P<0.0001); I2=91.55%  
Test for overall effect: Z=1.05(P=0.29)  
Test for subgroup differences: Chi2=0.46, df=1 (P=0.5), I2=0%  
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Analysis 4.6.   Comparison 4 Route of cell administration: subgroup
analysis, Outcome 6 Exercise capacity: short term follow-up (< 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.6.1 Intramyocardial  
Bartunek 2012 21 456 (142.8) 3 404 (97.5) 11.33% 0.36[-0.85,1.58]
Perin 2012a 51 184 (407) 29 80 (415) 19.55% 0.25[-0.21,0.71]
Pokushalov 2010 53 325 (81) 46 211 (48) 19.52% 1.67[1.21,2.13]
Trifunovic 2015 15 435 (90) 15 315 (80) 15.61% 1.37[0.56,2.18]
Tse 2007 19 6.1 (0.5) 9 5.7 (0.7) 15.6% 0.54[-0.27,1.34]
Van Ramshorst 2009 24 116 (32) 25 103 (41) 18.4% 0.35[-0.22,0.91]
Subtotal *** 183   127   100% 0.78[0.19,1.36]
Heterogeneity: Tau2=0.4; Chi2=24.53, df=5(P=0); I2=79.61%  
Test for overall effect: Z=2.61(P=0.01)  
   
4.6.2 Intracoronary  
Chen 2006 22 7 (3) 23 5 (2) 20.98% 0.77[0.17,1.38]
Erbs 2005 12 23.1 (5.8) 10 22.4 (4.7) 14.32% 0.13[-0.71,0.97]
Honold 2012 12 376 (198) 5 501 (175) 10.12% -0.62[-1.69,0.45]
Hu 2011 30 491 (47) 27 451 (66) 23.66% 0.69[0.16,1.23]
Wang 2010 56 8.9 (9.7) 56 6.8 (15.7) 30.91% 0.16[-0.21,0.53]
Subtotal *** 132   121   100% 0.33[-0.06,0.72]
Heterogeneity: Tau2=0.09; Chi2=7.87, df=4(P=0.1); I2=49.18%  
Test for overall effect: Z=1.67(P=0.09)  
Test for subgroup differences: Chi2=1.55, df=1 (P=0.21), I2=35.36%  
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Analysis 4.7.   Comparison 4 Route of cell administration: subgroup analysis,
Outcome 7 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.7.1 Intramyocardial  
Ang 2008 10 4.5 (4.5) 7 0.7 (4.2) 12.72% 3.8[-0.38,7.98]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 7.03% 2.5[-5.26,10.26]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 17.08% 6.3[4.3,8.3]
Nasseri 2012 26 31 (7) 22 33 (8) 12.5% -2[-6.29,2.29]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 10.56% -0.7[-6.01,4.61]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 9.89% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 16.14% 4[1.49,6.51]
Wang 2014 35 33 (7) 35 35 (8) 14.07% -2[-5.52,1.52]
Subtotal *** 180   129   100% 2.18[-0.41,4.77]
Heterogeneity: Tau2=9.19; Chi2=25.81, df=7(P=0); I2=72.87%  
Test for overall effect: Z=1.65(P=0.1)  
   
4.7.2 Intracoronary  
Ang 2008 8 -0.5 (4.3) 7 0.7 (4.2) 21.33% -1.2[-5.51,3.11]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 30.33% 3[0.31,5.69]
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 20.72% 6.7[2.26,11.14]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 8.75% 7.5[-1.07,16.07]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 18.88% 5.4[0.55,10.25]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 75   62   100% 3.72[0.86,6.57]
Heterogeneity: Tau2=5.11; Chi2=8.12, df=4(P=0.09); I2=50.74%  
Test for overall effect: Z=2.55(P=0.01)  
Test for subgroup differences: Chi2=0.61, df=1 (P=0.43), I2=0%  
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Comparison 5.   Cell type: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short
term follow-up (< 12 months)
33   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Mononuclear cells 20 966 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.28, 1.04]
1.2 Circulating progenitor cells 3 104 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.48]
1.3 Haematopoietic progenitor
cells
8 464 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.05, 1.46]
1.4 Mesenchymal stem cells 3 126 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.03, 7.59]
2 Mortality (all-cause): long
term follow-up (≥ 12 months)
19   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mononuclear cells 12 540 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.25, 0.70]
2.2 Haematopoietic progenitor
cells
4 302 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.10, 0.69]
2.3 Mesenchymal stem cells 3 111 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.15, 1.57]
3 NYHA classification: short
term follow-up (< 12 months)
15   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Mononuclear cells 12 547 Mean Difference (IV, Random, 95% CI) -0.42 [-0.86, 0.02]
3.2 Haematopoietic progenitor
cells
3 94 Mean Difference (IV, Random, 95% CI) -0.47 [-1.95, 1.02]
4 CCS class: short term fol-
low-up (< 12 months)
13   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Mononuclear cells 8 366 Mean Difference (IV, Random, 95% CI) -0.39 [-0.99, 0.21]
4.2 Haematopoietic progenitor
cells
5 242 Mean Difference (IV, Random, 95% CI) -0.54 [-1.55, 0.46]
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Analysis 5.1.   Comparison 5 Cell type: subgroup analysis, Outcome
1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.1 Mononuclear cells  
Ang 2008 1/42 1/19 5.9% 0.45[0.03,6.86]
Assmus 2006 0/28 1/23 4.38% 0.28[0.01,6.47]
Assmus 2013 5/43 6/39 35.72% 0.76[0.25,2.28]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 6.22% 1.09[0.08,15.41]
Hu 2011 0/31 1/29 4.36% 0.31[0.01,7.38]
Mozid 2014_IC 0/14 1/2 5.01% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 5.45% 0.12[0.01,1.98]
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 4.33% 1.55[0.06,36.94]
Pokushalov 2010 2/55 8/54 19.3% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Van Ramshorst 2009 1/25 0/25 4.38% 3[0.13,70.3]
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 2/18 0/18 4.95% 5[0.26,97.37]
Subtotal (95% CI) 552 414 100% 0.54[0.28,1.04]
Total events: 13 (Cells), 22 (No cells)  
Heterogeneity: Tau2=0; Chi2=8.76, df=10(P=0.55); I2=0%  
Test for overall effect: Z=1.86(P=0.06)  
   
5.1.2 Circulating progenitor cells  
Assmus 2006 0/24 1/23 100% 0.32[0.01,7.48]
Erbs 2005 0/13 0/12   Not estimable
Honold 2012 0/23 0/9   Not estimable
Subtotal (95% CI) 60 44 100% 0.32[0.01,7.48]
Total events: 0 (Cells), 1 (No cells)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
5.1.3 Haematopoietic progenitor cells  
Jimenez-Quevedo 2011 1/19 1/9 40.29% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 28.02% 0.17[0.01,4.06]
Nasseri 2012 0/30 2/30 31.68% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Perin 2012b 0/10 0/10   Not estimable
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Subtotal (95% CI) 271 193 100% 0.27[0.05,1.46]
Total events: 1 (Cells), 4 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.3, df=2(P=0.86); I2=0%  
Test for overall effect: Z=1.52(P=0.13)  
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.4 Mesenchymal stem cells  
Bartunek 2012 0/21 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Mathiasen 2015 1/40 1/20 100% 0.5[0.03,7.59]
Subtotal (95% CI) 80 46 100% 0.5[0.03,7.59]
Total events: 1 (Cells), 1 (No cells)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
Test for subgroup differences: Chi2=0.62, df=1 (P=0.89), I2=0%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 5.2.   Comparison 5 Cell type: subgroup analysis, Outcome
2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 Mononuclear cells  
Assmus 2013 6/43 8/39 27.53% 0.68[0.26,1.79]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hu 2011 1/31 2/29 4.66% 0.47[0.04,4.89]
Patel 2015 5/22 2/6 13.7% 0.68[0.17,2.68]
Patila 2014 0/13 0/17   Not estimable
Pokushalov 2010 6/55 21/54 37.64% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 2.97% 0.1[0.01,1.89]
Trifunovic 2015 2/15 4/15 10.84% 0.5[0.11,2.33]
Tse 2007 0/19 1/9 2.66% 0.17[0.01,3.73]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 304 236 100% 0.42[0.25,0.7]
Total events: 20 (Cells), 40 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.73, df=6(P=0.71); I2=0%  
Test for overall effect: Z=3.34(P=0)  
   
5.2.2 Haematopoietic progenitor cells  
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 10.9% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 19.43% 0.33[0.04,3.03]
Patel 2005 3/25 10/25 69.67% 0.3[0.09,0.96]
Subtotal (95% CI) 185 117 100% 0.26[0.1,0.69]
Total events: 4 (Cells), 16 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.85, df=2(P=0.65); I2=0%  
Test for overall effect: Z=2.7(P=0.01)  
   
5.2.3 Mesenchymal stem cells  
Bartunek 2012 1/21 2/15 26.02% 0.36[0.04,3.59]
Chen 2006 2/22 4/23 54.55% 0.52[0.11,2.57]
Heldman 2014_BM-MSC 1/19 1/11 19.43% 0.58[0.04,8.36]
Subtotal (95% CI) 62 49 100% 0.48[0.15,1.57]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 4 (Cells), 7 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.09, df=2(P=0.95); I2=0%  
Test for overall effect: Z=1.21(P=0.23)  
Test for subgroup differences: Chi2=0.86, df=1 (P=0.65), I2=0%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 5.3.   Comparison 5 Cell type: subgroup analysis, Outcome
3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.3.1 Mononuclear cells  
Assmus 2006 19 2 (0.8) 18 2.1 (0.9) 7.83% -0.12[-0.67,0.43]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 8.38% -0.45[-0.82,-0.08]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 8.26% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 8.44% 0.2[-0.15,0.55]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 7.6% -0.3[-0.91,0.31]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 8.73% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 8.44% -0.2[-0.55,0.15]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 8.88% -1.5[-1.56,-1.44]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 8.23% -0.27[-0.69,0.15]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 8.37% -0.38[-0.75,-0.01]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 8.35% -0.5[-0.88,-0.12]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 8.48% -0.8[-1.13,-0.47]
Subtotal *** 312   235   100% -0.42[-0.86,0.02]
Heterogeneity: Tau2=0.58; Chi2=345.96, df=11(P<0.0001); I2=96.82%  
Test for overall effect: Z=1.85(P=0.06)  
   
5.3.2 Haematopoietic progenitor cells  
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 33.25% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 33.1% -2.1[-2.59,-1.61]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 33.65% 0.2[-0.16,0.56]
Subtotal *** 48   46   100% -0.47[-1.95,1.02]
Heterogeneity: Tau2=1.67; Chi2=70.38, df=2(P<0.0001); I2=97.16%  
Test for overall effect: Z=0.62(P=0.54)  
Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%  
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Analysis 5.4.   Comparison 5 Cell type: subgroup analysis, Outcome 4 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.4.1 Mononuclear cells  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 12.8% 0.14[-0.21,0.49]
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 12.79% 0.18[-0.17,0.53]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 10.39% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 12.71% -0.2[-0.58,0.18]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 13.11% -1.8[-2.04,-1.56]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 12.67% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 12.53% -0.3[-0.73,0.13]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 13.01% -0.03[-0.31,0.25]
Subtotal *** 206   160   100% -0.39[-0.99,0.21]
Heterogeneity: Tau2=0.7; Chi2=157.51, df=7(P<0.0001); I2=95.56%  
Test for overall effect: Z=1.27(P=0.21)  
   
5.4.2 Haematopoietic progenitor cells  
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 17.98% -0.6[-2.03,0.83]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 25.67% 0.51[-0.1,1.12]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 26.9% 0[-0.44,0.44]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 24.03% -2[-2.8,-1.2]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 5.42% -1.6[-5.46,2.26]
Subtotal *** 128   114   100% -0.54[-1.55,0.46]
Heterogeneity: Tau2=0.92; Chi2=26.39, df=4(P<0.0001); I2=84.85%  
Test for overall effect: Z=1.07(P=0.29)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.79), I2=0%  
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Comparison 6.   Participant diagnosis: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short term follow-up (<
12 months)
33   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Chronic IHD 11 550 Risk Ratio (M-H, Random,
95% CI)
0.65 [0.26, 1.62]
1.2 HF (secondary to IHD) 15 645 Risk Ratio (M-H, Random,
95% CI)
0.33 [0.14, 0.82]
1.3 Refractory/intractable angina 7 442 Risk Ratio (M-H, Random,
95% CI)
0.61 [0.11, 3.35]
2 Mortality (all-cause): long term follow-up (≥
12 months)
21   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Chronic IHD 9 389 Risk Ratio (M-H, Random,
95% CI)
0.52 [0.27, 0.99]
2.2 HF (secondary to IHD) 9 401 Risk Ratio (M-H, Random,
95% CI)
0.33 [0.19, 0.58]
2.3 Refractory/intractable angina 3 220 Risk Ratio (M-H, Random,
95% CI)
0.11 [0.01, 0.91]
3 NYHA classification: short term follow-up (<
12 months)
16   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.1 Chronic IHD 6 296 Mean Difference (IV, Random,
95% CI)
-0.43 [-0.78, -0.07]
3.2 HF (secondary to IHD) 10 417 Mean Difference (IV, Random,
95% CI)
-0.47 [-1.02, 0.09]
4 NYHA classification: long term follow-up (≥ 12
months)
9   Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 Chronic IHD 3 105 Mean Difference (IV, Random,
95% CI)
-0.66 [-0.91, -0.42]
4.2 HF (secondary to IHD) 6 241 Mean Difference (IV, Random,
95% CI)
-0.92 [-1.47, -0.37]
5 CCS class: short term follow-up (< 12 months) 13   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 HF (secondary to IHD) 8 363 Mean Difference (IV, Random,
95% CI)
-0.25 [-0.90, 0.40]
5.2 Refractory/intractable angina 5 245 Mean Difference (IV, Random,
95% CI)
-0.78 [-1.44, -0.11]
6 Exercise capacity: short term follow-up (< 12
months)
11   Std. Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
6.1 Chronic IHD 4 114 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.48 [-0.26, 1.22]
6.2 HF (secondary to IHD) 4 260 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.79 [0.04, 1.53]
6.3 Refractory/intractable angina 3 189 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.26 [-0.03, 0.55]
7 LVEF (%) measured by MRI: short term fol-
low-up (< 12 months)
10   Mean Difference (IV, Random,
95% CI)
Subtotals only
7.1 Chronic IHD 6 178 Mean Difference (IV, Random,
95% CI)
2.58 [-0.16, 5.31]
7.2 HF (secondary to IHD) 4 195 Mean Difference (IV, Random,
95% CI)
2.50 [-1.97, 6.97]
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Analysis 6.1.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 Chronic IHD  
Ang 2008 1/42 1/19 11.31% 0.45[0.03,6.86]
Assmus 2006 0/52 1/23 8.34% 0.15[0.01,3.57]
Assmus 2013 5/43 6/39 68.44% 0.76[0.25,2.28]
Erbs 2005 0/13 0/12   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 11.91% 1.09[0.08,15.41]
Honold 2012 0/23 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Subtotal (95% CI) 329 221 100% 0.65[0.26,1.62]
Total events: 7 (Cells), 9 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.11, df=3(P=0.77); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
   
6.1.2 HF (secondary to IHD)  
Bartunek 2012 0/21 0/15   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hu 2011 0/31 1/29 8.06% 0.31[0.01,7.38]
Mathiasen 2015 1/40 1/20 10.89% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 9.25% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 10.06% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 8.98% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 8% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Pokushalov 2010 2/55 8/54 35.63% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Zhao 2008 2/18 0/18 9.14% 5[0.26,97.37]
Subtotal (95% CI) 369 276 100% 0.33[0.14,0.82]
Total events: 6 (Cells), 16 (No cells)  
Heterogeneity: Tau2=0; Chi2=6.18, df=7(P=0.52); I2=0%  
Test for overall effect: Z=2.4(P=0.02)  
   
6.1.3 Refractory/intractable angina  
Jimenez-Quevedo 2011 1/19 1/9 41.59% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 28.92% 0.17[0.01,4.06]
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 1/25 0/25 29.49% 3[0.13,70.3]
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Subtotal (95% CI) 265 177 100% 0.61[0.11,3.35]
Total events: 2 (Cells), 2 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.65, df=2(P=0.44); I2=0%  
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.58(P=0.57)  
Test for subgroup differences: Chi2=1.13, df=1 (P=0.57), I2=0%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 6.2.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 Chronic IHD  
Assmus 2013 6/43 8/39 43.94% 0.68[0.26,1.79]
Chen 2006 2/22 4/23 16.14% 0.52[0.11,2.57]
Erbs 2005 0/13 1/12 4.24% 0.31[0.01,6.94]
Heldman 2014_BM-MSC 1/19 1/11 5.75% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Honold 2012 0/23 1/9 4.22% 0.14[0.01,3.13]
Nasseri 2012 1/30 3/30 8.42% 0.33[0.04,3.03]
Trifunovic 2015 2/15 4/15 17.3% 0.5[0.11,2.33]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 222 167 100% 0.52[0.27,0.99]
Total events: 12 (Cells), 22 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.27, df=6(P=0.97); I2=0%  
Test for overall effect: Z=1.99(P=0.05)  
   
6.2.2 HF (secondary to IHD)  
Bartunek 2012 1/21 2/15 5.83% 0.36[0.04,3.59]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hu 2011 1/31 2/29 5.64% 0.47[0.04,4.89]
Patel 2005 3/25 10/25 22.87% 0.3[0.09,0.96]
Patel 2015 5/22 2/6 16.56% 0.68[0.17,2.68]
Patila 2014 0/13 0/17   Not estimable
Pokushalov 2010 6/55 21/54 45.5% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 3.59% 0.1[0.01,1.89]
Subtotal (95% CI) 216 185 100% 0.33[0.19,0.58]
Total events: 16 (Cells), 39 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.01, df=5(P=0.85); I2=0%  
Test for overall effect: Z=3.88(P=0)  
   
6.2.3 Refractory/intractable angina  
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 52.69% 0.07[0,1.37]
Tse 2007 0/19 1/9 47.31% 0.17[0.01,3.73]
Subtotal (95% CI) 149 71 100% 0.11[0.01,0.91]
Total events: 0 (Cells), 4 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=2.51, df=1 (P=0.29), I2=20.33%  
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Analysis 6.3.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.3.1 Chronic IHD  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 15.83% -0.14[-0.61,0.33]
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 17.74% -0.45[-0.82,-0.08]
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 17.51% -1.2[-1.58,-0.82]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 14.7% 0.11[-0.42,0.64]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 16.75% -0.27[-0.69,0.15]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 17.48% -0.5[-0.88,-0.12]
Subtotal *** 176   120   100% -0.43[-0.78,-0.07]
Heterogeneity: Tau2=0.15; Chi2=21.38, df=5(P=0); I2=76.61%  
Test for overall effect: Z=2.37(P=0.02)  
   
6.3.2 HF (secondary to IHD)  
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 9.92% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 10.1% 0.2[-0.15,0.55]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 9.3% -0.3[-0.91,0.31]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 9.81% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 9.71% -2.1[-2.59,-1.61]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 10.36% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 10.1% -0.2[-0.55,0.15]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 10.06% 0.2[-0.16,0.56]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 10.5% -1.5[-1.56,-1.44]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 10.13% -0.8[-1.13,-0.47]
Subtotal *** 232   185   100% -0.47[-1.02,0.09]
Heterogeneity: Tau2=0.75; Chi2=384.89, df=9(P<0.0001); I2=97.66%  
Test for overall effect: Z=1.65(P=0.1)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours no cell therapy 10.5-1 -0.5 0 Favours cell therapy
 
 
Analysis 6.4.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 4 NYHA classification: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.4.1 Chronic IHD  
Honold 2012 20 1.5 (0.8) 6 1.7 (0.8) 10.86% -0.25[-0.99,0.49]
Trifunovic 2015 15 1.1 (0.3) 15 1.8 (0.7) 43.32% -0.73[-1.1,-0.36]
Turan 2011 33 1.6 (0.6) 16 2.3 (0.6) 45.82% -0.7[-1.06,-0.34]
Subtotal *** 68   37   100% -0.66[-0.91,-0.42]
Heterogeneity: Tau2=0; Chi2=1.38, df=2(P=0.5); I2=0%  
Test for overall effect: Z=5.37(P<0.0001)  
   
6.4.2 HF (secondary to IHD)  
Chen 2006 20 1.4 (0.7) 19 2.4 (0.4) 17.95% -1[-1.36,-0.64]
Hamshere 2015_IC 15 2.1 (0.6) 15 2.4 (0.6) 17.24% -0.29[-0.73,0.15]
Hamshere 2015_IM 15 2.1 (0.7) 15 2.1 (0.6) 16.99% -0.01[-0.48,0.46]
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Patel 2015 17 1.8 (0.8) 4 2.3 (1) 11.74% -0.43[-1.45,0.59]
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 16.72% -2.2[-2.7,-1.7]
Pokushalov 2010 49 2.5 (0.1) 33 3.9 (0.1) 19.36% -1.4[-1.44,-1.36]
Subtotal *** 136   105   100% -0.92[-1.47,-0.37]
Heterogeneity: Tau2=0.41; Chi2=74.11, df=5(P<0.0001); I2=93.25%  
Test for overall effect: Z=3.26(P=0)  
Test for subgroup differences: Chi2=0.69, df=1 (P=0.41), I2=0%  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 6.5.   Comparison 6 Participant diagnosis: subgroup
analysis, Outcome 5 CCS class: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.5.1 HF (secondary to IHD)  
Hamshere 2015_IC 15 1.4 (0.5) 15 1.3 (0.5) 12.86% 0.14[-0.21,0.49]
Hamshere 2015_IM 15 1.3 (0.5) 15 1.1 (0.5) 12.85% 0.18[-0.17,0.53]
Nasseri 2012 28 -0.6 (1.2) 26 -1.1 (1.1) 11.97% 0.51[-0.1,1.12]
Perin 2011 20 -1.2 (1.4) 10 -0.4 (1) 10.75% -0.8[-1.68,0.08]
Perin 2012a 44 -0.5 (0.8) 22 -0.3 (0.7) 12.79% -0.2[-0.58,0.18]
Perin 2012b 10 2 (0.5) 10 2 (0.5) 12.6% 0[-0.44,0.44]
Pokushalov 2010 53 1.6 (0.6) 46 3.4 (0.6) 13.13% -1.8[-2.04,-1.56]
Zhao 2008 16 1.2 (0.4) 18 1.2 (0.4) 13.04% -0.03[-0.31,0.25]
Subtotal *** 201   162   100% -0.25[-0.9,0.4]
Heterogeneity: Tau2=0.83; Chi2=171.89, df=7(P<0.0001); I2=95.93%  
Test for overall effect: Z=0.75(P=0.45)  
   
6.5.2 Refractory/intractable angina  
Losordo 2007 18 -1.4 (0.9) 6 -0.8 (1.7) 13.35% -0.6[-2.03,0.83]
Tse 2007 19 2 (0.5) 9 2.3 (0.5) 30.75% -0.33[-0.72,0.06]
Van Ramshorst 2009 24 2.2 (0.6) 25 2.5 (0.9) 30.11% -0.3[-0.73,0.13]
Wang 2009 16 -3.5 (1.2) 16 -1.5 (1.1) 23.04% -2[-2.8,-1.2]
Wang 2010 56 -2.4 (7.5) 56 -0.8 (12.7) 2.74% -1.6[-5.46,2.26]
Subtotal *** 133   112   100% -0.78[-1.44,-0.11]
Heterogeneity: Tau2=0.34; Chi2=15.47, df=4(P=0); I2=74.15%  
Test for overall effect: Z=2.28(P=0.02)  
Test for subgroup differences: Chi2=1.23, df=1 (P=0.27), I2=18.48%  
Favours cell therapy 52.5-5 -2.5 0 Favours no cell therapy
 
 
Analysis 6.6.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 6 Exercise capacity: short term follow-up (< 12 months).
Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.6.1 Chronic IHD  
Chen 2006 22 7 (3) 23 5 (2) 29.17% 0.77[0.17,1.38]
Erbs 2005 12 23.1 (5.8) 10 22.4 (4.7) 24.76% 0.13[-0.71,0.97]
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Study or subgroup Cells No cells Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Honold 2012 12 376 (198) 5 501 (175) 20.68% -0.62[-1.69,0.45]
Trifunovic 2015 15 435 (90) 15 315 (80) 25.39% 1.37[0.56,2.18]
Subtotal *** 61   53   100% 0.48[-0.26,1.22]
Heterogeneity: Tau2=0.39; Chi2=10.02, df=3(P=0.02); I2=70.06%  
Test for overall effect: Z=1.26(P=0.21)  
   
6.6.2 HF (secondary to IHD)  
Bartunek 2012 21 456 (142.8) 3 404 (97.5) 17.09% 0.36[-0.85,1.58]
Hu 2011 30 491 (47) 27 451 (66) 26.94% 0.69[0.16,1.23]
Perin 2012a 51 184 (407) 29 80 (415) 28.01% 0.25[-0.21,0.71]
Pokushalov 2010 53 325 (81) 46 211 (48) 27.97% 1.67[1.21,2.13]
Subtotal *** 155   105   100% 0.79[0.04,1.53]
Heterogeneity: Tau2=0.46; Chi2=19.69, df=3(P=0); I2=84.76%  
Test for overall effect: Z=2.07(P=0.04)  
   
6.6.3 Refractory/intractable angina  
Tse 2007 19 6.1 (0.5) 9 5.7 (0.7) 12.85% 0.54[-0.27,1.34]
Van Ramshorst 2009 24 116 (32) 25 103 (41) 26.28% 0.35[-0.22,0.91]
Wang 2010 56 8.9 (9.7) 56 6.8 (15.7) 60.87% 0.16[-0.21,0.53]
Subtotal *** 99   90   100% 0.26[-0.03,0.55]
Heterogeneity: Tau2=0; Chi2=0.82, df=2(P=0.66); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
Test for subgroup differences: Chi2=1.82, df=1 (P=0.4), I2=0%  
Favours no cell therapy 21-2 -1 0 Favours cell therapy
 
 
Analysis 6.7.   Comparison 6 Participant diagnosis: subgroup analysis,
Outcome 7 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.7.1 Chronic IHD  
Ang 2008 18 2.1 (4.8) 7 0.7 (4.2) 19.89% 1.4[-2.42,5.22]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 24.73% 3[0.31,5.69]
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 17.52% 6.7[2.26,11.14]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 8.99% 2.5[-5.26,10.26]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 7.75% 7.5[-1.07,16.07]
Wang 2014 35 33 (7) 35 35 (8) 21.12% -2[-5.52,1.52]
Subtotal *** 99   79   100% 2.58[-0.16,5.31]
Heterogeneity: Tau2=5.99; Chi2=11.39, df=5(P=0.04); I2=56.1%  
Test for overall effect: Z=1.85(P=0.06)  
   
6.7.2 HF (secondary to IHD)  
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 23.23% 5.4[0.55,10.25]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 30.04% 6.3[4.3,8.3]
Nasseri 2012 26 31 (7) 22 33 (8) 24.7% -2[-6.29,2.29]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 22.03% -0.7[-6.01,4.61]
Subtotal *** 116   79   100% 2.5[-1.97,6.97]
Heterogeneity: Tau2=16.3; Chi2=15.7, df=3(P=0); I2=80.89%  
Test for overall effect: Z=1.09(P=0.27)  
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
Favours no cell therapy 2010-20 -10 0 Favours cell therapy
 
 
Comparison 7.   Co-interventions: subgroup analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause): short
term follow-up (< 12 months)
33   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Co-interventions 8 432 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.32, 1.70]
1.2 No co-interventions 25 1205 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.13, 0.72]
2 Mortality (all-cause): long
term follow-up (≥ 12 months)
21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Co-interventions 6 312 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.26, 0.88]
2.2 No co-interventions 15 698 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.19, 0.56]
3 NYHA classification: short
term follow-up (< 12 months)
17   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Co-interventions 6 233 Mean Difference (IV, Random, 95% CI) -0.57 [-1.20, 0.05]
3.2 No co-interventions 11 508 Mean Difference (IV, Random, 95% CI) -0.37 [-0.87, 0.13]
4 LVEF (%) measured by MRI:
short term follow-up (< 12
months)
12   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Co-interventions 5 179 Mean Difference (IV, Random, 95% CI) 2.01 [-0.26, 4.29]
4.2 No co-interventions 7 260 Mean Difference (IV, Random, 95% CI) 3.55 [0.82, 6.27]
 
 
Analysis 7.1.   Comparison 7 Co-interventions: subgroup analysis,
Outcome 1 Mortality (all-cause): short term follow-up (< 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.1.1 Co-interventions  
Ang 2008 1/42 1/19 9.52% 0.45[0.03,6.86]
Assmus 2013 5/43 6/39 57.61% 0.76[0.25,2.28]
Hendrikx 2006 1/11 1/12 10.03% 1.09[0.08,15.41]
Hu 2011 0/31 1/29 7.04% 0.31[0.01,7.38]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Nasseri 2012 0/30 2/30 7.84% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Wang 2015 0/45 0/45   Not estimable
Zhao 2008 2/18 0/18 7.98% 5[0.26,97.37]
Subtotal (95% CI) 230 202 100% 0.74[0.32,1.7]
Total events: 9 (Cells), 11 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.82, df=5(P=0.73); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
   
7.1.2 No co-interventions  
Assmus 2006 0/52 1/23 7.36% 0.15[0.01,3.57]
Bartunek 2012 0/21 0/15   Not estimable
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Honold 2012 0/23 0/9   Not estimable
Jimenez-Quevedo 2011 1/19 1/9 10.44% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 7.26% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 9.96% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 8.46% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 9.2% 0.12[0.01,1.98]
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 7.32% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Pokushalov 2010 2/55 8/54 32.59% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Van Ramshorst 2009 1/25 0/25 7.4% 3[0.13,70.3]
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Yao 2008 0/24 0/23   Not estimable
Subtotal (95% CI) 733 472 100% 0.31[0.13,0.72]
Total events: 6 (Cells), 16 (No cells)  
Heterogeneity: Tau2=0; Chi2=5.13, df=8(P=0.74); I2=0%  
Test for overall effect: Z=2.71(P=0.01)  
Test for subgroup differences: Chi2=2.06, df=1 (P=0.15), I2=51.5%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 7.2.   Comparison 7 Co-interventions: subgroup analysis,
Outcome 2 Mortality (all-cause): long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.2.1 Co-interventions  
Assmus 2013 6/43 8/39 40.95% 0.68[0.26,1.79]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hu 2011 1/31 2/29 6.94% 0.47[0.04,4.89]
Nasseri 2012 1/30 3/30 7.85% 0.33[0.04,3.03]
Patel 2005 3/25 10/25 28.14% 0.3[0.09,0.96]
Patila 2014 0/13 0/17   Not estimable
Trifunovic 2015 2/15 4/15 16.12% 0.5[0.11,2.33]
Subtotal (95% CI) 157 155 100% 0.47[0.26,0.88]
Total events: 13 (Cells), 27 (No cells)  
Heterogeneity: Tau2=0; Chi2=1.24, df=4(P=0.87); I2=0%  
Test for overall effect: Z=2.37(P=0.02)  
   
7.2.2 No co-interventions  
Bartunek 2012 1/21 2/15 5.76% 0.36[0.04,3.59]
Chen 2006 2/22 4/23 12.07% 0.52[0.11,2.57]
Erbs 2005 0/13 1/12 3.17% 0.31[0.01,6.94]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 1/19 1/11 4.3% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Honold 2012 0/23 1/9 3.16% 0.14[0.01,3.13]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 3.53% 0.07[0,1.37]
Patel 2015 5/22 2/6 16.36% 0.68[0.17,2.68]
Pokushalov 2010 6/55 21/54 44.94% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 3.55% 0.1[0.01,1.89]
Tse 2007 0/19 1/9 3.17% 0.17[0.01,3.73]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 430 268 100% 0.32[0.19,0.56]
Total events: 15 (Cells), 38 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.96, df=9(P=0.91); I2=0%  
Test for overall effect: Z=3.99(P<0.0001)  
Test for subgroup differences: Chi2=0.8, df=1 (P=0.37), I2=0%  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 7.3.   Comparison 7 Co-interventions: subgroup analysis,
Outcome 3 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.3.1 Co-interventions  
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 17.18% -0.45[-0.82,-0.08]
Mozid 2014_IM 10 2.2 (0.4) 5 2.5 (0.6) 15.52% -0.3[-0.91,0.31]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 16.64% 0.48[0.02,0.94]
Patel 2005 10 -2.8 (0.4) 10 -0.7 (0.7) 16.42% -2.1[-2.59,-1.61]
Trifunovic 2015 15 1 (0.6) 15 1.3 (0.6) 16.86% -0.27[-0.69,0.15]
Zhao 2008 16 1.5 (0.5) 18 2.3 (0.5) 17.38% -0.8[-1.13,-0.47]
Subtotal *** 121   112   100% -0.57[-1.2,0.05]
Heterogeneity: Tau2=0.55; Chi2=62.7, df=5(P<0.0001); I2=92.03%  
Test for overall effect: Z=1.81(P=0.07)  
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Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.3.2 No co-interventions  
Assmus 2006 43 2 (0.7) 18 2.1 (0.9) 8.82% -0.14[-0.61,0.33]
Chen 2006 22 1.3 (0.7) 23 2.5 (0.6) 9.06% -1.2[-1.58,-0.82]
Hamshere 2015_IC 15 2.2 (0.6) 15 2.2 (0.6) 8.97% 0[-0.42,0.42]
Hamshere 2015_IM 15 2 (0.6) 15 1.8 (0.4) 9.15% 0.2[-0.15,0.55]
Honold 2012 21 1.7 (0.7) 10 1.6 (0.7) 8.63% 0.11[-0.42,0.64]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 9.42% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 9.15% -0.2[-0.55,0.15]
Perin 2012b 10 2.3 (0.5) 10 2.1 (0.3) 9.11% 0.2[-0.16,0.56]
Pokushalov 2010 53 2.3 (0.2) 46 3.8 (0.1) 9.55% -1.5[-1.56,-1.44]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 9.08% -0.38[-0.75,-0.01]
Turan 2011 33 1.6 (0.5) 16 2.1 (0.7) 9.06% -0.5[-0.88,-0.12]
Subtotal *** 306   202   100% -0.37[-0.87,0.13]
Heterogeneity: Tau2=0.68; Chi2=383.11, df=10(P<0.0001); I2=97.39%  
Test for overall effect: Z=1.46(P=0.14)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.62), I2=0%  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
 
 
Analysis 7.4.   Comparison 7 Co-interventions: subgroup analysis,
Outcome 4 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.4.1 Co-interventions  
Ang 2008 18 2.1 (4.8) 7 0.7 (4.2) 22.8% 1.4[-2.42,5.22]
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 33.77% 3[0.31,5.69]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 7.57% 2.5[-5.26,10.26]
Hu 2011 31 13 (10.3) 28 7.6 (8.7) 16.35% 5.4[0.55,10.25]
Nasseri 2012 26 31 (7) 22 33 (8) 19.51% -2[-6.29,2.29]
Subtotal *** 100   79   100% 2.01[-0.26,4.29]
Heterogeneity: Tau2=2.1; Chi2=5.85, df=4(P=0.21); I2=31.66%  
Test for overall effect: Z=1.74(P=0.08)  
   
7.4.2 No co-interventions  
Erbs 2005 12 6.7 (6.2) 11 0 (4.6) 14.12% 6.7[2.26,11.14]
Honold 2012 9 32.8 (13.1) 4 25.3 (0.5) 6.99% 7.5[-1.07,16.07]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 20.09% 6.3[4.3,8.3]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 12.15% -0.7[-6.01,4.61]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 11.35% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 18.93% 4[1.49,6.51]
Wang 2014 35 33 (7) 35 35 (8) 16.38% -2[-5.52,1.52]
Subtotal *** 155   105   100% 3.55[0.82,6.27]
Heterogeneity: Tau2=8.61; Chi2=21.2, df=6(P=0); I2=71.7%  
Test for overall effect: Z=2.55(P=0.01)  
Test for subgroup differences: Chi2=0.71, df=1 (P=0.4), I2=0%  
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Comparison 8.   Sensitivity analysis: excluding studies with high/unclear risk of selection bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause) 15   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Short term follow-up (<
12 months)
14 744 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.32, 1.50]
1.2 Long term follow-up (≥ 12
months)
9 491 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.21, 0.87]
2 Non-fatal myocardial in-
farction
11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Short term follow-up (<
12 months)
6 288 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.05, 4.58]
2.2 Long term follow-up (≥ 12
months)
5 345 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.15, 0.97]
3 Rehospitalisation due to
heart failure
8   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Short term follow-up (<
12 months)
3 234 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.32, 1.32]
3.2 Long term follow-up (≥ 12
months)
6 375 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.36, 1.09]
4 Arrhythmias 7   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Short term follow-up (<
12 months)
6 224 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.21]
4.2 Long term follow-up (≥ 12
months)
1 82 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.18, 0.99]
5 Composite MACE 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Short term follow-up (<
12 months)
2 59 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Long term follow-up (≥ 12
months)
3 141 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.38, 1.08]
6 NYHA classification: short
term follow-up (< 12 months)
5   Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Combined 5 277 Mean Difference (IV, Random, 95% CI) -0.26 [-0.59, 0.07]
7 NYHA classification: long
term follow-up (≥ 12 months)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Combined 1 39 Mean Difference (IV, Random, 95% CI) -2.2 [-2.70, -1.70]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
8 LVEF (%) measured by MRI:
short term follow-up (< 12
months)
7   Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Combined 7 249 Mean Difference (IV, Random, 95% CI) 2.92 [0.67, 5.17]
9 LVEF (%) measured by MRI:
long term follow-up (≥ 12
months)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Combined 1 25 Mean Difference (IV, Random, 95% CI) -1.60 [-8.70, 5.50]
 
 
Analysis 8.1.   Comparison 8 Sensitivity analysis: excluding studies with
high/unclear risk of selection bias, Outcome 1 Mortality (all-cause).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.1.1 Short term follow-up (< 12 months)  
Assmus 2013 5/43 6/39 49.69% 0.76[0.25,2.28]
Bartunek 2012 0/21 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 8.65% 1.09[0.08,15.41]
Jimenez-Quevedo 2011 1/19 1/9 8.6% 0.47[0.03,6.74]
Losordo 2011 0/112 1/56 5.98% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 8.2% 0.5[0.03,7.59]
Nasseri 2012 0/30 2/30 6.76% 0.2[0.01,4]
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 6.03% 1.55[0.06,36.94]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 1/25 0/25 6.1% 3[0.13,70.3]
Subtotal (95% CI) 458 286 100% 0.69[0.32,1.5]
Total events: 10 (Cells), 12 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.77, df=7(P=0.91); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
   
8.1.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 8/39 55.27% 0.68[0.26,1.79]
Bartunek 2012 1/21 2/15 9.68% 0.36[0.04,3.59]
Heldman 2014_BM-MSC 1/19 1/11 7.23% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Losordo 2011 0/112 3/56 5.94% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 10.59% 0.33[0.04,3.03]
Patila 2014 0/13 0/17   Not estimable
Santoso 2014 0/19 2/9 5.96% 0.1[0.01,1.89]
Tse 2007 0/19 1/9 5.33% 0.17[0.01,3.73]
Subtotal (95% CI) 295 196 100% 0.42[0.21,0.87]
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 9 (Cells), 20 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.84, df=6(P=0.7); I2=0%  
Test for overall effect: Z=2.34(P=0.02)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 8.2.   Comparison 8 Sensitivity analysis: excluding studies with high/
unclear risk of selection bias, Outcome 2 Non-fatal myocardial infarction.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.2.1 Short term follow-up (< 12 months)  
Jimenez-Quevedo 2011 0/19 0/9   Not estimable
Mathiasen 2015 0/40 0/20   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 49% 1.55[0.06,36.94]
Tse 2007 0/19 1/9 51% 0.17[0.01,3.73]
Van Ramshorst 2009 0/25 0/25   Not estimable
Subtotal (95% CI) 184 104 100% 0.5[0.05,4.58]
Total events: 1 (Cells), 1 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.97, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.62(P=0.54)  
   
8.2.2 Long term follow-up (≥ 12 months)  
Assmus 2013 1/43 4/39 19.05% 0.23[0.03,1.94]
Heldman 2014_BM-MSC 0/22 0/11   Not estimable
Heldman 2014_BMMNC 0/22 0/10   Not estimable
Losordo 2011 6/112 7/56 80.95% 0.43[0.15,1.22]
Patila 2014 0/13 0/17   Not estimable
Subtotal (95% CI) 212 133 100% 0.38[0.15,0.97]
Total events: 7 (Cells), 11 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%  
Test for overall effect: Z=2.02(P=0.04)  
Favours cell therapy 1000.01 100.1 1 Favours no cell therapy
 
 
Analysis 8.3.   Comparison 8 Sensitivity analysis: excluding studies with high/
unclear risk of selection bias, Outcome 3 Rehospitalisation due to heart failure.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.3.1 Short term follow-up (< 12 months)  
Assmus 2013 8/43 11/39 56.08% 0.66[0.3,1.47]
Mathiasen 2015 6/40 2/20 20.02% 1.5[0.33,6.77]
Perin 2012a 3/61 5/31 23.89% 0.3[0.08,1.19]
Subtotal (95% CI) 144 90 100% 0.65[0.32,1.32]
Total events: 17 (Cells), 18 (No cells)  
Heterogeneity: Tau2=0.07; Chi2=2.37, df=2(P=0.31); I2=15.49%  
Test for overall effect: Z=1.2(P=0.23)  
Favours cell therapy 100.1 50.2 20.5 1 Favours no cell therapy
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
8.3.2 Long term follow-up (≥ 12 months)  
Assmus 2013 8/43 13/39 51.98% 0.56[0.26,1.2]
Bartunek 2012 6/21 4/15 26.31% 1.07[0.36,3.15]
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 1/10 3.15% 0.18[0.01,4.13]
Losordo 2011 3/112 4/56 14.29% 0.38[0.09,1.62]
Patila 2014 1/13 1/17 4.27% 1.31[0.09,19]
Subtotal (95% CI) 227 148 100% 0.63[0.36,1.09]
Total events: 18 (Cells), 23 (No cells)  
Heterogeneity: Tau2=0; Chi2=2.41, df=4(P=0.66); I2=0%  
Test for overall effect: Z=1.66(P=0.1)  
Favours cell therapy 100.1 50.2 20.5 1 Favours no cell therapy
 
 
Analysis 8.4.   Comparison 8 Sensitivity analysis: excluding studies
with high/unclear risk of selection bias, Outcome 4 Arrhythmias.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.4.1 Short term follow-up (< 12 months)  
Jimenez-Quevedo 2011 1/19 1/9 28.91% 0.47[0.03,6.74]
Mathiasen 2015 3/40 1/20 42.18% 1.5[0.17,13.52]
Perin 2011 0/20 0/10   Not estimable
Santoso 2014 1/19 1/9 28.91% 0.47[0.03,6.74]
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 0/25 0/25   Not estimable
Subtotal (95% CI) 142 82 100% 0.77[0.18,3.21]
Total events: 5 (Cells), 3 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.62, df=2(P=0.74); I2=0%  
Test for overall effect: Z=0.36(P=0.72)  
   
8.4.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 13/39 100% 0.42[0.18,0.99]
Subtotal (95% CI) 43 39 100% 0.42[0.18,0.99]
Total events: 6 (Cells), 13 (No cells)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.97(P=0.05)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 8.5.   Comparison 8 Sensitivity analysis: excluding studies
with high/unclear risk of selection bias, Outcome 5 Composite MACE.
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.5.1 Short term follow-up (< 12 months)  
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 38 21 Not estimable
Total events: 0 (Cells), 0 (No cells)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
8.5.2 Long term follow-up (≥ 12 months)  
Assmus 2013 14/43 19/39 93.44% 0.67[0.39,1.14]
Heldman 2014_BM-MSC 1/19 1/11 3.78% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 1/10 2.78% 0.18[0.01,4.13]
Subtotal (95% CI) 81 60 100% 0.64[0.38,1.08]
Total events: 15 (Cells), 21 (No cells)  
Heterogeneity: Tau2=0; Chi2=0.66, df=2(P=0.72); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
 
 
Analysis 8.6.   Comparison 8 Sensitivity analysis: excluding studies with high/unclear risk
of selection bias, Outcome 6 NYHA classification: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.6.1 Combined  
Assmus 2013 42 -0.3 (0.7) 38 0.1 (1) 19.55% -0.45[-0.82,-0.08]
Nasseri 2012 28 -0.5 (1) 26 -1 (0.7) 17.29% 0.48[0.02,0.94]
Perin 2011 20 1.8 (0.2) 10 2.4 (0.3) 23.56% -0.6[-0.81,-0.39]
Perin 2012a 55 -0.3 (0.9) 30 -0.1 (0.7) 20.16% -0.2[-0.55,0.15]
Tse 2007 19 2 (0.4) 9 2.3 (0.5) 19.45% -0.38[-0.75,-0.01]
Subtotal *** 164   113   100% -0.26[-0.59,0.07]
Heterogeneity: Tau2=0.11; Chi2=19.22, df=4(P=0); I2=79.19%  
Test for overall effect: Z=1.56(P=0.12)  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
 
 
Analysis 8.7.   Comparison 8 Sensitivity analysis: excluding studies with high/unclear
risk of selection bias, Outcome 7 NYHA classification: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.7.1 Combined  
Patila 2014 20 -1 (0.8) 19 1.2 (0.8) 100% -2.2[-2.7,-1.7]
Subtotal *** 20   19   100% -2.2[-2.7,-1.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.58(P<0.0001)  
Favours cell therapy 21-2 -1 0 Favours no cell therapy
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Analysis 8.8.   Comparison 8 Sensitivity analysis: excluding studies with high/unclear risk of
selection bias, Outcome 8 LVEF (%) measured by MRI: short term follow-up (< 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.8.1 Combined  
Assmus 2013 15 1.9 (3.6) 12 -1.1 (3.5) 18.89% 3[0.31,5.69]
Hendrikx 2006 10 6.1 (8.6) 10 3.6 (9.1) 6.36% 2.5[-5.26,10.26]
Mathiasen 2015 40 5 (3.8) 20 -1.3 (3.7) 21.47% 6.3[4.3,8.3]
Nasseri 2012 26 31 (7) 22 33 (8) 13.35% -2[-6.29,2.29]
Santoso 2014 19 1.9 (5.5) 9 2.6 (7.2) 10.61% -0.7[-6.01,4.61]
Tse 2007 18 3.7 (5.1) 8 -0.4 (7.5) 9.73% 4.1[-1.61,9.81]
Van Ramshorst 2009 22 3 (5) 18 -1 (3) 19.59% 4[1.49,6.51]
Subtotal *** 150   99   100% 2.92[0.67,5.17]
Heterogeneity: Tau2=5.12; Chi2=16.21, df=6(P=0.01); I2=62.99%  
Test for overall effect: Z=2.54(P=0.01)  
Favours no cell therapy 105-10 -5 0 Favours cell therapy
 
 
Analysis 8.9.   Comparison 8 Sensitivity analysis: excluding studies with high/unclear risk
of selection bias, Outcome 9 LVEF (%) measured by MRI: long term follow-up (≥ 12 months).
Study or subgroup Cells No cells Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.9.1 Combined  
Patila 2014 11 3.7 (9.7) 14 5.3 (8) 100% -1.6[-8.7,5.5]
Subtotal *** 11   14   100% -1.6[-8.7,5.5]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.44(P=0.66)  
Favours no cell therapy 2010-20 -10 0 Favours cell therapy
 
 
Comparison 9.   Sensitivity analysis: excluding studies with high/unclear risk of performance bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause) 26   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Short term follow-up (< 12
months)
25 1216 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.29, 1.16]
1.2 Long term follow-up (≥ 12
months)
13 624 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.21, 0.86]
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Analysis 9.1.   Comparison 9 Sensitivity analysis: excluding studies with
high/unclear risk of performance bias, Outcome 1 Mortality (all-cause).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
9.1.1 Short term follow-up (< 12 months)  
Assmus 2013 5/43 6/39 38.97% 0.76[0.25,2.28]
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 0/19 0/11   Not estimable
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hendrikx 2006 1/11 1/12 6.78% 1.09[0.08,15.41]
Hu 2011 0/31 1/29 4.76% 0.31[0.01,7.38]
Jimenez-Quevedo 2011 1/19 1/9 6.74% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 4.69% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 6.43% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 5.46% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 5.94% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 5.3% 0.2[0.01,4]
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 4.73% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Van Ramshorst 2009 1/25 0/25 4.78% 3[0.13,70.3]
Wang 2010 0/56 0/56   Not estimable
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 2/18 0/18 5.4% 5[0.26,97.37]
Subtotal (95% CI) 706 510 100% 0.58[0.29,1.16]
Total events: 12 (Cells), 17 (No cells)  
Heterogeneity: Tau2=0; Chi2=8.42, df=11(P=0.68); I2=0%  
Test for overall effect: Z=1.53(P=0.13)  
   
9.1.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 8/39 52.63% 0.68[0.26,1.79]
Erbs 2005 0/13 1/12 5.07% 0.31[0.01,6.94]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Heldman 2014_BM-MSC 1/19 1/11 6.88% 0.58[0.04,8.36]
Heldman 2014_BMMNC 0/19 0/10   Not estimable
Hu 2011 1/31 2/29 8.91% 0.47[0.04,4.89]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 5.66% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 10.09% 0.33[0.04,3.03]
Patila 2014 0/13 0/17   Not estimable
Santoso 2014 0/19 2/9 5.68% 0.1[0.01,1.89]
Tse 2007 0/19 1/9 5.08% 0.17[0.01,3.73]
Subtotal (95% CI) 366 258 100% 0.43[0.21,0.86]
Total events: 9 (Cells), 21 (No cells)  
Heterogeneity: Tau2=0; Chi2=3.86, df=7(P=0.8); I2=0%  
Test for overall effect: Z=2.37(P=0.02)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
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Comparison 10.   Sensitivity analysis: excluding studies with high/unclear risk of attrition bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality (all-cause) 32   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Short term follow-up (< 12
months)
28 1449 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.26, 0.89]
1.2 Long term follow-up (≥ 12
months)
17 883 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.25, 0.60]
 
 
Analysis 10.1.   Comparison 10 Sensitivity analysis: excluding studies
with high/unclear risk of attrition bias, Outcome 1 Mortality (all-cause).
Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.1.1 Short term follow-up (< 12 months)  
Assmus 2006 0/52 1/23 3.78% 0.15[0.01,3.57]
Assmus 2013 5/43 6/39 30.98% 0.76[0.25,2.28]
Erbs 2005 0/13 0/12   Not estimable
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hendrikx 2006 1/11 1/12 5.39% 1.09[0.08,15.41]
Hu 2011 0/31 1/29 3.78% 0.31[0.01,7.38]
Jimenez-Quevedo 2011 1/19 1/9 5.36% 0.47[0.03,6.74]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 1/56 3.73% 0.17[0.01,4.06]
Mathiasen 2015 1/40 1/20 5.11% 0.5[0.03,7.59]
Mozid 2014_IC 0/14 1/2 4.34% 0.07[0,1.27]
Mozid 2014_IM 0/10 3/8 4.72% 0.12[0.01,1.98]
Nasseri 2012 0/30 2/30 4.22% 0.2[0.01,4]
Patel 2005 0/10 0/10   Not estimable
Perin 2011 0/20 0/10   Not estimable
Perin 2012a 1/61 0/31 3.76% 1.55[0.06,36.94]
Perin 2012b 0/10 0/10   Not estimable
Pokushalov 2010 2/55 8/54 16.73% 0.25[0.05,1.1]
Santoso 2014 0/19 0/9   Not estimable
Tse 2007 0/19 0/9   Not estimable
Turan 2011 0/38 0/18   Not estimable
Van Ramshorst 2009 1/25 0/25 3.8% 3[0.13,70.3]
Wang 2009 0/16 0/16   Not estimable
Wang 2010 0/56 0/56   Not estimable
Wang 2015 0/45 0/45   Not estimable
Yao 2008 0/24 0/23   Not estimable
Zhao 2008 2/18 0/18 4.29% 5[0.26,97.37]
Subtotal (95% CI) 839 610 100% 0.48[0.26,0.89]
Total events: 14 (Cells), 26 (No cells)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
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Study or subgroup Cells No cells Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=10, df=13(P=0.69); I2=0%  
Test for overall effect: Z=2.34(P=0.02)  
   
10.1.2 Long term follow-up (≥ 12 months)  
Assmus 2013 6/43 8/39 19.68% 0.68[0.26,1.79]
Chen 2006 2/22 4/23 7.23% 0.52[0.11,2.57]
Erbs 2005 0/13 1/12 1.9% 0.31[0.01,6.94]
Hamshere 2015_IC 0/15 0/15   Not estimable
Hamshere 2015_IM 0/15 0/15   Not estimable
Hu 2011 1/31 2/29 3.33% 0.47[0.04,4.89]
Losordo 2007 0/18 0/6   Not estimable
Losordo 2011 0/112 3/56 2.11% 0.07[0,1.37]
Nasseri 2012 1/30 3/30 3.77% 0.33[0.04,3.03]
Patel 2005 3/25 10/25 13.52% 0.3[0.09,0.96]
Patel 2015 5/22 2/6 9.79% 0.68[0.17,2.68]
Patila 2014 0/13 0/17   Not estimable
Pokushalov 2010 6/55 21/54 26.9% 0.28[0.12,0.64]
Santoso 2014 0/19 2/9 2.12% 0.1[0.01,1.89]
Trifunovic 2015 2/15 4/15 7.75% 0.5[0.11,2.33]
Tse 2007 0/19 1/9 1.9% 0.17[0.01,3.73]
Turan 2011 0/38 0/18   Not estimable
Subtotal (95% CI) 505 378 100% 0.39[0.25,0.6]
Total events: 26 (Cells), 61 (No cells)  
Heterogeneity: Tau2=0; Chi2=5.5, df=11(P=0.9); I2=0%  
Test for overall effect: Z=4.33(P<0.0001)  
Favours cell therapy 2000.005 100.1 1 Favours no cell therapy
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Study ID Country of
study
Patient pop-
ulation
Mean (SD) age of participants (years) % Male No. ran-
domised
partici-
pants re-
ceiving in-
tervention
No. ran-
domised
partici-
pants re-
ceiving
comparator
Mean dura-
tion of fol-
low-up
Ang 2008 UK CIHD (> 1
chronic my-
ocardial
scar; elective
CABG)
BMMNC-IM: 64.7 (8.7)
BMMNC-IC: 62.1 (8.7)
Controls: 61.3 (8.3)
BMMNC-IM: 71.4%
BMMNC-IC: 90.5%
Controls: 90.0%
42 (21 IM, 21
IC)
21 6 months
Assmus
2006
Germany CIHD (MI > 3
months; LV
dysfunction)
BMMNC: 59 (12)
CPC: 54 (12)
Controls: 61 (9)
BMMNC: 89%
CPC: 79%
Controls: 100%
52 (28 MNC,
24 CPC)
23 3 months
Assmus
2013
Germany CIHD (MI > 3
months; LVEF
< 50%; NY-
HA class II or
greater)
BMMNC-LDSW: 65 (12)
BMMNC-HDSW: 58 (11)
Controls-LDSW: 60 (10)
Controls-HDSW: 63 (10)
BMMNC-LDSW: 77%
BMMNC-HDSW: 86%
Controls-LDSW: 80%
Controls-HDSW: 90%
43 (22
LDSW, 21
HDSW)
39 (20
LDSW, 19
HDSW)
45.7 (17)
months
Bartunek
2012
Belgium/
Serbia/
Switzerland
HF (LVEF
15% to 40%;
ischaemic
event > 2
months)
BM-MSC: 55.3 (SE 10.4)
Controls: 58.7 (SE 8.2)
BM-MSC: 90.5%
Controls: 86.7%
32 15 24 months
Chen 2006 China CIHD (isolat-
ed, chronic
LAD; LVEF <
40%)
BM-MSC: 59.3 (6.8)
Controls: 57.8 (7.2)
BM-MSC: 88%
Controls: 92%
24 24 12 months
Erbs 2005 Germany CIHD (chron-
ic total oc-
clusion; my-
ocardial is-
chaemia)
CPC: 63 (7)
Controls: 61 (9)
CPC: 71%
Controls: 86%
14 14 15 months
Table 1.   Characteristics of study participants 
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Hamshere
2015_IC
UK HF (NYHA
class II-IV; no
revascularisa-
tion options)
BMMNC: n/r
Controls: n/r
BMMNC: n/r
Controls: n/r
15 15 12 months
Hamshere
2015_IM
UK HF (NYHA
class II-IV; no
revascularisa-
tion options)
BMMNC: n/r
Controls: n/r
BMMNC: n/r
Controls: n/r
15 15 12 months
Heldman
2014_BMM-
NC
USA CIHD (chron-
ic MI; LV dys-
function)
BMMNC: 61.1 (8.4)
Controls: 61.3 (9.0)
BMMNC: 89.5%
Controls: 100%
22 10 12 months
Heldman
2014_BM-
MSC
USA CIHD (chron-
ic MI; LV dys-
function)
BM-MSC: 57.1 (10.6)
Controls: 60.0 (12.0)
BM-MSC: 94.7%
Controls: 90.9%
22 11 12 months
Hendrikx
2006
Belgium CIHD (trans-
mural MI;
LV dysfunc-
tion; elective
CABG)
BMMNC: 63.2 (8.5)
Controls: 66.8 (9.2)
BMMNC: 100%
Controls: 70%
11 12 4 months
Honold 2012 Germany CIHD (MI > 3
months; LV
regional wall
motion ab-
normality)
CPC: 53.4 (12.3)
Controls: 58.8 (7.3)
CPC: 82%
Controls: 100%
23 10 60 months
Hu 2011 China HF (MI > 3
months; LVEF
< 30%; elec-
tive CABG)
BMMNC: 56.6 (9.7)
Controls: 58.3 (8.9)
BMMNC: 88%
Controls: 96%
31 29 12 months
Jimenez-
Quevedo
2011
Spain Refractory
angina (CCS
class II-IV)
CD133+: median 70.0
Controls: median 58.2
CD133+: 78.9%
Controls: 100%
19 9 6 months
Losordo
2007
USA Refractory
angina (CCS
class III-IV)
CD34+/controls pooled: 62.4 (range 48 to
84)
CD34+/controls pooled:
80%
18 (6 LD, 6
MD 6, HD)
6 6 months
Table 1.   Characteristics of study participants  (Continued)
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Losordo
2011
USA Refractory
angina (CCS
class III-IV)
CD34+/LD: 61.3 (9.1)
CD34+/HD: 59.8 (9.2)
Controls: 61.8 (8.5)
CD34+/LD: 83.6%
CD34+/HD: 87.5%
Controls: 89.3%
112 (56 LD,
56 HD)
56 12 months
Mathiasen
2015
Denmark HF (NYHA
class II-III;
LVEF < 45%;
no revascu-
larisation op-
tions)
BM-MSC: 66.1 (7.7)
Controls: 64.2 (10.6)
BM-MSC: 90%
Controls: 70%
40 20 6 months
Mozid
2014_IC
UK HF (NYHA
class II-IV; no
revascularisa-
tion options)
BMMNC/controls pooled (16 participants):
70 (10)
BMMNC/controls pooled (16
participants): 94%
14 2 6 months
Mozid
2014_IM
UK HF (NYHA
class II-IV; no
revascularisa-
tion options)
BMMNC/controls pooled (18 participants):
64 (9)
BMMNC/controls pooled (18
participants): 100%
10 8 6 months
Nasseri 2012 Germany HF (LVEF <
35%; elective
CABG)
CD133+: 61.9 (7.3)
Controls: 62.7 (10.6)
CD133+: 93%
Controls: 97%
30 30 6 months
Patel 2005 Argentina HF (LVEF <
35%; NY-
HA class III-
IV; elective
CABG)
CD34+: 64.8 (7.1)
Controls: 63.6 (5.2)
CD34+: 80%
Controls: 80%
25 25 10 years
Patel 2015 USA/Ger-
many/India
HF (LVEF <
40%; NYHA
class III-IV)
BMAC: 58.5 (12.7)
Controls: 52.7 (8.5)
BMAC: 91.7%
Controls: 100%
24 6 12 months
Patila 2014 Finland HF (LVEF 15%
to 40%; NY-
HA class II-
IV; elective
CABG)
BMMNC: median 65 (range 57 to 73)
Controls: median 64 (range 58 to 70)
BMMNC: 94.7%
Controls: 95.0%
20 19 12 months
Perin 2011 USA HF (angina/HF
symptoms;
BMMNC: 56.3 (8.6) BMMNC: 50% 20 10 6 months
Table 1.   Characteristics of study participants  (Continued)
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chronic CAD;
LVEF < 40%;
no revascu-
larisation op-
tions)
Controls: 60.5 (6.4) Controls: 80%
Perin 2012a USA HF (CCS class
II-IV or NY-
HA class II-
III, or both;
LVEF < 45%;
no revascu-
larisation op-
tions)
BMMNC: 64.0 (10.9)
Controls: 62.3 (8.3)
BMMNC: 86.9%
Controls: 93.7%
61 31 6 months
Perin 2012b USA HF (CCS class
II-IV or NY-
HA class II-
III, or both;
LVEF < 45%;
no revascu-
larisation op-
tions)
ALDH+: 58.2 (6.1)
Controls: 57.8 (5.5)
ALDH+: 90%
Controls: 80%
10 10 6 months
Pokushalov
2010
Russia HF (LVEF
< 35%; no
revascularisa-
tion options)
BMMNC: 61 (9)
Controls: 62 (5)
BMMNC: 87%
Controls: 85%
55 54 12 months
Santoso
2014
Indone-
sia/China
HF (NYHA
class III-IV;
LVEF < 40%;
no revascu-
larisation op-
tions)
BMMNC: 58 (5.9)
Controls: 60 (5.6)
BMMNC: 95%
Controls: 100%
19 9 6 months
Trifunovic
2015
Serbia CIHD (MI < 30
days; LVEF
< 40%; NY-
HA class III-
IV; elective
CABG)
BMMNC: 53.8 (10.1)
Controls: 60.0 (6.8)
BMMNC: 93.3%
Controls: 93.3%
15 15 Median 5
years (IQR
2.5 to 7.5)
Table 1.   Characteristics of study participants  (Continued)
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Tse 2007 China/Aus-
tralia
Refractory
angina (CCS
class III-IV)
BMMNC: 65.2 (8.3)
Controls: 68.9 (6.3)
BMMNC: 79%
Controls: 88%
19 9 6 months
Turan 2011 Germany CIHD (MI > 3
months; LV
dysfunction)
BMMNC: 62 (10)
Controls: 60 (9)
BMMNC: 52.6%
Controls: 55.6%
38 18 12 months
Van
Ramshorst
2009
The Nether-
lands
Refractory
angina (CCS
class II-IV)
BMMNC: 64 (8)
Controls: 62 (9)
BMMNC: 92%
Controls: 80%
25 25 6 months
Wang 2009 China Refractory
angina (MI > 1
month)
CD34+: 60.6 (n/r)
Controls: 60.0 (n/r)
CD34+: 56.3%
Controls: 63.3%
16 16 6 months
Wang 2010 China Refractory
angina (CCS
class III-IV)
CD34+: range 42 to 80
Controls: range 43 to 80
CD34+: 51.8%
Controls: 50.0%
56 56 6 months
Wang 2014 China CIHD (LVEF <
35%)
CD133+: n/r
Controls: n/r
CD133+: n/r
Controls: n/r
35 35 6 months
Wang 2015 China CIHD (mul-
tivessel dis-
ease; MI > 4
weeks; elec-
tive CABG)
BMMNC: 61.4 (7.5)
Controls: 62.9 (6.9)
BMMNC: 82%
Controls: 78%
45 45 6 months
Yao 2008 China CIHD (MI > 6
months)
BMMNC: 54.8 (11.5)
Controls: 56.3 (7.9)
BMMNC: 96%
Controls: 96%
24 23 6 months
Zhao 2008 China HF (LVEF <
40%; elective
CABG)
BMMNC: 60.3 (10.4)
Controls: 59.1 (15.7)
BMMNC: 83.3%
Controls: 83.3%
18 18 6 months
Table 1.   Characteristics of study participants  (Continued)
ALDH: aldehyde dehydrogenase
BMAC: bone marrow aspirate concentrate
BMMNC: bone marrow mononuclear cells
BM-MSC: bone marrow-derived mesenchymal stem cells
CABG: coronary artery bypass graMing
CCS: Canadian Cardiovascular Society
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CIHD: chronic ischaemic heart disease
CPC: circulating progenitor cells
EF: ejection fraction
HD: high dose
HDSW: high dose shockwave
HF: heart failure
IC: intracoronary
IM: intramyocardial
IQR: interquartile range
LAD: leM ventricular assist device
LD: low dose
LDSW: low dose shockwave
LV: leM ventricular
LVEF: leM ventricular ejection fraction
MD: medium dose
MI: myocardial infarction
MNC: mononuclear cells
n/r: not reported
NYHA: New York Heart Association
SD: standard deviation
SE: standard error
SW: shockwave
 
 
Study ID Co-inter-
vention
Interven-
tion given
by:
Route of
cell ad-
ministra-
tion
Interven-
tion cell
type
How are cells ob-
tained?
What were they re-
suspended in?
Dose adminis-
tered?
Comparator arm (placebo or
control)
Ang 2008 CABG Cardiotho-
racic sur-
geon
IC or IM BMMNC BM aspiration (**) Autologous serum IM: 84 (56) million
cells
IC: 115 (73) million
cells
No additional therapy (control)
Assmus
2006
Standard
medical
therapy
Cardiolo-
gist
IC BMMNC or
CPC
BM aspiration (**)
for BMMNC. Vein
puncture, mononu-
clear cell isolation
by gradient cen-
trifugation and cul-
ture for 3 days for
CPC
n/r BMMNC: 205 (110)
million cells
CPC: 22 (11) million
cells
No additional therapy (control)
Table 2.   Characteristics of study interventions 
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Assmus
2013
Shock-
wave
Cardiolo-
gist
IC BMMNC BM aspiration (**) X-VIVO 10 medi-
um and autologous
serum
HDSW: 123 (69) mil-
lion cells
LDSW: 150 (77) mil-
lion cells
Placebo (10 mL X-VIVO 10 medi-
um and autologous serum)
Bartunek
2012
Standard
medical
therapy
Cardiolo-
gist
IC BM-MSC
(car-
diopoietic
cells)
BM aspiration (**),
culture for 6 days
and exposure to
cardiopoietic fac-
tors
Preservation solu-
tion (no details)
733 (range 605 to
1168) million cells
No additional therapy (control)
Chen 2006 Standard
medical
therapy
Cardiolo-
gist
IC BM-MSC BM aspiration (**),
culture for 7 days
to select MSC
Heparinised saline 5 million cells No additional therapy (control)
Erbs 2005 G-CSF Cardiolo-
gist
IC CPC G-CSF infusion for
4 days prior to vein
puncture, mononu-
clear cell isolation
by gradient cen-
trifugation and cul-
ture for 3 days for
CPC
Saline and 10% au-
tologous serum
69 (14) million cells Placebo (cell-free serum solu-
tion)
Hamshere
2015_IC
G-CSF Cardiolo-
gist
IC BMMNC G-CSF infusion for
5 days and BM aspi-
ration (**)
Autologous serum n/r Placebo (10 mL autologous
serum)
Hamshere
2015_IM
G-CSF Cardiolo-
gist
IM BMMNC G-CSF infusion for
5 days and BM aspi-
ration (**)
Autologous serum n/r Placebo (2 mL autologous
serum)
Heldman
2014_BMM-
NC
Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) n/r n/r Placebo (vehicle medium)
Heldman
2014_BM-
MSC
Standard
medical
therapy
Cardiolo-
gist
IM BM-MSC BM aspiration (**),
culture to select
MSC
n/r n/r Placebo (vehicle medium)
Hendrikx
2006
CABG Cardiotho-
racic sur-
geon
IM BMMNC BM aspiration (**) Heparinised saline 60 (31) million cells Placebo (heparinised saline)
Table 2.   Characteristics of study interventions  (Continued)
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Honold
2012
G-CSF Cardiolo-
gist
IC CPC G-CSF infusion for
5 days prior to vein
puncture, mononu-
clear cell isolation
by gradient cen-
trifugation and cul-
ture for 4 days for
CPC
n/r 29 (12) million cells No additional therapy (control)
Hu 2011 CABG Cardiotho-
racic sur-
geon
IC BMMNC BM aspiration (**) Saline solution and
20% autologous
serum
132 (107) million
cells
Placebo (8 mL saline; 2 mL au-
tologous serum)
Jimenez-
Quevedo
2011
G-CSF Cardiolo-
gist
IM CD133+ G-CSF infusion for 5
days prior to leuka-
pheresis, mononu-
clear cell isola-
tion by gradient
centrifugation im-
munomagnetic se-
lection to isolate
CD133+ cells
Normal saline solu-
tion
20 to 30 million
cells
No additional therapy (control)
Losordo
2007
G-CSF Cardiolo-
gist
IM CD34+ G-CSF infusion for 5
days prior to leuka-
pheresis, mononu-
clear cell isola-
tion by gradient
centrifugation im-
munomagnetic se-
lection to isolate
CD34+ cells
Saline solution and
5% autologous
serum
LD: 0.05 million
cells
MD: 0.1 million
cells
HD: 0.5 million cells
Placebo (0.9% sodium chloride;
5% autologous plasma)
Losordo
2011
G-CSF Cardiolo-
gist
IM CD34+ G-CSF infusion for 5
days prior to leuka-
pheresis, mononu-
clear cell isola-
tion by gradient
centrifugation im-
munomagnetic se-
lection to isolate
CD34+ cells
Saline solution and
5% autologous
serum
LD: 0.1 million cells
HD: 0.5 million cells
Placebo (0.9% sodium chloride;
5% autologous plasma)
Table 2.   Characteristics of study interventions  (Continued)
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Mathiasen
2015
Standard
medical
therapy
Cardiolo-
gist
IM BM-MSC BM aspiration (**),
culture for 14 to 35
days to select MSC
Phosphate buJered
saline with a drop
of the participant’s
blood
77.5 (68) million
cells
Placebo (phosphate buJered
saline mixed with drop of par-
ticipant’s blood)
Mozid
2014_IC
G-CSF Cardiolo-
gist
IC BMMNC G-CSF infusion for
5 days and BM aspi-
ration (**)
Autologous serum 86 (110) million
cells
Placebo (10 mL autologous
serum)
Mozid
2014_IM
G-CSF Cardiolo-
gist
IM BMMNC G-CSF infusion for
5 days and BM aspi-
ration (**)
Autologous serum 52 (53) million cells Placebo (2 mL autologous
serum)
Nasseri
2012
CABG Cardiotho-
racic sur-
geon
IM CD133+ BM aspiration (**),
immunomagnetic
selection to isolate
CD133+ cells
Sodium chloride
and 10% autologous
serum
Median 5.1 million
cells
Placebo (isotonic saline solu-
tion; 10% autologous serum)
Patel 2005 CABG Cardiotho-
racic sur-
geon
IM CD34+ BM aspiration (**),
immunomagnetic
selection to isolate
CD34+ cells
Heparinised saline
and autologous
serum
Median 22 million
cells
No additional therapy (control)
Patel 2015 Standard
medical
therapy
Cardiolo-
gist
IC BMAC BM aspiration (**)
and concentration
Autologous serum 3700 (900) million
cells
No additional therapy (control)
Patila
2014
CABG Cardiotho-
racic sur-
geon
IM BMMNC BM aspiration (**) Medium 199 contain-
ing albumin, heparin
Median 840 (range
52 to 135) million
cells
Placebo (vehicle medium)
Perin 2011 Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Saline containing 5%
human serum albu-
min
2 million cells No additional therapy (control)
Perin
2012a
Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Saline containing 5%
human serum albu-
min
100 million cells Placebo (cell-free suspension in
same volume)
Perin
2012b
Standard
medical
therapy
Cardiolo-
gist
IM ALDH+ BM aspiration (**)
and cell sorting
Pharmaceutical
grade human serum
albumin
2.4 (1.3) million
cells
Placebo (5% pharmaceutical
serum albumin)
Table 2.   Characteristics of study interventions  (Continued)
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Pokushalov
2010
Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Heparinised saline 41 (16) million cells No additional therapy (control)
Santoso
2014
Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Phosphate buJered
saline with 10% au-
tologous plasma
n/r Placebo (phosphate buJered
saline; 10% autologous plasma)
Trifunovic
2015
CABG Cardiotho-
racic sur-
geon
IM BMMNC BM aspiration (**) n/r 70.7 (32.4) million
cells
No additional therapy (control)
Tse 2007 Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Phosphate buJered
saline with 10% au-
tologous plasma
15 million cells Placebo (8 - 12 x 0.1 mL phos-
phate buJered saline with 10%
autologous serum)
Turan
2011
Standard
medical
therapy
Cardiolo-
gist
IC BMMNC BM aspiration (**) n/r 99 (25) million cells No additional therapy (control)
Van
Ramshorst
2009
Standard
medical
therapy
Cardiolo-
gist
IM BMMNC BM aspiration (**) Phosphate buJered
saline with 0.5% hu-
man serum albumin
98 (6) million cells Placebo (0.9% sodium chloride;
0.5% human serum albumin)
Wang 2009 Standard
medical
therapy
Cardiolo-
gist
IC CD34+ BM aspiration (**),
immunomagnetic
selection to isolate
CD34+ cells
Normal saline Range 1.0 to 6.1
million cells
No additional therapy (control)
Wang 2010 Standard
medical
therapy
Cardiolo-
gist
IC CD34+ BM aspiration (**),
immunomagnetic
selection to isolate
CD34+ cells
Saline and human
serum albumin
56 (23) million cells Placebo (saline; human serum
albumin)
Wang 2014 Standard
medical
therapy
Cardiolo-
gist
IM CD133+ n/r n/r n/r Placebo (n/r)
Wang 2015 CABG Cardiotho-
racic sur-
geon
IM BMMNC BM aspiration (**) Heparinised saline 521 (44) million
cells
Placebo (saline solution)
Table 2.   Characteristics of study interventions  (Continued)
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Yao 2008 Standard
medical
therapy
Cardiolo-
gist
IC BMMNC BM aspiration (**) Heparinised saline 72 million cells Placebo (0.9% sodium chloride
containing heparin)
Zhao 2008 CABG Cardiotho-
racic sur-
geon
IM BMMNC BM aspiration (**) Heparinised saline 659 (512) million
cells
Placebo (saline)
Table 2.   Characteristics of study interventions  (Continued)
**BM aspiration - bone marrow aspiration and isolation of bone marrow mononuclear cells by gradient centrifugation.
ALDH: aldehyde dehydrogenase
BM: bone marrow
BMAC: bone marrow aspirate concentrate
BMMNC: bone marrow mononuclear cells
BM-MSC: bone marrow-derived mesenchymal stem cells
CABG: coronary artery bypass graMing
CPC: circulating progenitor cells
G-CSF: granulocyte colony-stimulating factor
HD: high dose
HDSW: high dose shockwave
IC: intracoronary
IM: intramyocardial
LD: low dose
LDSW: low dose shockwave
MD: medium dose
MSC: mesenchymal stem cells
n/r: not reported
SW: shockwave
 
 
Primary outcomes Secondary outcomes
All-cause
mortality
Non-fatal
MI
Hospital
readmis-
sion for
HF
Compos-
ite MACEa
Arrhyth-
mias
NYHA
class
CCS class Angina
frequency
Exercise
tolerance
Quality of
life
LVEFb
Study ID
ST LT ST LT ST LT ST LT ST LT ST LT ST LT ST LT ST LT ST LT ST LT
Ang 2008 FR NR PR* NR NR NR NR NR PR* NR PR NR PR NR NR NR NR NR NR NR FR NR
Assmus 2006 FR NR FR NR FR NR FR NR FR NR FR NR NR NR NR NR NR NR NR NR FR NR
Table 3.   Summary of outcome reporting  (Continued)
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Assmus 2013 FR FR NR FR FR FR NR FR NR FR FR NR NR NR NR NR NR NR NR NR FR NR
Bartunek 2012 PR* FR NR NR NR FR NR NR PR PR PR NR NR NR NR NR FR NR PR NR FR NR
Chen 2006 NR FR NR NR NR NR NR NR PR* NR FR FR NR NR NR NR FR FR NR NR FR FR
Erbs 2005 PR* FR NR NR NR NR NR NR NR NR NR NR NR NR NR NR FR FR NR NR FR FR
Hamshere 2015_IC PR* PR* PR* FR PR* PR* PR* FR FR FR FR FR FR FR NR NR NR NR NR NR PR PR
Hamshere 2015_IM PR* PR* PR* PR* FR FR FR FR FR FR FR FR FR FR NR NR NR NR NR NR PR PR
Heldman
2014_BMMNC
PR* PR* NR PR* NR FR PR* FR NR NR NR PR NR NR NR NR FR FR FR FR NR PR
Heldman 2014_BM-
MSC
PR* FR NR PR* NR PR* PR* FR NR NR NR PR NR NR NR NR FR FR FR FR NR PR
Hendrikx 2006 FR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR FR NR
Honold 2012 PR* FR FR FR PR* FR NR NR NR NR FR FR NR NR NR NR FR FR NR NR FR FR
Hu 2011 FR FR PR* NR NR NR FR NR PR* FR NR NR NR NR NR NR FR NR NR NR FR FR
Jimenez-Quevedo
2011
FR NR PR* NR NR NR PR NR FR NR NR NR PR NR PR NR PR NR PR NR PR NR
Losordo 2007 PR* PR* PR* PR* NR NR NR NR FR FR NR NR FR NR FR NR FR NR PR NR NR NR
Losordo 2011 FR FR NR FR NR FR NR PR NR NR NR NR PR PR FR NR FR FR FR FR NR NR
Mathiasen 2015 FR NR PR* NR FR NR NR NR FR NR PR NR PR NR PR NR PR NR PR NR FR NR
Mozid 2014_IC FR NR PR* NR FR NR FR NR PR* NR FR NR FR NR NR NR NR NR NR NR NR NR
Mozid 2014_IM FR NR PR* NR PR* NR FR NR FR NR FR NR FR NR NR NR NR NR NR NR NR NR
Nasseri 2012 FR FR NR NR NR NR NR NR NR NR FR NR FR NR NR NR PR NR PR NR FR NR
Patel 2005 PR* FR NR NR NR NR NR NR PR* NR FR NR NR NR NR NR NR NR NR NR PR PR
Patel 2015 NR FR NR NR NR FR NR NR NR PR* NR FR NR PR NR NR NR NR NR PR PR PR
Table 3.   Summary of outcome reporting  (Continued)
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Patila 2014 NR PR* NR PR* NR FR NR NR NR NR NR FR NR NR NR NR NR NR NR PR NR FR
Perin 2011 PR* NR PR* NR NR NR NR NR PR* NR FR NR FR NR NR NR NR NR FR NR FR NR
Perin 2012a FR NR FR NR FR NR NR NR NR NR FR NR FR NR NR NR FR NR NR NR FR NR
Perin 2012b PR* NR FR NR NR NR NR NR FR NR FR NR FR NR NR NR NR NR NR NR FR NR
Pokushalov 2010 FR FR NR NR NR NR NR NR PR* PR* FR FR FR FR FR FR FR FR FR FR FR FR
Santoso 2014 PR* FR NR NR NR NR NR NR FR NR PR NR NR NR NR NR PR NR NR NR FR NR
Trifunovic 2015 NR FR NR NR NR NR NR NR NR NR FR FR NR NR NR NR FR FR NR NR FR FR
Tse 2007 PR* FR FR NR NR NR NR NR PR* NR FR NR FR NR NR NR FR NR NR NR FR NR
Turan 2011 PR* PR* NR NR NR NR NR NR NR NR FR FR NR NR NR NR NR NR NR NR FR FR
Van Ramshorst
2009
FR NR PR* NR NR NR NR NR PR* NR NR NR FR NR NR NR FR NR FR NR FR FR
Wang 2009 PR* NR PR* NR NR NR NR NR PR* NR NR NR FR NR FR NR FR NR NR NR NR NR
Wang 2010 PR* NR PR* NR NR NR NR NR FR NR NR NR FR NR FR NR FR NR NR NR NR NR
Wang 2014 NR NR NR NR NR NR NR NR NR NR PR NR NR NR NR NR PR NR NR NR FR NR
Wang 2015 PR* NR NR NR NR NR NR NR PR NR NR NR NR NR NR NR NR NR NR NR FR NR
Yao 2008 PR* NR FR NR FR NR NR NR PR* NR NR NR NR NR NR NR NR NR NR NR PR NR
Zhao 2008 FR NR PR* NR NR NR NR NR FR NR FR NR FR NR NR NR NR NR NR NR FR NR
Total (%)
analysedc
1637
(85.8)
1010
(53.0)
881
(46.2)
461
(24.2)
482
(25.3)
495
(26.0)
288
(15.1)
201
(10.5)
959
(50.3)
363
(19.0)
741
(38.9)
346
(18.1)
608
(31.9)
142
(7.4)
428
(22.4)
82
(4.3)d
535
(28.1)
227
(11.9)
197
(10.3)e
151
(7.9)e
439
(23.0)f
110
(5.8)f
Table 3.   Summary of outcome reporting  (Continued)
CCS: Canadian Cardiovascular Society; FR: full reporting, outcome included in analysis; HF: heart failure; LT: long-term follow-up (≥ 12 months); LVEF: leM ventricular ejection
fraction; MACE: major adverse clinical events; MI: myocardial infarction; NR: outcome not reported; NYHA: New York Heart Association; PR: partial reporting with insuJicient
information on outcome reported for inclusion in analysis; PR*: no incidence of outcome observed; ST: short-term follow-up (< 12 months)
aComposite measure of mortality, reinfarction, or rehospitalisation for heart failure.
bLVEF measured by any method.
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cTotal number of participants included in meta-analysis of outcome (% of total number of participants from all included studies).
dNo meta-analysis was performed, as only one study reported values suitable for inclusion.
eMinnesota Living with Heart Failure Questionnaire.
fTotal number analysed given for LVEF measured by magnetic resonance imaging.
 
 
Num-
ber of
analysed
partici-
pants
All-cause mortality
events
Non-fatal MI events Hospital readmission
for HF
Composite MACEa Arrhythmia eventsStudy ID
Cells No
cells
CellsNo
cells
Length of fol-
low-up
CellsNo
cells
Length of
follow-up
Cells No
cells
Length of
follow-up
Cells No
cells
Length
of fol-
low-up
CellsNo
cells
Length of
follow-up
Ang 2008 42 19 1 1 6 mthsa 0 0 6 mths n/r n/r n/r n/r n/r n/r 0 0 6 mths
Assmus 2006 52 23 0 1 3 mths 1 0 3 mths 1 1 3 mths 1 1 3 mths 0 1 3 mths
Assmus 2013 43 39 6 8 45.7 (17) mths 1 4 45.7 (17)
mths
8 13 45.7 (17)
mths
14 19 45.7 (17)
mths
6 13 45.7 (17)
mths
Bartunek 2012 21 15 1 2 24 mths n/
r
n/
r
n/r 6 4 24 mths n/r n/r n/r n/
r
n/
r
n/r
Chen 2006 22 23 2 4 12 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r 0 0 6 mths
Erbs 2005 13 12 0 1 15 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Hamshere 2015_IC 15 15 0 0 12 mths 1 0 12 mths 0 0 12 mths 1 0 12 mths 1 1 12 mths
Hamshere 2015_IM 15 15 0 0 12 mths 0 0 12 mths 1 1 12 mths 1 1 12 mths 0 1 12 mths
Heldman 2014_BMMNC 19 10 0 0 12 mths 0 0 12 mths 0 1 12 mths 0 1 12 mths n/
r
n/
r
n/r
Heldman 2014_BM-MSC 19 11 1 1 12 mths 0 0 12 mths 0 0 12 mths 1 1 12 mths n/
r
n/
r
n/r
Table 4.   Clinical (dichotomous) outcomes  (Continued)
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Hendrikx 2006 11 12 1 1 4 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Honold 2012 23 9 0 1 60 mths 1 2 60 mths 0 2 60 mths n/r n/r n/r n/
r
n/
r
n/r
Hu 2011 31 29 1 2 12 mths 0 0 6 mths n/r n/r n/r 3 4 6 mths 1 0 12 mths
Jimenez-Quevedo 2011 19 9 1 1 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 1 1 6 mths
Losordo 2007 18 6 0 0 12 mths 0 0 12 mths n/r n/r n/r n/r n/r n/r 0 1 12 mths
Losordo 2011 112 56 0 3 12 mths 6 7 12 mths 3 4 12 mths n/r n/r n/r n/
r
n/
r
n/r
Mathiasen 2015 40 20 1 1 6 mths 0 0 6 mths 6 2 6 mths n/r n/r n/r 3 1 6 mths
Mozid 2014_IC 14 2 0 1 6 mths 0 0 6 mths 1 0 6 mths 1 1 6 mths 0 0 6 mths
Mozid 2014_IM 10 8 0 3 6 mths 0 0 6 mths 0 0 6 mths 0 3 6 mths 2 2 6 mths
Nasseri 2012 30 30 1 3 34 mthsb n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Patel 2005 25 25 3 10 10 yrs n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r 0 0 6 mths
Patel 2015 22 6 5 2 12 mths n/
r
n/
r
n/r 2 0 12 mths n/r n/r n/r 0 0 12 mths
Patila 2014 13c 17c 0 0 Median 60 mths 0 0 Median 60
mths
1 1 Median 60
mths
n/r n/r n/r n/
r
n/
r
n/r
Perin 2011 20 10 0 0 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 0 0 6 mths
Perin 2012a 61 31 1 0 6 mths 1 0 6 mths 3 5 6 mths n/r n/r n/r n/
r
n/
r
n/r
Perin 2012b 10 10 0 0 6 mths 1 0 6 mths n/r n/r n/r n/r n/r n/r 3 2 6 mths
Pokushalov 2010 55 54 6 21 12 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r 0 0 12 mths
Table 4.   Clinical (dichotomous) outcomes  (Continued)
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Santoso 2014 19 9 0 2 23 (8) mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r 1 1 6 mths
Trifunovic 2015 15 15 2 4 Median 5 yrs n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Tse 2007 19 9 0 1 19 (9) mths 0 1 3 mths n/r n/r n/r n/r n/r n/r 0 0 6 mths
Turan 2011 38 18 0 0 12 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Van Ramshorst 2009 25 25 1 0 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 0 0 6 mths
Wang 2009 16 16 0 0 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 0 0 6 mths
Wang 2010 56 56 0 0 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 0 1 6 mthsd
Wang 2014 n/r n/r n/
r
n/
r
n/r n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Wang 2015 45 45 0 0 6 mths n/
r
n/
r
n/r n/r n/r n/r n/r n/r n/r n/
r
n/
r
n/r
Yao 2008 24 23 0 0 6 mths 0 1 6 mths 1 2 6 mths n/r n/r n/r 0 0 6 mths
Zhao 2008 18 18 2 0 6 mths 0 0 6 mths n/r n/r n/r n/r n/r n/r 1 0 6 mths
Table 4.   Clinical (dichotomous) outcomes  (Continued)
HF: heart failure; MACE: major adverse clinical events; MI: myocardial infarction; n/r: not reported
aAng 2008: participants followed up for six months; mortality reported as “death within 30 days of treatment”.
bNasseri 2012: deaths reported “beyond follow-up period” occurred at 31 and 34 months.
cPatila 2014: mortality rates reported in 20/19 participants at 12 months and 13/17 participants at 60 months.
dWang 2010: values are for ventricular arrhythmia (atrial arrhythmia also reported but unclear whether any participant overlap).
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Study ID Periprocedural adverse events
Ang 2008 2 deaths (1 control, 1 intracoronary cell therapy) occurred within 30 days of treatment. Reasons
were not given, but neither was considered to be related to cell therapy.
Assmus 2006 In-hospital events: MI occurred in 1 CPC participant and ventricular arrhythmia detected during
monitoring in 1 control participant.
Assmus 2013 n/r (only safety of shockwave procedure reported)
Bartunek 2012 In the cell therapy group, 1 participant had ventricular tachycardia during procedure which was re-
solved by cardioversion, and 1 participant had blurred vision after intervention (participant had
pre-existing ophthalmic migraines). Other reported adverse events (gastrointestinal, hepatobiliary,
respiratory, thoracic, mediastinal, and peripheral vascular disorders) were not considered to be re-
lated to cell therapy.
Chen 2006 3 participants in cell therapy group experienced a transient episode of pulmonary oedema during
the injection of stem cells. No sustained arrhythmias were monitored during the procedure.
Erbs 2005 1 cell therapy and 1 control participant reported headache, and 1 control participant developed
fever during G-CSF stimulation. G-CSF resulted in comparable increases in serum C-reactive protein
levels and blood leukocyte count in both CPC and control groups (returned to baseline values with-
in 4 days after G-CSF). Neither G-CSF injection nor intracoronary transplantation of CPC caused any
elevation in troponin T levels.
Hamshere 2015_IC n/r
Hamshere 2015_IM n/r
Heldman 2014_BMMNC No participant had significant postprocedural pericardial effusion. Small transient increases in
CK-MB and serum troponin I were observed. There were no treatment emergent serious adverse
events among any of participants who received cell therapy.
Heldman 2014_BM-MSC No participant had significant postprocedural pericardial effusion. Small transient increases in
CK-MB and serum troponin I were observed. There were no treatment emergent serious adverse
events among any of participants who received cell therapy.
Hendrikx 2006 1 cell therapy participant died on postoperative day 7 from a perforated oesophageal ulcer com-
plicated by mediastinitis. 1 control participant died on the 5th postoperative day from multiorgan
failure secondary to low cardiac output syndrome.
Honold 2012 Mild cephalgies and episodes of mild to moderate bone and muscular pain were reported during 5-
day course of G-CSF. No participant developed chest pain episodes or clinical signs of decompen-
sated HF. No novel ischaemia-related ECG changes were observed during G-CSF treatment and af-
ter intracoronary CPC infusion. Troponin T levels remained unchanged. Moreover, no specific G-
CSF-mediated severe complications occurred. Intracoronary infusions were successfully performed
without any procedural complications.
Hu 2011 2 participants (unclear which treatment arm) had neurological complications but recovered and
were discharged. No participants had arrhythmia.
Jimenez-Quevedo 2011 G-CSF treatment was well tolerated, all participants presented bone pain as the only symptom. Af-
ter cell injection, none of the participants had a significant rise in creatine phosphokinase, symp-
toms, ECG changes, or echocardiographic abnormalities.
Losordo 2007 13 participants reported transient increase in angina frequency after administration of G-CSF.
There were no cardiac enzyme elevations, MIs, acute coronary syndromes, or deaths. 1 partici-
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pant in the placebo group developed ventricular tachycardia during the mapping procedure. No ar-
rhythmias were detected by implantable cardioverter defibrillator, LifeVest, or Holter monitoring in
any participant during or after the injection procedure.
Losordo 2011 Administration of G-CSF was associated with bone pain (20.1%), angina (17.4%), CHF (2 partici-
pants), and 8 participants had troponin elevations consistent with non-STEMI. In 1 participant a
thrombus was observed on the mapping catheter tip as it was removed. 2 participants experienced
an apparent myocardial perforation during the injection procedure (1 resulted in haemothorax,
which was successfully treated; 1 resulted in cardiac tamponade; this participant died after unsuc-
cessful pericardiocentesis procedure). Elevated troponin levels were observed in 28% of partici-
pants at some point during the mobilisation and injection period, all of which were minor and sub-
clinical except for those mentioned above.
Mathiasen 2015 1 participant with a history of episodic ventricular tachycardia developed ventricular tachycardia
during the NOGA mapping procedure. Another participant experienced double vision and dizzi-
ness during the injection procedure; cerebral-CT afterwards was normal, but the incident was di-
agnosed as a minor stroke by the neurologist. 1 participant from the treatment group suffered a
stroke 12 days after treatment.
Mozid 2014_IC The most common side effects from G‑CSF were bone pain (22%) and low grade pyrexia (65%) (re-
ported in all G-CSF groups combined). Bleeding from the arterial access site did not differ signifi-
cantly between the 2 intervention arms. All episodes were minor and resolved with conservative
treatment within 24 h of the procedure. As expected, there were increases in troponin and creatine
kinase levels postprocedure in both arms.
Mozid 2014_IM The most common side effects from G‑CSF were bone pain (22%) and low grade pyrexia (65%) (re-
ported in all G-CSF groups combined). There were 3 cases of arrhythmia during the intramyocardial
procedure that required treatment. Of these, 1 participant developed atrial fibrillation, which re-
verted to sinus rhythm within 24 h of the procedure. Another participant developed transient com-
plete heart block periprocedure requiring temporary pacing only. The final participant suffered an
episode of pulseless ventricular tachycardia following intramyocardial injection, which was suc-
cessfully cardioverted with a single 200 J external defibrillation and remained haemodynamically
stable afterwards. 1 participant died from suspected acute LV failure 6 days after discharge. Bleed-
ing from the arterial access site did not differ significantly between the two intervention arms. All
episodes were minor and resolved with conservative treatment within 24 h of the procedure. As ex-
pected, there were increases in troponin and creatine kinase levels postprocedure in both arms.
Nasseri 2012 2 participants in the placebo group died early postoperatively: 1 died on day 8 after developing
Candida sepsis following LV failure despite intra-aortic balloon pump and catecholamine treat-
ment and mechanical assist device implantation, and 1 died on day 22 (reason not given).
Patel 2005 1 participant in the OPCAB plus stem cell therapy group had a haematoma at the bone marrow har-
vest site. There were no other adverse events in either group (i.e. neurologic, haematologic, vascu-
lar, death, or infection events). No participants had any postoperative arrhythmias.
Patel 2015 5 participants who received BMAC experienced “non-serious adverse events possibly related to the
procedure”. Procedure-related complications included haematomas at the catheterisation site and
elevated serum creatinine levels.
Patila 2014 There were no differences between treatment groups in participants’ haemodynamics, arterial
blood gases, systemic vein oxygen level, blood glucose, acid–base balance, lactate, haemoglobin,
body temperature, and diuresis, as well as medications needed. Perioperative measures are re-
ported in detail in Lehtinen 2014.
Perin 2011 No perforations or arrhythmias were associated with cell injection procedures. Postprocedural
transient leM bundle-branch block (resolved in 24 h) was seen in 1 treated and 1 control partici-
pant. 1 treated participant had non-significant pericardial effusion. No sustained ventricular ar-
rhythmias were observed by Holter monitoring in any participant. Transient fever but no sepsis oc-
curred in 1 control participant.
Table 5.   Periprocedural adverse events  (Continued)
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Perin 2012a 1 participant experienced a limited retrograde catheter-related dissection of the abdominal aorta
(withdrawn from study). 1 participant experienced recurrent ventricular tachycardia with hypoten-
sion (and received only a small volume of cell product).
Perin 2012b No major adverse clinical cardiac events were associated with the cell injection procedures, includ-
ing no perforations. Electromechanical mapping–related ventricular tachycardia occurred in 2 con-
trol participants, and ventricular fibrillation occurred in 1 control participant. No deaths occurred,
and HF was not exacerbated in any participant. Holter monitoring showed no sustained ventricular
arrhythmia in any participant.
Pokushalov 2010 No periprocedural complications occurred in participants who received cell therapy. 2-dimensional
echocardiography did not reveal postprocedural pericardial effusion. Creatine kinase activity and
peak troponin T level remained unaltered. No new periprocedural arrhythmias were recorded dur-
ing 24 h of consecutive electrocardiographic monitoring. An implantable cardioverter defibrillator
was implanted to 2 participants with ventricular tachycardia prior to cell injections.
Santoso 2014 There were no acute procedural-related complications, including stroke, transient ischaemic at-
tack, ECG changes, sustained ventricular or atrial arrhythmias, and elevation of CPK-MB. There was
also no echocardiographic evidence of pericardial effusion in any participant within the first 24 h of
the procedure.
Trifunovic 2015 The early postoperative course was uneventful in both groups with no significant differences be-
tween them with regard to adverse side effects during hospital stay. There were no significant dif-
ferences in cardiac-specific enzymes activities after the operation or the number of atrial fibrilla-
tion episodes or appearance of pericardial effusion between the groups.
Tse 2007 There were no acute procedure-related complications, including stroke, transient ischaemic at-
tack, ECG changes, sustained ventricular or atrial arrhythmias, elevation of CPK-MB, or echocardio-
graphic evidence of pericardial effusion within the first 24 h after the procedure.
Turan 2011 There was no inflammatory response or myocardial reaction (white blood cell count, C-reactive
protein, CK, troponin) after cell therapy. There were no immediate pre- or postprocedure adverse
complications, new electrocardiographic changes, or significant elevations in CK or troponin, and
no inflammatory response was observed in participants with bone marrow cell transplant.
Van Ramshorst 2009 In the placebo group, a greater than 0.5-centimetre pericardial effusion was detected on 2-dimen-
sional echocardiography in an asymptomatic participant 2 days after the injection procedure, and
pericardiocentesis was subsequently performed.
Wang 2009 No periprocedural adverse events; cardiac proteins in normal range.
Wang 2010 No increase in angina frequency or usage of sublingual NTG was observed in participants of either
group. There were no cardiac enzyme elevations, MIs, acute coronary syndromes, or deaths. No
participants from either group developed ventricular tachycardia during the cell or saline infusion
procedure. No arrhythmias were detected by Holter monitoring in any participant during or after
the infusion process.
Wang 2014 n/r
Wang 2015 Predischarge arrhythmias were reported (as number of events) in both cell therapy and control
participants.
Yao 2008 Intracoronary application of BMC was performed without any acute or long-term side effects. There
was no inflammatory response or myocardial reaction (i.e. white blood cell count, C-reactive pro-
tein, and creatinine phosphokinase) after cell therapy.
Zhao 2008 In the perioperative period, sporadic ventricular premature beats and self terminating bouts of
rapid atrial fibrillation were observed in both groups. However, 2 participants developed VF, and 1
Table 5.   Periprocedural adverse events  (Continued)
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died in the BMMNC group: 1 participant developed VF on the 5th day postoperatively but was suc-
cessfully resuscitated and VF well-controlled, and the other developed refractory VF 5 hours' post-
operatively with death on postoperative day 3. There were no ventricular arrhythmias in the con-
trol group.
Table 5.   Periprocedural adverse events  (Continued)
AMI: acute myocardial infarction
BM: bone marrow
BMAC: bone marrow aspirate concentrate
BMC: bone marrow cells
BMMNC: bone marrow mononuclear cells
CHF: congestive heart failure
CK-MB: creatine kinase-MB
CPC: circulating progenitor cells
CPK-MB: creatine phosphokinase-MB
CT: computed tomography
ECG: electrocardiogram
G-CSF: granulocyte colony-stimulating factor
HF: heart failure
LV: leM ventricular
MI: myocardial infarction
MSC: mesenchymal stem cells
non-STEMI: non-ST elevation myocardial infarction
n/r: not reported
NTG: nitroglycerine
OPCAB: oJ-pump coronary artery bypass
PCI: percutaneous coronary intervention
ULN: upper limit of normal
VF: ventricular fibrillation
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No.
analysed
partici-
pants
Mean follow-up No.
analysed
partic-
ipants
Mean fol-
low-up
Study ID
Cells No
cells
Performance assessment
ST LT CellsNo
cells
Quality of life
assessment
ST LT
21 21 NYHA class (SR)a 6 mths n/r - - - - -Ang 2008
21 21 CCS class (SR)b 6 mths n/r - - - - -
Assmus 2006 43 18 NYHA class (EP) 3 mths n/r - - - - -
Assmus 2013 43 39 NYHA class (EP/MC) 4 mths n/r - - - - -
21 15 NYHA class (SR)c 6 mths n/r 21 15 MLHFQ (SR)c 6
mths
n/rBartunek 2012
21 15 6MWT (distance) (EP) 6 mths n/r - - - - -
22d 23d NYHA class (EP) 6 mths 12 mths - - - - -Chen 2006
22d 23d ETT (METs) (EP) 6 mths 12 mths - - - - -
Erbs 2005 12 10 Bike test (max O2 update) (EP) 3 mths 15 mths - - - - -
15 15 NYHA class (EP) 6 mths 12 mths - - - - -Hamshere
2015_IC
15 15 CCS class (EP) 6 mths 12 mths - - - - -
15 15 NYHA class (EP) 6 mths 12 mths - - - - -Hamshere
2015_IM
15 15 CCS class (EP) 6 mths 12 mths - - - - -
17 16 NYHA class (SR)e n/r 12 mths 15 19 MLHFQ (MC) 6
mths
12
mths
Heldman
2014_BMMNC
15f 19f 6MWT (distance) (MC) 6 mths 12 mths - - - - -
Heldman
2014_BM-MSC
17 16 NYHA class (SR)e n/r 12 mths 19g 19g MLHFQ (MC) 6
mths
12
mths
Table 6.   Quality of life and performance measures  (Continued)
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18h 19h 6MWT (distance) (MC) 6 mths 12 mths - - - - -
21j 10j NYHA class (EP) 3 mths 60 mths - - - - -Honold 2012
12k 5k Bike test (sec) (EP) 3 mths 12 mths - - - - -
Hu 2011 30 27 6MWT (distance) (EP/MC) 6 mths n/r - - - - -
19 9 CCS class (median)m 6 mths n/r n/
r
n/
r
SAQ (median)m 6
mths
n/rJimenez-Queve-
do 2011
15 7 ETT (time; METs) (median)m 6 mths n/r 19 9 Angina frequen-
cy (median)n
6
mths
n/r
18 6 CCS class (MC) 6 mths n/r 18 6 SAQ (SR)p 6
mths
n/rLosordo 2007
18 6 ETT (time) (MC) 6 mths n/r 17 6 Angina frequen-
cy (EP/MC)
6
mths
n/r
109q 53q CCS class (SR)r 6 mths 12 mths 109q 53q SAQ (MC) 6
mths
12
mths
Losordo 2011
109q 53q ETT (time) (MC) 6 mths 12 mths 109 53 Angina frequen-
cy (EP)
6
mths
n/r
40 40 NYHA class (SR)s 6 mths n/r 40 40 KCCQ-QOL
(SR)s
6
mths
n/r
40 40 CCS class (SR)s 6 mths n/r 40 40 SAQ (SR)s 6
mths
n/r
Mathiasen 2015
40 40 6MWT (SR)s 6 mths n/r 40 40 Angina frequen-
cy (SR)s
6
mths
n/r
14 2 NYHA class (EP) 6 mths n/r - - - - -Mozid 2014_IC
14 2 CCS class (SR) 6 mths n/r - - - - -
10 8 NYHA class (EP) 6 mths n/r - - - - -Mozid 2014_IM
10 8 CCS class (SR) 6 mths n/r - - - - -
Table 6.   Quality of life and performance measures  (Continued)
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28 26 NYHA class (EP/MC)t 6 mths n/r 28 26 MLHFQu 6
mths
n/r
28 26 6MWTu 6 mths n/r - - - - -
Nasseri 2012
28 26 CCS class (EP/MC)t 6 mths n/r - - - - -
Patel 2005 10 10 NYHA class (EP/MC)t 6 mths n/r - - - - -
17 4 NYHA class (EP)t n/r 12 mths 17 4 MLHFQ (SR) n/r 12
mths
Patel 2015
17 4 CCS class (SR) n/r 12 mths - - - - -
Patila 2014 20 19 NYHA class (EP/MC) n/r 12 mthsv 20 19 SF-36w n/r 60
mths
20 10 NYHA class (EP) 6 mths n/r 17 9 MLHFQ (EP) 6
mths
n/rPerin 2011
20 10 CCS class (EP/MC) 6 mths n/r 13 10 SF-36 (physi-
cal/mental) (EP)
6
mths
n/r
55 30 NYHA class (MC) 6 mths n/r - - - - -
44 22 CCS class (MC) 6 mths n/r - - - - -
Perin 2012a
51 29 6MWT (distance) (EP) 6 mths n/r - - - - -
10 10 NYHA class (EP) 6 mths n/r - - - - -Perin 2012b
10 10 CCS class (EP) 6 mths n/r - - - - -
53x 46x NYHA class (EP) 6 mths 12 mths 53x 46x MLHFQ (EP) 6
mths
12
mths
53x 46x CCS class (EP) 6 mths 12 mths 53x 46x Angina frequen-
cy (EP)
6
mths
12
mths
Pokushalov 2010
53x 46x 6MWT (distance) (EP) 6 mths 12 mths - - - - -
Santoso 2014 19 9 NYHA class (EP)y 6 mths n/r - - - - -
Table 6.   Quality of life and performance measures  (Continued)
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19 9 6MWT (distance) (EP)y 6 mths n/r - - - - -
15 15 NYHA class (EP) 6 mths 12 mths - - - - -Trifunovic 2015
15 15 6MWT (distance) (EP) 6 mths 12 mths - - - - -
19 9 NYHA class (EP)t 6 mths n/r - - - - -
19 9 CCS class (EP)t 6 mths n/r - - - - -
Tse 2007
19 9 Treadmill test (time; METs) (EP/MC) 6 mths n/r - - - - -
Turan 2011 33 16 NYHA class (EP) 6 mths 12 mths - - - - -
24 25 CCS class (EP) 6 mths n/r 24 25 SAQ (EP/MC) 6
mths
n/rVan Ramshorst
2009
24 25 Bike test (workload) (EP/MC) 6 mths n/r - - - - -
16 16 CCS class (MC) 6 mths n/r 16 16 Angina frequen-
cy (MC)
6
mths
n/rWang 2009
16 16 ETT (min) (MC) 6 mths n/r - - - - -
56 56 CCS class (EP/MC) 6 mths n/r 56 56 Angina frequen-
cy (EP/MC)
6
mths
n/rWang 2010
56 56 ETT (min) (EP/MC) 6 mths n/r - - - - -
n/r n/r NYHA class (SR) 6 mths n/r - - - - -Wang 2014
n/r n/r 5MWT (distance) (SR) 6 mths n/r - - - - -
16 18 NYHA class (EP) 6 mths n/r - - - - -Zhao 2008
16 18 CCS class (EP) 6 mths n/r - - - - -
Table 6.   Quality of life and performance measures  (Continued)
CCS: Canadian Cardiovascular Society; EP: endpoint; ETT: exercise tolerance test; KCCQ-QOL: Kansas City Cardiomyopathy Questionnaire – Quality of Life; LT: long term; MC:
mean change from baseline; MET: metabolic equivalent test (mL/kg/min); MLHFQ: Minnesota Living with Heart Failure Questionnaire; n/r: not reported; NYHA: New York Heart
Association; SAQ: Seattle Angina Questionnaire; SF-36: 36-Item Short Form Health Survey; SR: summary results; ST: short term; 5MWT: 5-minute walk test; 6MWT: 6-minute walk
test
aReported as number of participants in NYHA class III/IV.
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bReported as number of participants in CCS class II or greater.
cReported graphically as percentage of participants showing improvement or deterioration.
d20/19 at 12 months.
eReported as number who improved/did not change/deteriorated.
f17/19 at 12 months.
g16/19 at 12 months.
h16/19 at 12 months.
j20/6 at 5 years.
k10/5 at 12 months.
mReported as median absolute diJerence with 95% confidence interval.
nMedian time to onset of angina also reported.
pResults presented graphically.
q106/50 at 12 months.
rReported as percentage of participants changed.
sResults presented graphically with P values for diJerences between groups.
tCalculated from frequency data.
uUnclear whether mean or median values are reported.
vAlso reported: median values at 60 months.
wReported graphically for each of eight components of SF-36 at 60 months.
x49/33 at 12 months.
yReported as diJerence between groups at endpoint.
 
 
No. randomised partic-
ipants
No. analysed partici-
pants
Baseline LVEF: Mean (SD) Mean follow-up of LVEFStudy ID
Cells No cells Cells No cells Cells No cells ST LT
Measured by MRI
Ang 2008 42 21 18 7 IM: 25.4
(8.1)
IC: 28.5
(6.5)
20.9 (8.9) 6 mths -
Assmus 2013 43 39 15 12 n/r n/r 4 mths -
Erbs 2005 14 14 12a 11a 51.0
(12.1)
55.8 (12.4) 3 mths 15 mths
Table 7.   Surrogate (continous) outcome: LVEF  (Continued)
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Hendrikx 2006 11 12 10 10 42.9
(10.3)
39.5 (5.5) 4 mths -
Honold 2012 23 10 9 4 33.4
(SEM
12.7)
23.3 (SEM 7.2) 3 mths 12 mths
Hu 2011 31 29 31b 28b 23.5 (6.7) 24.8 (5.2) 6 mths 12 mths
Mathiasen 2015 40 20 40 20 28.2 (9.3) 25.1 (8.5) 6 mths -
Nasseri 2012 30 30 26 22 27 (6) 26 (6) 6 mths -
Patila 2014 20 19 18 7 37.1 (9.5) 38.5 (13.5) - 60 mths
Santoso 2014 19 9 19 9 23.6 (8.4) 26.8 (8.8) 6 mths -
Tse 2007 19 9 18 8 51.9 (8.5) 45.7 (8.3) 6 mths -
Van Ramshorst 2009 25 25 22 18 56 (12) 54 (10) 6 mths -
Wang 2014 35 35 35 35 29 (7) 28 (6) 6 mths -
Measured by echocardiography
Bartunek 2012 32 15 21 15 27.5
(95%
CI 25.5,
29.5)
27.8 (95% CI 25.9, 29.8) 6 mths -
Hu 2011 31 29 24 18 36.0 (1.2) 34.7 (1.4) - 12 mths
Perin 2011 20 10 20 10 37.0
(10.6)
39.0 (9.1) 6 mths -
Perin 2012a 61 31 54 28 34.7 (8.8) 32.3 (8.6) 6 mths -
Perin 2012b 10 10 10 10 36.1
(10.9)
32.1 (10.6) 6 mths -
Pokushalov 2010 55 54 53c 46c 27.8 (3.4) 26.8 (3.8) 6 mths 12 mths
Table 7.   Surrogate (continous) outcome: LVEF  (Continued)
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Trifunovic 2015 15 15 15 15 35.3 (3.9) 36.5 (5.3) 6 mths 12 mths
Van Ramshorst 2009 25 25 24 25 50 (5) 52 (5) 6 mths -
Wang 2015 45 45 45 45 39.3 (6.2) 38.2 (8.0) 6 mths -
Zhao 2008 18 18 16 18 35.8 (7.3) 36.7 (9.2) 6 mths -
Measured by SPECT
Chen 2006 24 24 22d 23d 26 (6) 23 (8) 6 mths 12 mths
Perin 2011 20 10 20 10 41.5
(11.2)
43.0 (10.4) 6 mths -
Van Ramshorst 2009 25 25 24 25 53 (12) 54 (12) 6 mths 12 mths
Measured by LV angiography
Assmus 2006 52 23 43 18 BMMNC:
41 (11)
CPC: 39
(10)
43 (13) 3 mths -
Assmus 2013 43 39 41 38 LDSW:
37.2
(95%
CI 31.7,
42.7)
HDSW:
32.4
(95%
CI 26.9,
37.9)
LDSW: 29.9 (95% CI 24.0, 35.7)
HDSW: 32.3 (95% CI 26.5, 38.1)
4 mths -
Honold 2012 23 10 21 5 37.5
(SEM
12.9)
37.6 (SEM 7.5) 3 mths -
Perin 2011 20 10 20 10 37.5 (8.2) 40.0 (3.2) 6 mths -
Table 7.   Surrogate (continous) outcome: LVEF  (Continued)
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Perin 2012b 10 10 10 10 38.0
(17.5)
41.9 (11.8) 6 mths -
Turan 2011 38 18 33 16 46 (10) 46 (10) 3 mths 12 mths
Table 7.   Surrogate (continous) outcome: LVEF  (Continued)
95% CI: 95% confidence interval; BMMNC: bone marrow mononuclear cells; CPC: circulating progenitor cells; HDSW: high-dose shockwave; IC: intracoronary; IM: intramyocardial;
LDSW: low-dose shockwave; LT: long term; LV: leM ventricular; LVEF: leM ventricular ejection fraction; SD: standard deviation; SEM: standard error of the mean; SPECT: single-
photon emission computed tomography; ST: short term
a12/10 at 15 months.
b25/25 at 12 months.
c20/19 at 12 months.
d49/33 at 12 months.
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A P P E N D I C E S
Appendix 1. Search strategies (March 2013)
THE COCHRANE LIBRARY
#1 STEM CELL TRANSPLANTATION explode all trees (MeSH)
#2 HEMATOPOIETIC STEM CELL MOBILIZATION single term (MeSH)
#3 STEM CELLS explode all trees (MeSH)
#4 CELL TRANSPLANTATION single term (MeSH)
#5 haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or marrow NEAR cell* or stem
cell* or progenitor cell* or precursor cell* or cell* therapy
#6 ((myoblast* or cell*) NEAR (transplant* or graM* or implant*))
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MYOCARDIAL ISCHEMIA explode all trees (MeSH)
#9 HEART FAILURE explode all trees (MeSH)
#10 HEART DISEASES single term (MeSH)
#11 (myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) NEAR (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insuJicien*)
#12 heart disease* or coronary disease* or IHD or CIHD
#13 chronic myocardial dysfunction or angina or stenocardia
#14 (ischemi* or ischaemi*) NEAR (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or
cardiomyopath*)
#15 (artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) NEAR coronary
#16 (heart or cardiac or cardial or myocardium or myocardial) NEAR (repair* or reparation or improve* or regenerat*)
#17 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #7 AND #17
#19 (cellular NEXT cardiomyoplast*) or (cardiomyocyte* NEAR transplant*) or (intramyocardial* NEAR (transplant* or stem or bone
marrow)) or (transendocardial* NEAR stem NEXT cell*) or (intracoronary NEAR progenitor NEXT cell*) or (transcoronary NEAR transplant*)
#20 #18 or #19
MEDLINE (Ovid)
1. CELL TRANSPLANTATION/
2. exp STEM CELL TRANSPLANTATION/
3. BONE MARROW TRANSPLANTATION//
4. exp STEM CELLS/
5. (haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or (marrow adj2 cell*) or stem
cell* or progenitor cell* or precursor cell* or cell* therapy or bone marrow).ti,ab.
6. ((mesenchymal or stromal) AND marrow).ti,ab.
7. (cell*) adj3 (transplant* or graM* or implant*)).ti,ab
8. cell transplantation.jn. or cell stem cell.jn. or stem cell reviews.jn. or bone marrow transplantation.jn.
9. or/1-8
10. exp MYOCARDIAL ISCHEMIA/
11. exp HEART FAILURE/
12. HEART DISEASES/
13. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insuJicien*)).ti,ab.
14. (heart disease* or coronary disease* or IHD or CIHD).ti,ab.
15. (myocardial dysfunction or angina or stenocardia).ti,ab.
16. ((ischemi* or ischaemi*) adj2 (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or
cardiomyopath*)).ti,ab.
17. ((end stage or endstage) adj cardiomyopath*).ti,ab.
18. ((artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) adj2 coronary).ti,ab.
19. ((heart or cardiac or cardial or myocardium or myocardial) adj3 (repair* or reparation or improve* or regenerat*)).ti,ab.
20. or/10-19
21. 9 and 20
22. ((cellular adj cardiomyoplast*) or (cardiomyocyte* adj5 transplant*) or (intramyocardial* adj6 (transplant* or stem or bone marrow))
or (transendocardial* adj5 stem adj cell*) or (intracoronary adj5 progenitor adj cell*) or (transcoronary adj3 transplant*)).mp.
23. 21 or 22
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EMBASE (Ovid)
1. exp CELL THERAPY/
2. exp STEM CELL/
3. BONE MARROW CELL/
4. ((mesenchymal or stromal) AND marrow).ti,ab.
5. (haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or marrow adj2 cell* or stem
cell* or progenitor cell* or precursor cell* or cell* therapy or bone marrow).ti,ab.
6. (cell* adj3 (transplant* or graM* or implant*)).ti,ab.
7. cell transplantation.jn. or cell stem cell.jn. or stem cell reviews.jn.
8. or/1-7
9. exp ISCHEMIC HEART DISEASE/
10. exp HEART FAILURE/
11. exp MYOCARDIAL DISEASE/
12. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insuJicien*).ti,ab.
13. (heart disease* or coronary disease* or IHD or CIHD).ti,ab.
14. (chronic myocardial dysfunction or angina or stenocardia).ti,ab.
15. ((ischemi* or ischaemi*) adj2 (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or
cardiomyopath*)).ti,ab.
16. ((artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) adj2 coronary).ti,ab.
17. ((end stage or endstage) adj cardiomyopath*).ti,ab.
18. ((heart or cardiac or cardial or myocardium or myocardial) adj3 (repair* or reparation or improve* or regenerat*)).ti,ab.
19. or/9-18
20. 8 AND 19
21. ((cellular adj cardiomyoplast*) or (cardiomyocyte* adj5 transplant*) or (intramyocardial adj6 (transplant* or stem or bone marrow)) or
(transendocardial adj5 stem adj cell*) or (intracoronary adj5 progenitor adj cell*) or (transcoronary adj3 transplant*)).mp.
22. 20 or 21
CINAHL (EBSCOhost)
S1 (MH "Cell Transplantation+")
S2 (MH "Stem Cells+")
S3 TI ( (haematopoietic OR hematopoietic OR haematopoetic OR hematopoetic OR hemopoietic OR haemopoietic OR (marrow N2 cell*) OR
"stem cell*" OR "progenitor cell*" OR "precursor cell*" OR "cell* therapy" OR "bone marrow") ) OR AB ( (haematopoietic OR hematopoietic
OR haematopoetic OR hematopoetic OR hemopoietic OR haemopoietic OR (marrow N2 cell*) OR "stem cell*" OR "progenitor cell*" OR
"precursor cell*" OR "cell* therapy" OR "bone marrow") )
S4 TX ((mesenchymal or stromal) AND marrow)
S5 TI ( ((cell* N3 transplant*) OR (cell* N3 graM*) OR (cell* N3 implant*)) ) OR AB ( ((cell* N3 transplant*) OR (cell* N3 graM*) OR (cell* N3
implant*)) )
S6 S1 OR S2 OR S3 OR S4 OR S5
S7 (MH "Heart Diseases") OR (MH "Heart Failure+") OR (MH "Heart Valve Diseases+") OR (MH "Myocardial Diseases+") OR (MH "Myocardial
Ischemia+")
S8 TI ( (myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) N6 (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insuJicien*) ) OR AB ( (myocardial or myocardium or subendocardial or transmural
or cardiac or cardial or coronary or heart) N6 (infarct* or postinfarct* or hypoxi* or anoxi* or failure* or decompensation or insuJicien*) )
S9 TI ( ("heart disease*" or "coronary disease*" or IHD or CIHD) ) AND AB ( ("heart disease*" or "coronary disease*" or IHD or CIHD) )
S10 TI ( ("chronic myocardial dysfunction" OR angina OR stenocardia) ) OR AB ( ("chronic myocardial dysfunction" OR angina OR
stenocardia) )
S11 TI ( ((ischemi* or ischaemi*) N5 (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or
cardiomyopath*)) ) OR AB ( ((ischemi* or ischaemi*) N5 (myocardium or myocardial or heart or coronary or cardiac or cardial or
subendocardial or cardiomyopath*)) )
S12 TI ( ((chronic or artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) AND coronary) ) OR AB ( ((chronic or artery
occlusion* or artery disease* or arterioscleros* or atheroscleros*) AND coronary) )
S13 TI ( ((heart or cardiac or cardial or myocardium or myocardial) AND (repair* or reparation or improve* or regenerat*)) ) OR AB ( ((heart
or cardiac or cardial or myocardium or myocardial) AND (repair* or reparation or improve* or regenerat*)) )
S14 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15 S6 AND S14
S16 TX (transplant* N5 (cardiomyocyte* or transcoronary)) or (cellular N2 cardiomyoplast*) or (intramyocardial* N6 (transplant* or stem
or marrow)) or (transendocardial* N5 stem cell*) or (intracoronary N5 progenitor cell*)
S17 S15 OR S16
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
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TRANSFUSION EVIDENCE LIBRARY (www.transfusionevidencelibrary.com)
("marrow cell*" OR "stem cell*" OR "progenitor cell*" OR "precursor cell*") AND (infarct* OR coronar* OR myocard* OR heart OR cardiac*
OR cardiomyo* OR intramyocardial* OR ischemi* OR ischaemi* OR angina)
PubMed (epublications only)
(stem[TI] OR marrow[TI] OR progenitor[TI] OR precursor[TI] OR cell[TI] OR cells[TI]) AND (infarct*[TI] OR coronar*[TI] OR heart*[TI]
OR myocard*[TI] OR cardial[TI] OR cardiac[TI] OR transmural*[TI] OR ischemia[TI] OR ischemic[TI] OR subendocardial[TI] OR
cardiomyopath*[TI] OR angina[TI]) AND (random* OR blind* OR control group* OR controlled OR placebo OR trial) AND (publisher[sb] NOT
pubstatusnihms)
LILACS
("marrow cell$" OR "stem cell$" OR "progenitor cell$" OR "precursor cell$") AND (infarct$ OR coronar$ OR myocard$ OR heart OR cardiac
$ OR cardiomyo$ OR intramyocardial$ OR ischemi$ OR ischaemi$ OR angina) AND (random$ OR blind$ OR control$ OR placebo$ OR trial)
KoreaMed & PakMediNet
(stem or marrow or progenitor or precursor or cell or cells) AND random*
IndMed
((marrow OR stem OR progenitor OR precursor) AND (infarct$ OR coronar$ OR myocard$ OR heart OR cardiac$ OR cardiomyo$ OR
intramyocardial$ OR ischemi$ OR ischaemi$) AND (random$ OR blind$ OR control$ OR placebo$ OR trial))
ISRCTN Register (Current Controlled Trials)
("stem cells" or "stem cell" or marrow or "progenitor cells" or "precursor cells") and (infarction or infarct or coronary or myocardial or heart
or myocardium or cardial or transmural or ischemia or ischemic or subendocardial or cardiomyopathy OR angina)
ClinicalTrials.gov
Study Type: Intervention Studies
Conditions: heart failure
Search Terms: marrow OR stem OR progenitor OR precursor OR myoblast OR myocell OR mesenchymal OR stromal
WHO ICTRP
Title: marrow OR stem OR progenitor OR precursor OR myoblast OR myocell OR mesenchymal OR stromal
Condition: heart OR cardiac OR myocardial
Recruitment Status: ALL
Appendix 2. Search strategies (June 2014; March/December 2015)
CENTRAL, the Cochrane Library
#1 MeSH descriptor: [Stem Cell Transplantation] explode all trees
#2 MeSH descriptor: [Bone Marrow Cells] explode all trees
#3 MeSH descriptor: [Stem Cells] explode all trees
#4 MeSH descriptor: [Cell Transplantation] this term only
#5 MeSH descriptor: [Bone Marrow Transplantation] this term only
#6 MeSH descriptor: [Stromal Cells] explode all trees
#7 ((stem or haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or progenitor or
precursor or bone marrow or mononuclear or "adipose tissue" or mesenchymal or stromal or autologous or allogeneic or allogenic or
ALDH* or C-KIT*) next/2 cell*)
#8 "cell transplantation":so or "stem cell":so or "bone marrow transplantation":so
#9 (autologous next/3 transplant*) or "cell* therap*"
#10 ((cell* or myoblast*) near/3 (autologous or transplant* or autotransplant* or allotransplant* or graM* or implant*))
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Heart Diseases] explode all trees
#13 ((ischemi* or ischaemi* or nonischemi* or nonischaemi*) near/2 (myocardium or myocardial or cardiomyopath* or heart or coronary
or cardiac or cardial or subendocardial))
#14 ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) near/2 (failure* or
decompensation or insuJicien*))
#15 (IHD or CIHD or DCM or IDCM)
#16 ((myocardial near/3 dysfunction*) or stenocardia or angina*)
#17 ((end stage or endstage or dilated or idiopathic or congestive) near/2 cardiomyopath*)
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#18 (arter* occlusion* or arter* disease* or arterioscleros* or atheroscleros*) near/2 coronary
#19 ((heart or cardiac or cardial or myocardium or myocardial) near/3 (repair* or reparation or improv* or regenerat*))
#20 (heart disease* or coronary disease* or cardiovascular disease*)
#21 ((end stage or endstage or dilated or idiopathic or congestive) near/2 cardiomyopath*)
#22 ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart or acute) near/3 (infarct* or
postinfarct* or hypoxi* or anoxi*))
#23 heart attack* or coronary attack* or acute coronary syndrome* or AMI
#24 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #11 and #24
#26 cellular cardiomyoplast* or ((cardiomyocyte* or cardiac cell*) near/6 transplant*) or ((intramyocardial* or intracoronary or
transendocardial* or transcoronary) near/6 (transplant* or stem or bone marrow or marrow cell* or BMC* or stromal or mesenchymal or
progenitor cell* or precursor cell*))
#27 #25 or #26 [Publication Year from 2014 to 2015]
MEDLINE (OvidSP)
1. exp STEM CELL TRANSPLANTATION/
2. BONE MARROW TRANSPLANTATION/
3. CELL TRANSPLANTATION/
4. exp STEM CELLS/
5. BONE MARROW CELLS/
6. exp STROMAL CELLS/
7. ((stem or haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or progenitor or
precursor or bone marrow or mononuclear or adipose tissue or mesenchymal or stromal or autologous or allogeneic or allogenic or ALDH*
or C-KIT*) adj2 cell*).ti,ab.
8. (cell transplantation or stem cell* or bone marrow transplantation).jn.
9. ((autologous adj3 transplant*) or cell* therap*).tw.
10. ((cell* or myoblast*) adj3 (autologous or transplant* or autotransplant* or allotransplant* or graM* or implant*)).ti,ab.
11. or/1-10
12. exp HEART DISEASES/
13. ((ischemi* or ischaemi* or nonischemi* or nonischaemi*) adj2 (myocardium or myocardial or cardiomyopath* or heart or coronary or
cardiac or cardial or subendocardial)).ti,ab.
14. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (failure* or
decompensation or insuJicien*)).ti,ab.
15. (IHD or CIHD or DCM or IDCM).ti,ab.
16. ((myocardial adj3 dysfunction*) or stenocardia or angina*).ti,ab.
17. ((arter* occlusion* or arter* disease* or arterioscleros* or atheroscleros*) adj2 coronary).ti,ab.
18. (heart disease* or coronary disease* or cardiovascular disease*).ti,ab.
19. ((end stage or endstage or dilated or idiopathic or congestive) adj2 cardiomyopath*).ti,ab.
20. ((heart or cardiac or cardial or myocardium or myocardial) adj3 (repair* or reparation or improv* or regenerat*)).ti,ab.
21. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart or acute) adj3 (infarct* or
postinfarct* or hypoxi* or anoxi*)).ti,ab.
22. (heart attack* or coronary attack* or acute coronary syndrome* or AMI).ti,ab.
23. or/12-22
24. 11 and 23
25. (cellular cardiomyoplast* or ((cardiomyocyte* or cardiac cell*) adj6 transplant*) or ((intramyocardial* or intracoronary or
transendocardial* or transcoronary) adj6 (transplant* or stem or bone marrow or marrow cell* or BMC* or stromal or mesenchymal or
progenitor cell* or precursor cell*))).mp.
26. 24 or 25
Embase (OvidSP)
1. exp STEM CELL TRANSPLANTATION/
2. exp BONE MARROW TRANSPLANTATION/
3. exp STEM CELL/
4. BONE MARROW CELL/
5. exp STROMA CELLS/
6. ((stem or haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or progenitor or
precursor or bone marrow or mononuclear or adipose tissue or mesenchymal or stromal or autologous or allogeneic or allogenic or ALDH*
or C-KIT*) adj2 cell*).ti,ab.
7. (cell transplantation or stem cell* or bone marrow transplantation).jn.
8. ((autologous adj3 transplant*) or cell* therap*).tw.
9. ((cell* or myoblast*) adj3 (autologous or transplant* or autotransplant* or allotransplant* or graM* or implant*)).ti,ab.
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10. or/1-9
11. exp ISCHEMIC HEART DISEASE/
12. exp HEART FAILURE/
13. exp MYOCARDIAL DISEASE/
14. ((ischemi* or ischaemi* or nonischemi* or nonischaemi*) adj2 (myocardium or myocardial or cardiomyopath* or heart or coronary or
cardiac or cardial or subendocardial)).ti,ab.
15. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (failure* or
decompensation or insuJicien*)).ti,ab.
16. (IHD or CIHD or DCM or IDCM).ti,ab.
17. ((myocardial adj3 dysfunction*) or stenocardia or angina*).ti,ab.
18. ((arter* occlusion* or arter* disease* or arterioscleros* or atheroscleros*) adj2 coronary).ti,ab.
19. (heart disease* or coronary disease* or cardiovascular disease*).ti,ab.
20. ((end stage or endstage or dilated or idiopathic or congestive) adj2 cardiomyopath*).ti,ab.
21. ((heart or cardiac or cardial or myocardium or myocardial) adj3 (repair* or reparation or improv* or regenerat*)).ti,ab.
22. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart or acute) adj3 (infarct* or
postinfarct* or hypoxi* or anoxi*)).ti,ab.
23. (heart attack* or coronary attack* or acute coronary syndrome* or AMI).ti,ab.
24. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 10 and 24
26. (cellular cardiomyoplast* or ((cardiomyocyte* or cardiac cell*) adj6 transplant*) or ((intramyocardial* or intracoronary or
transendocardial* or transcoronary) adj6 (transplant* or stem or bone marrow or marrow cell* or BMC* or stromal or mesenchymal or
progenitor cell* or precursor cell*))).mp.
27. 25 or 26
PubMed (epublications)
#1 (stem[TI] OR haematopoietic[TI] OR hematopoietic[TI] OR haematopoetic[TI] OR hematopoetic[TI] OR hemopoietic[TI] OR
haemopoietic[TI] OR progenitor[TI] OR precursor[TI] OR bone marrow[TI] OR mononuclear[TI] OR "adipose tissue"[TI] OR
mesenchymal[TI] OR stromal[TI] OR autologous[TI] OR allogeneic[TI] OR allogenic[TI] OR ALDH*[TI] OR C-KIT*[TI]) AND cell*[TI]
#2 cell transplantation[TA] OR stem cell*[TA] OR bone marrow transplant*[TA]
#3 "autologous transplant*"[TI] OR "cell therapy"[TI] OR "cell therapies"[TI] OR "cellular therapy"[TI]
#4 (cell[TI] OR cells[TI] OR cellular[TI] OR myoblast*[TI]) AND (transplant[TI] OR transplantation[TI] OR transplants[TI] OR transplanting[TI]
OR transplanted[TI] OR autotransplant*[TI] or allotransplant*[TI] or graM*[TI] or implant[TI] OR implants[TI] OR implantation[TI] OR
implanted[TI])
#5 #1 OR #2 OR #3 OR #4
#6 (ischemi*[TI] OR ischaemi*[TI] OR nonischemi*[TI] OR nonischaemi*) AND (myocardium[TI] OR myocardial[TI] OR cardiomyopath*[TI]
OR heart[TI] OR coronary[TI] OR cardiac[TI] OR cardial[TI] OR subendocardial[TI])
#7 (myocardial[TI] OR myocardium[TI] OR subendocardial[TI] OR transmural[TI] OR cardiac[TI] OR cardial[TI] OR coronary[TI] OR heart)
AND (failure*[TI] OR decompensation[TI] OR insuJicien*[TI])
#8 "myocardial dysfunction*"[TI] OR stenocardia[TI] OR angina*[TI] OR IHD[TI] OR CIHD[TI] OR DCM[TI] OR IDCM[TI] OR "heart disease"[TI]
OR "coronary disease"[TI] OR "coronary artery disease"[TI] OR "cardiovascular disease"[TI]
#9 ("arterial occlusion*"[TI] OR "arterial disease*"[TI] OR arterioscleros*[TI] OR atheroscleros*[TI]) AND coronary[TI]
#10 ("end stage"[TI] OR endstage[TI] OR dilated[TI] OR idiopathic[TI] OR congestive[TI]) AND cardiomyopath*[TI]
#11 (heart[TI] OR cardiac[TI] OR cardial[TI] OR myocardium[TI] OR myocardial[TI]) AND (repair*[TI] OR reparation[TI] OR improv*[TI] OR
regenerat*[TI])
#12 (myocardial[TI] OR myocardium [TI] OR subendocardial [TI] OR transmural [TI] OR cardiac [TI] OR cardial [TI] OR coronary [TI] OR heart
[TI] OR acute[TI]) AND (infarct* [TI] OR postinfarct* [TI] OR hypoxi* [TI] OR anoxi*)
#13 heart attack* [TI] OR coronary attack* [TI] OR acute coronary syndrome* [TI] OR AMI[TI]
#14 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#15 #5 AND #14
#16 (cellular cardiomyoplast* OR ((cardiomyocyte* OR cardiac cell*) AND transplant*) OR ((intramyocardial* OR intracoronary OR
transendocardial* OR transcoronary) AND (transplant* OR stem OR bone marrow OR marrow cell* OR BMC* OR stromal OR mesenchymal
OR progenitor cell* OR precursor cell*)))
#17 #15 OR #16
#18 (random* OR blind* OR control group* OR placebo OR controlled trial OR controlled study OR trials OR systematic review OR
meta-analysis OR metaanalysis OR literature search OR medline OR cochrane OR embase) AND ((publisher[sb] OR inprocess[sb]) NOT
pubstatusnihms)
#19 #17 AND #18
CINAHL (EBSCOhost)
S1 (MH "Cell Transplantation+")
S2 (MH "Stem Cells+")
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S3 TI ( (stem or haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic or progenitor or
precursor or bone marrow or mononuclear or adipose tissue or mesenchymal or stromal or autologous or allogeneic or allogenic or ALDH*
or C-KIT*) N2 cell* ) OR AB ( (stem or haematopoietic or hematopoietic or haematopoetic or hematopoetic or hemopoietic or haemopoietic
or progenitor or precursor or bone marrow or mononuclear or adipose tissue or mesenchymal or stromal or autologous or allogeneic or
allogenic or ALDH* or C-KIT*) N2 cell)
S4 TX ( (autologous N3 transplant*) or cell* therap* )
S5 TI ( (cell* or myoblast*) N3 (autologous or transplant* or autotransplant* or allotransplant* or graM* or implant*) ) OR AB ( (cell* or
myoblast*) N3 (autologous or transplant* or autotransplant* or allotransplant* or graM* or implant*) )
S6 S1 OR S2 OR S3 OR S4 OR S5
S7 (MH "Heart Diseases+")
S8 TI ( (myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart or acute) N3 (infarct* or
postinfarct* or hypoxi* or anoxi*) ) OR AB ( (myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary
or heart or acute) N3 (infarct* or postinfarct* or hypoxi* or anoxi*) )
S9 TI ( ("heart disease*" or "coronary disease*" or IHD or CIHD or DCM or IDCM) ) AND AB ( ("heart disease*" or "coronary disease*" or IHD
or CIHD or DCM or IDCM) )
S10 TI ( ((myocardial N3 dysfunction) OR angina OR stenocardia) ) OR AB ( ((myocardial N3 dysfunction) OR angina OR stenocardia) )
S11 TI ( ((ischemi* or ischaemi* or nonischemi* or nonischaemi*) N5 (myocardium or myocardial or heart or coronary or cardiac or cardial
or subendocardial or cardiomyopath*)) ) OR AB ( ((ischemi* or ischaemi* or nonischemi* or nonischaemi*) N5 (myocardium or myocardial
or heart or coronary or cardiac or cardial or subendocardial or cardiomyopath*)) )
S12 TI ( ((arter* occlusion* or arter* disease* or arterioscleros* or atheroscleros*) N2 coronary) ) OR AB ( ((arter* occlusion* or arter* disease*
or arterioscleros* or atheroscleros*) N2 coronary) )
S13 TI ( ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) N2 (failure* or
decompensation or insuJicien*)) ) OR AB ( ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary
or heart) N2 (failure* or decompensation or insuJicien*)) )
S14 TI ( (end stage or endstage or dilated or idiopathic or congestive) N2 cardiomyopath* ) OR AB ( (end stage or endstage or dilated or
idiopathic or congestive) N2 cardiomyopath* )
S15 TI ( (heart or cardiac or cardial or myocardium or myocardial) N3 (repair* or reparation or improv* or regenerat*) ) OR AB ( (heart or
cardiac or cardial or myocardium or myocardial) N3 (repair* or reparation or improv* or regenerat*) )
S16 TI (heart attack* or coronary attack* or acute coronary syndrome* or AMI) OR AB (heart attack* or coronary attack* or acute coronary
syndrome* or AMI)
S17 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
S18 S6 AND S17
S19 TI ( cellular cardiomyoplast* or ((cardiomyocyte* or cardiac cell*) N6 transplant*) or ((intramyocardial* or intracoronary or
transendocardial* or transcoronary) N6 (transplant* or stem or bone marrow or marrow cell* or BMC* or stromal or mesenchymal
or progenitor cell* or precursor cell*)) ) OR AB ( cellular cardiomyoplast* or ((cardiomyocyte* or cardiac cell*) N6 transplant*) or
((intramyocardial* or intracoronary or transendocardial* or transcoronary) N6 (transplant* or stem or bone marrow or marrow cell* or
BMC* or stromal or mesenchymal or progenitor cell* or precursor cell*))
S20 S18 OR S19 {Limiters - Published Date: 20140101-20151214}
LILACS
(tw:((infarct OR infarction OR coronary OR myocardial OR heart OR cardiac OR cardiomyopathy OR myocardial OR subendocardial OR
intramyocardial OR intracoronary OR ischemia OR ischemic OR nonischemic))) AND (tw:((bone marrow OR marrow cell OR marrow cells OR
stem cell OR stem cells OR progenitor cells OR precursor cells OR cell therapy OR cellular therapy OR cell-based therapy OR mononuclear
cells OR mesenchymal cells OR stromal cells))) AND (instance:"regional") AND ( db:("LILACS") AND type_of_study:("clinical_trials"))
IndMED
(bone marrow OR marrow cell OR marrow cells OR stem cell OR stem cells OR progenitor cell OR precursor cell OR cell therapy OR cellular
therapy OR mesenchymal cells OR stromal cells) AND (infarct OR infarction OR coronary OR intracoronary OR myocardial OR heart OR
cardiac OR congestive OR cardiomyopathy OR intramyocardial OR intracoronary OR ischemia OR ischemic OR ischaemia OR ischaemic OR
nonischemic OR nonischaemic) AND (randomised OR randomly OR randomized OR blind OR blinded OR trial OR study OR control group)
KoreaMed [N.B. Search lines run separately: presented this way for brevity]
(stem [ALL] OR marrow [ALL] OR mesenchymal[ALL] OR stromal[ALL]) AND (myocardial [ALL] OR heart[ALL] OR cardiac[ALL] OR
coronary[ALL] OR cardiomyopathy[ALL]) AND "Randomized Controlled Trial" [PT]
PakMediNet
Combinations of the following free text terms were used:
stem cell, stem cells, bone marrow, marrow cells, progenitor cells, precursor cells, mesenchymal cells, stromal cells
AND
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myocardial infarction, heart attack, cardiac ischemia, coronary ischemia, myocardial ischemia, cardiomyopathy, heart failure, cardiac
failure, angina, coronary artery disease
Web of Science CPCI-S
TI=("cardiac failure" OR "heart attack" OR "heart failure" OR "coronary disease" OR "cardiovascular disease" OR "coronary artery" OR
"coronary arterial" OR "myocardial infarction" OR cardiomyopathy OR "heart disease" OR "heart diseases" OR "cardiac insuJiciency" OR
AMI OR IHD OR CIHD OR DCM OR IDCM OR "myocardial dysfunction" OR stenocardia OR angina) AND TI=("stem cell" OR "stem cells" OR
"bone marrow" OR "marrow cells" OR "cellular therapy" OR "mesenchymal cells" OR "stromal cells" OR "cell transplant" OR "precursor
cells" OR "progenitor cells" OR (c-kit* NEAR/5 cells) OR HSCT OR SCT OR MSC OR MSCs OR BMT OR BMC OR BMAC OR BMCs OR HST OR
HSTs) AND TS=(randomised OR randomly OR randomized OR blind OR blinded OR trial OR study OR "control group" OR groups)
ClinicalTrials.gov
Search Terms: randomized OR randomised OR random OR randomly
Study Type: Intervention Studies
Condition: cardiac OR heart attack OR heart failure OR coronary OR myocardial OR cardiomyopathy OR heart disease OR angina
Intervention: stem cells OR bone marrow cells OR cellular therapy OR mesenchymal cells OR stromal cells OR cell transplant OR marrow
transplant OR precursor cells OR progenitor cells OR HSCT OR SCT OR MSC OR MSCs OR BMT OR BMC OR BMAC OR BMCs OR HST OR HSTs
ISRCTN Register
(("marrow cell" OR "marrow cells" OR "stem cell" OR "stem cells" OR "progenitor cells" OR "precursor cells" OR "mesenchymal cells" OR
"stromal cells") AND ("myocardial infarction" OR "heart attack" OR cardiomyopathy OR intramyocardial OR intracoronary))
OR
(("marrow cell" OR "marrow cells" OR "stem cell" OR "stem cells" OR "progenitor cells" OR "precursor cells" OR "mesenchymal cells" OR
"stromal cells") AND ("cardiac ischemia" OR "coronary ischemia" OR "myocardial ischemia" OR "heart failure" OR "cardiac failure" OR
congestive OR "coronary artery disease"))
OR
(("cell therapy" OR "cellular therapy" OR "cell transplant" OR "marrow transplant") AND ("myocardial infarction" OR "heart attack" OR
cardiomyopathy OR intramyocardial OR intracoronary OR "cardiac ischemia" OR "coronary ischemia" OR "myocardial ischemia" OR "heart
failure" OR "cardiac failure" OR congestive OR "coronary artery disease" OR angina))
WHO ICTRP Search Portal
Intervention OR Title: stem cells OR bone marrow cells OR cellular therapy OR mesenchymal cells OR stromal cells OR cell transplant OR
marrow transplant OR precursor cells OR progenitor cells OR HSCT OR SCT OR MSC OR MSCs OR BMT OR BMC OR BMAC OR BMCs OR HST
OR HSTs
Condition OR Title: cardiac OR heart OR coronary OR myocardial OR angina OR cardiomyopathy
Recruitment Status: ALL
Hong Kong Clinical Trials Registry
Combinations of the following free text terms were used:
stem cell, stem cells, bone marrow, marrow cells, progenitor cells, precursor cells, mesenchymal cells, stromal cells
AND
myocardial infarction, heart attack, cardiac ischemia, coronary ischemia, myocardial ischemia, cardiomyopathy, heart failure, cardiac
failure, angina, coronary artery disease
W H A T ' S   N E W
 
Date Event Description
1 December 2016 New citation required and conclusions
have changed
The original review has been updated to include 39 randomised
controlled trials (1921 participants). The defined primary and
secondary outcomes of the review have been revised in this ver-
sion of the review and now focus on clinical outcomes.
5 May 2016 New search has been performed The evidence is up-to-date to 14 December 2015.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Several outcomes listed in the protocol for this review, Martin-Rendon 2009, were based on those of a previous review of acute myocardial
infarction, CliJord 2012a, and were not as relevant for ischaemic heart disease and congestive heart failure. In addition, the original
outcomes of this review have been revised in this update, focusing on clinical outcomes. However, the surrogate outcome of leM ventricular
ejection fraction (LVEF) is a standard, widely reported marker for cardiac function and has been retained as a reference point in other trials
and systematic reviews in acute myocardial infarction. Surrogate outcomes other than LVEF reported in previous versions of this review,
namely engraMment and survival of the infused stem cells, leM ventricular end-systolic volume, leM ventricular end-diastolic volume, stroke
volume index, and infarct size are no longer included. Our revised primary outcomes are (i) all-cause mortality and (ii) periprocedural
adverse events. We have defined our secondary outcomes as morbidity (non-fatal myocardial infarction, rehospitalisation for heart failure,
and arrhythmias), composite measure of mortality, non-fatal myocardial infarction, and rehospitalisation for heart failure; quality of life;
performance measures; and LVEF.
In the protocol and previous versions of this review, we implemented fixed-eJect models in the first instance. It is now clear that there
are many potential sources of heterogeneity across trials, and in this version of the review we performed meta-analyses using random-
eJects models throughout.
At the protocol stage of this review, we had intended to consider clinical and surrogate outcome data at 30 days, six months, and 12 months
aMer baseline, however this was not possible due to the variation in follow-up periods reported in individual studies. We therefore stratified
outcome data into short-term (up to 12 months) and long-term (12 months or longer) follow-up.
Subgroup analyses by cell type and participant diagnosis are considered as hypothesis-generating. In this version of the review, we
assessed co-interventions by subgroup analyses (considering the eJect of cell therapy in participants who receive co-interventions as well
as in those who do not) rather than by sensitivity analyses restricted to studies without co-interventions, as we considered the eJect of
cell therapy to be relevant in both subgroups.
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
250
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Adult Stem Cells  [transplantation];  Arrhythmias, Cardiac  [epidemiology];  Bone Marrow Cells  [cytology];  Chronic Disease;  Heart
Failure  [mortality]  [*surgery];  Hospitalization  [statistics & numerical data];  Myocardial Infarction  [epidemiology];  Myocardial Ischemia
 [mortality]  [*surgery];  Patient Readmission;  Randomized Controlled Trials as Topic;  Stem Cell Transplantation  [adverse eJects]
 [*methods]  [mortality];  Stroke Volume  [physiology]
MeSH check words
Humans
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